olmesartan profile

olmesartan: an active metabolite of CS 866 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	158781
CHEMBL ID	1516
CHEBI ID	48416
SCHEMBL ID	94037
MeSH ID	M0403284

Synonym
HY-17004
HMS3393K12
olmesartan (usan/inn)
144689-24-7
D05246
MLS001424016
MLS000759446
smr000466337
4-(1-hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1h-tetrazol-5-yl)biphenyl-4-yl]methyl}-1h-imidazole-5-carboxylic acid
olmesartan
DB00275
4-(hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1h-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl}-1h-imidazole-5-carboxylic acid
1h-imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1h-tetrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-
olmesartan [usan]
votum
rnh-6270
4-(2-hydroxypropan-2-yl)-2-propyl-1-{[2'-(1h-tetrazol-5-yl)biphenyl-4-yl]methyl}-1h-imidazole-5-carboxylic acid
CHEBI:48416 ,
4-(1-hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1h-imidazole-5-carboxylic acid
HMS2051K12
4-(hydroxy-1-methylethyl)-2-propyl-1-{[2''-(1h-tetrazol-5-yl)-1,1''-biphenyl-4-yl]methyl}-1h-imidazole-5-carboxylic acid
bdbm50241364
4-(1-hydroxy-1-methylethyl)-2-propyl-1-{[2''-(1h-tetrazol-5-yl)biphenyl-4-yl]methyl}-1h-imidazole-5-carboxylic acid
4-(1-hydroxy-1-methylethyl)-2-propyl-1-{[2''-(1h-tetrazol-5-yl)[1,1''-biphenyl]-4-yl]methyl}-1h-imidazole-5-carboxylic acid
CHEMBL1516 ,
nsc-759810
olmesartan medoxomil impurity, olmesartan-
rnh 6270
4-(hydroxy-1-methylethyl)-2-propyl-1-((2'-(1h-tetrazol-5-yl)-1,1'-biphenyl-4-yl)methyl)-1h-imidazole-5-carboxylic acid
omesartan
cs-088 ,
L001097
cs 088
4-(2-hydroxypropan-2-yl)-2-propyl-1-({4-[2-(1h-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1h-imidazole-5-carboxylic acid
5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylic acid
NCGC00246968-01
nsc759810
pharmakon1600-01505206
de-092
olmesartan medoximil
8w1iqp3u10 ,
hsdb 8214
olmesartan [usan:inn:ban]
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-((2'-(2h-tetrazol-5-yl)biphenyl-4-yl)methyl)-1h-imidazole-5-carboxylate
ec 646-413-5
unii-8w1iqp3u10
nsc 759810
HMS2235O24
CCG-100868
FT-0631169
NCGC00246968-02
olmesartan medoxomil impurity, olmesartan- [usp impurity]
olmesartan [vandf]
olmesartan medoxomil impurity a [ep impurity]
olmesartan [who-dd]
olmesartan [mi]
olmesartan [inn]
CS-0576
AKOS015900241
olmesartan acid
S5581
HMS3369I09
4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl}methylimidazole-5-carboxylic acid
4-(1-hydroxy-1-methylethyl) -2-propyl-1-{4-[2-(tetrazole-5-yl)phenyl]phenyl}methylimidazole-5-carboxylic acid
VTRAEEWXHOVJFV-UHFFFAOYSA-N
4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazole-5-yl)phenyl]phenyl}methylimidazole-5-carboxylic acid
4-(1-hydroxy-1-methylethyl) -2-propyl-1-{4-[2-(tetrazole -5-yl)phenyl]phenyl}methylimidazole-5-carboxylic acid
OLM ,
SCHEMBL94037
NC00118
MLS006011945
smr004703526
W-201270
4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(2h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1h-imidazole-5-carboxylic acid
diclofenacdiethylamine
1-((2'-(1h-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1h-imidazole-5-carboxylic acid
AKOS024458255
HMS3604J06
mfcd00914967
DTXSID2040571 ,
C21543
AC-9385
olmesartan, >=98% (hplc)
olmesartan medoxomil imp. a (ep); 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1h-tetrazol-5-yl)biphenyl-4-yl]methyl]-1h-imidazole-5-carboxylic acid; olmesartan; olmesartan acid; olmesartan medoxomil impurity a
4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1h-tetrazol-5-yl)biphenyl-4-yl]methyl]-1h-imidazole-5-carboxylic acid (olmesartan)
1h-imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(2h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-
1-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1h-imidazole-5-carboxylic acid
benicar;olmetec
Q421156
1-((2'-(2H-TETRAZOL-5-YL)-[1,1'-BIPHENYL]-4-YL)METHYL)-4-(2-HYDROXYPROPAN-2-YL)-2-PROPYL-1H-IMIDAZOLE-5-CARBOXYLIC ACID
AS-10242
O0507
BCP12007
EN300-122328
4-(2-hydroxypropan-2-yl)-2-propyl-1-{[2'-(1h-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}-1h-imidazole-5-carboxylic acid
CCG-269198
NCGC00246968-04
5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylic acid.
O-125
olmesartan 100 microg/ml in acetonitrile:methanol
1h-imidazole-5-carboxylicacid,4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(2h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-
A853148
Z1541758605
4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1h-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-1h-imidazole-5-carboxylic acid
4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)-1h-imidazole-5-carboxylic acid
dtxcid0020571

Excerpt	Reference	Relevance
"Olmesartan, which is an angiotensin II receptor blocker, reportedly causes spruelike enteropathy, with intestinal villous atrophy as its typical histopathological finding. "	( Severe spruelike enteropathy and collagenous colitis caused by olmesartan. Ehira, N; Kaneko, S; Kishi, K; Kobayashi, H; Matsuda, K; Mizuta, Y; Nakamura, A; Shiratori, S; Uebayashi, M; Yagisawa, M, 2021)	2.3
"Olmesartan is an inhibitor of the angiotensin II receptor developed for the treatment of hypertension, and recent studies show that it exerts anti-inflammatory effects in arthritis."	( The protective effects of Olmesartan against interleukin-29 (IL-29)-induced type 2 collagen degradation in human chondrocytes. Chen, Q; Liu, J; Liu, Y; Ma, Y; Shang, Y; Yang, X; Zhang, Y, 2022)	1.74
"Olmesartan is a potent angiotensin II receptor antagonist commonly used in the treatment of high blood pressure. "	( [Olmesartan and enteropathy a decade later: a perhaps not so exceptional association]. Albaladejo Blanco, C; Martín García, JA; Martínez Capilla, L, )	2.48
"Olmesartan is a novel angiotensin receptor blocker with promising antihypertensive properties and has recently been reported to exert anti-inflammatory and antioxidative stress effects."	( Olmesartan Prevents Oligomerized Amyloid β (Aβ)-Induced Cellular Senescence in Neuronal Cells. Wang, J; Yang, S; Zheng, B; Zhou, D, 2021)	2.79
"Olmesartan is an angiotensin II receptor blocker, approved in 2002 by the Food and Drug Administration for the treatment of hypertension. "	( An unusual cause of diarrhoea: case report and literature review of olmesartan-associated enteropathy. Barbara, G; Bellacosa, L; Capuani, F; Cogliandro, RF; Cremon, C; Marasco, G; Mauloni, PA; Paone, C; Stanghellini, V; Vasuri, F, 2021)	2.3
"Olmesartan is an effective antihypertensive medication; however, physicians must be mindful of its side effect of causing a sprue-like enteropathy and liver injury."	( Sprue-Like Enteropathy and Liver Injury: A Rare Emerging Association with Olmesartan. Alfraji, N; Odak, M; Udongwo, N; Zaidi, S; Zheng, M, )	1.08
"Olmesartan is an angiotensin receptor blockers with actions similar to those of losartan; it is used for the treatment of high blood pressure by relaxing blood vessels for this reason blood can flow more easily. "	( Olmesartan. Abdel Aziz, HA; Al-Jallal, AAM; Al-Majed, AA; Bakheit, AHH, )	3.02
"Olmesartan medoxomil is an antihypertensive drug of the class of angiotensin II type 1 (AT1) receptor antagonists (or blockers), characterized by tight and prolonged binding to AT1 receptor compared to other molecules within the same class. "	( Monotherapy and Dual Combination Therapies Based on Olmesartan: A Comprehensive Strategy to Improve Blood Pressure Control. Battistoni, A; Coluccia, R; Mastromarino, V; Santolamazza, C; Tocci, G; Volpe, M, 2017)	2.15
"Olmesartan is an angiotensin II type 1 receptor blocker commonly used in the treatment of hypertension. "	( [Olmesartan-associated enteropathy: attention to an emerging iatrogenic phenomenon]. Aguiar Losada, B; Elejalde Guerra, JI; González Recio, P; Leturia Frade, I; Modesto Dos Santos, JL; Terry López, OA, 2017)	2.81
"Olmesartan is an angiotensin II receptor blocker, used to treat arterial hypertension. "	( [Olmesartan therapy and enteropathy: About two cases and review of the literature]. Héron, F; Le Besnerais, M; Marie, I; Sadki, A, 2019)	2.87
"Olmesartan is a long-lasting ARB which proved to achieve a comparable or more effective action in lowering BP when compared to other ARBs."	( Management of arterial hypertension with angiotensin receptor blockers: Current evidence and the role of olmesartan. Omboni, S; Volpe, M, 2018)	1.42
"Olmesartan is an angiotensin II receptor antagonist, used in the treatment of hypertension. "	( Olmesartan-associated severe gastritis and enteropathy. Shenbagaraj, L; Swift, G, 2018)	3.37
"Olmesartan is an effective and safe antihypertensive agent, but special attention should be paid to high-risk patients, such as those with coronary disease, to avoid an excessive reduction in blood pressure."	( An evaluation of the latest evidence relating to renin-angiotensin system inhibitors. Barrios, V; Escobar, C, 2013)	1.11
"Olmesartan medoxomil is an angiotensin receptor blocker (ARB) which is shown to be effective and well tolerated in hypertensive patients. "	( Olmesartan: induced maculopapular rash. Bhushan, A; Ved Bhushan, ST, )	3.02
"Olmesartan is a promising ARB for BP control in hypertensive type 2 diabetics."	( Difference in the effects of switching from candesartan to olmesartan or telmisartan to olmesartan in hypertensive patients with type 2 diabetes: the COTO study. Daikuhara, H; Fukunaga, K; Ohshima, T, 2014)	2.09
"Olmesartan is a relatively newer ARB used in hypertension management."	( WIN OVER study: Efficacy and safety of olmesartan in Indian hypertensive patients: results of an open label, non-comparative, multi-centric, post marketing observational study. Kumar, S; Kumbla, DK; Naik, M; Reddy, YV; Trailokya, A, )	1.12
"Olmesartan is a type of angiotensin II receptor inhibitor that can reduce the incidence of cardiovascular events. "	( Effects of olmesartan on endothelial progenitor cell mobilization and function in carotid atherosclerosis. Fu, YM; Gong, X; Shao, L; Zou, Y, 2015)	2.25
"The olmesartan is a selective antagonist of angiotensin II indicated for the treatment of essential hypertension. "	( [Enteropathy due to olmesartan]. Colardelle, P; Ould Sidi Mohamed, M, 2016)	1.32
"Olmesartan is an antihypertensive medication belonging to the angiotensin II receptor blocker class of drugs that has recently been associated with severe enteropathy. "	( Olmesartan-Associated Enteropathy: A Review of Clinical and Histologic Findings. Choi, EY; McKenna, BJ, 2015)	3.3
"Olmesartan is a therapy used for the management of hypertension available since 2002. "	( Sprue-like enteropathy linked to olmesartan. Campos Ruiz, A; Marra-López Valenciano, C; Urtasun Arlegui, L, 2016)	2.16
"The olmesartan is a selective antagonist of angiotensin II indicated for the treatment of essential hypertension. "	( [Enteropathy due to olmesartan]. Colardelle, P; Ould Sidi Mohamed, M, 2016)	1.32
"Olmesartan medoxomil is an orally given angiotensin II receptor antagonist indicated for the treatment of hypertension."	( Population Pharmacokinetic Modeling of Olmesartan, the Active Metabolite of Olmesartan Medoxomil, in Patients with Hypertension. Kodati, D; Kotakonda, HK; Yellu, N, 2017)	2.17
"Thus olmesartan/HCTZ is a well-tolerated option for patients who fail to respond to monotherapy and as initial therapy in those who require large reductions in diastolic blood pressure or systolic blood pressure to achieve goal blood pressure."	( Clinical efficacy and safety of olmesartan/hydrochlorothiazide combination therapy in patients with essential hypertension. Ruilope, LM, 2008)	1.08
"Olmesartan is a potential ARB inducing activation of angiotensin-converting enzyme 2 (ACE2) that hydrolyzes Ang II to Ang 1-7, and has shown a beneficial effect on ventricular remodeling."	( Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension. Fujii, M; Horie, M; Kawahara, C; Nishiyama, K; Tsutamoto, T; Yamaji, M; Yamamoto, T, 2010)	1.33
"Olmesartan medoxomil is an angiotensin II (Ang II) receptor blocker (ARB) that has been approved by the US Food and Drug Administration (FDA) for the treatment of hypertension. "	( Treatment of hypertension with olmesartan medoxomil, alone and in combination with a diuretic: an update. Chrysant, SG; Dimas, B; Shiraz, M, 2007)	2.07
"Olmesartan is a selective angiotensin II type 1 receptor (AT1) antagonist. "	( Improvement of stunned myocardium in dogs with olmesartan, an angiotensin II type 1 receptor antagonist, is independent of type 2 receptors. Ichihara, K; Kaneta, S; Kano, S; Satoh, K, 2008)	2.05

Excerpt	Reference	Relevance
"Olmesartan has a reverse-remodeling effect on AF-induced structural changes, indicating that it may be useful for preventing AF recurrence after the termination of sustained AF."	( Reverse-remodeling effects of angiotensin II type 1 receptor blocker in a canine atrial fibrillation model. Kumagai, K; Nakashima, H, 2007)	1.78
"Olmesartan (OLM) has potent anti-oxidant and anti-inflammatory characters, yet having limited bioavailability."	( Olmesartan niosomes ameliorates the Indomethacin-induced gastric ulcer in rats: Insights on MAPK and Nrf2/HO-1 signaling pathway. Darwish, SF; El-Dakroury, WA; Radwan, E; Sallam, AM, 2021)	2.79
"Olmesartan has significant blood pressure lowering effect via modulating renin-angiotensin system although its mechanism of action in DNR-induced renal injury is largely unknown."	( Olmesartan protects against oxidative stress possibly through the Nrf2 signaling pathway and inhibits inflammation in daunorubicin-induced nephrotoxicity in rats. Arozal, W; Arumugam, S; Gounder, VK; Harima, M; Nomoto, M; Pitchaimani, V; Suzuki, K; Thandavarayan, RA; Watanabe, K, 2014)	2.57
"Olmesartan has been linked with increased risk of cardiovascular mortality and sprue-like enteropathy. "	( Comparative effectiveness of olmesartan and other angiotensin receptor blockers in diabetes mellitus: retrospective cohort study. Etminan, M; Eurich, DT; Lin, M; Padwal, R, 2014)	2.14
"Olmesartan use has been associated with chronic diarrhoea and weight loss due to severe sprue-like enteropathy, yet this is still not well known among clinicians. "	( An atypical case of chronic diarrhoea: olmesartan-induced sprue-like enteropathy. Gonzalo, DH; Martelli, MG; Naik, DK; Pannu, D; Sharma, AK, 2015)	2.13
"Olmesartan has been also widely examined in combination of either hydrochlorothiazide or amlodipine, as well as with both drugs in a single-pill triple combination, showing improvements in antihypertensive efficacy without significant effects on tolerability."	( Olmesartan-based therapies: an effective way to improve blood pressure control and cardiovascular protection. de la Sierra, A; Volpe, M, 2013)	2.55
"Olmesartan has a reverse-remodeling effect on AF-induced structural changes, indicating that it may be useful for preventing AF recurrence after the termination of sustained AF."	( Reverse-remodeling effects of angiotensin II type 1 receptor blocker in a canine atrial fibrillation model. Kumagai, K; Nakashima, H, 2007)	1.78

Excerpt	Reference	Relevance
"Olmesartan can increase circulating endothelial progenitor cells number and the serum levels of eNOS and NO."	( Effects of olmesartan on endothelial progenitor cell mobilization and function in carotid atherosclerosis. Fu, YM; Gong, X; Shao, L; Zou, Y, 2015)	1.53
"Olmesartan may increase TAS, yet inhibit oxidative stress, AP-1, inflammatory, and heart rate with improved artery stiffness in elderly hypertensive patients."	( The association between oxidative stress, activator protein-1, inflammatory, total antioxidant status and artery stiffness and the efficacy of olmesartan in elderly patients with mild-to-moderate essential hypertension. Du, Q; Han, L; Liu, Q; Shen, X; Zhang, M; Zhou, S, )	1.05
"Olmesartan may suppress atherosclerosis via reducing not only superoxide production but also the overload of oxidative stress in this animal model."	( Olmesartan, a novel angiotensin II type 1 receptor antagonist, reduces severity of atherosclerosis in apolipoprotein E deficient mice associated with reducing superoxide production. Fujita, M; Kishimoto, C; Kita, T; Murayama, T; Shimada, K; Yokode, M, 2011)	3.25
"Olmesartan abolished the increase in p21 expression, whereas neither eplerenone nor hydralazine affected it."	( Aldosterone does not contribute to renal p21 expression during the development of angiotensin II-induced hypertension in mice. Deguchi, K; Hitomi, H; Kitada, K; Kobori, H; Lei, B; Masaki, T; Minamino, T; Mori, H; Nakano, D; Nishiyama, A, 2012)	1.1

Excerpt	Reference	Relevance
"40 olmesartan-treated patients (14.3%) and 53 placebo-treated patients (18.7%) developed secondary cardiovascular outcomes (HR: 0.65, P = 0.042)."	( Effects of dual blockade of the renin-angiotensin system on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy and hypertension in the ORIENT: a post-hoc analysis (ORIENT-Hypertension). Chan, JC; Haneda, M; Harada, A; Imai, E; Ito, S; Kobayashi, F; Makino, H; Yamasaki, T, 2013)	0.9
"Olmesartan treatment was found to generate beneficial effects on MetS parameters in HT patients but did not produce any significant increases in serum PPAR-γ transcription factor concentration."	( Peroxisome proliferator-activated receptor gamma concentrations in newly diagnosed hypertension patients and the metabolic effects of olmesartan. Akbal, E; Akyürek, N; Akyürek, Ö; Güneş, F, 2014)	2.05
"Olmesartan treatment (3 mg/kg per day) for 4 weeks significantly lowered systolic blood pressure but did not affect body weight during the study period in KKAy mice."	( Effects of the Angiotensin receptor blocker olmesartan on adipocyte hypertrophy and function in mice with metabolic disorders. Azushima, K; Kanaoka, T; Kobayashi, R; Maeda, A; Matsuda, M; Ohki, K; Ohsawa, M; Tamura, K; Tokita, Y; Tsurumi-Ikeya, Y; Umemura, S; Uneda, K; Wakui, H; Yamashita, A, 2014)	1.38
"Olmesartan treatment significantly ameliorated blood-brain barrier (BBB) disruption induced by CKD in 5XFAD mice."	( Chronic kidney disease accelerates cognitive impairment in a mouse model of Alzheimer's disease, through angiotensin II. Hasegawa, Y; Kim-Mitsuyama, S; Nakagawa, T; Uekawa, K, 2017)	1.18
"Olmesartan treatment substantially elevated both the baseline SI and SG levels of the ZF rats."	( [Effects of angiotensin II type 1 receptor blocker on triglyceride metabolism in the liver: experiment with Zucker fatty rats]. Feng, Q; Guo, J; Lao, GC; Liu, W; Ran, JM; Xie, B; Xu, G; Zhang, Y, 2008)	1.07
"Olmesartan treatment significantly lowered the blood pressure of PAH mice, and hypertrophy as well as increased plasma levels of cardiac injury markers were also markedly reduced."	( Angiotensin type 1 receptor blockade prevents cardiac remodeling in mice with pregnancy-associated hypertension. Fukamizu, A; Honjo, K; Inaba, S; Ishida, J; Nakamura, S; Sakairi, A; Sugiyama, F; Yagami, K, 2008)	1.07
"In olmesartan-treated patients, CBF significantly increased in the affected and unaffected hemispheres, and CRC increased significantly in the affected hemisphere."	( Benefits of the angiotensin II receptor antagonist olmesartan in controlling hypertension and cerebral hemodynamics after stroke. Kawahira, K; Matsumoto, S; Miyata, R; Shimodozono, M, 2009)	1.12
"Olmesartan treatment significantly decreased SBP to 130.4+/-4.2mm Hg (P < .001) and DBP to 78.2+/-7.0mm Hg (P < .001)."	( Olmesartan, an angiotensin II receptor blocker, restores cerebral hypoperfusion in elderly patients with hypertension. Ikeda, K; Kawabe, K; Nagata, R, 2010)	2.52
"Olmesartan treatment resulted in a significant decrease in CAVI, serum A-FABP levels, and hsCRP, besides a significant reduction of blood pressure."	( Olmesartan reduces arterial stiffness and serum adipocyte fatty acid-binding protein in hypertensive patients. Doi, M; Hirohata, S; Izumi, R; Kamikawa, S; Kusachi, S; Miyoshi, T; Ninomiya, Y; Ogawa, H; Sakane, K; Usui, S, 2011)	2.53
"Olmesartan treatment effectively suppressed the myocardial protein expressions of inflammatory markers in comparison to the vehicle-treated rats."	( Olmesartan attenuates the development of heart failure after experimental autoimmune myocarditis in rats through the modulation of ANG 1-7 mas receptor. Gurusamy, N; Kodama, M; Lakshmanan, AP; Ma, M; Nagata, M; Sukumaran, V; Suzuki, K; Takagi, R; Veeraveedu, PT; Watanabe, K; Yamaguchi, K, 2012)	2.54
"Olmesartan treatment led to a decrease of cystatin C level."	( Effect of Olmesartan on serum cystatin C levels in the patients with essential hypertension. Ahbap, E; Basturk, T; Borlu, F; Damar, AB; Koc, Y; Mazi, E; Sakaci, T; Unsal, A, 2011)	1.49
"The olmesartan treatment induced a 16.2 ± 7.7% decrement of the mean R2* in CKD patients, suggesting that this drug had an intrarenal hypoxia ameliorating effect."	( Angiotensin II receptor blocker partially ameliorated intrarenal hypoxia in chronic kidney disease patients: a pre-/post-study. Chetsurakarn, S; Eiam-Ong, S; Limkuansuwan, P; Manotham, K; Ongvilawan, B; Tanamai, J; Tungsanga, K; Urusopone, P, 2012)	0.86
"Olmesartan-treated mice also showed significant attenuation of left ventricular dilatation and dysfunction, as well as significantly greater infarct wall thickness, although the absolute size of the infarct scar was unchanged."	( Inhibition of Fas-associated apoptosis in granulation tissue cells accompanies attenuation of postinfarction left ventricular remodeling by olmesartan. Aoyama, T; Esaki, M; Fujiwara, H; Kanamori, H; Kawasaki, M; Li, Y; Maruyama, R; Minatoguchi, S; Miyata, S; Nakagawa, M; Ogino, A; Okada, H; Takemura, G; Ushikoshi, H, 2007)	1.26
"Olmesartan treatment significantly ameliorated glomerulosclerosis and dramatically decreased urinary Smad1 (from 3.9 +/- 2.9 to 0.3 +/- 0.3 ng/mg creatinine, P < 0.05)."	( Urinary Smad1 is a novel marker to predict later onset of mesangial matrix expansion in diabetic nephropathy. Abe, H; Arai, H; Araki, M; Doi, T; Fukatsu, A; Iehara, N; Kanamori, H; Kita, T; Matsubara, T; Matsuura, M; Mima, A; Nagai, K; Takahashi, T; Tamura, Y; Tominaga, T; Torikoshi, K, 2008)	1.07
"Olmesartan treatment reversed virtually all neuroendocrine and histopathological cardiac changes induced by EAM, thus providing a mechanistic insight into this phenomenon."	( Angiotensin II receptor antagonism reverts the selective cardiac BNP upregulation and secretion observed in myocarditis. de Bold, AJ; Georgalis, T; Kuroski de Bold, ML; Ogawa, T; Veinot, JP, 2008)	1.07
"Olmesartan treatment caused a 61% reduction in the cross-sectional area of the neointima, from 0.27+/-0.01 mm2 in vehicle-treated rats to 0.11+/-0.01 mm2 in olmesartan-treated rats."	( Increased expression of angiotensin converting enzyme 2 in conjunction with reduction of neointima by angiotensin II type 1 receptor blockade. Ferrario, CM; Igase, M; Kohara, K; Miki, T; Nagai, T, 2008)	1.07
"Treatment with olmesartan/azelnidipine for 2 years resulted in greater improvements in CBP, LVMI, and LV diastolic function, and arterial stiffness compared with olmesartan/amlodipine. "	( Azelnidipine plus olmesartan versus amlodipine plus olmesartan on arterial stiffness and cardiac function in hypertensive patients: a randomized trial. Saito, Y; Takami, T, 2013)	1.08
"Treatment with olmesartan and nifedipine significantly improved BP."	( Olmesartan ameliorates urinary dysfunction in the spontaneously hypertensive rat via recovering bladder blood flow and decreasing oxidative stress. Dimitriadis, F; Kinoshita, Y; Martin, DT; Ohmasa, F; Oikawa, R; Oiwa, H; Saito, M; Satoh, I; Shimizu, S; Tomita, S; Tsounapi, P, 2014)	2.18
"Treatment with olmesartan significantly decreased systolic blood pressure and ventricular hypertrophy, attenuated fibrosis, and improved diastolic function (all P < 0.05)."	( Olmesartan attenuates cardiac hypertrophy and improves cardiac diastolic function in spontaneously hypertensive rats through inhibition of calcineurin pathway. Cui, X; Fu, M; Ge, J; Hu, K; Liao, J; Sun, A; Xu, J; Zhou, J; Zhu, H; Zou, Y, 2014)	2.18
"Treatment with olmesartan reversed tacrolimus-induced changes in the biochemical markers (BUN and creatinine) of nephrotoxicity."	( Olmesartan attenuates tacrolimus-induced biochemical and ultrastructural changes in rat kidney tissue. Al-Harbi, MM; Al-Harbi, NO; Alabidy, AD; Almukhallafi, AF; Imam, F; Iqbal, M; Nadeem, A; Sayed-Ahmed, MM, 2014)	2.18
"Treatment with olmesartan or valsartan significantly ameliorated these changes in aged SHR."	( Blood pressure variability, impaired autonomic function and vascular senescence in aged spontaneously hypertensive rats are ameliorated by angiotensin blockade. Hasegawa, Y; Katayama, T; Kim-Mitsuyama, S; Koibuchi, N; Ma, M; Maeda, M; Nakagawa, T; Ogawa, H; Sueta, D; Toyama, K; Uekawa, K; Waki, H, 2014)	0.74
"Treatment with olmesartan for 8 weeks does not improve fatty acid oxidation or the activity of enzymes associated with oxidative metabolism in skeletal muscle from overweight and obese individuals. "	( Angiotensin II receptor blockade and skeletal muscle metabolism in overweight and obese adults with elevated blood pressure. Anderson, AS; Boutagy, NE; Davy, BM; Davy, KP; Frisard, MI; Hulver, MW; Marinik, EL; McMillan, RP; Rivero, JM, 2015)	0.77
"Posttreatment with olmesartan significantly reduced escape latency (P < 0.01) on water maze test, retention trial latency (P < 0.05) on passive avoidance test, and retention time of outer zone (P < 0.01) on open-field test in 5XFAD subjected to BCCAO."	( Transient Mild Cerebral Ischemia Significantly Deteriorated Cognitive Impairment in a Mouse Model of Alzheimer's Disease via Angiotensin AT1 Receptor. Hasegawa, Y; Kim-Mitsuyama, S; Matsui, K; Nakagata, N; Nakagawa, T; Senju, S; Uekawa, K, 2017)	0.77
"The treatment with olmesartan normalized insulin signaling, including expression of glucose transporter-4, whereas the treatment with enalapril was ineffective for the insulin receptor and less effective than olmesartan on the insulin-receptor substrate-1, phosphorylated-mammalian target of rapamycin and glucose transporter-4."	( Angiotensin receptor blockers improve insulin signaling and prevent microvascular rarefaction in the skeletal muscle of spontaneously hypertensive rats. Agabiti-Rosei, E; Assanelli, D; Boari, GE; De Ciuceis, C; Favero, G; Flati, V; Martinotti, S; Paiardi, S; Pasini, E; Platto, C; Porteri, E; Rezzani, R; Rizzoni, D; Rodella, LF; Speca, S; Toniato, E, 2008)	0.66
"Treatment with olmesartan, nifedipine, or both drugs had no effect on systolic blood pressure, and each treatment achieved similar suppression of 4-HNE expression."	( Efficacy of olmesartan and nifedipine on recurrent hypoxia-induced left ventricular remodeling in diabetic mice. Hayashi, T; Kitada, K; Kitaura, Y; Matsumoto, C; Matsumura, Y; Miyamura, M; Mori, T; Okada, Y; Sohmiya, K; Ukimura, A; Yamashita, C; Yoshioka, T, 2010)	1.08
"Treatment with olmesartan reduced urinary protein-to-creatinine ratio independent of blood glucose and increased average renal vessel lumen diameter in the perfused kidneys of STZ-induced DM rats, predominantly in preglomerular vessels, and then improved renal excretory capability. "	( Effects of angiotensin II receptor antagonist olmesartan on renal hemodynamic variables and vascular structural properties in streptozotocin-induced diabetic rats. Chen, JF; Li, HW; Song, HF; Sun, NL, 2011)	0.98
"Treatment with olmesartan attenuated the myocardial mRNA expressions of proinflammatory cytokines, [Interleukin (IL)-1β, monocyte chemoattractant protein-1, tumor necrosis factor-α and interferon-γ)] and the protein expression of tumor necrosis factor-α compared with that of vehicle-treated rats."	( Olmesartan, an AT1 antagonist, attenuates oxidative stress, endoplasmic reticulum stress and cardiac inflammatory mediators in rats with heart failure induced by experimental autoimmune myocarditis. Gurusamy, N; Kodama, M; Lakshmanan, AP; Ma, M; Sukumaran, V; Suzuki, K; Thandavarayan, RA; Veeraveedu, PT; Watanabe, K; Yamaguchi, K, 2011)	2.15
"Treatment with olmesartan delayed the onset of microalbuminuria independent of the baseline BP and the degree of BP reduction."	( Prevention of microalbuminuria in patients with type 2 diabetes and hypertension. Chatzykirkou, C; Haller, H; Ito, S; Izzo, JL; Januszewicz, A; Katayama, S; Menne, J; Mimran, A; Rabelink, TJ; Ritz, E; Ruilope, LM; Rump, LC; Viberti, G, 2012)	0.72
"Treatment with olmesartan (3 mg/kg per day) significantly inhibited oxidative stress and atherosclerosis, whereas its inhibitory effects were more marked in female than in male or ovariectomized mice."	( Inhibitory effects of AT1 receptor blocker, olmesartan, and estrogen on atherosclerosis via anti-oxidative stress. Horiuchi, M; Ide, A; Iwai, M; Li, HS; Li, JM; Min, LJ; Mogi, M; Okumura, M; Suzuki, H; Suzuki, J; Tsuda, M, 2005)	0.93
"Treatment with olmesartan (n=9) significantly increased EPCs from 231+/-24 to 465+/-71 per high-power field (P<0.05), but not hematopoietic progenitor cells."	( Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists. Bahlmann, FH; de Groot, K; Fliser, D; Haller, H; Hertel, B; Mueller, O, 2005)	0.67
"Treatment with olmesartan (10 or 100 mg/kg/day) had no effect on blood pressure but attenuated proteinuria in a dose-dependent manner."	( Augmentation of intrarenal angiotensin II levels in uninephrectomized aldosterone/salt-treated hypertensive rats; renoprotective effects of an ultrahigh dose of olmesartan. Abe, Y; Baba, R; Fan, YY; Fujita, M; Hosomi, N; Kimura, S; Kohno, M; Miyatake, A; Nagai, Y; Nishiyama, A; Sun, GP, 2006)	0.87
"Treatment with olmesartan or pravastatin reduced the development of atherosclerosis as compared to the control group (-46 and -39%, respectively)."	( Olmesartan and pravastatin additively reduce development of atherosclerosis in APOE*3Leiden transgenic mice. Havekes, LM; Jukema, JW; Kleemann, R; Kooistra, T; Princen, HM; van der Hoorn, JW, 2007)	2.12
"Treatment with olmesartan significantly decreased serum glucose and cholesterol levels in HSCD mice, with a slight decrease in blood pressure."	( Inhibition of cognitive decline in mice fed a high-salt and cholesterol diet by the angiotensin receptor blocker, olmesartan. Fujita, T; Horiuchi, M; Iwai, M; Iwanami, J; Li, JM; Min, LJ; Mogi, M; Sakata, A; Tsukuda, K, 2007)	0.89
"Treatment with olmesartan blocked leukocyte recruitment by antagonizing mononuclear cells-associated oxidative stress."	( Oxidative stress in mononuclear cells plays a dominant role in their adhesion to mouse femoral artery after injury. Hagita, S; Osaka, M; Shimokado, K; Yoshida, M, 2008)	0.69

Excerpt	Reference	Relevance
" The combination of A 10 + Val 160 was well tolerated, and the observed adverse events (15."	( Efficacy and safety of the single pill combination of amlodipine 10 mg plus valsartan 160 mg in hypertensive patients not controlled by amlodipine 10 mg plus olmesartan 20 mg in free combination. Ansari, A; Braun, N; Handrock, R; Klebs, S; Ulmer, HJ, 2009)	0.55
" There were no critical adverse effects in the ARB group throughout the study period."	( Safety and efficacy of antihypertensive therapy with add-on angiotensin II type 1 receptor blocker after successful coronary stent implantation. Arimura, T; Iwata, A; Kawamura, A; Kiya, Y; Miura, S; Nishikawa, H; Saku, K; Sugihara, M; Takamiya, Y; Uehara, Y, 2009)	0.35
"We assessed the safety of olmesartan by monitoring adverse drug reactions (ADRs)."	( Safety and efficacy of olmesartan: an observational pooled-analysis of 156,682 hypertensive patients. Kreutz, R; Schaefer, A; Scholze, J, 2011)	0.98
" Most treatment-emergent adverse events were mild to moderate in severity."	( Efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in study participants with hypertension and diabetes: a subpopulation analysis of the TRINITY study. Chrysant, SG; Fernandez, V; Heyrman, R; Izzo, JL; Kereiakes, DJ; Lee, J; Littlejohn, T; Melino, M; Oparil, S, )	0.38
"Olme/Amlo single pill combination can be a safe and effective option to reduce blood pressure, improve insulin sensitivity and decrease inflammatory markers."	( Evaluation of safety and efficacy of a fixed olmesartan/amlodipine combination therapy compared to single monotherapies. Carbone, A; Cicero, AF; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Querci, F, 2013)	0.65
" Adverse drug reactions were rare (n = 19), and no serious adverse drug reactions occurred."	( Safety, tolerability, and efficacy of a fixed-dose combination of olmesartan 40 mg and hydrochlorothiazide 12.5/25 mg in daily practice. Bramlage, P; Fronk, EM; Ketelhut, R; Schmieder, RE; Wolf, WP; Zemmrich, C, 2013)	0.63
"Our data confirm randomized trial data concerning safe and efficient blood pressure reduction using a fixed-dose combination of olmesartan 40 mg and HCTZ 12."	( Safety, tolerability, and efficacy of a fixed-dose combination of olmesartan 40 mg and hydrochlorothiazide 12.5/25 mg in daily practice. Bramlage, P; Fronk, EM; Ketelhut, R; Schmieder, RE; Wolf, WP; Zemmrich, C, 2013)	0.83
" The incidence of adverse events was similar across the treatment groups."	( Open-label study assessing the long-term efficacy and safety of triple olmesartan/amlodipine/hydrochlorothiazide combination therapy for hypertension. Ammentorp, B; de la Sierra, A; Laeis, P; Volpe, M, 2014)	0.64
" All reported adverse events were recorded."	( WIN OVER study: Efficacy and safety of olmesartan in Indian hypertensive patients: results of an open label, non-comparative, multi-centric, post marketing observational study. Kumar, S; Kumbla, DK; Naik, M; Reddy, YV; Trailokya, A, )	0.4
"08% patients reported the adverse events."	( WIN OVER study: Efficacy and safety of olmesartan in Indian hypertensive patients: results of an open label, non-comparative, multi-centric, post marketing observational study. Kumar, S; Kumbla, DK; Naik, M; Reddy, YV; Trailokya, A, )	0.4
"Olmesartan 20 mg/40 mg is effective and well tolerated without any serious adverse events in patients with hypertension."	( WIN OVER study: Efficacy and safety of olmesartan in Indian hypertensive patients: results of an open label, non-comparative, multi-centric, post marketing observational study. Kumar, S; Kumbla, DK; Naik, M; Reddy, YV; Trailokya, A, )	1.84
" The primary endpoint was a composite of fatal and non fatal cardiovascular events, whereas adverse events (AEs) and the percentage of patients who discontinued the allocated treatment were evaluated as secondary endpoints."	( Comparison of olmesartan combined with a calcium channel blocker or a diuretic in elderly hypertensive patients (COLM Study): safety and tolerability. Higaki, J; Ito, S; Matsuoka, H; Ogihara, T; Rakugi, H; Saito, I; Saruta, T; Shimada, K; Shimamoto, K; Teramukai, S, 2015)	0.78
" Overall, the olmesartan/amlodipine FDC was well tolerated, and there were no serious adverse events associated with medication."	( A multicenter, non-comparative study to evaluate the efficacy and safety of fixed-dose olmesartan/amlodipine in Korean patients with hypertension who are naïve or non-responders to anti-hypertensive monotherapy (ACE-HY study). Ahn, Y; Bae, JH; Jung, HW; Kang, DH; Kim, CH; Kim, KI; Park, CG, 2015)	1
" The overall incidence of adverse events was comparable between the groups."	( Efficacy and safety of sacubitril/valsartan in patients with essential hypertension uncontrolled by olmesartan: A randomized, double-blind, 8-week study. Aizenberg, D; Chen, CW; Cheung, DG; Gorbunov, V; Hafeez, K; Zhang, J, 2018)	0.7
" Treatment with sacubitril/valsartan 200 or 400 mg once daily is effective and provided superior BP reduction than olmesartan 20 mg in Asian patients with mild-to-moderate hypertension and is generally safe and well tolerated."	( Efficacy and safety of sacubitril/valsartan compared with olmesartan in Asian patients with essential hypertension: A randomized, double-blind, 8-week study. Guo, W; Huo, Y; Li, W; Wang, Q; Webb, R; Zhao, L, 2019)	0.97
" The therapy was safe and well tolerated."	( Real-World Effectiveness and Safety of a Single-Pill Combination of Olmesartan/Amlodipine/Hydrochlorothiazide in Korean Patients with Hypertension and Cardiovascular Risk Factors. Hong, JH; Hyun, D; Kim, GH; Kim, HL; Kim, W; Lim, S; Min, KW; Oh, J; Park, SD; Shin, J, 2023)	1.15

Excerpt	Reference	Relevance
"8 hours, and the terminal elimination half-life ranged from 12 to 18 hours."	( Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects. Masonson, HN; Schwocho, LR, 2001)	0.31
"To develop a population pharmacokinetic model for olmesartan (RNH-6270), the active metabolite of olmesartan medoxomil, in healthy volunteers and hypertensive patients, and to evaluate effects of covariates on the apparent oral clearance (CL/F), with particular emphasis on the effect of race."	( Population pharmacokinetics of olmesartan following oral administration of its prodrug, olmesartan medoxomil: in healthy volunteers and hypertensive patients. Gao, Y; Hisaoka, M; Shiga, H; Wada, DR; Yoshihara, K, 2005)	0.87
"The pharmacokinetic data of olmesartan were well described by a two-compartment linear model with first-order absorption and an absorption lag-time, parameterised in terms of CL/F (6."	( Population pharmacokinetics of olmesartan following oral administration of its prodrug, olmesartan medoxomil: in healthy volunteers and hypertensive patients. Gao, Y; Hisaoka, M; Shiga, H; Wada, DR; Yoshihara, K, 2005)	0.91
"The population pharmacokinetic analysis of olmesartan showed that: (i) severe renal impairment (serum creatinine >265 micromol/L [approximately 3 mg/dL]) could cause a clearance decrease of > or =30%; (ii) older age, lower bodyweight and being female were determinants of lower clearance but their effects on olmesartan clearance were within 20%; (iii) no statistically significant difference in clearance was found between Westerners and Japanese."	( Population pharmacokinetics of olmesartan following oral administration of its prodrug, olmesartan medoxomil: in healthy volunteers and hypertensive patients. Gao, Y; Hisaoka, M; Shiga, H; Wada, DR; Yoshihara, K, 2005)	0.88
" From a pharmacokinetic perspective, the 2 drugs are well suited to coadministration in a fixed-dose combination."	( Pharmacokinetics of amlodipine and olmesartan after administration of amlodipine besylate and olmesartan medoxomil in separate dosage forms and as a fixed-dose combination. Allison, M; Bathala, MS; Haworth, S; Heyrman, R; Lee, J; Noveck, R; Rohatagi, S; Rubets, I; Salazar, DE; Shenouda, M, 2008)	0.62
" In conclusion, the effects of olmesartan medoxomil and azelnidipine were modestly correlated with pharmacokinetic profiles, and the pre-treatment PRA level could be a useful determinant of responsiveness in selecting olmesartan medoxomil and azelnidipine."	( Comparative pharmacodynamics of olmesartan and azelnidipine in patients with hypertension: a population pharmacokinetic/pharmacodynamic analysis. Arakawa, K; Kuramoto, K; Tanigawara, Y; Yoshihara, K, 2009)	0.92
" The pharmacokinetic parameters of IIa were studied and compared with those of olmesartan medoxomil."	( Novel amides and esters prodrugs of olmesartan: Synthesis, bioconversion, and pharmacokinetic evaluation. Chang, JS; Cho, YJ; Choi, WK; Choi, YW; Chung, HJ; El-Gamal, MI; Jeon, HR; Kim, HI; Lee, BS; Lee, J; Lee, WS; Lee, YS; Oh, CH; Park, JH, 2010)	0.86
" The method proved highly reproducible and sensitive and was successfully applied in a pharmacokinetic study after single dose oral administration of olmesartan and pioglitazone to the rat."	( Development and validation of an LC-ESI-MS/MS method for simultaneous quantitation of olmesartan and pioglitazone in rat plasma and its pharmacokinetic application. Bhaumik, U; Chakraborty, US; Chatterjee, B; Pal, TK; Roy, B; Sarkar, AK; Sengupta, P, 2010)	0.78
" And the pharmacokinetic parameters for olmesartan after their oral administration were also estimated and compared with those in case of olmesartan medoxomil."	( Design, synthesis, bioconversion, and pharmacokinetics evaluation of new ester prodrugs of olmesartan. Anbar, HS; Chang, JS; Cho, YJ; Choi, YW; Chung, HJ; El-Gamal, MI; Jeon, HR; Kim, HI; Lee, BS; Lee, DJ; Lee, J; Lee, SA; Lee, WS; Moon, JY; Oh, CH, 2011)	0.86
" A fixed-dose combination (FDC) tablet of these 2 drugs was recently developed to enhance the dosing convenience and to increase patient compliance while yielding pharmacokinetic profiles comparable to coadministration of each drug as individual tablets."	( Pharmacokinetics of rosuvastatin/olmesartan fixed-dose combination: a single-dose, randomized, open-label, 2-period crossover study in healthy Korean subjects. Chang, H; Kim, J; Lee, D; Park, K; Roh, H; Son, H; Yun, C, 2013)	0.67
"The goal of present study was to compare the pharmacokinetic profiles of single-dose administration of an FDC tablet containing rosuvastatin/olmesartan 20/40 mg (test formulation) with coadministration of a rosuvastatin 20-mg tablet and a olmesartan 40-mg tablet (reference formulation) in healthy Korean male volunteers, for the purpose of determining bioequivalence."	( Pharmacokinetics of rosuvastatin/olmesartan fixed-dose combination: a single-dose, randomized, open-label, 2-period crossover study in healthy Korean subjects. Chang, H; Kim, J; Lee, D; Park, K; Roh, H; Son, H; Yun, C, 2013)	0.87
" Blood samples were collected up to 72 hours after dosing, and pharmacokinetic parameters were determined for rosuvastatin, its active metabolite (N-desmethyl rosuvastatin), and olmesartan."	( Pharmacokinetics of rosuvastatin/olmesartan fixed-dose combination: a single-dose, randomized, open-label, 2-period crossover study in healthy Korean subjects. Chang, H; Kim, J; Lee, D; Park, K; Roh, H; Son, H; Yun, C, 2013)	0.86
" The 90% CIs of the geometric mean ratios of the primary pharmacokinetic parameters were as follows: rosuvastatin: AUC(last), 85."	( Pharmacokinetics of rosuvastatin/olmesartan fixed-dose combination: a single-dose, randomized, open-label, 2-period crossover study in healthy Korean subjects. Chang, H; Kim, J; Lee, D; Park, K; Roh, H; Son, H; Yun, C, 2013)	0.67
"The pharmacokinetic properties of the newly developed FDC tablet of rosuvastatin/olmesartan 20/40 mg suggest that it is bioequivalent to co-administration of each drug as individual tablets in these healthy Korean male subjects."	( Pharmacokinetics of rosuvastatin/olmesartan fixed-dose combination: a single-dose, randomized, open-label, 2-period crossover study in healthy Korean subjects. Chang, H; Kim, J; Lee, D; Park, K; Roh, H; Son, H; Yun, C, 2013)	0.9
" With no information currently available on the interaction between the 2 drugs, a pharmacokinetic study was conducted to investigate the influence of rosuvastatin on olmesartan and vice versa when the 2 drugs were coadministered."	( Pharmacokinetic interaction between rosuvastatin and olmesartan: a randomized, open-label, 3-period, multiple-dose crossover study in healthy Korean male subjects. Chang, H; Lee, D; Park, K; Roh, H; Son, H; Yun, C, 2014)	0.85
" Blood samples were collected up to 72 hours after dosing, and pharmacokinetic parameters were determined for rosuvastatin, its active metabolite (N-desmethyl rosuvastatin), and olmesartan."	( Pharmacokinetic interaction between rosuvastatin and olmesartan: a randomized, open-label, 3-period, multiple-dose crossover study in healthy Korean male subjects. Chang, H; Lee, D; Park, K; Roh, H; Son, H; Yun, C, 2014)	0.84
" The 90% CIs of the geometric mean ratios for the primary pharmacokinetic parameters for the coadministration of the 2 drugs to the mono-administration of each drug were 85."	( Pharmacokinetic interaction between rosuvastatin and olmesartan: a randomized, open-label, 3-period, multiple-dose crossover study in healthy Korean male subjects. Chang, H; Lee, D; Park, K; Roh, H; Son, H; Yun, C, 2014)	0.65
"The aim of the study was to establish a population pharmacokinetic model for olmesartan, the active metabolite of olmesartan medoxomil, in Indian hypertensive patients, and to evaluate effects of covariates on the volume of distribution (V/F) and oral clearance (CL/F) of olmesartan."	( Population Pharmacokinetic Modeling of Olmesartan, the Active Metabolite of Olmesartan Medoxomil, in Patients with Hypertension. Kodati, D; Kotakonda, HK; Yellu, N, 2017)	0.95
" The pharmacokinetic data of olmesartan was well described by a two-compartment linear pharmacokinetic model with first-order absorption and an absorption lag-time."	( Population Pharmacokinetic Modeling of Olmesartan, the Active Metabolite of Olmesartan Medoxomil, in Patients with Hypertension. Kodati, D; Kotakonda, HK; Yellu, N, 2017)	1.02
"The final population pharmacokinetic model was demonstrated to be appropriate and effective and it can be used to assess the pharmacokinetic parameters of olmesartan in Indian patients with hypertension."	( Population Pharmacokinetic Modeling of Olmesartan, the Active Metabolite of Olmesartan Medoxomil, in Patients with Hypertension. Kodati, D; Kotakonda, HK; Yellu, N, 2017)	0.92

Excerpt	Reference	Relevance
" In addition, the BP lowering effect of olmesartan, like the other members of its class, is greatly enhanced in combination with a diuretic."	( Treatment of hypertension with olmesartan medoxomil, alone and in combination with a diuretic: an update. Chrysant, SG; Dimas, B; Shiraz, M, 2007)	0.89
"The aim of this study was to compare the effects between calcium channel blockers and diuretics when used in combination with angiotensin II receptor blocker on aortic systolic blood pressure (BP) and brachial ambulatory systolic BP."	( Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients. Eguchi, K; Ishikawa, J; Kario, K; Matsui, Y; Miyashita, H; O'Rourke, MF; Shimada, K, 2009)	0.35
" In this study, the efficacy of treatment using an angiotensin II receptor antagonist (ARB) combined with a calcium channel blocker (CCB) or a diuretic was compared from multiple perspectives in patients with hypertension."	( Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension. Akabane, T; Ishimitsu, T; Masuda, T; Matsuoka, H; Minami, J; Numabe, A; Okamura, A, 2009)	0.35
" The present study was designed to investigate whether calcium channel blockers (CCBs) in combination with an ARB differentially affect kidney function."	( Renoprotective effect of calcium channel blockers in combination with an angiotensin receptor blocker in elderly patients with hypertension. A randomized crossover trial between benidipine and amlodipine. Dohi, Y; Kimura, G; Miyagawa, K; Nakazawa, A; Sato, K; Sugiura, T; Yamashita, S, 2010)	0.36
"Ketoconazole and rifampin are the most widely used compounds examined in recent drug-drug interaction (DDI) studies, and they have multiple roles in modulating drug metabolizing enzymes and transporters."	( Inhibitory effects of ketoconazole and rifampin on OAT1 and OATP1B1 transport activities: considerations on drug-drug interactions. Ahn, SH; Bae, MA; Choi, MK; Choi, YL; Jin, QR; Song, IS, 2011)	0.37
"A thiazide diuretic used in combination with benazepril is superior to amlodipine plus benazepril in reducing albuminuria in hypertensive patients with diabetes."	( Kidney-protective effects of azelnidipine versus a diuretic in combination with olmesartan in hypertensive patients with diabetes and albuminuria: a randomized study. Dohi, Y; Hirota, H; Isaka, N; Ito, M; Kato, T; Kimura, G; Kojima, M; Machida, H; Makino, K; Miyagawa, K; Mizubayashi, R; Mizuno, O; Nakatani, K; Okamoto, S; Okubo, S; Okura, T; Takeuchi, M, 2013)	0.62
"Azelnidipine is equally effective as a thiazide diuretic in reducing urinary albumin when used in combination with olmesartan."	( Kidney-protective effects of azelnidipine versus a diuretic in combination with olmesartan in hypertensive patients with diabetes and albuminuria: a randomized study. Dohi, Y; Hirota, H; Isaka, N; Ito, M; Kato, T; Kimura, G; Kojima, M; Machida, H; Makino, K; Miyagawa, K; Mizubayashi, R; Mizuno, O; Nakatani, K; Okamoto, S; Okubo, S; Okura, T; Takeuchi, M, 2013)	0.83
" High-risk hypertensive patients aged 65-84 years were enrolled and were randomized to receive olmesartan combined with either a CCB (amlodipine or azelnidipine) or a low-dose diuretic for at least 3 years."	( Comparison of olmesartan combined with a calcium channel blocker or a diuretic in elderly hypertensive patients (COLM Study): safety and tolerability. Higaki, J; Ito, S; Matsuoka, H; Ogihara, T; Rakugi, H; Saito, I; Saruta, T; Shimada, K; Shimamoto, K; Teramukai, S, 2015)	1
" During the next 12 weeks, they took olmesartan (1st group) or telmisartan (2nd group) in combination with atorvastatin."	( The effect of therapy with olmesartan or telmisartan in patients with arterial hypertension combined with obesity. Bazylevych, AY; Bochar, OM; Bochar, VT; Faynyk, AF; Kuzminov, YB; Sklyarova, HY, 2020)	1.13
" After treatment with olmesartan in combination with atorvastatin, the adiponectin content in the blood increased by 41."	( The effect of therapy with olmesartan or telmisartan in patients with arterial hypertension combined with obesity. Bazylevych, AY; Bochar, OM; Bochar, VT; Faynyk, AF; Kuzminov, YB; Sklyarova, HY, 2020)	1.17
" The availability of OM combined with HCTZ, AML or both at different dosages makes it a valuable option to customize therapy based on the levels of BP and the clinical characteristics of hypertensive patients."	( Single-Pill Combination with Three Antihypertensive Agents to Improve Blood Pressure Control in Hypertension: Focus on Olmesartan-Based Combinations. Burnier, M; Redon, J; Volpe, M, 2023)	1.12

Excerpt	Reference	Relevance
" Absolute bioavailability of RNH-6270 after oral administration of CS-866 was 26%."	( Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects. Masonson, HN; Schwocho, LR, 2001)	0.31
" Bioavailability (Cmax and area under the curve) increased approximately in proportion with dose, after single and multiple daily oral doses, over the therapeutic dose range (up to 40-80 mg daily), above which systemic availability of olmesartan increased less than proportionally with increase in dose."	( The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. Kirch, W; Laeis, P; Püchler, K, 2001)	0.75
" We conclude that in NTG-treated rabbits, endothelial nitric oxide production in mesenteric resistance arteries is reduced, possibly through a reduction in the bioavailability of L-arginine via an action mediated by superoxide."	( Chronic nitroglycerine administration reduces endothelial nitric oxide production in rabbit mesenteric resistance artery. Itoh, T; Kajikuri, J; Suzuki, Y; Suzumori, K; Watanabe, Y; Yamamoto, T, 2005)	0.33
"66 L/h for a typical male Western hypertensive patient), absorption rate constant (1."	( Population pharmacokinetics of olmesartan following oral administration of its prodrug, olmesartan medoxomil: in healthy volunteers and hypertensive patients. Gao, Y; Hisaoka, M; Shiga, H; Wada, DR; Yoshihara, K, 2005)	0.61
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."	( Hologram QSAR model for the prediction of human oral bioavailability. Andricopulo, AD; Moda, TL; Montanari, CA, 2007)	0.34
"The method is sensitive, rapid and suitable for the study of pharmacokinetics and bioavailability of olmesartan."	( [High-performance liquid chromatography-mass spectrometry for determining olmesartan in human plasma]. Chen, BM; Chen, SH; Pei, Q; Tan, HY; Wu, CF; Yang, GP; Yang, L, 2008)	0.79
" These findings may explain the known interaction of telmisartan with digoxin and suggest that it may modulate the bioavailability of drugs whose absorption is restricted by P-gp and possibly also by BCRP or MRP2."	( Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. Benndorf, RA; Böger, RH; Divac, N; Haefeli, WE; Herzog, M; Sauer, A; Schwedhelm, E; Weiss, J, 2010)	0.36
" Higher bioavailability compared to commercial oral tablets with a more sustainment behavior was achieved."	( Development and characterization of colloidal soft nano-carriers for transdermal delivery and bioavailability enhancement of an angiotensin II receptor blocker. Elshafeey, AH; Hathout, RM, 2012)	0.38
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" The main challenge was the poor bioavailability of azelnidipine due to its poor aqueous solubility and first-pass effect."	( Chronological Delivery of Antihypertensive Drugs in Bilayered Core-in-Cup Buccoadhesive Tablets: In Vitro and In Vivo Evaluation. Abd El Rehim, RT; El-Gazayerly, ON; Nageeb El-Helaly, S; Rashad, AA, 2019)	0.51
" Hence, MasR activation may contribute to the favorable effects of AT1R antagonism on NO bioavailability and microvascular remodeling, independently of AT2R activation and blood pressure control."	( Mas Receptor Activation Contributes to the Improvement of Nitric Oxide Bioavailability and Vascular Remodeling During Chronic AT1R (Angiotensin Type-1 Receptor) Blockade in Experimental Hypertension. Arrabito, E; Battistoni, A; Filippini, A; Madaro, L; Nicoletti, C; Parente, R; Savoia, C; Steckelings, UM; Touyz, RM; Volpe, M, 2020)	0.56

Excerpt	Relevance	Reference
"Olmesartan medoxomil monotherapy at the recommended dosage of 20 mg once daily is effective and well tolerated in patients with mild-to-moderate hypertension."	( Blood pressure reduction with olmesartan in mild-to-moderate essential hypertension: a planned interim analysis of an open label sub-study in German patients. Böhm, M; Ewald, S, 2006)	2.07
" Dosing time did not exert statistically significant differences on the efficacy of olmesartan: the reduction from baseline in the 24 h mean systolic (SBP) and DBP was, respectively, 18."	( Comparison of the efficacy of morning versus evening administration of olmesartan in uncomplicated essential hypertension. Hermida, RC; Portaluppi, F; Smolensky, MH, 2007)	0.8
"The pharmacokinetics of amlodipine and olmesartan in healthy volunteers after coadministration of amlodipine besylate and olmesartan medoxomil concomitantly as separate dosage forms and together in a fixed-dose combination tablet were characterized in 5 phase I, randomized, crossover studies."	( Pharmacokinetics of amlodipine and olmesartan after administration of amlodipine besylate and olmesartan medoxomil in separate dosage forms and as a fixed-dose combination. Allison, M; Bathala, MS; Haworth, S; Heyrman, R; Lee, J; Noveck, R; Rohatagi, S; Rubets, I; Salazar, DE; Shenouda, M, 2008)	0.89
" Nocturnal BP regulation was significantly better achieved with bedtime as compared to morning dosing of olmesartan."	( Administration-time-dependent effects of olmesartan on the ambulatory blood pressure of essential hypertension patients. Ayala, DE; Chayan, L; Fernandez, JR; Hermida, RC; Mojon, A, 2009)	0.83
" The authors evaluated the impact on 24-hour blood pressure, NBPF, and albuminuria of olmesartan 40 mg, administered in a morning- vs a nocturnal-based dosing scheme, in type 2 diabetic patients with newly diagnosed hypertension."	( 24-hour and nighttime blood pressures in type 2 diabetic hypertensive patients following morning or evening administration of olmesartan. García De La Villa, B; Tofé Povedano, S, 2009)	0.78
" Secondary endpoints included: change in ambulatory diastolic BP (DBP) from baseline to Week 12; changes in ambulatory SBP and DBP during daytime, nighttime, and the last 2, 4, and 6 hours of the dosing interval; and achievement of prespecified ambulatory BP targets."	( Effects of an olmesartan medoxomil based treatment algorithm on 24-hour blood pressure control in patients with hypertension and type 2 diabetes. Kereiakes, DJ; Neutel, JM; Shojaee, A; Stoakes, KA; Waverczak, WF; Xu, J, 2010)	0.72
"The aim of the present study was to use ambulatory blood pressure (BP) monitoring (ABPM) to determine the efficacy of a fixed-dose combination of amlodipine (AML) and olmesartan medoxomil (OM) over the 24-hour dosing interval."	( Efficacy of amlodipine and olmesartan medoxomil in patients with hypertension: the AZOR Trial Evaluating Blood Pressure Reductions and Control (AZTEC) study. Dubiel, R; Kereiakes, DJ; Maa, JF; Neutel, JM; Punzi, H; Shojaee, A; Waverczak, WF, 2010)	0.85
"A simple, rapid, and precise method is developed for the quantitative simultaneous estimation of amlodipine (AM) and olmesartan (OL) in combined pharmaceutical dosage form."	( Stability indicating LC method for the simultaneous determination of amlodipine and olmesartan in dosage form. Patil, KR; Rane, VP; Sangshetti, JN; Shinde, DB; Yeole, RD, 2010)	0.79
" The bedtime dosing of amlodipine and olmesartan seems more apt than the morning dose to obtain the therapeutic goal."	( The bedtime administration ameliorates blood pressure variability and reduces urinary albumin excretion in amlodipine-olmesartan combination therapy. Hoshino, A; Matsubara, H; Nakamura, T, 2010)	0.84
" In particular, mean 24-h BP and BP variability both correlate closely with hypertension end-organ damage and rate of CV events, which suggests that antihypertensive therapy should provide smooth BP control over the full 24-h dosing interval."	( Efficacy and tolerability of olmesartan/amlodipine combination therapy in patients with mild-to-severe hypertension: focus on 24-h blood pressure control. Bilo, G; Hoshide, S; Lonati, L; Ochoa, JE; Parati, G; Ramos, C, 2010)	0.65
" Moreover, consistent reductions in BP were observed over the 24-hour dosing interval using ambulatory measurements."	( Olmesartan/amlodipine: a review of its use in the management of hypertension. Kreutz, R, 2011)	1.81
" Greater efficacy was also found during daytime and nighttime hours and during the last 6, 4, or 2 hours of the dosing interval."	( 24-hour efficacy and safety of Triple-Combination Therapy With Olmesartan, Amlodipine, and Hydrochlorothiazide: the TRINITY ambulatory blood pressure substudy. Chrysant, SG; Fernandez, V; Heyrman, R; Izzo, JL; Kereiakes, DJ; Lee, J; Littlejohn Iii, T; Melino, M; Oparil, S, 2011)	0.61
" Olmesartan medoxomil showed larger BP reductions in the last 6 h from the dosing interval and higher smoothness indices than ramipril."	( Twenty-four hour and early morning blood pressure control of olmesartan vs. ramipril in elderly hypertensive patients: pooled individual data analysis of two randomized, double-blind, parallel-group studies. Malacco, E; Mallion, JM; Omboni, S; Volpe, M; Zanchetti, A, 2012)	1.53
" The mean blood pressure in the final 6 hours of the dosing interval dropped from 135."	( Reduction of the morning blood pressure surge treated with olmesartan in Chinese patients with mild to moderate essential hypertension--a multicenter, open-label, single treatment group clinical study. Deng, W; Jiao, Y; Ke, Y; Sun, N; Wang, J; Zhu, J, 2012)	0.62
"Two reversed phase liquid chromatographic (RP-LC) techniques are presented for the rapid, accurate, precise, simultaneous determination of olmesartan-hydrochlorothiazide and zofenopril-hydrochlorothiazide binary mixtures in their dosage forms."	( Simultaneous estimation and validation of some binary mixtures of antihypertensive drugs by RP-LC methods using two new generation silica columns. Gumustas, M; Kurbanoglu, S; Ozkan, SA, 2013)	0.59
" A fixed-dose combination (FDC) tablet of these 2 drugs was recently developed to enhance the dosing convenience and to increase patient compliance while yielding pharmacokinetic profiles comparable to coadministration of each drug as individual tablets."	( Pharmacokinetics of rosuvastatin/olmesartan fixed-dose combination: a single-dose, randomized, open-label, 2-period crossover study in healthy Korean subjects. Chang, H; Kim, J; Lee, D; Park, K; Roh, H; Son, H; Yun, C, 2013)	0.67
" Randomized and observational studies have shown that OM provides effective BP control across the 24 h dosing interval in the elderly."	( Olmesartan in the treatment of hypertension in elderly patients: a review of the primary evidence. Tocci, G; Volpe, M, 2013)	1.83
" The ANCOVA showed that changes in patients' HRQoL was likely to have been influenced by patients' achievement of blood pressure control, the amount of concomitant medication and patients' last used dosage strength of antihypertensive."	( Health-related quality of life impact of a triple combination of olmesartan medoxomil, amlodipine besylate and hydrochlorotiazide in subjects with hypertension. Brazier, JE; Guest, JF; Haag, U; Marques da Silva, P; Soro, M, 2015)	0.65
" Achieving blood pressure control, amount of concomitant medication and dosage strength of antihypertensive impacted on patients' HRQoL."	( Health-related quality of life impact of a triple combination of olmesartan medoxomil, amlodipine besylate and hydrochlorotiazide in subjects with hypertension. Brazier, JE; Guest, JF; Haag, U; Marques da Silva, P; Soro, M, 2015)	0.65
"Simultaneous spectrophotometric analysis of a multi-component dosage form of olmesartan, amlodipine and hydrochlorothiazide used for the treatment of hypertension has been carried out using various chemometric methods."	( Simultaneous quantitative analysis of olmesartan, amlodipine and hydrochlorothiazide in their combined dosage form utilizing classical and alternating least squares based chemometric methods. Abdelhameed, AS; Bakheit, AH; Darwish, HW, 2016)	0.93
" The dosage of olmesartan and azilsartan increased significantly and slightly for 16 weeks (OL group: 20."	( Practical efficacy of olmesartan versus azilsartan in patients with hypertension: a multicenter randomized-controlled trial (MUSCAT-4 study). Hanayama, Y; Kakio, Y; Okuyama, Y; Takeuchi, H; Uchida, HA; Umebayashi, R; Wada, J, 2017)	1.12
" After all patients received any of OLM 10, 20, and 40 mg/day as an initial dose, the dosage of OLM was titrated up to 40 mg as needed during follow-up period."	( [Effects of Olmesartan Medoxomil on Patients with Thoracic and Thoracoabdominal Aortic Aneurysm;Evaluation of Anti-hypertensive Effect and Possible Suppression of Aneurysmal Dilation( OLM 40 Study)]. Adachi, O; Akiyama, M; Kumagai, K; Motoyoshi, N; Saiki, Y; Sasaki, K; Sato, M; Sugawara, Y, 2020)	0.94
" During follow-up, the OA dosage is adjusted according to the ABPM and OBPM results."	( The effects of Olmesartan/amlodipine administered in the Morning or At Night on nocturnal blood pressure reduction in Chinese patients with mild-moderate essential hypertension (OMAN Trial): study protocol for a prospective, multicenter, randomized, open- Chen, X; Jia, S; Li, X; Liao, H; Liu, K; Liu, X; Meng, Q; Shi, R; Sun, L; Wang, S; Wang, Z; Xu, M; Ye, R; Zhang, X; Zhang, Z, 2023)	1.26

Role	Description
antihypertensive agent	Any drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
angiotensin receptor antagonist	A hormone antagonist that blocks angiotensin receptors.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
biphenylyltetrazole	A member of the class of biphenyls that consists of a biphenyl ring system substituted by a tetrazole ring at an unspecified position.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Metabolism	1496	1108
Biological oxidations	150	276
Phase I - Functionalization of compounds	69	175
Olmesartan Action Pathway	7	4

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, Beta-lactamase	Escherichia coli K-12	Potency	44.6684	0.0447	17.8581	100.0000	AID485294
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	25.1189	0.0355	20.9770	89.1251	AID504332
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	Potency	39.8107	0.0096	10.5250	35.4813	AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Cytochrome P450 2C9	Homo sapiens (human)	IC50 (µMol)	50.0000	0.0000	2.8005	10.0000	AID1210069
Cytochrome P450 2J2	Homo sapiens (human)	IC50 (µMol)	50.0000	0.0120	2.5312	9.4700	AID1210069
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Platelet glycoprotein VI	Homo sapiens (human)	Kd	300.0000	0.0411	0.0411	0.0411	AID1692279
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)	Km	71.8000	0.0391	2.9388	6.4000	AID680212
Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)	Km	42.6000	0.0076	3.2018	10.0000	AID680560
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2C9	Homo sapiens (human)
urea metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
monocarboxylic acid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2C9	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2C9	Homo sapiens (human)
amide metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
icosanoid biosynthetic process	Cytochrome P450 2C9	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 2C9	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 2C9	Homo sapiens (human)
fatty acid metabolic process	Cytochrome P450 2J2	Homo sapiens (human)
icosanoid metabolic process	Cytochrome P450 2J2	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2J2	Homo sapiens (human)
regulation of heart contraction	Cytochrome P450 2J2	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2J2	Homo sapiens (human)
linoleic acid metabolic process	Cytochrome P450 2J2	Homo sapiens (human)
organic acid metabolic process	Cytochrome P450 2J2	Homo sapiens (human)
positive regulation of platelet aggregation	Platelet glycoprotein VI	Homo sapiens (human)
enzyme-linked receptor protein signaling pathway	Platelet glycoprotein VI	Homo sapiens (human)
platelet activation	Platelet glycoprotein VI	Homo sapiens (human)
collagen-activated tyrosine kinase receptor signaling pathway	Platelet glycoprotein VI	Homo sapiens (human)
collagen-activated signaling pathway	Platelet glycoprotein VI	Homo sapiens (human)
platelet aggregation	Platelet glycoprotein VI	Homo sapiens (human)
immune response-regulating signaling pathway	Platelet glycoprotein VI	Homo sapiens (human)
xenobiotic metabolic process	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
monoatomic ion transport	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
organic anion transport	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
bile acid and bile salt transport	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
heme catabolic process	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
sodium-independent organic anion transport	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
transmembrane transport	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
xenobiotic metabolic process	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
monoatomic ion transport	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
organic anion transport	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
bile acid and bile salt transport	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
prostaglandin transport	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
heme catabolic process	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
sodium-independent organic anion transport	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
transmembrane transport	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
thyroid hormone transport	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 7-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 2C9	Homo sapiens (human)
(R)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C9	Homo sapiens (human)
heme binding	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C9	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2J2	Homo sapiens (human)
iron ion binding	Cytochrome P450 2J2	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2J2	Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activity	Cytochrome P450 2J2	Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activity	Cytochrome P450 2J2	Homo sapiens (human)
isomerase activity	Cytochrome P450 2J2	Homo sapiens (human)
linoleic acid epoxygenase activity	Cytochrome P450 2J2	Homo sapiens (human)
hydroperoxy icosatetraenoate isomerase activity	Cytochrome P450 2J2	Homo sapiens (human)
arachidonic acid 5,6-epoxygenase activity	Cytochrome P450 2J2	Homo sapiens (human)
heme binding	Cytochrome P450 2J2	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2J2	Homo sapiens (human)
transmembrane signaling receptor activity	Platelet glycoprotein VI	Homo sapiens (human)
protein binding	Platelet glycoprotein VI	Homo sapiens (human)
collagen binding	Platelet glycoprotein VI	Homo sapiens (human)
signaling receptor activity	Platelet glycoprotein VI	Homo sapiens (human)
collagen receptor activity	Platelet glycoprotein VI	Homo sapiens (human)
protein tyrosine kinase binding	Platelet glycoprotein VI	Homo sapiens (human)
serine-type endopeptidase inhibitor activity	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
organic anion transmembrane transporter activity	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
bile acid transmembrane transporter activity	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activity	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
organic anion transmembrane transporter activity	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
bile acid transmembrane transporter activity	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activity	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
thyroid hormone transmembrane transporter activity	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
endoplasmic reticulum membrane	Cytochrome P450 2C9	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2J2	Homo sapiens (human)
extracellular exosome	Cytochrome P450 2J2	Homo sapiens (human)
cytoplasm	Cytochrome P450 2J2	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2J2	Homo sapiens (human)
virion membrane	Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus
membrane raft	Platelet glycoprotein VI	Homo sapiens (human)
plasma membrane	Platelet glycoprotein VI	Homo sapiens (human)
cell surface	Platelet glycoprotein VI	Homo sapiens (human)
extracellular exosome	Platelet glycoprotein VI	Homo sapiens (human)
tetraspanin-enriched microdomain	Platelet glycoprotein VI	Homo sapiens (human)
plasma membrane	Platelet glycoprotein VI	Homo sapiens (human)
plasma membrane	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
basal plasma membrane	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
basolateral plasma membrane	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
plasma membrane	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
basal plasma membrane	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
membrane	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
basolateral plasma membrane	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID680560	TP_TRANSPORTER: transport in OATP1B1-expressing oocytes	2006	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 34, Issue:5	OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker.
AID568788	Binding affinity to angiotensin AT1 receptor in bovine adrenal cortex membranes	2010	Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24	Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
AID1217705	Time dependent inhibition of CYP2B6 (unknown origin) at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1211555	In vitro apparent biliary clearance in sandwich cultured Sprague-Dawley rat hepatocytes after 15 mins by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
AID1211548	In vivo apparent biliary clearance in iv dosed Sprague-Dawley rat by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
AID1217711	Metabolic activation in human liver microsomes assessed as [3H]GSH adduct formation rate measured per mg of protein at 100 uM by [3H]GSH trapping assay	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1217712	Time dependent inhibition of CYP2C8 (unknown origin) at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1216814	Metabolic activation assessed as CYP2C9 activation-induced cytotoxicity in human HepG2 cells transfected with human AdCYP2C9 at MOI 10 for 2 days in presence of siNrf2 at 25 to 100 uM after 24 hrs by WST-8 assay	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.
AID678715	Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID183748	Inhibitory activity against AII-Induced Pressor response at 1 mg/Kg at 6 hour	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds.
AID183742	Inhibitory activity against AII-Induced Pressor response at 0.3 mg/Kg at 1 hr	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds.
AID183745	Inhibitory activity against AII-Induced Pressor response at 0.3 mg/Kg at 6 hour	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds.
AID1211549	Unbound fraction in Sprague-Dawley rat plasma at 100 uM by equilibrium dialysis method	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
AID1217729	Intrinsic clearance for reactive metabolites formation assessed as summation of [3H]GSH adduct formation rate-based reactive metabolites formation and cytochrome P450 (unknown origin) inactivation rate-based reactive metabolites formation	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID678712	Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID568885	Antagonist activity at angiotensin AT1 receptor in guinea pig aorta assessed as reduction of angiotensin 2-induced contractile response	2010	Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24	Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
AID1211554	Biliary excretion index in sandwich cultured Sprague-Dawley rat hepatocytes after 15 mins by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
AID1737435	Agonist activity at human PPARgammaDEF receptor expressed in african green monkey COS7 cells transfected with pGal5-TK-pGL3/pRenilla-CMV assessed as intrinsic activity measured after 39 hrs by dual luciferase reporter assay	2020	European journal of medicinal chemistry, Jun-01, Volume: 195	Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.
AID1217704	Time dependent inhibition of CYP1A2 (unknown origin) at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID680780	TP_TRANSPORTER: transport in hCMV cells	2006	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 34, Issue:5	OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker.
AID1217707	Time dependent inhibition of CYP2C19 in human liver microsomes at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID182953	In vivo inhibitory activity against angiotensin II induced pressor response in anesthetized normotensive rats	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds.
AID1217728	Intrinsic clearance for reactive metabolites formation per mg of protein based on cytochrome P450 (unknown origin) inactivation rate by TDI assay	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1737443	Cytotoxicity against human HS5 cells assessed as cell death at 10 uM measured after 72 hrs by Propidium iodide stain based FACS analysis	2020	European journal of medicinal chemistry, Jun-01, Volume: 195	Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.
AID678713	Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID183743	Inhibitory activity against AII-Induced Pressor response at 0.3 mg/Kg at 3 hour	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds.
AID680781	TP_TRANSPORTER: transport in MRP2-expressing vesicles	2006	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 34, Issue:5	OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker.
AID1217727	Intrinsic clearance for reactive metabolites formation per mg of protein in human liver microsomes based on [3H]GSH adduct formation rate at 100 uM by [3H]GSH trapping assay	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID588962	Substrates of transporters of clinical importance in the absorption and disposition of drugs, OATP1B1	2010	Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3	Membrane transporters in drug development.
AID679052	TP_TRANSPORTER: biliary excretion in EHBR rat	2006	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 34, Issue:5	OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker.
AID1211551	Drug uptake in sandwich cultured Sprague-Dawley rat hepatocytes by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
AID588963	Substrates of transporters of clinical importance in the absorption and disposition of drugs, OATP1B3	2010	Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3	Membrane transporters in drug development.
AID679564	TP_TRANSPORTER: transport in NTCP-transfected HEK-293 cells	2006	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 34, Issue:5	OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker.
AID183746	Inhibitory activity against AII-Induced Pressor response at 1 mg/Kg at 1 hr	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds.
AID1217708	Time dependent inhibition of CYP2D6 (unknown origin) at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID678717	Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID39641	In vitro for inhibition of [125I]-angiotensin II (0.1 nM) binding to angiotensin II receptor type 1 in membrane fractions of bovine adrenal cortex	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds.
AID1282228	Displacement of 125I-[Sar1, Ile8] AngII from rat AT1 receptor expressed in COS1 cells	2016	Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3	Tactical Approaches to Interconverting GPCR Agonists and Antagonists.
AID1211552	In vitro intrinsic biliary clearance in sandwich cultured Sprague-Dawley rat hepatocytes by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
AID311524	Oral bioavailability in human	2007	Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24	Hologram QSAR model for the prediction of human oral bioavailability.
AID680212	TP_TRANSPORTER: transport in OATP1B3-expressing oocytes	2006	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 34, Issue:5	OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker.
AID183747	Inhibitory activity against AII-Induced Pressor response at 1 mg/Kg at 3 hour	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds.
AID568884	Displacement of radiolabeled angiotensin 2 from angiotensin AT1 receptor in bovine adrenal cortex membranes	2010	Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24	Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
AID1737437	Cytotoxicity against African green monkey COS7 cells assessed as effect on metabolic activity at 20 uM measured after 72 hrs by MTT assay	2020	European journal of medicinal chemistry, Jun-01, Volume: 195	Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.
AID1692279	Binding affinity to recombinant GP6 (unknown origin) at protein to compound ratio of 1 : 1 to 1 : 10 by 2D 15N-1H TROSY-HSQC NMR spectroscopy	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Progress toward a Glycoprotein VI Modulator for the Treatment of Thrombosis.
AID588210	Human drug-induced liver injury (DILI) modelling dataset from Ekins et al	2010	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12	A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID588977	Substrates of transporters of clinical importance in the absorption and disposition of drugs, MRP2	2010	Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3	Membrane transporters in drug development.
AID678722	Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1217709	Time dependent inhibition of CYP3A4 (unknown origin) at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1211553	Drug uptake in iv dosed Sprague-Dawley rat liver after 5 hrs by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
AID1210069	Inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation by LC-MS/MS method	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
AID1737434	Agonist activity at human PPARgammaDEF receptor expressed in african green monkey COS7 cells transfected with pGal5-TK-pGL3/pRenilla-CMV assessed as maximal activation at 10 uM measured after 39 hrs by dual luciferase reporter assay relative to pioglitazo	2020	European journal of medicinal chemistry, Jun-01, Volume: 195	Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.
AID1217710	Covalent binding in human liver microsomes measured per mg of protein using radiolabelled compound at 10 uM after 1 hr incubation by liquid scintillation counting	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID678716	Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1217706	Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID678714	Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1737436	Cytotoxicity against African green monkey COS7 cells assessed as effect on metabolic activity at 10 uM measured after 72 hrs by MTT assay	2020	European journal of medicinal chemistry, Jun-01, Volume: 195	Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.
AID1211550	In vivo intrinsic biliary clearance in iv dosed Sprague-Dawley rat by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
AID1745854	NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745855	NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	1 (0.12)	18.2507
2000's	187 (23.29)	29.6817
2010's	532 (66.25)	24.3611
2020's	83 (10.34)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	185 (22.00%)	5.53%
Reviews	64 (7.61%)	6.00%
Case Studies	99 (11.77%)	4.05%
Observational	23 (2.73%)	0.25%
Other	470 (55.89%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (133)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized, Double Blind Study To Compare The Effects Of Olmesartan Medoxomil Versus Placebo In Patients With Established Atherosclerosis [NCT00382213]	Phase 3	210 participants	Interventional	2000-06-30	Completed
Prospective, Multicentric, Large Scale Observational Study to Evaluate the Effectiveness & Safety of Xirtam H in Indian Patients Suffering From Hypertension. [NCT01219556]		8,704 participants (Actual)	Observational	2010-11-30	Completed
Phase IV Study for Effect of Intensive Blood-Pressure Control Using Anti-hypertensive Agents in Essential Hypertension With History of Stroke [NCT01198496]	Phase 4	5,000 participants (Anticipated)	Interventional	2010-10-31	Recruiting
Efficacy of Sevikar® Compared to the Combination of Perindopril/ Amlodipine on Central Arterial Blood Pressure in Patients With Moderate to Severe Hypertension- [NCT01101009]	Phase 4	486 participants (Actual)	Interventional	2010-04-30	Completed
Single Dose Crossover Comparative Bioavailability Study of Olmesartan Medoxomil 40 mg Film-coated Tablets in Healthy Adult Subjects Under Fasting Conditions. [NCT03951051]	Phase 1	32 participants (Actual)	Interventional	2019-05-06	Completed
A Phase 3, Double-Blind, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential Hypertension [NCT02407210]	Phase 3	304 participants (Anticipated)	Interventional	2015-01-31	Recruiting
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Zilebesiran Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication [NCT05103332]	Phase 2	672 participants (Actual)	Interventional	2021-11-05	Active, not recruiting
Olmesartan Versus Nebivolol in Management of Hypertension in Acute Ischemic Stroke [NCT03655964]	Phase 2	60 participants (Actual)	Interventional	2018-08-20	Completed
Efficacy Study of Olmesartan Medoxomil on Coronary Atherosclerosis Progression and Epicardial Adipose Tissue(EAT) Volume Reduction in Patients With Coronary Atherosclerosis Detected by Coronary CT Angiography(CCTA) [NCT02360956]	Phase 4	100 participants (Anticipated)	Interventional	2014-12-31	Recruiting
An Open-label, Randomized, 2X2 Crossover Study to Compare the Pharmacokinetics and Safety Between DWJ1351 and Co-administration of Amlodipine/Olmesartan and Rosuvastatin in Healthy Male Subjects [NCT03753477]	Phase 1	64 participants (Actual)	Interventional	2017-12-22	Completed
A Multi-center, Randomized, Double-blind, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Olmesartan/Amlodipine/Rosuvastatin Combination Treatment in Patients With Concomitant Hypertension and Hyperlipidemia [NCT03009487]	Phase 3	265 participants (Actual)	Interventional	2017-01-31	Completed
A Multi-center, Prospective, Observational Study to Evaluate the Therapeutic Effectiveness and Safety of Olomax Tab. for Patients With Hypertension and Dyslipidemia [NCT05184179]		7,000 participants (Anticipated)	Observational	2019-12-01	Enrolling by invitation
Use of Impedance Cardiography and Applanation Tonometry for Prediction of the Antihypertensive Effect. Comparison Between an ATII Receptor Antagonist and a Diuretic. [NCT03560804]		60 participants (Actual)	Interventional	2014-11-10	Completed
A Prospective, Open Label, Single Arm Study to Evaluate the Safety and Efficacy of an Olmesartan Medoxomil Based Treatment Regimen in Type II Diabetic Patients With Hypertension [NCT00403481]	Phase 4	192 participants (Actual)	Interventional	2006-11-30	Completed
ACCESS STUDY (Angiotensin Receptor Blocker Combined With Calcium Antagonist Evaluation of Safety and Lowering of Systolic Blood Pressure Study) ARB/CCB Combination Therapy: Efficacy vs an ACE-inhibitor/CCB Combination and Use as First Line Therapy. [NCT01089452]	Phase 4	0 participants (Actual)	Interventional		Withdrawn(stopped due to Study not started due to administrative reasons.)
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Study Comparing the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs Benicar HCT® (Olmesartan Medoxomil-Hydrochlorothiazide) in Subjects With Moderate to Severe Essential Hypertension [NCT00846365]	Phase 3	1,085 participants (Actual)	Interventional	2009-03-31	Completed
A Randomized, Double-blind, Active Control, 3-parallel Group, Forced Titration, Multicenter, Phase IV Study to Evaluate the Efficacy and Safety of Fimasartan Versus Valsartan Monotherapy in Patients With Mild to Moderate Essential Hypertension [NCT02495324]	Phase 4	369 participants (Actual)	Interventional	2015-06-30	Completed
An Open Label, Randomized, 2-Period, 2-Treatment,2-Sequence, Crossover, Single-Dose BE of Olmesartan Medoxomil Tablets 40 mg [Torrent,India] Versus Benicar 40 mg Tablets [Daiichi Sankyo Inc., USA] in Healthy Subjects-Fed Condition. [NCT03319706]	Phase 1	34 participants (Actual)	Interventional	2010-08-31	Completed
Phase 4 Study on Olmesartan, an Angiotensin Receptor Blocker, on Ambulatory Blood Pressure Change, Vitamin D Levels and Urinary Sodium Excretion of Patients With Hypertension [NCT00854763]		100 participants (Anticipated)	Observational	2009-04-30	Not yet recruiting
Efficacy and Safety of Hydrochlorothiazide (HCTZ) Used as Add-on Therapy in Moderately to Severely Hypertensive Patients Not Adequately Controlled by Olmesartan Medoxomil (OM) 40 mg Monotherapy [NCT00430508]	Phase 3	972 participants (Actual)	Interventional	2007-02-28	Completed
Comparison of the Efficacy of Olmesartan Medoxomil Versus Nitrendipine on Systolic Blood Pressure in Elderly and Very Elderly Patients With Isolated Systolic Hypertension [NCT00751829]	Phase 3	417 participants (Actual)	Interventional	2003-07-31	Completed
Add-on Study of CCBs or Diuretics in Essential Hypertension Not Achieving Target Blood Pressure on Olmesartan Medoxomil Alone [NCT00858702]	Phase 4	105 participants (Actual)	Interventional	2005-02-28	Completed
Efficacy and Safety of Olmesartan Medoxomil/Hydrochlorothiazide Combination 20/25 mg Versus 40/25 mg in Moderately to Severely Hypertensive Patients Not Adequately Controlled by Olmesartan Medoxomil 40 mg Monotherapy [NCT00430950]	Phase 3	1,011 participants (Actual)	Interventional	2007-02-28	Completed
A Prospective, Open Label, Single Arm Study to Evaluation the Safety and Efficacy of an Olmesartan Medoxomil Based Treatment Regimen in Elderly Patients With Hypertension [NCT00412932]	Phase 4	178 participants (Actual)	Interventional	2006-12-31	Completed
Effects of Angiotensin-Receptor Blockade With Olmesartan on Carotid Atherosclerosis in Patients With Hypertension: The Confirmatory Olmesartan Plaque Regression Study [NCT01132768]	Phase 4	114 participants (Actual)	Interventional	2010-05-31	Terminated(stopped due to Low recruitment)
A Post Marketing Surveillance, Multicenter, Open-Label, Dose-Titrating, 4-Week Study Evaluating The Efficacy, Tolerability And Safety Of Olmesartan Medoxomil 20mg In Combination With 12.5mg Hydrochlorothiazide In Subjects With Stage 1 To Stage 2 Hypertens [NCT00796159]		1,723 participants (Actual)	Observational	2007-07-31	Completed
A TElmisartan and AMlodipine STudy to Assess the Cardiovascular PROTECTive Effects as Measured by Endothelial Dysfunction in Hypertensive at Risk Patients Beyond Blood Pressure [NCT01180205]	Phase 4	576 participants (Anticipated)	Interventional	2010-08-31	Active, not recruiting
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-491 in Subjects With Essential Hypertension [NCT00696241]	Phase 3	1,275 participants (Actual)	Interventional	2007-06-30	Completed
A Phase 3, Open-Label, Randomized, Long-Term Comparison of the Safety and Tolerability of the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs. Olmesartan Medoxomil-Hydrochlorothiazide Fixed-Dose Combination in Subjects With Essential Hypertension [NCT00996281]	Phase 3	837 participants (Actual)	Interventional	2009-10-31	Completed
Effect of Olmesartan Medoxomil on Arterial Stiffness and Thickness in Subjects With Metabolic Syndrome [NCT00676845]	Phase 3	133 participants (Actual)	Interventional	2008-08-31	Completed
A Prospective, Open-label, Ambulatory Blood Pressure Monitoring (ABPM) Dose Titration Study to Evaluate the Safety and Efficacy of an Olmesartan Medoxomil and Amlodipine Based Treatment Regimen in Hypertensive, Type 2 Diabetic Subjects [NCT00654745]	Phase 4	207 participants (Actual)	Interventional	2008-05-31	Completed
Reduction Efficacy of OLOMAX for Blood Pressure and Low-density Lipoprotein Cholesterol in Hypertensive Patients With Dyslipidemia: a Multi-center-database Real-world Study [NCT05660135]		4,000 participants (Anticipated)	Observational	2022-06-20	Recruiting
A Non-interventional, Multi Center, Prospective Observational Study to Evaluate the Effect of Improving Systolic Blood Pressure and Low-density Lipoprotein Cholesterol Compared to Conventional Treatments and the Convenience of Taking Medication of Olostar [NCT05411887]		3,000 participants (Anticipated)	Observational	2022-06-20	Recruiting
Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease [NCT04394117]	Phase 4	787 participants (Actual)	Interventional	2020-06-19	Completed
An Open Label, Randomized, 2-Sequence, Multiple-Dose, Cross-Over Study to Investigate the Drug-Drug Interaction of Sevikar and Crestor in Healthy Adult Volunteers [NCT02089399]	Phase 1	32 participants (Actual)	Interventional	2014-05-31	Completed
Comparison of the Efficacy of Olmesartan Medoxomil Versus Losartan on Diastolic Blood Pressure in Elderly and Very Elderly Patients With Essential Hypertension. [NCT00751751]	Phase 3	441 participants (Actual)	Interventional	2003-06-30	Completed
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study of the Efficacy, Safety, and Tolerability of TAK-536 in Patients With Mild to Moderate Uncomplicated Essential Hypertension [NCT00759551]	Phase 2	555 participants (Actual)	Interventional	2004-08-31	Completed
Vascular Improvement With Olmesartan Medoxomil Study [NCT00772499]	Phase 4	100 participants (Actual)	Interventional	2002-11-30	Completed
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia [NCT02735707]	Phase 3	10,000 participants (Anticipated)	Interventional	2016-04-11	Recruiting
CS-866DM Phase 3 Clinical Study: A Double-Blind Controlled Trial in Patients With Diabetic Nephropathy and Overt Proteinuria Secondary to Type 2 Diabetes Mellitus [NCT00141453]	Phase 3	577 participants (Actual)	Interventional	2003-04-30	Completed
Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans [NCT04467931]		22,213 participants (Actual)	Observational	2020-01-19	Completed
Single-Dose Fed In Vivo Bioequivalence Study of Olmesartan Medoxomil Tablets (40 mg; Mylan) to Benicar® Tablets (40 mg; Sankyo) in Healthy Volunteers [NCT00648219]	Phase 1	36 participants (Actual)	Interventional	2005-12-31	Completed
Single-Dose Fasting In Vivo Bioequivalence Study of Olmesartan Medoxomil Tablets (40 mg; Mylan) to Benicar® Tablets (40 mg; Sankyo) in Healthy Volunteers [NCT00649623]	Phase 1	36 participants (Actual)	Interventional	2005-12-31	Completed
A Randomized, Open-label, Single-Dose, 2-Way Cross-over Study To Compare the Safety and Pharmacokinetic Characteristics of Combination of Amlodipine, Olmesartan and Rosuvastatin and DWJ1351 in Healthy Male Volunteers [NCT02665832]	Phase 1	58 participants (Anticipated)	Interventional	2016-01-31	Not yet recruiting
A Randomized, Double-blind, Double-dummy, Multi-center Study to Investigate the Safety and Efficacy of Olmesartan Medoxomil Compared With Losartan Potassium in Patients With Mild to Moderate Essential Hypertension [NCT00856271]	Phase 3	287 participants (Actual)	Interventional	2004-08-31	Completed
A Prospective, Open-label Study to Assess the Efficacy and Safety of an Olmesartan and Amlodipine Based Treatment Regimen in Subjects With Stage 1 and Stage 2 Hypertension [NCT00527514]	Phase 3	185 participants (Actual)	Interventional	2007-09-30	Completed
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Dose-Ranging Study of the Efficacy, Safety and Tolerability of TAK-491 in Subjects With Mild to Moderate Uncomplicated Essential Hypertension [NCT00362115]	Phase 2	449 participants (Actual)	Interventional	2006-05-31	Completed
A Double-Blind, Randomized, Placebo-Controlled, 5-Arm Titration Study to Evaluate the Efficacy and Safety of TAK-491 When Compared With Valsartan and Olmesartan in Subjects With Essential Hypertension [NCT00696436]	Phase 3	1,291 participants (Actual)	Interventional	2008-04-30	Completed
A 24-Week Multicentre, Randomized, Double-Blind, Controlled, Parallel Group Non-Inferiority Study to Assess the Efficacy and Safety of Olmesartan Medoxomil Versus Candesartan Cilexetil in Patients With Symptomatic Heart Failure (NYHA II-IV) [NCT00679484]	Phase 3	400 participants (Anticipated)	Interventional	2008-06-30	Terminated(stopped due to Lack of subject recruitment)
Effects of Mineralocorticoid and AT-1 Receptor Antagonism on the Aldosterone-Renin Ratio (ARR) In Primary Aldosteronism Patients (EMIRA Study): Rationale and Design [NCT04185857]		50 participants (Actual)	Observational	2018-01-01	Completed
A Prospective, Open-Label, Titration Study to Evaluate the Efficacy and Safety Safety of AZOR in Multiple Subgroups of Hypertensive Subjects Who Are Non-Responders to Anti-Hypertensive Monotherapy [NCT00791258]	Phase 4	999 participants (Actual)	Interventional	2008-11-30	Completed
A Multi-center, Randomized, Double-blind, Double-dummy, With Olmesartan Medoxomil as Positive Control Parallel Clinical Study to Evaluate the the Safety and Efficacy of Azilsartan in Chinese Patients With Primary Mild and Moderate Hypertension [NCT02609490]	Phase 3	304 participants (Actual)	Interventional	2015-09-30	Completed
Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment [NCT00741585]	Phase 4	21,983 participants (Actual)	Interventional	2008-09-01	Completed
A Phase 3b, Double-Blind, Randomized, 12-Week Efficacy and Safety Study Comparing the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs Olmesartan Medoxomil-Hydrochlorothiazide in Subjects With Moderate to Severe Hypertension [NCT01033071]	Phase 3	1,071 participants (Actual)	Interventional	2010-01-31	Completed
AN OPEN LABEL, NON-INTERVENTIONAL STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF AMLODIPINE AND OLMESARTAN MEDOXOMIL (NORMETECTM) IN FILIPINO PATIENTS WITH HYPERTENSION: A POST MARKETING SURVEILLANCE STUDY [NCT01200407]		615 participants (Actual)	Observational	2010-06-09	Terminated(stopped due to The requirement for Post Marketing Surveillance was lifted by the Philippine FDA)
A Multi-center, Randomized, Double-Blind, Phase III Clinical Trial to Evaluate the Efficacy and Safety of DWJ1451 in Patients With Hypertension and Dyslipidemia [NCT04161001]	Phase 3	237 participants (Anticipated)	Interventional	2019-11-20	Recruiting
A Randomized, Double-Blind, Parallel Group Study Evaluating the Efficacy and Safety of Co-Administration of a Triple Combination Therapy of Olmesartan Medoxomil, Amlodipine Besylate and Hydrochlorothiazide in Subjects With Hypertension [NCT00649389]	Phase 3	2,500 participants (Actual)	Interventional	2008-05-31	Completed
Randomised, Double-Blind, Parallel-Group Study Evaluating Efficacy and Safety of Co-Administration of Triple Combinations of Olmesartan Medoxomil, Amlodipine Besylate, and Hydrochlorothiazide Compared With Corresponding Olmesartan - Amlodipine Combination [NCT00923091]	Phase 3	2,689 participants (Actual)	Interventional	2009-06-30	Completed
Effect of Olmesartan Medoxomil on Vascular Markers in Hypertensive Patients With Metabolic Syndrome [NCT00891267]	Phase 3	60 participants (Anticipated)	Interventional	2008-10-31	Completed
Single-Dose Fed Bioequivalence Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets (40 mg/25 mg; Mylan) to Benicar HCT® Tablets (40 mg/25 mg; Sankyo) in Healthy Volunteers [NCT01019590]	Phase 1	36 participants (Actual)	Interventional	2006-11-30	Completed
Single-Dose Fasting Bioequivalence Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets (40 mg/25 mg; Mylan) to Benicar HCT® Tablets (40 mg/25 mg; Sankyo) in Healthy Volunteers [NCT01020214]	Phase 1	36 participants (Actual)	Interventional	2006-11-30	Completed
A Randomized, Double-blind, Active-comparator, 8-week Forced-titration Study of the Efficacy and Safety of Olmesartan Medoxomil Versus Losartan Potassium in Hypertensive Subjects [NCT00949884]	Phase 4	941 participants (Actual)	Interventional	2009-08-31	Completed
Single Dose Crossover Comparative Bioavailability Study of Olmesartan Medoxomil/Hydrochlorothiazide 40 mg/25 mg Film-Coated Tablets in Healthy Adult Subjects / Fasting State [NCT04138888]	Phase 1	32 participants (Anticipated)	Interventional	2019-10-31	Recruiting
An Exploratory Study of CS-3150 to Evaluate the Relation Between Antihypertensive Effect and Baseline Factors Compared to Olmesartan Medoxomil in Patients With Essential Hypertension [NCT02848170]		40 participants (Actual)	Interventional	2016-08-31	Completed
Add-on Study of Hydrochlorothiazide in Patients With Moderate to Severe Hypertension Not Achieving Target Blood Pressure on Olmesartan/Amlodipine Alone [NCT00902538]	Phase 3	2,204 participants (Actual)	Interventional	2009-04-30	Completed
An Open-label, Multicenter Study to Evaluate the Efficacy and Tolerability of a 4 Week Therapy With the Fixed Dose Combination of Amlodipine 10 mg Plus Valsartan 160 mg in Hypertensive Patients Not Adequately Responding to a 4 Week Therapy With the Free C [NCT00523744]	Phase 3	257 participants (Actual)	Interventional	2007-07-31	Completed
Treat-to-Target Study of Olmesartan Medoxomil and an Add-on Treatment Algorithm Consisting of Hydrochlorothiazide and Amlodipine Besylate in Patients With Mild to Moderate Hypertension [NCT00311155]	Phase 4	694 participants (Actual)	Interventional	2006-03-31	Completed
A Clinical Trial of Renin Profiling in Selection of Initial Antihypertensive Drug [NCT00834600]		185 participants (Actual)	Interventional	2005-12-31	Completed
Phase III Study of Irbersartan for the Early Treatment of Severe Sepsis Patients [NCT01992796]	Phase 3	300 participants (Anticipated)	Interventional	2014-01-31	Not yet recruiting
Efficacy and Safety of Olmesartan Medoxomil Compared With Losartan in Patients With Hypertension and Mild to Moderate Renal Impairment [NCT00151827]	Phase 3	393 participants (Actual)	Interventional	2003-08-31	Completed
A Randomized, Double-blind, Double-dummy, Multicenter Clinical Trial to Evaluate the Additional Efficacy and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential Hypertension [NCT00872586]	Phase 3	304 participants (Actual)	Interventional	2006-08-31	Completed
Prospective, Multicentric, Open Clinic Essay to Evaluate the Use of OLMETEC® (Olmesartan Medoxomile) and OLMETEC PLUS® (Olmesartan Medoxomile Hydrochlorothiazide) in Stade I and II, According to JNC VII [NCT00811226]		450 participants (Anticipated)	Observational	2007-04-30	Completed
Comparison of the Effects of Different Antihypertensive Drugs in Patients With Hypertension and Obstructive Sleep Apnea [NCT01028534]		150 participants (Anticipated)	Interventional	2010-07-31	Completed
A Double-Blind, Randomized, Placebo Controlled, Parallel Group Study to Compare the Safety and Efficacy of an Olmesartan Medoxomil Based Treatment Regimen to Placebo in Patients With Stage I and Stage II Hypertension [NCT00430638]	Phase 4	278 participants (Actual)	Interventional	2006-12-31	Completed
Evaluation of Vascular Function, Effects of Exercise Training and Angiotensin Receptor II Antagonist in Patients With Type II Diabetes and Hypertension by Using Near-infrared Spectroscopy, Rapid Laser Doppler Blood Flow Imaging and Circulating Biomarkers [NCT01053026]		15 participants (Actual)	Observational	2009-12-31	Completed
Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection? [NCT04606563]	Phase 3	341 participants (Actual)	Interventional	2020-10-09	Terminated(stopped due to DSMC recommendation due to futility)
Effect of Probenecid on Pharmacokinetics, and Tolerability of Olmesartan in Healthy Chinese Volunteers [NCT01907373]	Phase 4	12 participants (Actual)	Interventional	2009-08-31	Completed
Open-label, Randomized, Single Center, Paralleled Clinical Study to Evaluate Adherence Improvement Fixed-dose Combination of Olostar Tab. in Patients With Hypertension and Dyslipidemia [NCT04061824]	Phase 4	150 participants (Actual)	Interventional	2016-05-24	Completed
The Japan-Combined Treatment With Olmesartan and a Calcium Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study (J-CORE) [NCT00607035]	Phase 4	220 participants (Actual)	Interventional	2006-05-31	Completed
The Relative Effects of Single Doses of Olmesartan Medoxomil, Irbesartan and Valsartan at High Dosage Levels on the Renin-Angiotensin-Aldosterone System in Healthy Normal Subjects [NCT00185055]	Phase 4	20 participants	Interventional	2004-11-30	Completed
The Effects of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on Insulin Sensitivity in Overweight and Obese Subjects With Hypertension [NCT00185094]	Phase 4	60 participants	Interventional	2004-02-29	Completed
A Randomized, Double-blind, Placebo-controlled Factorial Study Evaluating the Efficacy and Safety of Co-administration of Olmesartan Medoxomil Plus Amlodipine Compared to Monotherapy in Patients With Mild to Severe Hypertension [NCT00185133]	Phase 3	1,900 participants	Interventional	2005-05-31	Completed
An Open-label Study of Olmesartan Medoxomil (CS-866) in Normotensive Patients With Chronic Glomerulonephritis or Diabetic Nephropathy [NCT00914524]	Phase 2	49 participants (Actual)	Interventional	2005-01-31	Completed
A Study on the Efficacy and Safety of Olmesartan Medoxomil and Its Combination With Hydrochlorothiazide Compared With an ACE Inhibitor and Its Combination With a Calcium Channel Blocker in Patients With Stage 2 Hypertension [NCT00185120]	Phase 4	152 participants	Interventional	2005-09-30	Completed
Randomized Olmesartan and Diabetes Microalbuminuria Prevention Study (ROADMAP) [NCT00185159]	Phase 3	4,449 participants (Actual)	Interventional	2004-10-31	Completed
Add-on Study of Olmesartan Medoxomil in Patients With Moderate to Severe Hypertension Not Achieving Target Blood Pressure on Amlodipine 5 mg Alone [NCT00220233]	Phase 3	632 participants	Interventional	2005-04-30	Completed
Combination of OLMesartan and Calcium Channel Blocker or Low Dose Diuretics in High Risk Elderly Hypertensive Patients Study (COLM-Study) [NCT00454662]	Phase 4	5,141 participants (Actual)	Interventional	2007-04-30	Completed
Multi-Omics to Predict the Blood Pressure Response to Antihypertensives [NCT05917275]	Phase 4	96 participants (Anticipated)	Interventional	2023-10-31	Not yet recruiting
[NCT01831479]	Phase 1	36 participants (Actual)	Interventional	2011-08-31	Completed
Efficacy of Olmesartan on Cerebral Glucose Metabolism, Vascular Inflammation and Adipose Tissue [NCT02996916]	Phase 4	100 participants (Anticipated)	Interventional	2015-12-31	Recruiting
An Open Label, Randomized, 2-Period, 2-Treatment,2-Sequence, Crossover, Single-Dose BE of FDC of Olmesaartan Medoxomil, Amlopdipine and Hydrochlorothiazide (40+10+25) mg Tab [Torrent,India] Vs Tribenzor(40+10+25) mg Tab [ Daichi Sankyo, Inc USA] in Health [NCT02962336]	Phase 1	34 participants (Actual)	Interventional	2011-05-31	Completed
The Study Comparing the Incidence of Cardiovascular Events Between High-dose ARB Monotherapy and Combination Therapy With ARB and Calcium Channel Blocker in Japanese Elderly Hypertensive Patients at High Cardiovascular Risk [NCT00134160]	Phase 4	1,000 participants (Anticipated)	Interventional	2005-08-31	Completed
A Phase III, Multicenter, Open-Label, Dose-Titrating, 16-Week Study Evaluating The Efficacy, Tolerability and Safety of Olmesartan Medoxomil 20 Mg and 40 Mg Alone or in Combination With 12.5 Mg to 25 Mg of Hydrochlorothiazide in Subjects With Mild to Mode [NCT00139698]	Phase 3	410 participants	Interventional	2005-09-30	Completed
Efficacy and Safety of Olmesartan: Reduction of Blood Pressure in the Treatment of Patients Suffering From Mild to Moderate Essential Hypertension [NCT00185172]	Phase 3	2,333 participants (Actual)	Interventional	2002-01-31	Completed
Efficacy and Safety of Amlodipine Used as add-on Therapy in Moderately to Severely Hypertensive Patients Not Adequately Controlled by Olmesartan Medoxomil 20 mg Monotherapy [NCT00220220]	Phase 3	429 participants (Anticipated)	Interventional	2005-04-30	Completed
A Randomized, Open-Label, Phase 3 Study to Compare Long-Term Safety and Tolerability of the TAK-491 and Chlorthalidone Fixed-Dose Combination Versus Olmesartan Medoxomil and Hydrochlorothiazide Fixed-Dose Combination in Hypertensive Subjects With Moderate [NCT01309828]	Phase 3	153 participants (Actual)	Interventional	2011-03-31	Completed
Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation Trial (ANTIPAF Trial) [NCT00098137]	Phase 3	422 participants (Actual)	Interventional	2005-01-31	Completed
A Prospective, Open Label, Titration Study to Assess the Efficacy and Safety of Benicar® and Benicar ®HCT in Patients With Stage II Systolic Hypertension [NCT00185068]	Phase 4	110 participants	Interventional	2004-03-31	Completed
Multi-Centre Olmesartan Atherosclerosis Regression Evaluation (MORE) [NCT00185185]	Phase 3	165 participants (Actual)	Interventional	2001-11-30	Completed
Optimization of Blood Pressure Management After Acute Ischemic Stroke and Its Prognostic Significance: Prospective, Randomized, Open, Blinded Outcome Evaluation, and Feasibility Trial [NCT03024476]	Phase 2	67 participants (Actual)	Interventional	2016-09-01	Completed
Effect of Olmesartan or Amlodipine on Serum Angiotensin(1-7) Levels and Vascular Functions in Patients With Type 2 Diabetes and Hypertension [NCT05189015]	Phase 4	80 participants (Actual)	Interventional	2021-01-01	Completed
Supplemental Benefit of Angiotensin II Receptor Blocker in Hypertensive Patients With Stable Heart Failure Using Olmesartan (SUPPORT Trial) [NCT00417222]	Phase 3	1,145 participants (Actual)	Interventional	2006-11-30	Completed
Prognostic Value of Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of Chronotherapy in Relation to Risk (the MAPEC Study). [NCT00295542]	Phase 4	3,344 participants (Actual)	Interventional	2000-03-31	Completed
Randomized, Single-Blind, Multicenter, Phase III, Non-Inferiority Clinical Trial to Evaluate the Efficacy and Safety of the Fixed-dose Combination of Olmesartan + Indapamide When Compared to the Isolated Drugs in the Treatment of Hypertension. [NCT05110898]	Phase 3	400 participants (Anticipated)	Interventional	2022-08-01	Not yet recruiting
Multi-institutional, Randomized, Double-Blind, Placebo-Control, Factorial Design, 4-arms, 8 Week Administration, Phase 3 Clinical Study for Patients With Hypertension Associated With Dyslipidemia [NCT01764295]	Phase 3	150 participants (Anticipated)	Interventional	2012-09-30	Completed
Prospective Monitoring of Angiotensin Receptor Neprilysin Inhibitor in Older Adults With Heart Failure and Frailty [NCT04743063]		40,000 participants (Anticipated)	Observational	2021-01-14	Active, not recruiting
Angiotensin II Blockade and Adipose Tissue Inflammation in Obesity [NCT01684748]	Phase 4	20 participants (Actual)	Interventional	2009-02-28	Completed
National, Multicenter, Open-Label and Prospective Study Assessment of Efficacy and Safety in Stage 1 and 2 Essential Hypertension With Olmesartan Medoxomil Based Treatment Algorithm From Monotherapy to Association With Hydrochlorothiazide and Amlodipine B [NCT00890591]	Phase 4	144 participants (Actual)	Interventional	2006-08-31	Completed
"A Multi-center, Double Blind, Efficacy, and Safety Study of the Oral Angiotensin II Receptor Blocker Olmesartan Medoxomil Versus Losartan in Patients With Mild to Moderate Essential Hypertension" [NCT00857285]	Phase 3	130 participants (Actual)	Interventional	2002-05-31	Completed
Efficacy and Safety Evaluation of the New Association on Fixed Dose of Olmesartan Medoxomil + Chlorthalidone (40mg + 12.5mg and 40mg + 25mg) Compared With BENICAR HCT® in Hypertension Control [NCT02483936]	Phase 3	348 participants (Anticipated)	Interventional	2023-04-30	Not yet recruiting
The CORONAvirus Disease 2019 Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker InvestigatiON (CORONACION) Randomized Clinical Trial [NCT04330300]	Phase 4	2,414 participants (Anticipated)	Interventional	2020-04-30	Suspended(stopped due to Challenges with funding and very low incidence of COVID-19 at Irish study site)
An Open-label Study of the Single-dose Pharmacokinetics of Olmesartan Medoxomil in Pediatric Patients With Hypertension [NCT00151814]	Phase 1	24 participants (Actual)	Interventional	2005-09-30	Completed
A Multi-center, Randomized, Open-label, Active-controlled, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of OLOMAX Tab in Hypertension Patients With Low-Intermediate Risk for Cardiovascular Disease [NCT04120753]	Phase 4	106 participants (Actual)	Interventional	2019-08-26	Completed
CVD Risk and Prevention in Early Glucose Intolerance [NCT00122447]		84 participants (Actual)	Interventional	2005-05-31	Completed
Efficacy and Safety of a Sequential Therapy Change From Candesartan 32 mg to the Fixed Combination of Olmesartan 40 mg/Amlodipine 10 mg in Patients With Poorly Controlled Moderate Hypertension - an Open Phase IV Trial [NCT01611077]	Phase 4	88 participants (Actual)	Interventional	2012-01-31	Completed
Sevicontrol-1: Efficacy and Safety of a Fixed Combination of Olmesartan 40 mg / Amlodipine 10 mg in Patients With Insufficiently Controlled Hypertension Under Monotherapy With Candesartan 32 mg - an Open Phase IIIb Trial [NCT01613209]	Phase 3	83 participants (Actual)	Interventional	2011-12-31	Completed
A Randomized, Double-blind, Active-controlled, Parallel Group, 52-week Study to Evaluate the Effect of LCZ696 Compared to Olmesartan on Regional Aortic Stiffness in Subjects With Essential Hypertension [NCT01870739]	Phase 2	115 participants (Actual)	Interventional	2013-10-31	Completed
A 14 Week, Randomized, Double-blind, Multi-center, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension [NCT01615198]	Phase 3	588 participants (Actual)	Interventional	2012-08-31	Completed
Effect of Different Doses of Olmesartan Medoxomil Compared to Losartan on Proteinuria, Renal Function and Inflammatory Markers in Type 2 Diabetics With Nephropathy [NCT00362960]	Phase 3	300 participants	Interventional	2003-05-31	Completed
[NCT02373462]	Phase 4	1 participants (Actual)	Interventional	2015-08-25	Terminated(stopped due to The data of the paper referenced in the preparation of the protocols in this task were manipulated and the paper was withdrawn.)
Single-center, Randomized, Open-label, Parallel-group Study to Characterize Renin-angiotensin-system (RAS) Peptide Profiles Before and After Treatment Initiation With Different Antihypertensive Drug-classes in Patients With Treatment-naive Arterial Hypert [NCT02449811]		107 participants (Actual)	Observational	2015-04-30	Completed
Lowering Blood Pressure in Primary Care in Vienna [NCT02377661]	Phase 4	229 participants (Actual)	Interventional	2015-03-31	Completed
Dose-ranging Study to Evaluate the Safety and Efficacy of Olmesartan Medoxomil in Children and Adolescents With Hypertension [NCT00151775]	Phase 2/Phase 3	362 participants (Actual)	Interventional	2005-05-31	Completed
A Multi-center, Randomized, Double-blind, Active-controlled, 8-week Study to Evaluate the Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Patients With Essential Hypertension [NCT01785472]	Phase 3	1,438 participants (Actual)	Interventional	2013-04-30	Completed
Efficacy and Safety Evaluation of the New Association on Fixed Dose of Olmesartan + Chlorthalidone, Produced by EMS S.A,in Arterial Hypertension Control [NCT02493322]	Phase 3	261 participants (Anticipated)	Interventional	2023-04-30	Not yet recruiting
Changes in Central Aortic Pressure, Endothelial Function and Biomarkers in African Americans With Cardiometabolic Syndrome: Comparison of Amlodipine/Olmesartan Versus Hydrochlorothiazide/Losartan [NCT01271374]	Phase 4	80 participants (Anticipated)	Interventional	2010-04-30	Active, not recruiting
A Randomized, Double-blind 52-week Study to Evaluate the Safety and Efficacy of an LCZ696 Regimen Compared to an Olmesartan Regimen on Arterial Stiffness Through Assessment of Central Blood Pressure in Elderly Patients With Hypertension [NCT01692301]	Phase 2	454 participants (Actual)	Interventional	2012-12-31	Completed
A Two-arm, Open-label, Single-sequence, Multiple Oral Dosings, Cross-over Design Clinical Trial to Evaluate the Safety and Pharmacokinetic Interaction of ATB-1011 and ATB-1012 in Healthy Adult Volunteers [NCT04856969]	Phase 1	38 participants (Actual)	Interventional	2021-03-30	Completed
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan [NCT01876368]	Phase 3	376 participants (Actual)	Interventional	2013-09-30	Completed
The Effect of Rosuvastatin and Olmesartan on the Progression of Coronary Atherosclerotic Disease by Smart Angioplasty Research Team: SMART-ROAD Trial [NCT02516826]	Phase 2	504 participants (Anticipated)	Interventional	2015-08-31	Not yet recruiting
An Open Label, Randomized, 2-Period, 2-Treatment,2-Sequence, Crossover, Single-Dose BE of Olmesartan Medoxomil Tablets 40 mg [Torrent,India] Versus Benicar 40 mg Tablets [Daiichi Sankyo Inc., USA] in Healthy Subjects-Fasted Condition [NCT03318354]	Phase 1	34 participants (Actual)	Interventional	2010-05-31	Completed
Efficacy and Safety of s086 Tablets in the Treatment of Mild to Moderate Essential Hypertension:a Randomized,Double-blind,Placebo-controlled,Multicenter Phase II Clinical Trial [NCT05033535]	Phase 2	10 participants (Anticipated)	Interventional	2020-07-01	Recruiting
A Multi-center, Randomized, Double-blind, Active-controlled, 8-week Study to Evaluate the Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension [NCT01599104]	Phase 3	1,161 participants (Actual)	Interventional	2012-06-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00122447 (2) [back to overview]	AIM 1: Change in hsCRP (High Sensitivity C-reactive Peptide) Level
NCT00122447 (2) [back to overview]	AIM 1: Change in Flow Mediated Dilation (FMD) (%)
NCT00141453 (4) [back to overview]	Number of Participants Experiencing Cardiovascular Composite Outcomes
NCT00141453 (4) [back to overview]	The Change in Proteinuria
NCT00141453 (4) [back to overview]	Renal Composite Outcomes
NCT00141453 (4) [back to overview]	Reciprocal (1/Serum Creatinine) of Serum Creatinine
NCT00151775 (6) [back to overview]	Mean Change From Period 3 Baseline in Seated Systolic and Diastolic Blood Pressure Measurements to the End of Period 3
NCT00151775 (6) [back to overview]	Mean Change From Baseline in Seated Systolic and Diastolic Blood Pressure Measurements to the End of Period 4 (End of Study)
NCT00151775 (6) [back to overview]	Mean Change From Period 3 Baseline in Seated Systolic and Diastolic Blood Pressure Measurements to the End of Period 3
NCT00151775 (6) [back to overview]	Mean Change From Baseline in Seated Systolic and Diastolic Blood Pressure Measurements to the End of Period 4 (End of Study)
NCT00151775 (6) [back to overview]	Mean Change From Baseline in Seated Systolic and Diastolic Blood Pressure Measurements to the End of Period 2 (3 Weeks)
NCT00151775 (6) [back to overview]	Least Squares Mean Change From Baseline in Seated Systolic Blood Pressure to the End of Period 2 (3 Weeks)
NCT00151814 (8) [back to overview]	For Olmesartan, the Apparent Oral Clearance
NCT00151814 (8) [back to overview]	For Olmesartan, the Maximum Plasma Concentration Over the Entire Sampling Phase
NCT00151814 (8) [back to overview]	For Olmesartan, Area Under the Concentration-time Curve From the Time of the Dose to Infinity
NCT00151814 (8) [back to overview]	For Olmesartan, the Elimination Half-life of the Drug in Plasma
NCT00151814 (8) [back to overview]	For Olmesartan, the Elimination Constant Rate
NCT00151814 (8) [back to overview]	For Olmesartan, the Area Under the Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC 0-t)
NCT00151814 (8) [back to overview]	For Olmesartan, the Apparent Oral Volume of Distribution
NCT00151814 (8) [back to overview]	Foe Olmesartan, the Time of Maximum Plasma Concentration
NCT00311155 (6) [back to overview]	The Percentage of Participants Treated to Target Blood Pressure Goals Overall and for Each Treatment Step From Baseline to Completion of Treatment During Which the Goal Was Achieved.
NCT00311155 (6) [back to overview]	Percentage of Participants Who Were Systolic Responders Overall and for Each Treatment From Baseline to the Completion of the Treatment During Which Blood Pressure Goals Were Achieved
NCT00311155 (6) [back to overview]	Percentage of Participants Who Were Diastolic Responders Overall and for Each Treatment From Baseline to the Completion of Treatment During Which Blood Pressure Goals Were Achieved.
NCT00311155 (6) [back to overview]	Percentage of Participants Who Achieved Normalized Blood Pressure Overall and for Each Treatment From Baseline to Completion of the Treatment During Which Blood Pressure Goals Were Achieved
NCT00311155 (6) [back to overview]	Mean Change in Systolic Blood Pressure Overall and for Each Treatment From Baseline to the Completion of the Treatment
NCT00311155 (6) [back to overview]	Mean Change in Diastolic Blood Pressure Overall and for Each Treatment From Baseline to the Completion of the Treatment
NCT00362115 (20) [back to overview]	Change From Baseline in the 24-36-Hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00362115 (20) [back to overview]	Change From Baseline in the 24-36-Hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00362115 (20) [back to overview]	Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00362115 (20) [back to overview]	Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00362115 (20) [back to overview]	Change From Baseline in the 10-12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00362115 (20) [back to overview]	Change From Baseline in Standing Clinic Systolic Blood Pressure.
NCT00362115 (20) [back to overview]	Change From Baseline in Standing Clinic Diastolic Blood Pressure.
NCT00362115 (20) [back to overview]	Change From Baseline in Sitting Clinic Systolic Blood Pressure.
NCT00362115 (20) [back to overview]	Change From Baseline in Sitting Clinic Diastolic Blood Pressure.
NCT00362115 (20) [back to overview]	Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00362115 (20) [back to overview]	Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00362115 (20) [back to overview]	Change From Baseline in 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00362115 (20) [back to overview]	Change From Baseline in 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00362115 (20) [back to overview]	Change From Baseline in the 10-12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00362115 (20) [back to overview]	Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00362115 (20) [back to overview]	Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00362115 (20) [back to overview]	Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00362115 (20) [back to overview]	Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00362115 (20) [back to overview]	Change From Baseline in the 34-36-Hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00362115 (20) [back to overview]	Change From Baseline in the 34-36-Hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00403481 (9) [back to overview]	Change From Baseline to Week 12 in Ambulatory BP Measurement (Systolic)During the Last 4 Hours of the Last (Week 12 ) 24-hour Dosing Period.
NCT00403481 (9) [back to overview]	Change From Baseline to Week 12 in Ambulatory BP Measurement (Systolic)During the Last 6 Hours of the Last (Week 12 ) 24-hour Dosing Period.
NCT00403481 (9) [back to overview]	Change From Baseline to Week 12 in Mean 24-hour Ambulatory BP (Diastolic)
NCT00403481 (9) [back to overview]	Change From Baseline to Week 12 in Systolic BP (SBP) as Measured by 24-hour ABPM.
NCT00403481 (9) [back to overview]	Change in Ambulatory Blood Pressure (Diastolic) From Baseline to Week 12 During the Last 2 Hours of the Last (Week 12 ) 24-hour Dosing Period.
NCT00403481 (9) [back to overview]	Change From Baseline to Week 12 in Mean Daytime and Nighttime Ambulatory Blood Pressure Measurement (Systolic).
NCT00403481 (9) [back to overview]	Change in Ambulatory BP (Diastolic) From Baseline to Week 12 During the Last (Week 12 ) 4 and 6 Hours of the Last 24-hour Dosing Period.
NCT00403481 (9) [back to overview]	Change in Daytime and Nighttime Ambulatory Blood Pressure (Diastolic) From Baseline to Week 12
NCT00403481 (9) [back to overview]	Change From Baseline to Week 12 in Ambulatory BP Measurement (Systolic)During the Last 2 Hours of the Last (Week 12) 24-hour Dosing Period.
NCT00412932 (7) [back to overview]	Change From Baseline in Mean Daytime (8am-4pm) and Mean Nighttime (10 Pm-6am) Ambulatory Blood Pressure Monitored Diastolic Blood Pressure After 12 Weeks of Active Treatment
NCT00412932 (7) [back to overview]	Change From Baseline in Mean Daytime (8am-4pm) and Mean Nighttime (10pm-6am)Ambulatory Systolic Blood Pressure After 12 Weeks of Active Treatment
NCT00412932 (7) [back to overview]	Number of Subjects Who Achieved Mean 24-hour Ambluatory Blood Pressure of <140/90 mm Hg, Systolic Blood Pressure <140 mm Hg, and Diastolic Blood Pressure <90 mm Hg After 12 Weeks of Active Treatment
NCT00412932 (7) [back to overview]	Number of Subjects Who Achieved Mean Daytime (8am - 4pm) Ambulatory Blood Pressure of <140/90 mm Hg, Systolic Blood Pressure <140 mm Hg, and Diastolic Blood Pressure <90 mm Hg After 12 Weeks of Active Treatment.
NCT00412932 (7) [back to overview]	Number of Subjects Who Achieved Mean Nighttime (10pm - 6am) Ambulatory Blood Pressure of <140/90 mm Hg, Systolic Blood Pressure <140 mm Hg, and Diastolic Blood Pressure <90 mm Hg After 12 Weeks of Active Treatment.
NCT00412932 (7) [back to overview]	Change From Baseline in Mean 24-hour Ambulatory Diastolic Blood Pressure After 12 Weeks of Active Treatment.
NCT00412932 (7) [back to overview]	Change From Baseline in Mean 24-hour Ambulatory Systolic Blood Pressure After 12 Weeks of Active Treatment
NCT00430508 (8) [back to overview]	Change in Mean 24-hour Ambulatory Blood Pressure Monitoring Diastolic Blood Pressure From Week 8(Baseline) to Week 16.
NCT00430508 (8) [back to overview]	Change in Mean Daytime Ambulatory Blood Pressure Monitoring Diastolic Blood Pressure From Week 8(Baseline) to Week 16.
NCT00430508 (8) [back to overview]	Change in Mean Night-time Ambulatory Blood Pressure Monitoring Diastolic Blood Pressure From Week 8(Baseline) to Week 16.
NCT00430508 (8) [back to overview]	Change in Mean Trough Sitting Diastolic Blood Pressure From Week 8(Baseline) to Week 12.
NCT00430508 (8) [back to overview]	Change in Mean Trough Sitting Systolic Blood Pressure From Week 8(Baseline) to Week 12.
NCT00430508 (8) [back to overview]	Change in Mean Trough Sitting Diastolic Blood Pressure From Week 8(Baseline) to Week 16
NCT00430508 (8) [back to overview]	Number of Patients Achieving Target Blood Pressure at Week 16
NCT00430508 (8) [back to overview]	Change in Mean Trough Sitting Systolic Blood Pressure From Week 8(Baseline) to Week 16.
NCT00430638 (10) [back to overview]	The Difference in the Change From Baseline to Week 12 in Seated Systolic and Diastolic Blood Pressure Between the Olmesartan Group and the Placebo Group for Non-Black Participants.
NCT00430638 (10) [back to overview]	The Difference in the Change From Baseline to Week 12 in Seated Systolic and Diastolic Blood Pressure Between the Olmesartan Group and the Placebo Group for Stage 2 Hypertensives
NCT00430638 (10) [back to overview]	The Difference in the Change From Baseline to Week 12 in Seated Systolic and Diastolic Blood Pressure Between the Olmesartan Group and the Placebo Group for Stage 1 Hypertensives
NCT00430638 (10) [back to overview]	The Difference in the Change From Baseline to Week 12 in Seated Systolic and Diastolic Blood Pressure Between the Olmesartan Group and the Placebo Group for Participants Less Than 65 Years Old.
NCT00430638 (10) [back to overview]	The Difference in the Change From Baseline to Week 12 in Seated Systolic and Diastolic Blood Pressure Between the Olmesartan Group and the Placebo Group for Participants Greater Than or Equal to 65 Years Old.
NCT00430638 (10) [back to overview]	The Difference in the Change From Baseline to Week 12 in Seated Systolic and Diastolic Blood Pressure Between the Olmesartan Group and the Placebo Group for Males.
NCT00430638 (10) [back to overview]	The Difference in the Change From Baseline to Week 12 in Seated Systolic and Diastolic Blood Pressure Between the Olmesartan Group and the Placebo Group for Females.
NCT00430638 (10) [back to overview]	The Difference in the Change From Baseline to Week 12 in Seated Systolic and Diastolic Blood Pressure Between the Olmesartan Group and the Placebo Group for Black Participants.
NCT00430638 (10) [back to overview]	Change From Baseline in Mean Systolic Blood Pressure (SBP) After 12 Weeks of Randomized Treatment as Measured by Omron Device.
NCT00430638 (10) [back to overview]	Change From Baseline in Mean Diastolic Blood Pressure (DBP) After 12 Weeks of Randomized Treatment as Measured by Omron Device.
NCT00430950 (5) [back to overview]	Change in Mean Trough Sitting Diastolic Blood Pressure From Week 8(Baseline) to Week 12
NCT00430950 (5) [back to overview]	Number of Participants Achieving Blood Pressure Goal.
NCT00430950 (5) [back to overview]	Change in Daytime, Nighttime and 24-hour Blood Pressure Evaluated by Ambulatory Blood Pressure Monitoring 8 Weeks After Baseline.
NCT00430950 (5) [back to overview]	Change in Sitting Systolic Blood Pressure 4 Weeks and 8 Weeks After Baseline.
NCT00430950 (5) [back to overview]	Change in Mean Trough Sitting Diastolic Blood Pressure
NCT00523744 (12) [back to overview]	Change in Mean Sitting Systolic Blood Pressure (msSBP) During the Core Phase of the Study
NCT00523744 (12) [back to overview]	Change in Mean Sitting Diastolic Blood Pressure (msDBP) During the Core Phase of the Study
NCT00523744 (12) [back to overview]	Change in Sitting Pulse Pressure During the Extension Phase of the Study
NCT00523744 (12) [back to overview]	Change in Mean Sitting Diastolic Blood Pressure (msDBP) During the Extension Phase of the Study
NCT00523744 (12) [back to overview]	Change in Mean Sitting Systolic Blood Pressure (msSBP) During the Extension Phase of the Study
NCT00523744 (12) [back to overview]	Change in Sitting Pulse Pressure During the Core Phase of the Study
NCT00523744 (12) [back to overview]	Change in Sitting Pulse Rate During the Core Phase of the Study
NCT00523744 (12) [back to overview]	Change in Sitting Pulse Rate During the Extension Phase of the Study
NCT00523744 (12) [back to overview]	Percentage of Patients Who Achieved a Protocol-defined Blood Pressure Response During the Core Phase of the Study
NCT00523744 (12) [back to overview]	Percentage of Patients Who Achieved a Protocol-defined Blood Pressure Response During the Extension Phase of the Study
NCT00523744 (12) [back to overview]	Percentage of Patients Who Achieved Normalized Blood Pressure During the Core Phase of the Study
NCT00523744 (12) [back to overview]	Percentage of Patients Who Achieved Normalized Blood Pressure During the Extension Phase of the Study
NCT00527514 (6) [back to overview]	Change From Baseline in Cuff Systolic Blood Pressure for the Amlodipine 10 mg + Olmesartan 40 mg Group
NCT00527514 (6) [back to overview]	Change From Baseline in Cuff Systolic Blood Pressure for the Amlodipine 5mg + Olmesartan 20 mg Group.
NCT00527514 (6) [back to overview]	Change From Baseline in Cuff Systolic Blood Pressure for the Amlodipine 5mg + Olmesartan 40 mg Group
NCT00527514 (6) [back to overview]	Change From Baseline in Cuff Systolic Blood Pressure for the Amlodipine 5mg Group.
NCT00527514 (6) [back to overview]	Change From Baseline in Mean 24-hour Systolic Blood Pressure Measured by Ambulatory Monitoring
NCT00527514 (6) [back to overview]	Change From Baseline in Daytime and Nighttime Ambulatory Systolic Blood Pressure
NCT00649389 (4) [back to overview]	Change From Baseline to Week 12 in Seated Diastolic Blood Pressure (SeDBP).
NCT00649389 (4) [back to overview]	Change in Mean 24-hour Ambulatory Blood Pressure From Baseline to Week 12 or Early Termination
NCT00649389 (4) [back to overview]	Change in Seated Systolic Blood Pressure From Baseline to Week 12
NCT00649389 (4) [back to overview]	Percentage of Subjects Who Reached Blood Pressure Goal (<140/90 mmHg; <130/80 mmHg for Subjects With Diabetes, Chronic Renal Disease, or Chronic Cardiovascular Disease)by 12 Weeks
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 12
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean Nighttime Ambulatory Blood Pressure Thresholds at Week 12
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean Last 6 Hour Ambulatory Systolic and Diastolic Blood Pressure Reductions at Week 12
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 15
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean Last 6 Hour Ambulatory Blood Pressure Thresholds at Week 12
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean Last 4 Hour Ambulatory Systolic and Diastolic Blood Pressure Reductions
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean Last 4 Hour Ambulatory Blood Pressure Thresholds at Week 12
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean Last 2 Hour Ambulatory Systolic and Diastolic Blood Pressure Reductions at Week 12
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean Last 2 Hour Ambulatory Blood Pressure Thresholds at Week 12
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean Daytime Ambulatory Systolic and Diastolic Blood Pressure Reductions at Week 12
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean Daytime Ambulatory Blood Pressure Thresholds at Week 12
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean 24-hour Ambulatory Blood Pressure Thresholds at Week 12
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean 24 Hour Ambulatory Systolic and Diastolic Blood Pressure Reductions at Week 12
NCT00654745 (29) [back to overview]	Change in Mean Seated Systolic Blood Pressure (SeSBP) From Week 0 (Baseline) After 3, 6, 9, 12, 15, and 18 Weeks
NCT00654745 (29) [back to overview]	Change in Mean Seated Diastolic Blood Pressure (SeDBP) From Week 0 (Baseline) After 3, 6, 9, 12, 15, and 18 Weeks
NCT00654745 (29) [back to overview]	Change From Week 0 (Baseline) in Mean ABPM SBP After 12 Weeks of Active Treatment
NCT00654745 (29) [back to overview]	Change From Week 0 (Baseline) in Mean ABPM Diastolic Blood Pressure (DBP) After 12 Weeks of Active Treatment
NCT00654745 (29) [back to overview]	Change From Week 0 (Baseline) in Mean 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Systolic Blood Pressure (SBP) After 12 Weeks of Active Treatment
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean Nighttime Ambulatory Systolic and Diastolic Blood Pressure Reductions at Week 12
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 3
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 6
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 9
NCT00654745 (29) [back to overview]	Number of Participants Achieving Seated Systolic and Diastolic Blood Pressure Thresholds at Week 12
NCT00654745 (29) [back to overview]	Number of Participants Achieving Seated Systolic and Diastolic Blood Pressure Thresholds at Week 15
NCT00654745 (29) [back to overview]	Number of Participants Achieving Seated Systolic and Diastolic Blood Pressure Thresholds at Week 18
NCT00654745 (29) [back to overview]	Number of Participants Achieving Seated Systolic and Diastolic Blood Pressure Thresholds at Week 3
NCT00654745 (29) [back to overview]	Number of Participants Achieving Seated Systolic and Diastolic Blood Pressure Thresholds at Week 6
NCT00654745 (29) [back to overview]	Number of Participants Achieving Seated Systolic and Diastolic Blood Pressure Thresholds at Week 9
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 18
NCT00696241 (15) [back to overview]	Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00696241 (15) [back to overview]	Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00696241 (15) [back to overview]	Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00696241 (15) [back to overview]	Change From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00696241 (15) [back to overview]	Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring
NCT00696241 (15) [back to overview]	Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring
NCT00696241 (15) [back to overview]	Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure
NCT00696241 (15) [back to overview]	Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure
NCT00696241 (15) [back to overview]	Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00696241 (15) [back to overview]	Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00696241 (15) [back to overview]	Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00696241 (15) [back to overview]	Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as < 90 mm Hg and/or Reduction From Baseline ≥ 10 mm Hg
NCT00696241 (15) [back to overview]	Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as < 140 mm Hg and/or Reduction From Baseline ≥ 20 mm Hg
NCT00696241 (15) [back to overview]	Percentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response
NCT00696241 (15) [back to overview]	Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00696436 (15) [back to overview]	Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as < 90 mm Hg and/or Reduction From Baseline ≥ 10 mm Hg
NCT00696436 (15) [back to overview]	Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as < 140 mm Hg and/or Reduction From Baseline ≥ 20 mm Hg
NCT00696436 (15) [back to overview]	Percentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response
NCT00696436 (15) [back to overview]	Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00696436 (15) [back to overview]	Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure
NCT00696436 (15) [back to overview]	Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure.
NCT00696436 (15) [back to overview]	Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00696436 (15) [back to overview]	Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00696436 (15) [back to overview]	Change From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00696436 (15) [back to overview]	Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00696436 (15) [back to overview]	Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00696436 (15) [back to overview]	Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00696436 (15) [back to overview]	Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00696436 (15) [back to overview]	Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00696436 (15) [back to overview]	Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00791258 (59) [back to overview]	Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 12 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 12 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	The Percentage of Subjects Who Achieve BP Goal (<140/90 mmHg for Non-diabetics or <130/80 mmHg for Diabetics) From Baseline to 12 and 20 Weeks
NCT00791258 (59) [back to overview]	The Percentage of Patients Who Achieve Seated Systolic Blood Pressure Goal (<140 mm Hg for Non-diabetics and <130 mm Hg for Diabetics) From Baseline to 12 Weeks
NCT00791258 (59) [back to overview]	The Percentage of Subjects Achieving Seated Diastolic BP Goal (<90 mmHg for Non-diabetics or < 80 mmHg for Subjects With Diabetes) From Baseline to 12 Weeks
NCT00791258 (59) [back to overview]	Change From Baseline to Week 12 in Ambulatory Systolic and Diastolic Blood Pressure Values
NCT00791258 (59) [back to overview]	Change From Baseline to Week 20 in Ambulatory Systolic and Diastolic Blood Pressure Values
NCT00791258 (59) [back to overview]	Change in Mean Seated Diastolic Blood Pressure From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Change in Mean Seated Systolic Blood Pressure From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of African American/Black Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Asain Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Asian Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00846365 (16) [back to overview]	Percentage of Participants Who Achieve a Clinic Diastolic AND Systolic Blood Pressure Response, Defined as <140/90 mm Hg for Participants Without Diabetes or Chronic Kidney Disease (CKD) or <130/80 mm Hg for Participants With Diabetes or CKD
NCT00846365 (16) [back to overview]	Change From Baseline in Trough, Sitting, Clinic Diastolic Blood Pressure
NCT00846365 (16) [back to overview]	Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as Defined as <90 mm Hg for Participants Without Diabetes or CKD or <80 mm Hg for Participants With Diabetes or CKD
NCT00846365 (16) [back to overview]	Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as <140 mm Hg for Participants Without Diabetes or CKD or <130 mm Hg for Participants With Diabetes or CKD
NCT00846365 (16) [back to overview]	Change From Baseline in 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00846365 (16) [back to overview]	Change From Baseline in 12-hr Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00846365 (16) [back to overview]	Change From Baseline in 12-hr Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00846365 (16) [back to overview]	Change From Baseline to Week 8 in Trough, Sitting, Clinic Systolic Blood Pressure.
NCT00846365 (16) [back to overview]	Change From Baseline to Week 4 in Trough, Sitting, Clinic Systolic Blood Pressure.
NCT00846365 (16) [back to overview]	Change From Baseline in 24-hour Mean Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring.
NCT00846365 (16) [back to overview]	Change From Baseline in Daytime Mean (6am to 10pm) Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00846365 (16) [back to overview]	Change From Baseline in Daytime Mean (6am to 10pm) Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00846365 (16) [back to overview]	Change From Baseline in Nighttime Mean (12am to 6am) Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00846365 (16) [back to overview]	Change From Baseline in Nighttime Mean (12am to 6am) Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring
NCT00846365 (16) [back to overview]	Change From Baseline in Trough Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00846365 (16) [back to overview]	Change From Baseline in Trough Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00857285 (1) [back to overview]	Mean Change of Sitting dBP From Baseline to Week 12
NCT00858702 (3) [back to overview]	Percent of Patients With Drug-related Adverse Events (Laboratory Changes in Clinical Laboratory Values)
NCT00858702 (3) [back to overview]	Percentage of Patients With Drug-related Adverse Events (Subjective Symptoms/Objective Findings)
NCT00858702 (3) [back to overview]	The Percentage of Patients Achieving Target Sitting Blood Pressure of Less Than 130/85
NCT00890591 (4) [back to overview]	Number of Patients That Achieved a Blood Pressure Goal of Less Than 130/85 in Second Titrated Group (Olmesartan 40 mg + 25 mg Hydrochlorothiazide)
NCT00890591 (4) [back to overview]	Number of Patients That Achieved a Blood Pressure Goal of Less Than 130/85 in Third Titrated Group (Olmesartan + Hydrochorothiazide + Amlodipine)
NCT00890591 (4) [back to overview]	Number of Patients That Achieved a Blood Pressure Goal of Less Than 130/85 (Olmesartan 20 mg Monotherapy)
NCT00890591 (4) [back to overview]	Number of Patients That Achieved a Blood Pressure Goal of Less Than 130/85 in First Titrated Group (Olmesartan 20 mg + 12.5 mg Hydrochlorothiazide)
NCT00902538 (10) [back to overview]	In Non-responders, the Change in Seated Systolic Blood Pressure Associated With the Triple Combinations OM/AML/HCTZ 40/10/12.5 and 40/10/25 mg.
NCT00902538 (10) [back to overview]	In Non-responders, the Change in Seated Diastolic Blood Pressure Associated With the Triple Combinations OM/AML/HCTZ 40/10/12.5 and 40/10/25 mg.
NCT00902538 (10) [back to overview]	Change in 24-hour Diastolic Blood Pressure (DBP) Assessed by 24-hour Ambulatory Blood Pressure Measurement (ABPM).
NCT00902538 (10) [back to overview]	Change in 24-hour Systolic Blood Pressure Assessed by 24-hour Ambulatory Blood Pressure Measurement.
NCT00902538 (10) [back to overview]	Change in Seated Diastolic Blood Pressure (SeDBP) of the Triple Combinations OM/AML/HCTZ 40/10/12.5 and 40/10/25 mg vs. OM/AML 40/10 mg
NCT00902538 (10) [back to overview]	Change in Seated Systolic Blood Pressure (SeSBP) of the Triple Combinations OM/AML/HCTZ 40/10/12.5 and 40/10/25 mg vs. OM/AML 40/10 mg
NCT00902538 (10) [back to overview]	In Non-responders, the Change in 24-hour Diastolic Blood Pressure Assessed by 24-hour Ambulatory Blood Pressure Measurement.
NCT00902538 (10) [back to overview]	Number of Subjects Achieving Blood Pressure (BP) Goal at Week 16.
NCT00902538 (10) [back to overview]	In Non-responders, the Number of Subject Meeting Their Blood Pressure Goals Associated With the Triple Combinations OM/AML/HCTZ 40/10/12.5 and 40/10/25 mg.
NCT00902538 (10) [back to overview]	In Non-responders, the Change in 24-hour Systolic Blood Pressure Assessed by 24-hour Ambulatory Blood Pressure Measurement.
NCT00923091 (10) [back to overview]	Change in Seated Systolic Blood Pressure (SeDBP).
NCT00923091 (10) [back to overview]	Change in Seated Systolic Blood Pressure From Week 18 to Week 22
NCT00923091 (10) [back to overview]	Change in Seated Systolic Blood Pressure From Week 22 to Week 26
NCT00923091 (10) [back to overview]	Number of Subjects Reaching Blood Pressure Goal at Week 10
NCT00923091 (10) [back to overview]	Number of Subjects Reaching Blood Pressure Goal From Week 18 to Week 22
NCT00923091 (10) [back to overview]	Change in Seated Diastolic Blood Pressure From Week 18 to Week 22
NCT00923091 (10) [back to overview]	Number of Subjects Reaching Blood Pressure Goal at Week 26
NCT00923091 (10) [back to overview]	Change in Seated Diastolic Blood Pressure From Week 22 to Week 26
NCT00923091 (10) [back to overview]	Change in Seated Systolic Blood Pressure (SeDBP) During Open-Label Period VI (Titration Effect From OM/AML/HCTZ 40/5/25 to 40/10/25.
NCT00923091 (10) [back to overview]	Change in Seated Diastolic Blood Pressure (SeDBP).
NCT00949884 (16) [back to overview]	Change From Baseline to Week 8 in Trough, Cuff, Seated Diastolic Blood Pressure (SDBP)
NCT00949884 (16) [back to overview]	Change From Baseline to Week 4 in Trough, Cuff, Seated Systolic Blood Pressure (SSBP)
NCT00949884 (16) [back to overview]	Change From Baseline to Week 4 in Trough, Cuff, Seated Diastolic Blood Pressure (SDBP)
NCT00949884 (16) [back to overview]	Percentage of Participants Achieving Blood Pressure Goals at Week 4
NCT00949884 (16) [back to overview]	Percentage of Participants Achieving Ambulatory Blood Pressure Goal of < 135/85 mmHg at Week 8
NCT00949884 (16) [back to overview]	Change From Baseline to Week 2 in Trough, Cuff, Seated Blood Pressure
NCT00949884 (16) [back to overview]	Change From Baseline in Mean Daytime (8am to 4pm) and Mean Nighttime (10pm to 6am) Ambulatory Blood Pressure at Week 8
NCT00949884 (16) [back to overview]	Change From Baseline in Mean Ambulatory Blood Pressure During the Final 2, 4, and 6 Hours of the Dosing Interval at Week 8
NCT00949884 (16) [back to overview]	Change From Baseline in Mean Ambulatory Blood Pressure During the Final 2, 4, and 6 Hours of the Dosing Interval at Week 4
NCT00949884 (16) [back to overview]	Change From Baseline in Mean Daytime (8am to 4pm) and Mean Nighttime (10pm to 6am) Ambulatory Blood Pressure at Week 4
NCT00949884 (16) [back to overview]	Percentage of Participants Achieving Blood Pressure Goals at Week 8
NCT00949884 (16) [back to overview]	Change From Baseline in Mean 24-Hour Ambulatory Blood Pressure at Week 8
NCT00949884 (16) [back to overview]	Change From Baseline in Mean 24-Hour Ambulatory Blood Pressure at Week 4
NCT00949884 (16) [back to overview]	Incremental Change From Week 4 to Week 8 in Trough, Cuff, Seated Systolic Blood Pressure (SSBP)
NCT00949884 (16) [back to overview]	Incremental Change From Week 4 to Week 8 in Trough, Cuff, Seated Diastolic Blood Pressure (SDBP)
NCT00949884 (16) [back to overview]	Change From Baseline to Week 8 in Trough, Cuff, Seated Systolic Blood Pressure (SSBP)
NCT00996281 (2) [back to overview]	Percentage of Participants With at Least 1 Adverse Event
NCT00996281 (2) [back to overview]	Percentage of Participants With Serum Creatinine Elevations Greater Than 50% From Baseline and Greater Than the Upper Limit of Normal (ULN)
NCT01033071 (18) [back to overview]	Change From Baseline in 24-hour Mean Diastolic Blood Pressure by Ambulatory Blood Pressure Monitoring.
NCT01033071 (18) [back to overview]	Change From Baseline in 24-hour Mean Systolic Blood Pressure by Ambulatory Blood Pressure Monitoring.
NCT01033071 (18) [back to overview]	Change From Baseline in Mean Daytime (6 AM to 10 PM) Diastolic Blood Pressure by Ambulatory Blood Pressure Monitoring.
NCT01033071 (18) [back to overview]	Change From Baseline in Mean Daytime (6 AM to 10 PM) Systolic Blood Pressure by Ambulatory Blood Pressure Monitoring.
NCT01033071 (18) [back to overview]	Change From Baseline in Mean Nighttime (12 AM to 6 AM) Diastolic Blood Pressure by Ambulatory Blood Pressure Monitoring.
NCT01033071 (18) [back to overview]	Change From Baseline in Mean Nighttime (12 AM to 6 AM) Systolic Blood Pressure by Ambulatory Blood Pressure Monitoring.
NCT01033071 (18) [back to overview]	Change From Baseline in Mean Trough Diastolic Blood Pressure by Ambulatory Blood Pressure Monitoring.
NCT01033071 (18) [back to overview]	Change From Baseline in Mean Trough Systolic Blood Pressure by Ambulatory Blood Pressure Monitoring.
NCT01033071 (18) [back to overview]	Change From Baseline in the Mean Diastolic Blood Pressure at 0 to 12 Hours After Dosing by Ambulatory Blood Pressure Monitoring.
NCT01033071 (18) [back to overview]	Change From Baseline in the Mean Systolic Blood Pressure at 0 to 12 Hours After Dosing by Ambulatory Blood Pressure Monitoring.
NCT01033071 (18) [back to overview]	Change From Baseline in Trough, Sitting, Clinic Systolic Blood Pressure.
NCT01033071 (18) [back to overview]	Change From Baseline in the Mean Diastolic Blood Pressure During Each Hour of the 24-hour Ambulatory Blood Pressure Monitoring.
NCT01033071 (18) [back to overview]	Change From Baseline in the Mean Systolic Blood Pressure During Each Hour of the 24-hour Ambulatory Blood Pressure Monitoring.
NCT01033071 (18) [back to overview]	Change From Baseline in Trough, Sitting, Clinic Diastolic Blood Pressure.
NCT01033071 (18) [back to overview]	Change From Baseline in Trough, Sitting, Clinic Systolic Blood Pressure.
NCT01033071 (18) [back to overview]	Percent of Participants Who Reached Target Clinic Systolic Blood Pressure of <140 mm Hg and/or Reduction of ≥20 mm Hg From Baseline and Target Clinic Diastolic Blood Pressure of <90 mm Hg and/or Reduction of ≥10 mm Hg From Baseline.
NCT01033071 (18) [back to overview]	Percentage of Participants Who Reached Target Clinic Diastolic Blood Pressure of <90 mm Hg and/or Reduction of ≥10 mm Hg From Baseline.
NCT01033071 (18) [back to overview]	Percentage of Participants Who Reached Target Clinic Systolic Blood Pressure of <140 mm Hg and/or Reduction of ≥20 mm Hg From Baseline.
NCT01200407 (4) [back to overview]	Percentage of Participants Achieving JNC VII Recommended Blood Pressure Goal at Week 12 With LOCF
NCT01200407 (4) [back to overview]	Change From Baseline in SBP and DBP at Week 12 With Last Observation Carried Forward (LOCF)
NCT01200407 (4) [back to overview]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Weeks 4, 8 and 12 Without (w/o) LOCF
NCT01200407 (4) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT01309828 (4) [back to overview]	Number of Participants With at Least 1 Adverse Event (AE)
NCT01309828 (4) [back to overview]	Percentage of Participants at Final Visit Who Achieved Target Diastolic Blood Pressure <80 mm Hg
NCT01309828 (4) [back to overview]	Percentage of Participants at Final Visit Who Achieve Target Systolic Blood Pressure <130 mm Hg
NCT01309828 (4) [back to overview]	Percentage of Participants at Final Visit Who Achieved Both a Clinic Systolic and Diastolic Blood Pressure Response
NCT01599104 (11) [back to overview]	Percentage of Participants Achieving a Successful msDBP Response
NCT01599104 (11) [back to overview]	Change From Baseline in Office Pulse Pressure
NCT01599104 (11) [back to overview]	Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)
NCT01599104 (11) [back to overview]	Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)
NCT01599104 (11) [back to overview]	Change From Baseline in Mean 24-hour Ambulatory SBP (maSBP) at Week 8
NCT01599104 (11) [back to overview]	Number of Patients With Adverse Events, Serious Adverse Events and Death
NCT01599104 (11) [back to overview]	Change From Baseline in Mean 24-hour Ambulatory DBP (maDBP) at Week 8
NCT01599104 (11) [back to overview]	Change From Baseline in Mean 24-hour Ambulatory Pulse Pressure
NCT01599104 (11) [back to overview]	Percentage of Participants Achieving a Successful Response in Overall Blood Pressure Control at Week 8
NCT01599104 (11) [back to overview]	Percentage of Participants Achieving a Successful msSBP Response
NCT01599104 (11) [back to overview]	Change From Baseline in maSBP and maDBP for Daytime/Nighttime
NCT01615198 (12) [back to overview]	Change in Baseline in Mean 24 Hour Ambulatory Diastolic Blood Pressure (maDBP)
NCT01615198 (12) [back to overview]	Change From Baseline in maSBP and maDBP Lowering Based on Nocturnal BP Dipping (Dipper Versus Non-dipper) in Dippers
NCT01615198 (12) [back to overview]	Change From Baseline in maSBP and maDBP Lowering Based on Nocturnal BP Dipping (Dipper Versus Non-dipper) Status in Non-dippers
NCT01615198 (12) [back to overview]	Change From Baseline in Mean Sitting Pulse Pressure
NCT01615198 (12) [back to overview]	Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic Blood Pressure (msDBP)
NCT01615198 (12) [back to overview]	Number of Participants Achieving Overall Blood Pressure Control in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic Blood Pressure (msDBP)
NCT01615198 (12) [back to overview]	Number of Participants Achieving Successful Response in msSBP and msDBP
NCT01615198 (12) [back to overview]	Number of Participants With Adverse Events, Serious Adverse Events and Death
NCT01615198 (12) [back to overview]	Change From Baseline in Daytime and Nighttime maSBP/maDBP
NCT01615198 (12) [back to overview]	Change From Baseline in Mean 24 Hour Ambulatory Systolic Blood Pressure (maSBP)
NCT01615198 (12) [back to overview]	Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)
NCT01615198 (12) [back to overview]	Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)
NCT01684748 (2) [back to overview]	Collagen Gene Expression in Skeletal Muscle (Change Over Time)
NCT01684748 (2) [back to overview]	Insulin Sensitivity by Intravenous Glucose Tolerance Testing (Change Over Time)
NCT01692301 (11) [back to overview]	Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)
NCT01692301 (11) [back to overview]	Change From Baseline in Mean Central Aortic Systolic Pressure (CASP) at 12 Weeks
NCT01692301 (11) [back to overview]	Change From Baseline in Mean Central Aortic Systolic Pressure (CASP) at 52 Weeks
NCT01692301 (11) [back to overview]	Change From Baseline in Mean 24-hour Ambulatory Pulse Pressure (maPP)
NCT01692301 (11) [back to overview]	Change From Baseline in Mean 24-hour Diastolic Blood Pressure (maDBP)
NCT01692301 (11) [back to overview]	Change From Baseline in Mean Sitting Pulse Pressure (msPP)
NCT01692301 (11) [back to overview]	Change From Baseline in Mean 24-hour Systolic Blood Pressure (maSBP)
NCT01692301 (11) [back to overview]	Change From Baseline in Mean Arterial Pressure (MAP)
NCT01692301 (11) [back to overview]	Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)
NCT01692301 (11) [back to overview]	Change From Baseline in Mean Central Pulse (CPP) Pressure
NCT01692301 (11) [back to overview]	Change From Baseline in Mean Pulse Wave Velocity (PWV)
NCT01785472 (13) [back to overview]	Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers.
NCT01785472 (13) [back to overview]	Number of Patients Achieving Successful Blood Pressure Control
NCT01785472 (13) [back to overview]	Change From Baseline in Office Pulse Pressure (msPP)
NCT01785472 (13) [back to overview]	Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) Between LCZ696 400 mg Versus Olmesartan 20 mg
NCT01785472 (13) [back to overview]	Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) Between LCZ696 200 mg Versus Olmesartan 20 mg
NCT01785472 (13) [back to overview]	Change From Baseline in Ambulatory Pulse Pressure
NCT01785472 (13) [back to overview]	Number of Patients With Adverse Events, Serious Adverse Events, and Death as Assessment of Safety and Tolerability
NCT01785472 (13) [back to overview]	Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers.
NCT01785472 (13) [back to overview]	Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers.
NCT01785472 (13) [back to overview]	Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers.
NCT01785472 (13) [back to overview]	Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) Between LCZ696 200, and LCZ696 400 mg Versus Olmesartan 20 mg
NCT01785472 (13) [back to overview]	Change From Baseline in Mean 24-hour Ambulatory Blood Pressure
NCT01785472 (13) [back to overview]	Number of Responders
NCT01870739 (10) [back to overview]	Change From Baseline in Augmentation Index at 52 Weeks
NCT01870739 (10) [back to overview]	Change From Baseline in Augmentation Pressure at 52 Weeks
NCT01870739 (10) [back to overview]	Change From Baseline in Carotid-femoral Pulse Wave Velocity at 52 Weeks
NCT01870739 (10) [back to overview]	Change From Baseline in Distal Descending Aorta Distensibility at 52 Weeks
NCT01870739 (10) [back to overview]	Change From Baseline in Central Blood Pressure at 52 Weeks
NCT01870739 (10) [back to overview]	Change From Baseline in Regional Aortic Pulse Wave Velocity at 52 Weeks
NCT01870739 (10) [back to overview]	Change From Baseline in Ascending Aorta Distensibility at 52 Week
NCT01870739 (10) [back to overview]	Number of Patients With Reported Adverse Events, Serious Adverse Events and Death
NCT01870739 (10) [back to overview]	Change From Baseline in Local Aortic Strain at 52 Weeks
NCT01870739 (10) [back to overview]	Change From Baseline in Proximal Descending Aorta Distensibility at 52 Weeks
NCT01876368 (11) [back to overview]	Number of Patients Achieving Successful Mean Sitting Diastolic Blood Pressure (msDBP) Response
NCT01876368 (11) [back to overview]	Number of Patients Achieving Successful Mean Sitting Systolic Blood Pressure (msSBP) Control
NCT01876368 (11) [back to overview]	Number of Patients Achieving Successful Mean Sitting Systolic Blood Pressure (msSBP) Response
NCT01876368 (11) [back to overview]	Number of Patients Achieving Successful Overall Blood Pressure Control
NCT01876368 (11) [back to overview]	Number of Patients With Total Adverse Events, Serious Adverse Events and Death
NCT01876368 (11) [back to overview]	Change From Baseline in Mean 24-hour Ambulatory Diastolic Blood Pressure (maDBP)
NCT01876368 (11) [back to overview]	Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)
NCT01876368 (11) [back to overview]	Change From Baseline in 24-hour Mean Ambulatory Systolic Blood Pressure (maSBP)
NCT01876368 (11) [back to overview]	Change From Baseline in Office Pulse Pressure
NCT01876368 (11) [back to overview]	Number of Patients Achieving Successful Mean Sitting Diastolic Blood Pressure (msDBP) Control
NCT01876368 (11) [back to overview]	Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)

AIM 1: Change in hsCRP (High Sensitivity C-reactive Peptide) Level

Inflammatory marker (NCT00122447)
Timeframe: 12 months of intervention

Intervention	mg/L (Mean)
Aspirin (ASA) 325 mg PO Once Daily	-1.27
Olmesartan (ARB) 40 mg PO Once Daily	-2.34
Alpha Lipoic Acid (ALA) 600 mg PO Twice Daily	0.23
Placebo	0.32

[back to top]

AIM 1: Change in Flow Mediated Dilation (FMD) (%)

Surrogate measure of endothelial function defined as the percent change in dilation of the brachial artery after cuff compression of arm compared to before cuff compression (NCT00122447)
Timeframe: 12 months of intervention

Intervention	percentage of arterial dilation change (Mean)
Aspirin (ASA) 325 mg PO Once Daily	-0.0012
Olmesartan (ARB) 40 mg PO Once Daily	0.018
Alpha Lipoic Acid (ALA) 600 mg PO Twice Daily	0.014
Placebo	0.0053

[back to top]

Number of Participants Experiencing Cardiovascular Composite Outcomes

Number of participants experiencing the first occurence of any of the following: Cardiovascular death; non-fatal stroke; non-fatal myocardial infarction; hospitalization for unstable angina; lower extremity amputation; coronary/carotid/peripheral revascularization. (NCT00141453)
Timeframe: Within 5 years

Intervention	participants (Number)
Olmesartan Medoxomil	40
Placebo Comparator	53

[back to top]

The Change in Proteinuria

The median percentage change from baseline value in urinary protein:creatinine ratio (NCT00141453)
Timeframe: Randomization to 5 years

Intervention	Median percentage change in ratio (Number)
	12-week value	48-week value	144 -week value
Olmesartan Medoxomil	-19.5	-20.0	-24.9
Placebo Comparator	12.6	6.9	3.1

[back to top]

Renal Composite Outcomes

first occurrence of any of the following events: Doubling of serum creatinine level; Death; End stage renal disease (NCT00141453)
Timeframe: Randomization to 5 years

Intervention	participants (Number)
Olmesartan Medoxomil	116
Placebo Comparator	129

[back to top]

Reciprocal (1/Serum Creatinine) of Serum Creatinine

The amount of serum creatinine was determined by blood tests periodically during the study. The amount of creatinine is an indication of kidney function. The reciprocal of serum creatinine is used in an equation to determine the change in kidney function from baseline. The reciprocal of the serum creatinine was monitored to detect kidney function changes over duration of the study. (NCT00141453)
Timeframe: Randomization to 5 years

Intervention	dL/mg/year (Median)
Olmesartan Medoxomil	-0.071
Placebo Comparator	-0.089

[back to top]

Mean Change From Period 3 Baseline in Seated Systolic and Diastolic Blood Pressure Measurements to the End of Period 3

Mean change from period 3 baseline (completion of the dose adjustment period and prior to starting the treatment of period 3) to the end of period 3 (double-blind placebo-controlled period) in seated systolic and diastolic blood pressure readings for Cohort A, Cohort B and Cohorts A+B combined. (NCT00151775)
Timeframe: Week 3 (period 3 baseline) to week 5 (end of Period 3)

,,,,,

Intervention	mm Hg (Mean)
	Change in Systolic Blood Pressure	Change in Diastolic Blood Pressure
Cohort A: OM Period 3	0.43	0.24
Cohort A: Placebo Period 3	4.93	4.43
Cohort B: OM Period 3	1.37	1.94
Cohort B: Placebo Period 3	3.79	3.25
Cohorts A + B: OM Period 3	0.77	0.85
Cohorts A + B: Placebo Period 3	4.50	3.99

[back to top]

Mean Change From Baseline in Seated Systolic and Diastolic Blood Pressure Measurements to the End of Period 4 (End of Study)

Mean change from baseline to the end of the open label Period 4 in seated systolic and diastolic blood pressure readings for Cohort C. (NCT00151775)
Timeframe: Day 0 to week 51 week (end of study)

Intervention	mm Hg (Mean)
	Change in Systolic Blood Pressure	Change in Diastolic Blood Pressure
Cohort C: OM (Olmesartan Medoxomil)	-15.7	-13.3

[back to top]

Mean Change From Period 3 Baseline in Seated Systolic and Diastolic Blood Pressure Measurements to the End of Period 3

Mean change from period 3 baseline (completion of the dose adjustment period and prior to starting the treatment of period 3) to the end of period 3 (double-blind placebo-controlled period) in seated systolic and diastolic blood pressure readings for Cohort C. (NCT00151775)
Timeframe: Week 3 (period 3 baseline) to week 5 (end of Period 3)

Intervention	mm Hg (Mean)
	Seated Systolic Blood Pressure	Seated Diastolic Blood Pressure
Cohort C: OM Period 3	1.36	0.31
Cohort C: Placebo Period 3	4.95	3.77

[back to top]

Mean Change From Baseline in Seated Systolic and Diastolic Blood Pressure Measurements to the End of Period 4 (End of Study)

Mean change from baseline to the end of the open label Period 4 in seated systolic and diastolic blood pressure readings for Cohort A, Cohort B and Cohorts A+B combined. (NCT00151775)
Timeframe: Day 0 to week 51 (end of study)

Intervention	mm Hg (Mean)
	Change in Systolic Blood Pressure	Change in Diastolic Blood Pressure
Cohort A: Period 4 Open-label OM	-10.8	-7.4
Cohort B: Period 4 Open-label OM	-7.7	-5.1
Cohorts A + B: Period 4 Open-label OM	-9.7	-6.6

[back to top]

Mean Change From Baseline in Seated Systolic and Diastolic Blood Pressure Measurements to the End of Period 2 (3 Weeks)

Mean change from baseline to the end of the dose ranging period in systolic and diastolic blood pressure readings for Cohort A, Cohort B and Cohorts A+B combined. (NCT00151775)
Timeframe: Day 0 (baseline) to 3 weeks

,,,,,

Intervention	mm Hg (Mean)
	Change in Systolic Blood Pressure	Change in Diastolic Blood Pressure
Cohort A: High Dose OM	-12.58	-9.50
Cohort A: Low Dose OM	-7.76	-5.52
Cohort B: High Dose OM	-10.68	-7.58
Cohort B: Low Dose OM	-4.73	-3.49
Cohorts A + B: High Dose OM	-11.87	-8.78
Cohorts A + B: Low Dose OM	-6.63	-4.76

[back to top]

Least Squares Mean Change From Baseline in Seated Systolic Blood Pressure to the End of Period 2 (3 Weeks)

The efficacy dose response change in trough seated systolic blood pressure (both non-weight adjusted and weight adjusted results) from baseline to the end of the dose-ranging period (Period 2). Non-weight adjusted dose was the fixed olmesartan medoxomil dose; weight adjusted dose calculated mg of olmesartan medoxomil per kg of weight at baseline. (NCT00151775)
Timeframe: Day 0 to 3 weeks

Intervention	mm Hg (Least Squares Mean)
	Non-weight adjusted dosage	Weight adjusted dosage
Cohort A	-0.69	-8.97
Cohort B	-0.85	-7.17
Cohorts A + B	-0.75	-8.36

[back to top]

For Olmesartan, the Apparent Oral Clearance

(NCT00151814)
Timeframe: PK samples were collected pre-dose and at 1,2,4,8,12,24,48 hours after dosing

Intervention	L/hr (Mean)
6-12 Years of Age Olmesartan Group	4.3
13-16 Years of Age Olmesartan Group	6.1

[back to top]

For Olmesartan, the Maximum Plasma Concentration Over the Entire Sampling Phase

(NCT00151814)
Timeframe: PK samples were collected pre-dose and at 1,2,4,8,12,24,48 hours after dosing

Intervention	ng/mL (Mean)
6-12 Years of Age Olmesartan Group	1227
13-16 Years of Age Olmesartan Group	895

[back to top]

For Olmesartan, Area Under the Concentration-time Curve From the Time of the Dose to Infinity

(NCT00151814)
Timeframe: PK samples were collected pre-dose and at 1,2,4,8,12,24,48 hours after dosing

Intervention	ng/mL*hr (Mean)
6-12 Years of Age Olmesartan Group	7988
13-16 Years of Age Olmesartan Group	5982

[back to top]

For Olmesartan, the Elimination Half-life of the Drug in Plasma

(NCT00151814)
Timeframe: PK samples were collected pre-dose and at 1,2,4,8,12,24,48 hours after dosing

Intervention	hr (Mean)
6-12 Years of Age Olmesartan Group	8.4
13-16 Years of Age Olmesartan Group	9.1

[back to top]

For Olmesartan, the Elimination Constant Rate

(NCT00151814)
Timeframe: PK samples were collected pre-dose and at 1,2,4,8,12,24,48 hours after dosing

Intervention	L/hr (Mean)
6-12 Years of Age Olmesartan Group	0.090
13-16 Years of Age Olmesartan Group	0.079

[back to top]

For Olmesartan, the Area Under the Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC 0-t)

(NCT00151814)
Timeframe: PK samples were collected pre-dose and at 1,2,4,8,12,24,48 hours after dosing

Intervention	ng/mL*hr (Mean)
6-12 Years of Age Olmesartan Group	7874
13-16 Years of Age Olmesartan Group	5851

[back to top]

For Olmesartan, the Apparent Oral Volume of Distribution

(NCT00151814)
Timeframe: PK samples were collected pre-dose and at 1,2,4,8,12,24,48 hours after dosing

Intervention	L (Mean)
6-12 Years of Age Olmesartan Group	50.9
13-16 Years of Age Olmesartan Group	81.3

[back to top]

Foe Olmesartan, the Time of Maximum Plasma Concentration

(NCT00151814)
Timeframe: PK samples were collected pre-dose and at 1,2,4,8,12,24,48 hours after dosing

Intervention	hr (Mean)
6-12 Years of Age Olmesartan Group	2.8
13-16 Years of Age Olmesartan Group	2.5

[back to top]

The Percentage of Participants Treated to Target Blood Pressure Goals Overall and for Each Treatment Step From Baseline to Completion of Treatment During Which the Goal Was Achieved.

For non-diabetic participants the target seated blood pressure goals were: Systolic - ≤130 mm Hg; Diastolic - ≤85 mm Hg. For diabetic participants the target seated blood pressure goals were: Systolic - <130 mm Hg; Diastolic - <80 mm Hg. (NCT00311155)
Timeframe: Baseline to ≤20 weeks

Intervention	Percentage of participants (Number)
	Overall N=691	OLM 20 mg N=688	OLM 20 mg+HCTZ 12.5 mg N=580	OLM 20 mg+HCTZ 25 mg N=446	OLM 20 mg+HCTZ 25 mg+AML 5 mg N=296	OLM 20 mg+HCTZ 25 mg+AML 10 mg N=176
Olmesartan+Hydrochlorothiazide,if Needed+Amlodipine, if Needed	71.8	12.3	16.4	19.2	14.9	8.5

[back to top]

Percentage of Participants Who Were Systolic Responders Overall and for Each Treatment From Baseline to the Completion of the Treatment During Which Blood Pressure Goals Were Achieved

Systolic responders defined as a participant who is a normaliser or has a lowering of the mean sitting systolic blood pressure of ≥20 mmHg at trough (NCT00311155)
Timeframe: Baseline to ≤20 weeks

Intervention	Percentage of Participants (Number)
	Overall N=691	OLM 20 mg N=688	OLM 20 mg + HCTZ 12.5 mg N=580	OLM 20 mg + HCTZ 25 mg N=446	OLM 20 mg + HCTZ 25 mg + AML 5 mg N=296	OLM 20 mg + HCTZ 25 mg + AML 10 mg N=176
Olmesartan+Hydrochlorothiazide,if Needed+Amlodipine, if Needed	92.6	34.2	49.6	46.6	33.3	20.5

[back to top]

Percentage of Participants Who Were Diastolic Responders Overall and for Each Treatment From Baseline to the Completion of Treatment During Which Blood Pressure Goals Were Achieved.

Diastolic responders were defined as a participant who is a normaliser or has a lowering of the mean sitting diastolic blood pressure of ≥10 mmHg at trough. (NCT00311155)
Timeframe: Baseline to ≤20 weeks

Intervention	Percentage of participants (Number)
	Overall N=691	OLM 20 mg N=688	OLM 20 mg + HCTZ 12.5 mg N=580	OLM 20 mg + HCTZ 25 mg N=446	OLM 20 mg + HCTZ 25 mg + AML 5 mg N=296	OLM 20 mg + HCTZ 25 mg + AML 10 mg N=176
Olmesartan+Hydrochlorothiazide,if Needed+Amlodipine, if Needed	93.3	36.6	52.4	48.6	33.4	20.4

[back to top]

Percentage of Participants Who Achieved Normalized Blood Pressure Overall and for Each Treatment From Baseline to Completion of the Treatment During Which Blood Pressure Goals Were Achieved

Normalized blood pressure is defined as a mean sitting systolic blood (sBP) pressure at trough of <140 mmHg and mean sitting diastolic blood pressure (dBP)of <90 mmHg for non-diabetic patients or a mean sitting sBP at trough of <130 mmHg and mean sitting dBP <80 mmHg for diabetic patients. (NCT00311155)
Timeframe: Baseline to ≤20 weeks

Intervention	Percentage of participants (Number)
	Overall N=691	OLM 20 mg N=688	OLM 20 mg + HCTZ 12.5 mg N=580	OLM 20 mg + HCTZ 25 mg N=446	OLM 20 mg + HCTZ 25 mg + AML 5 mg N=296	OLM 20 mg + HCTZ 25 mg + AML 10 mg N=176
Olmesartan+Hydrochlorothiazide,if Needed+Amlodipine, if Needed	84.5	22.7	31.1	32.7	23.9	14.8

[back to top]

Mean Change in Systolic Blood Pressure Overall and for Each Treatment From Baseline to the Completion of the Treatment

(NCT00311155)
Timeframe: Baseline to ≤20 weeks

Intervention	mm Hg (Mean)
	Overall N=691	OLM 20 mg N=688	OLM 20 mg + HCTZ 12.5 mg N=580	OLM 20 mg + HCTZ 25 mg N=446	OLM 20 mg + HCTZ 25 mg + AML 5 mg N=296	OLM 20 mg + HCTZ 25 mg + AML 10 mg N=176
Olmesartan+Hydrochlorothiazide,if Needed+Amlodipine, if Needed	-29.58	-11.97	-19.55	-24.51	-27.06	-28.02

[back to top]

Mean Change in Diastolic Blood Pressure Overall and for Each Treatment From Baseline to the Completion of the Treatment

(NCT00311155)
Timeframe: Baseline to ≤20 weeks

Intervention	mm Hg (Mean)
	Overall N=691	OLM 20 mg N=688	OLM 20 mg + HCTZ 12.5 mg N=580	OLM 20 mg + HCTZ 25 mg N=446	OLM 20 mg + HCTZ 25 mg + AML 5 mg N=296	OLM 20 mg + HCTZ 25 mg + AML 10 mg N=176
Olmesartan+Hydrochlorothiazide,if Needed+Amlodipine, if Needed	-15.73	-6.44	-10.15	-13.04	-14.03	-14.47

[back to top]

Change From Baseline in the 24-36-Hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in the 24-36-hour mean systolic blood pressure measured at week 8 relative to the 12-hour mean measured at baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-36-hour mean is the average of all measurements recorded from 24 to 36 hours after dosing; the 12-hour mean is the average of the first 12 hours after dosing. (NCT00362115)
Timeframe: Baseline and Week 8.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 5 mg QD	-9.4
Azilsartan Medoxomil 10 mg QD	-12.0
Azilsartan Medoxomil 20 mg QD	-11.5
Azilsartan Medoxomil 40 mg QD	-14.6
Azilsartan Medoxomil 80 mg QD	-13.5
Olmesartan 20 mg QD	-8.9
Placebo QD	-1.4

[back to top]

Change From Baseline in the 24-36-Hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in the 24-36-hour mean diastolic blood pressure measured at week 8 relative to the 12-hour mean measured at baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-36-hour mean is the average of all measurements recorded from 24 to 36 hours after dosing; the 12-hour mean is the average of the first 12 hours after dosing. (NCT00362115)
Timeframe: Baseline and Week 8.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 5 mg QD	-5.6
Azilsartan Medoxomil 10 mg QD	-7.9
Azilsartan Medoxomil 20 mg QD	-8.6
Azilsartan Medoxomil 40 mg QD	-9.5
Azilsartan Medoxomil 80 mg QD	-7.9
Olmesartan 20 mg QD	-6.5
Placebo QD	-0.4

[back to top]

Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in the 12-hour mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing. (NCT00362115)
Timeframe: Baseline and Week 8.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 5 mg QD	-7.2
Azilsartan Medoxomil 10 mg QD	-13.0
Azilsartan Medoxomil 20 mg QD	-11.8
Azilsartan Medoxomil 40 mg QD	-17.2
Azilsartan Medoxomil 80 mg QD	-13.0
Olmesartan 20 mg QD	-7.4
Placebo QD	0.6

[back to top]

Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in the 12-hour mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing. (NCT00362115)
Timeframe: Baseline and Week 8.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 5 mg QD	-3.6
Azilsartan Medoxomil 10 mg QD	-7.3
Azilsartan Medoxomil 20 mg QD	-8.0
Azilsartan Medoxomil 40 mg QD	-10.0
Azilsartan Medoxomil 80 mg QD	-8.7
Olmesartan 20 mg QD	-5.1
Placebo QD	0.6

[back to top]

Change From Baseline in the 10-12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in the 10 to 12-hour mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 10-12-hour mean is the average of all measurements recorded after dosing during these 2 hours. (NCT00362115)
Timeframe: Baseline and Week 8.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 5 mg QD	-3.8
Azilsartan Medoxomil 10 mg QD	-5.7
Azilsartan Medoxomil 20 mg QD	-7.4
Azilsartan Medoxomil 40 mg QD	-9.1
Azilsartan Medoxomil 80 mg QD	-8.8
Olmesartan 20 mg QD	-4.7
Placebo QD	0.5

[back to top]

Change From Baseline in Standing Clinic Systolic Blood Pressure.

The change in standing clinic systolic blood pressure measured at final visit or week 8 relative to baseline. Systolic blood pressure is the arithmetic mean of the 3 trough standing systolic blood pressure measurements. (NCT00362115)
Timeframe: Baseline and Week 8.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 5 mg QD	-11.4
Azilsartan Medoxomil 10 mg QD	-13.4
Azilsartan Medoxomil 20 mg QD	-16.1
Azilsartan Medoxomil 40 mg QD	-14.6
Azilsartan Medoxomil 80 mg QD	-14.0
Olmesartan 20 mg QD	-11.4
Placebo QD	-3.3

[back to top]

Change From Baseline in Standing Clinic Diastolic Blood Pressure.

The change in standing clinic diastolic blood pressure measured at final visit or week 8 relative to baseline. Diastolic blood pressure is the arithmetic mean of the 3 trough standing diastolic blood pressure measurements. (NCT00362115)
Timeframe: Baseline and Week 8.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 5 mg QD	-9.2
Azilsartan Medoxomil 10 mg QD	-11.0
Azilsartan Medoxomil 20 mg QD	-10.2
Azilsartan Medoxomil 40 mg QD	-11.3
Azilsartan Medoxomil 80 mg QD	-11.2
Olmesartan 20 mg QD	-10.8
Placebo QD	-6.9

[back to top]

Change From Baseline in Sitting Clinic Systolic Blood Pressure.

The change in sitting clinic systolic blood pressure measured at final visit or week 8 relative to baseline. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements. (NCT00362115)
Timeframe: Baseline and Week 8

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 5 mg QD	-11.0
Azilsartan Medoxomil 10 mg QD	-15.7
Azilsartan Medoxomil 20 mg QD	-14.7
Azilsartan Medoxomil 40 mg QD	-17.1
Azilsartan Medoxomil 80 mg QD	-13.3
Olmesartan 20 mg QD	-13.5
Placebo QD	-4.9

[back to top]

Change From Baseline in Sitting Clinic Diastolic Blood Pressure.

The change in sitting clinic diastolic blood pressure measured at final visit or week 8 relative to baseline. Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements. (NCT00362115)
Timeframe: Baseline and Week 8.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 5 mg QD	-10.8
Azilsartan Medoxomil 10 mg QD	-13.1
Azilsartan Medoxomil 20 mg QD	-11.5
Azilsartan Medoxomil 40 mg QD	-13.6
Azilsartan Medoxomil 80 mg QD	-11.6
Olmesartan 20 mg QD	-11.0
Placebo QD	-7.9

[back to top]

Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in daytime (6am to 10pm) mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm. (NCT00362115)
Timeframe: Baseline and Week 8.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 5 mg QD	-7.8
Azilsartan Medoxomil 10 mg QD	-13.0
Azilsartan Medoxomil 20 mg QD	-11.6
Azilsartan Medoxomil 40 mg QD	-17.3
Azilsartan Medoxomil 80 mg QD	-13.1
Olmesartan 20 mg QD	-8.6
Placebo QD	0.7

[back to top]

Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in daytime (6am to 10pm) mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm. (NCT00362115)
Timeframe: Baseline and Week 8.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 5 mg QD	-4.2
Azilsartan Medoxomil 10 mg QD	-7.7
Azilsartan Medoxomil 20 mg QD	-8.0
Azilsartan Medoxomil 40 mg QD	-10.6
Azilsartan Medoxomil 80 mg QD	-8.7
Olmesartan 20 mg QD	-6.0
Placebo QD	0.7

[back to top]

Change From Baseline in 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in 24-hour mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing. (NCT00362115)
Timeframe: Baseline and Week 8.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 5 mg QD	-7.5
Azilsartan Medoxomil 10 mg QD	-12.1
Azilsartan Medoxomil 20 mg QD	-11.1
Azilsartan Medoxomil 40 mg QD	-15.8
Azilsartan Medoxomil 80 mg QD	-12.4
Olmesartan 20 mg QD	-9.3
Placebo QD	1.0

[back to top]

Change From Baseline in 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in 24-hour mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing. (NCT00362115)
Timeframe: Baseline and Week 8.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 5 mg QD	-4.2
Azilsartan Medoxomil 10 mg QD	-7.3
Azilsartan Medoxomil 20 mg QD	-7.5
Azilsartan Medoxomil 40 mg QD	-9.6
Azilsartan Medoxomil 80 mg QD	-8.2
Olmesartan 20 mg QD	-6.2
Placebo QD	1.2

[back to top]

Change From Baseline in the 10-12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in the 10 to 12-hour mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 10-12-hour mean is the average of all measurements recorded after dosing during these 2 hours. (NCT00362115)
Timeframe: Baseline and Week 8.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 5 mg QD	-8.0
Azilsartan Medoxomil 10 mg QD	-11.4
Azilsartan Medoxomil 20 mg QD	-12.2
Azilsartan Medoxomil 40 mg QD	-17.4
Azilsartan Medoxomil 80 mg QD	-13.7
Olmesartan 20 mg QD	-7.8
Placebo QD	0.1

[back to top]

Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in trough mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing. (NCT00362115)
Timeframe: Baseline and Week 8

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 5 mg QD	-10.9
Azilsartan Medoxomil 10 mg QD	-14.9
Azilsartan Medoxomil 20 mg QD	-12.0
Azilsartan Medoxomil 40 mg QD	-18.8
Azilsartan Medoxomil 80 mg QD	-13.9
Olmesartan 20 mg QD	-13.8
Placebo QD	-1.5

[back to top]

Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in trough mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing. (NCT00362115)
Timeframe: Baseline and Week 8.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 5 mg QD	-7.6
Azilsartan Medoxomil 10 mg QD	-11.3
Azilsartan Medoxomil 20 mg QD	-8.9
Azilsartan Medoxomil 40 mg QD	-14.0
Azilsartan Medoxomil 80 mg QD	-9.0
Olmesartan 20 mg QD	-9.6
Placebo QD	-0.3

[back to top]

Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in nighttime (12am to 6am) mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am. (NCT00362115)
Timeframe: Baseline and Week 8.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 5 mg QD	-7.3
Azilsartan Medoxomil 10 mg QD	-11.1
Azilsartan Medoxomil 20 mg QD	-10.4
Azilsartan Medoxomil 40 mg QD	-13.1
Azilsartan Medoxomil 80 mg QD	-11.4
Olmesartan 20 mg QD	-10.6
Placebo QD	1.3

[back to top]

Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in nighttime (12am to 6am) mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am. (NCT00362115)
Timeframe: Baseline and Week 8.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 5 mg QD	-4.8
Azilsartan Medoxomil 10 mg QD	-7.4
Azilsartan Medoxomil 20 mg QD	-6.8
Azilsartan Medoxomil 40 mg QD	-8.5
Azilsartan Medoxomil 80 mg QD	-7.8
Olmesartan 20 mg QD	-6.1
Placebo QD	1.9

[back to top]

Change From Baseline in the 34-36-Hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in the 34-36-hour mean systolic blood pressure measured at week 8 relative to the 10-12-hour mean measured at baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-36-hour mean is the average of all measurements recorded from 34 to 36 hours after dosing; the 10-12-hour mean is the average from these 2 hours after dosing. (NCT00362115)
Timeframe: Baseline and Week 8

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 5 mg QD	-10.1
Azilsartan Medoxomil 10 mg QD	-11.2
Azilsartan Medoxomil 20 mg QD	-9.8
Azilsartan Medoxomil 40 mg QD	-13.5
Azilsartan Medoxomil 80 mg QD	-11.8
Olmesartan 20 mg QD	-7.4
Placebo QD	-0.9

[back to top]

Change From Baseline in the 34-36-Hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in the 34-36-hour mean diastolic blood pressure measured at week 8 relative to the 10-12-hour mean measured at baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-36-hour mean is the average of all measurements recorded from 34 to 36 hours after dosing; the 10-12-hour mean is the average from these 2 hours after dosing. (NCT00362115)
Timeframe: Baseline and Week 8.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 5 mg QD	-0.4
Azilsartan Medoxomil 10 mg QD	0.3
Azilsartan Medoxomil 20 mg QD	0.9
Azilsartan Medoxomil 40 mg QD	0.4
Azilsartan Medoxomil 80 mg QD	-0.6
Olmesartan 20 mg QD	1.9
Placebo QD	2.4

[back to top]

Change From Baseline to Week 12 in Ambulatory BP Measurement (Systolic)During the Last 4 Hours of the Last (Week 12 ) 24-hour Dosing Period.

Participants had a 24-hour ambulatory blood pressure session at baseline and after 12 weeks of treatment. This outcome measure pooled all participants regardless of their titration history during the study. (NCT00403481)
Timeframe: baseline and 12 weeks

Intervention	mm Hg (Mean)
Overall Study Population	-18.2

[back to top]

Change From Baseline to Week 12 in Ambulatory BP Measurement (Systolic)During the Last 6 Hours of the Last (Week 12 ) 24-hour Dosing Period.

Intervention	mm Hg (Mean)
Overall Study Population	-18.6

[back to top]

Change From Baseline to Week 12 in Mean 24-hour Ambulatory BP (Diastolic)

Intervention	mm Hg (Mean)
Overall Study Population	-11.1

[back to top]

Change From Baseline to Week 12 in Systolic BP (SBP) as Measured by 24-hour ABPM.

Intervention	mm Hg (Mean)
Overall Study Population	-20.4

[back to top]

Change in Ambulatory Blood Pressure (Diastolic) From Baseline to Week 12 During the Last 2 Hours of the Last (Week 12 ) 24-hour Dosing Period.

Intervention	mm Hg (Mean)
Overall Study Population	-10.6

[back to top]

Change From Baseline to Week 12 in Mean Daytime and Nighttime Ambulatory Blood Pressure Measurement (Systolic).

Intervention	mm Hg (Mean)
	Daytime	Nighttime
Overall Study Population	-22.3	-18.8

[back to top]

Change in Ambulatory BP (Diastolic) From Baseline to Week 12 During the Last (Week 12 ) 4 and 6 Hours of the Last 24-hour Dosing Period.

Intervention	mm Hg (Mean)
	4 hours	6 hours
Overall Study Population	-10.7	-10.8

[back to top]

Change in Daytime and Nighttime Ambulatory Blood Pressure (Diastolic) From Baseline to Week 12

Intervention	mm Hg (Mean)
	Daytime	Nighttime
Overall Study Population	-12.0	-10.2

[back to top]

Change From Baseline to Week 12 in Ambulatory BP Measurement (Systolic)During the Last 2 Hours of the Last (Week 12) 24-hour Dosing Period.

Intervention	mm Hg (Mean)
Overall Study Population	-18.6

[back to top]

Change From Baseline in Mean Daytime (8am-4pm) and Mean Nighttime (10 Pm-6am) Ambulatory Blood Pressure Monitored Diastolic Blood Pressure After 12 Weeks of Active Treatment

All participants started the treatment arm with 20 mg olmesartan medoxomil (Olm). If their blood pressure was not controlled, participants were titrated at 3-week intervals to: Olm 40 mg, then, if needed Olm 40 mg + hydrochlorothiazide (HCTZ) 12.5 mg, then, if needed Olm 40 mg + HCTZ 25 mg This outcome measure included all participants at the end of the 12-week treatment period regardless of whether or not they were titrated. They had to have both baseline and 12-week ambulatory blood pressure measurements. (NCT00412932)
Timeframe: baseline to 12 weeks

Intervention	mm Hg (Mean)
	Daytime	Nighttime
Overall Study	-13.0	-11.5

[back to top]

Change From Baseline in Mean Daytime (8am-4pm) and Mean Nighttime (10pm-6am)Ambulatory Systolic Blood Pressure After 12 Weeks of Active Treatment

Intervention	mm Hg (Mean)
	Daytime	Nighttime
Overall Study	-26.5	-24.4

[back to top]

Number of Subjects Who Achieved Mean 24-hour Ambluatory Blood Pressure of <140/90 mm Hg, Systolic Blood Pressure <140 mm Hg, and Diastolic Blood Pressure <90 mm Hg After 12 Weeks of Active Treatment

Intervention	participants (Number)
	BP<140/90 mm Hg	SBP<140 mm Hg	DBP<90 mm Hg
Overall Study	133	133	149

[back to top]

Number of Subjects Who Achieved Mean Daytime (8am - 4pm) Ambulatory Blood Pressure of <140/90 mm Hg, Systolic Blood Pressure <140 mm Hg, and Diastolic Blood Pressure <90 mm Hg After 12 Weeks of Active Treatment.

Intervention	participants (Number)
	BP<140/90 mm Hg	SBP<140 mm Hg	DBP<90 mm Hg
Overall Study	120	120	145

[back to top]

Number of Subjects Who Achieved Mean Nighttime (10pm - 6am) Ambulatory Blood Pressure of <140/90 mm Hg, Systolic Blood Pressure <140 mm Hg, and Diastolic Blood Pressure <90 mm Hg After 12 Weeks of Active Treatment.

Intervention	participants (Number)
	BP<140/90 mm Hg	SBP<140 mm Hg	DBP<90 mm Hg
Overall Study	143	143	149

[back to top]

Change From Baseline in Mean 24-hour Ambulatory Diastolic Blood Pressure After 12 Weeks of Active Treatment.

Intervention	mm Hg (Mean)
Overall Study	-12.3

[back to top]

Change From Baseline in Mean 24-hour Ambulatory Systolic Blood Pressure After 12 Weeks of Active Treatment

Intervention	mm Hg (Mean)
Overall Study	-25.7

[back to top]

Change in Mean 24-hour Ambulatory Blood Pressure Monitoring Diastolic Blood Pressure From Week 8(Baseline) to Week 16.

Change = Week 16 - Week 8 (baseline). (NCT00430508)
Timeframe: 8 weeks, change = week 16 - week 8

Intervention	mm Hg (Mean)
OM/HCTZ 40/25mg + 20/12.5 Matching Placebo	-7.2
OM/HCTZ 40/12.5mg + 20/12.5 Matching Placebo	-5.3
OM/HCTZ 20/12.5mg + 40/0 Matching Placebo	-4.1
OM/HCTZ 40/0mg + 20/12.5 Matching Placebo	-2.0

[back to top]

Change in Mean Daytime Ambulatory Blood Pressure Monitoring Diastolic Blood Pressure From Week 8(Baseline) to Week 16.

Change = Week 16 - Week 8 (baseline). (NCT00430508)
Timeframe: 8 weeks, change = week 16 - week 8

Intervention	mm Hg (Mean)
OM/HCTZ 40/25mg + 20/12.5 Matching Placebo	-7.0
OM/HCTZ 40/12.5mg + 20/12.5 Matching Placebo	-5.5
OM/HCTZ 20/12.5mg + 40/0 Matching Placebo	-4.0
OM/HCTZ 40/0mg + 20/12.5 Matching Placebo	-1.8

[back to top]

Change in Mean Night-time Ambulatory Blood Pressure Monitoring Diastolic Blood Pressure From Week 8(Baseline) to Week 16.

Change = Week 16 - Week 8 (baseline). (NCT00430508)
Timeframe: 8 weeks, change = week 16 - week 8

Intervention	mm Hg (Mean)
OM/HCTZ 40/25mg + 20/12.5 Matching Placebo	-7.9
OM/HCTZ 40/12.5mg + 20/12.5 Matching Placebo	-4.5
OM/HCTZ 20/12.5mg + 40/0 Matching Placebo	-4.2
OM/HCTZ 40/0mg + 20/12.5 Matching Placebo	-2.3

[back to top]

Change in Mean Trough Sitting Diastolic Blood Pressure From Week 8(Baseline) to Week 12.

Change = Week 12 - Week 8 (baseline). (NCT00430508)
Timeframe: 4 weeks, change = week 12 - week 8

Intervention	mm Hg (Mean)
OM/HCTZ 40/25mg + 20/12.5 Matching Placebo	-8.74
OM/HCTZ 40/12.5mg + 20/12.5 Matching Placebo	-7.72
OM/HCTZ 20/12.5mg + 40/0 Matching Placebo	-6.66
OM/HCTZ 40/0mg + 20/12.5 Matching Placebo	-4.47

[back to top]

Change in Mean Trough Sitting Systolic Blood Pressure From Week 8(Baseline) to Week 12.

Change = Week 12 - Week 8 (baseline). (NCT00430508)
Timeframe: 4 weeks, change = week 12 - week 8

Intervention	mm Hg (Mean)
OM/HCTZ 40/25mg + 20/12.5 Matching Placebo	-13.16
OM/HCTZ 40/12.5mg + 20/12.5 Matching Placebo	-10.90
OM/HCTZ 20/12.5mg + 40/0 Matching Placebo	-9.65
OM/HCTZ 40/0mg + 20/12.5 Matching Placebo	-6.60

[back to top]

Change in Mean Trough Sitting Diastolic Blood Pressure From Week 8(Baseline) to Week 16

Change = Week 16 - Week 8 (baseline). (NCT00430508)
Timeframe: 8 weeks, change = week 16 - week 8

Intervention	mm Hg (Mean)
OM/HCTZ 40/25mg + 20/12.5 Matching Placebo	-11.16
OM/HCTZ 40/12.5mg + 20/12.5 Matching Placebo	-9.13
OM/HCTZ 20/12.5mg + 40/0 Matching Placebo	-8.10
OM/HCTZ 40/0mg + 20/12.5 Matching Placebo	-5.66

[back to top]

Number of Patients Achieving Target Blood Pressure at Week 16

Target Blood Pressure is diastolic blood pressure (dBP) < 90 mmHg and systolic blood pressure (sBP) < 140 mmHg for non-diabetics, and dBP < 80 mmHg and sBP < 130 mmHg for diabetics (NCT00430508)
Timeframe: 8 weeks

Intervention	participants (Number)
OM/HCTZ 40/25mg + 20/12.5 Matching Placebo	59
OM/HCTZ 40/12.5mg + 20/12.5 Matching Placebo	110
OM/HCTZ 20/12.5mg + 40/0 Matching Placebo	88
OM/HCTZ 40/0mg + 20/12.5 Matching Placebo	68

[back to top]

Change in Mean Trough Sitting Systolic Blood Pressure From Week 8(Baseline) to Week 16.

Change = Week 16 - Week 8 (baseline). (NCT00430508)
Timeframe: 8 weeks, change = week 16 - week 8

Intervention	mm Hg (Mean)
OM/HCTZ 40/25mg + 20/12.5 Matching Placebo	-16.17
OM/HCTZ 40/12.5mg + 20/12.5 Matching Placebo	-13.52
OM/HCTZ 20/12.5mg + 40/0 Matching Placebo	-11.46
OM/HCTZ 40/0mg + 20/12.5 Matching Placebo	-8.85

[back to top]

The Difference in the Change From Baseline to Week 12 in Seated Systolic and Diastolic Blood Pressure Between the Olmesartan Group and the Placebo Group for Non-Black Participants.

(NCT00430638)
Timeframe: Baseline to 12 weeks

Intervention	mm Hg (Least Squares Mean)
	Systolic blood pressure	Diastolic blood pressure
Olmesartan vs. Placebo	-22.3	-12.8

[back to top]

The Difference in the Change From Baseline to Week 12 in Seated Systolic and Diastolic Blood Pressure Between the Olmesartan Group and the Placebo Group for Stage 2 Hypertensives

(NCT00430638)
Timeframe: Baseline to 12 months

Intervention	mm Hg (Least Squares Mean)
	Systolic blood pressure	Diastolic blood pressure
Olmesartan vs. Placebo	-22.5	-13.2

[back to top]

The Difference in the Change From Baseline to Week 12 in Seated Systolic and Diastolic Blood Pressure Between the Olmesartan Group and the Placebo Group for Stage 1 Hypertensives

(NCT00430638)
Timeframe: Baseline to 12 weeks

Intervention	mm Hg (Least Squares Mean)
	Systolic blood pressure	Diastolic blood pressure
Olmesartan vs. Placebo	-22.1	-12.2

[back to top]

The Difference in the Change From Baseline to Week 12 in Seated Systolic and Diastolic Blood Pressure Between the Olmesartan Group and the Placebo Group for Participants Less Than 65 Years Old.

(NCT00430638)
Timeframe: Baseline to 12 weeks

Intervention	mm Hg (Least Squares Mean)
	Systolic blood pressure	Diastolic blood pressure
Olmesartan vs. Placebo	-23.8	-13.6

[back to top]

The Difference in the Change From Baseline to Week 12 in Seated Systolic and Diastolic Blood Pressure Between the Olmesartan Group and the Placebo Group for Participants Greater Than or Equal to 65 Years Old.

(NCT00430638)
Timeframe: Baseline to 12 weeks

Intervention	mm Hg (Least Squares Mean)
	Systolic blood pressure	Diastolic blood pressure
Olmesartan vs. Placebo	-16.1	-9.0

[back to top]

The Difference in the Change From Baseline to Week 12 in Seated Systolic and Diastolic Blood Pressure Between the Olmesartan Group and the Placebo Group for Males.

The difference in the change from baseline to week 12 in seated systolic and diastolic blood pressure for males in the olmesartan group vs. the placebo group was analyzed. (NCT00430638)
Timeframe: Baseline to week 12

Intervention	mm Hg (Least Squares Mean)
	Systolic Blood Pressure	Diastolic Blood Pressure
Olmesartan vs. Placebo	-22.6	-13.5

[back to top]

The Difference in the Change From Baseline to Week 12 in Seated Systolic and Diastolic Blood Pressure Between the Olmesartan Group and the Placebo Group for Females.

The difference in the change from baseline to week 12 in seated blood pressure for females in the olmesartan group vs. the placebo group was analyzed. (NCT00430638)
Timeframe: Baseline to week 12

Intervention	mm Hg (Least Squares Mean)
	Systolic blood pressure	Diastolic blood pressure
Olmesartan vs. Placebo	-21.6	-12.0

[back to top]

The Difference in the Change From Baseline to Week 12 in Seated Systolic and Diastolic Blood Pressure Between the Olmesartan Group and the Placebo Group for Black Participants.

(NCT00430638)
Timeframe: Baseline to week 12

Intervention	mm Hg (Least Squares Mean)
	Systolic blood pressure	Diastolic blood pressure
Olmesartan vs. Placebo	-21.3	-12.5

[back to top]

Change From Baseline in Mean Systolic Blood Pressure (SBP) After 12 Weeks of Randomized Treatment as Measured by Omron Device.

The change from baseline in mean systolic blood pressure (SBP) after 12 weeks of randomized treatment was compared between the olmesartan based treatment group and the placebo treatment group. (NCT00430638)
Timeframe: baseline to 12 weeks

Intervention	mm Hg (Least Squares Mean)
Placebo	-0.1
Olmesartan Group	-22.3

[back to top]

Change From Baseline in Mean Diastolic Blood Pressure (DBP) After 12 Weeks of Randomized Treatment as Measured by Omron Device.

Change from study baseline (average of triplicate DBP measurements at the last 2 qualifying visits during placebo run-in period) in DBP to the end of 12 weeks of randomized treatment using a last observation carried forward (LOCF) approach. (NCT00430638)
Timeframe: baseline to 12 weeks

Intervention	mm Hg (Least Squares Mean)
Placebo Group	-0.8
Olmesartan Group	-12.1

[back to top]

Change in Mean Trough Sitting Diastolic Blood Pressure From Week 8(Baseline) to Week 12

Change = Week 12 - Week 8 (baseline). (NCT00430950)
Timeframe: 4 weeks

Intervention	mm Hg (Mean)
OM/HCTZ 40/25 mg + 20/25 mg Matching Placebo	-9.32
OM/HCTZ 20/25 mg + 40/25 mg Matching Placebo	-8.83

[back to top]

Number of Participants Achieving Blood Pressure Goal.

(NCT00430950)
Timeframe: 8 weeks

Intervention	participants (Number)
OM/HCTZ 40/25 mg + 20/25 mg Matching Placebo	260
OM/HCTZ 20/25 mg + 40/25 mg Matching Placebo	255

[back to top]

Change in Daytime, Nighttime and 24-hour Blood Pressure Evaluated by Ambulatory Blood Pressure Monitoring 8 Weeks After Baseline.

Change = Week 16 - Week 8 (baseline). (NCT00430950)
Timeframe: 8 weeks

Intervention	mm Hg (Mean)
	Change from Week 8 to Wk 16 in mean 24-hr ABPM dBP	Change from Week 8 to wk16 in daytime ABPM dBP	Change from Week 8 to wk16 in nighttime ABPM dBP	Change from Week 8 to wk16 in mean 24-hr ABPM sBP	Change from Week 8 to wk16 in daytime ABPM sBP	Change from Week 8 to wk16 in nighttime ABPM sBP
OM/HCTZ 20/25 mg + 40/25 mg Matching Placebo	-7.6	-7.7	-7.0	-12.0	-12.3	-10.7
OM/HCTZ 40/25 mg + 20/25 mg Matching Placebo	-9.2	-9.3	-8.6	-14.7	-15.0	-13.4

[back to top]

Change in Sitting Systolic Blood Pressure 4 Weeks and 8 Weeks After Baseline.

4 weeks Change = Week 12 - Week 8 (baseline). 8 weeks Change = Week 16 - Week 8 (baseline). (NCT00430950)
Timeframe: 8 weeks

Intervention	mm Hg (Mean)
	Change from baseline (Week 8) to Week 16 in sBP	Change from baseline (Week 8) to Week 12 in sBP
OM/HCTZ 20/25 mg + 40/25 mg Matching Placebo	-17.09	-13.80
OM/HCTZ 40/25 mg + 20/25 mg Matching Placebo	-17.41	-14.07

[back to top]

Change in Mean Trough Sitting Diastolic Blood Pressure

"Change in mean trough sitting diastolic Blood Pressure between OM/HCTZ 20/25 mg vs. 40/25 mg, in those patients inadequately controlled on OM 40 mg monotherapy, after eight weeks of double blind treatment, as compared to baseline.~Change = Week 16 - Week 8 (baseline)." (NCT00430950)
Timeframe: 8 weeks

Intervention	mm Hg (Mean)
OM/HCTZ 40/25 mg + 20/25 mg Matching Placebo	-11.16
OM/HCTZ 20/25 mg + 40/25 mg Matching Placebo	-10.45

[back to top]

Change in Mean Sitting Systolic Blood Pressure (msSBP) During the Core Phase of the Study

The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement. (NCT00523744)
Timeframe: Baseline Phase 2 (Week 4) to end of Phase 2 (Week 8)

Intervention	mmHg (Mean)
Amlodipine+Valsartan - Phase 2	-7.87

[back to top]

Change in Mean Sitting Diastolic Blood Pressure (msDBP) During the Core Phase of the Study

Intervention	mmHg (Mean)
Amlodipine+Valsartan - Phase 2	-9.13

[back to top]

Change in Sitting Pulse Pressure During the Extension Phase of the Study

Pulse pressure is systolic pressure (SP) minus diastolic pressure (DP). The arm in which the highest sitting DPs were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, SP and DP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement. (NCT00523744)
Timeframe: Baseline Phase 3 (Week 8) to end of Phase 3 (Week 12)

Intervention	mmHg (Mean)
Amlodipine+Valsartan+HCTZ - Phase 3	-5.62

[back to top]

Change in Mean Sitting Diastolic Blood Pressure (msDBP) During the Extension Phase of the Study

Intervention	mmHg (Mean)
Amlodipine+Valsartan+HCTZ - Phase 3	-5.22

[back to top]

Change in Mean Sitting Systolic Blood Pressure (msSBP) During the Extension Phase of the Study

Intervention	mmHg (Mean)
Amlodipine+Valsartan+HCTZ - Phase 3	-10.84

[back to top]

Change in Sitting Pulse Pressure During the Core Phase of the Study

Intervention	mmHg (Mean)
Amlodipine+Valsartan - Phase 2	1.26

[back to top]

Change in Sitting Pulse Rate During the Core Phase of the Study

Pulse rate was measured once for 30 seconds just prior to blood pressure measurements in the sitting position. (NCT00523744)
Timeframe: Baseline Phase 2 (Week 4) to end of Phase 2 (Week 8)

Intervention	BPM (beats per minute) (Mean)
Amlodipine+Valsartan - Phase 2	-1.93

[back to top]

Change in Sitting Pulse Rate During the Extension Phase of the Study

Pulse rate was measured once for 30 seconds just prior to blood pressure measurements in the sitting position. (NCT00523744)
Timeframe: Baseline Phase 3 (Week 8) to end of Phase 3 (week 12)

Intervention	BPM (beats per minute) (Mean)
Amlodipine+Valsartan+HCTZ - Phase 3	0.09

[back to top]

Percentage of Patients Who Achieved a Protocol-defined Blood Pressure Response During the Core Phase of the Study

Blood pressure response was defined as msSBP < 140 mmHg or a 20 mmHg decrease in msSBP at the end of Phase 2 (Week 8) compared to Baseline in Phase 2 (week 4) or a msDBP < 90 mmHg or a 10 mmHg decrease in msDBP at the end of Phase 2 compared to Baseline in Phase 2. (NCT00523744)
Timeframe: Baseline of Phase 2 (Week 4) to end of Phase 2 (Week 8)

Intervention	Percentage of participants (Number)
	msSBP response	msDBP response
Amlodipine+Valsartan - Phase 2	47.4	73.1

[back to top]

Percentage of Patients Who Achieved a Protocol-defined Blood Pressure Response During the Extension Phase of the Study

Blood pressure response was defined as msSBP < 140 mmHg or a 20 mmHg decrease in msSBP at the end of Phase 3 compared to Baseline in Phase 3 or a msDBP < 90 mmHg or a 10 mmHg decrease in msDBP at the end of Phase 3 compared to Baseline in Phase 3. (NCT00523744)
Timeframe: Baseline of Phase 3 (Week 8) to end of Phase 3 (Week 12)

Intervention	Percentage of participants (Number)
	msSBP response	msDBP response
Amlodipine+Valsartan+HCTZ - Phase 3	61.5	83.5

[back to top]

Percentage of Patients Who Achieved Normalized Blood Pressure During the Core Phase of the Study

Normalized Blood Pressure was defined as a msSBP < 140 mmHg and/or a msDBP < 90 mmHg. (NCT00523744)
Timeframe: Baseline Phase 2 (Week 4) to end of Phase 2 (Week 8)

Intervention	Percentage of participants (Number)
	msSBP < 140 mmHg	msDBP < 90 mmHg
Amlodipine+Valsartan - Phase 2	44.6	72.6

[back to top]

Percentage of Patients Who Achieved Normalized Blood Pressure During the Extension Phase of the Study

Normalized Blood Pressure was defined as a msSBP < 140 mmHg and/or a msDBP < 90 mmHg. (NCT00523744)
Timeframe: Baseline Phase 3 (Week 8) to end of Phase 3 (Week 12)

Intervention	Percentage of participants (Number)
	msSBP < 140 mmHg	msDBP < 90 mmHg
Amlodipine+Valsartan+HCTZ - Phase 3	59.3	83.5

[back to top]

Change From Baseline in Cuff Systolic Blood Pressure for the Amlodipine 10 mg + Olmesartan 40 mg Group

Change from study baseline in cuff systolic pressure (as measured by an Omron device) to the end of the treatment period. The Last Observation Carried Forwarded (LOCF) approach was used for the analysis. (NCT00527514)
Timeframe: Baseline to end end of week 12

Intervention	mm Hg (Mean)
Group 4 - Aml 10 mg + Olm 40 mg	-24.6

[back to top]

Change From Baseline in Cuff Systolic Blood Pressure for the Amlodipine 5mg + Olmesartan 20 mg Group.

Intervention	mm Hg (Mean)
Group 2 - Aml 5 mg + Olmesartan 20 mg	-18.0

[back to top]

Change From Baseline in Cuff Systolic Blood Pressure for the Amlodipine 5mg + Olmesartan 40 mg Group

Intervention	mm Hg (Mean)
Group 3 - Aml 5 mg + Olm 40 mg	-20.5

[back to top]

Change From Baseline in Cuff Systolic Blood Pressure for the Amlodipine 5mg Group.

Intervention	mm Hg (Mean)
Group 1 Amlodipine 5 mg	-10.1

[back to top]

Change From Baseline in Mean 24-hour Systolic Blood Pressure Measured by Ambulatory Monitoring

(NCT00527514)
Timeframe: Baseline to 12 Weeks

Intervention	mm Hg (Mean)
Overall Active Treatment Period	-21.4

[back to top]

Change From Baseline in Daytime and Nighttime Ambulatory Systolic Blood Pressure

(NCT00527514)
Timeframe: Baseline to 12 weeks

Intervention	mm Hg (Mean)
	Daytime	Nighttime
Overall Active Treatment Period	-23.1	-18.5

[back to top]

Change From Baseline to Week 12 in Seated Diastolic Blood Pressure (SeDBP).

(NCT00649389)
Timeframe: baseline to 12 weeks

Intervention	mm Hg (Mean)
OM40/AML10	-17.8
OM40/HCTZ25	-16.5
AML10/HCTZ25	-14.8
OM40/AML10/HCTZ25	-21.5

[back to top]

Change in Mean 24-hour Ambulatory Blood Pressure From Baseline to Week 12 or Early Termination

(NCT00649389)
Timeframe: Baseline to 12 weeks or early termination

,,,

Intervention	mm Hg (Mean)
	Diastolic blood pressure	Systolic blood pressure
AML10/HCTZ25	-10.7	-18.5
OM40/AML10	-13.9	-23.5
OM40/AML10/HCTZ25	-18.0	-30.3
OM40/HCTZ25	-14.5	-23.9

[back to top]

Change in Seated Systolic Blood Pressure From Baseline to Week 12

(NCT00649389)
Timeframe: Baseline to week 12

Intervention	mm Hg (Mean)
OM40/AML10	-31.1
OM40/HCTZ25	-31.2
AML10/HCTZ25	-28.9
OM40/AML10/HCTZ25	-38.1

[back to top]

Percentage of Subjects Who Reached Blood Pressure Goal (<140/90 mmHg; <130/80 mmHg for Subjects With Diabetes, Chronic Renal Disease, or Chronic Cardiovascular Disease)by 12 Weeks

(NCT00649389)
Timeframe: Baseline to 12 weeks

Intervention	Percentage of subjects (Number)
OM40/AML10	46.0
OM40/HCTZ25	46.6
AML10/HCTZ25	34.9
OM40/AML10/HCTZ25	64.3

[back to top]

Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 12

number of participants achieving mean seated systolic and diastolic blood pressure reductions of; SBP reduction <= 15 mmHg, SBP reduction > 15 mmHg & <= 30 mmHg, SBP reduction > 30 mmHg & <= 45 mmHg, SBP reduction > 45 mmHg, DBP reduction <= 10 mmHg, DBP reduction > 10 mmHg & <= 15 mmHg, DBP reduction > 15 mmHg & <= 20 mmHg, DBP reduction > 20 mmHg at week 12 (NCT00654745)
Timeframe: week 0 - week 12

Intervention	participants (Number)
	mean seated SBP reduction =<15 mm Hg	mean seated SBP reduction >15 & =<30 mm Hg	mean seated SBP reduction >30 & =<45 mm Hg	mean seated SBP reduction >45 mm Hg	mean seated DBP reduction =<10 mm Hg	mean seated DBP reduction >10 & =<15 mm Hg	mean seated DBP reduction >15 & =<20 mm Hg	mean seated DBP reduction >20 mm Hg
Aml + Olm + Hctz	48	73	45	11	85	42	27	23

[back to top]

Number of Participants Achieving Mean Nighttime Ambulatory Blood Pressure Thresholds at Week 12

number of participants achieving mean nighttime ambulatory blood pressure thresholds BP<135/85, BP<130/80, BP<125/75, BP<120/80, BP<120/70, SBP<135, SBP<130, SBP<125, SBP<120, DBP<85, DBP<80, DBP<75, DBP<70 at week 12 (NCT00654745)
Timeframe: week 0 - week 12

Intervention	participants (Number)
	mean nighttime BP < 135/85	mean nighttime BP < 130/80	mean nighttime BP < 125/75	mean nighttime BP < 120/80	mean nighttime BP < 120/70	mean nighttime SBP < 135	mean nighttime SBP < 130	mean nighttime SBP < 125	mean nighttime SBP < 120	mean nighttime DBP < 85	mean nighttime DBP < 80	mean nighttime DBP < 75	mean nighttime DBP < 70
Aml + Olm + Hctz	152	137	119	112	101	154	139	123	112	160	158	147	124

[back to top]

Number of Participants Achieving Mean Last 6 Hour Ambulatory Systolic and Diastolic Blood Pressure Reductions at Week 12

number of participants achieving mean last 6 hour ambulatory systolic and diastolic blood pressure reductions of; SBP reduction <= 15 mmHg, SBP reduction > 15 mmHg & <= 30 mmHg, SBP reduction > 30 mmHg & <= 45 mmHg, SBP reduction > 45 mmHg, DBP reduction <= 10 mmHg, DBP reduction > 10 mmHg & <= 15 mmHg, DBP reduction > 15 mmHg & <= 20 mmHg, DBP reduction > 20 mmHg at week 12 (NCT00654745)
Timeframe: week 0 - week 12

Intervention	participants (Number)
	mean last 6 hour SBP reduction =<15 mm Hg	mean last 6 hour SBP reduction >15 & =<30 mm Hg	mean last 6 hour SBP reduction >30 & =<45 mm Hg	mean last 6 hour SBP reduction >45 mm Hg	mean last 6 hour DBP reduction =<10 mm Hg	mean last 6 hour DBP reduction >10 & =<15 mm Hg	mean last 6 hour DBP reduction >15 & =<20 mm Hg	mean last 6 hour DBP reduction >20 mm Hg
Aml + Olm + Hctz	61	76	23	5	76	41	27	21

[back to top]

Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 15

Intervention	participants (Number)
	mean seated SBP reduction =<15 mm Hg	mean seated SBP reduction >15 & =<30 mm Hg	mean seated SBP reduction >30 & =<45 mm Hg	mean seated SBP reduction >45 mm Hg	mean seated DBP reduction =<10 mm Hg	mean seated DBP reduction >10 & =<15 mm Hg	mean seated DBP reduction >15 & =<20 mm Hg	mean seated DBP reduction >20 mm Hg
Aml + Olm + Hctz	31	66	55	20	52	45	32	43

[back to top]

Number of Participants Achieving Mean Last 6 Hour Ambulatory Blood Pressure Thresholds at Week 12

number participants achieving mean last 6 hour ambulatory blood pressure thresholds BP<135/85, BP<130/80, BP<125/75, BP<120/80, SBP<135, SBP<130, SBP<125, SBP<120, DBP<85, DBP<80, DBP<75 at week 12 (NCT00654745)
Timeframe: week 0 - week 12

Intervention	participants (Number)
	mean last 6 hour BP < 135/85	mean last 6 hour BP < 130/80	mean last 6 hour BP < 125/75	mean last 6 hour BP < 120/80	mean last 6 hour SBP < 135	mean last 6 hour SBP < 130	mean last 6 hour SBP < 125	mean last 6 hour SBP < 120	mean last 6 hour DBP < 85	mean last 6 hour DBP < 80	mean last 6 hour DBP < 75
Aml + Olm + Hctz	135	124	101	85	143	127	108	85	157	146	130

[back to top]

Number of Participants Achieving Mean Last 4 Hour Ambulatory Systolic and Diastolic Blood Pressure Reductions

number of participants achieving mean last 4 hour ambulatory systolic and diastolic blood pressure reductions of; SBP reduction <= 15 mmHg, SBP reduction > 15 mmHg & <= 30 mmHg, SBP reduction > 30 mmHg & <= 45 mmHg, SBP reduction > 45 mmHg, DBP reduction <= 10 mmHg, DBP reduction > 10 mmHg & <= 15 mmHg, DBP reduction > 15 mmHg & <= 20 mmHg, DBP reduction > 20 mmHg at week 12 (NCT00654745)
Timeframe: week 0 - week 12

Intervention	participants (Number)
	mean last 4 hour SBP reduction =<15 mm Hg	mean last 4 hour SBP reduction >15 & =<30 mm Hg	mean last 4 hour SBP reduction >30 & =<45 mm Hg	mean last 4 hour SBP reduction >45 mm Hg	mean last 4 hour DBP reduction =<10 mm Hg	mean last 4 hour DBP reduction >10 & =<15 mm Hg	mean last 4 hour DBP reduction >15 & =<20 mm Hg	mean last 4 hour DBP reduction >20 mm Hg
Aml + Olm + Hctz	67	65	28	5	76	36	25	28

[back to top]

Number of Participants Achieving Mean Last 4 Hour Ambulatory Blood Pressure Thresholds at Week 12

number of participants achieving mean last 4 hour ambulatory blood pressure thresholds BP<135/85, BP<130/80, BP<125/75, BP<120/80, SBP<135, SBP<130, SBP<125, SBP<120, DBP<85, DBP<80, DBP<75 at week 12 (NCT00654745)
Timeframe: week 0 - week 12

Intervention	participants (Number)
	mean last 4 hour BP < 135/85	mean last 4 hour BP < 130/80	mean last 4 hour BP < 125/75	mean last 4 hour BP < 120/80	mean last 4 hour SBP < 135	mean last 4 hour SBP < 130	mean last 4 hour SBP < 125	mean last 4 hour SBP < 120	mean last 4 hour DBP < 85	mean last 4 hour DBP < 80	mean last 4 hour DBP < 75
Aml + Olm + Hctz	129	107	92	72	131	114	102	72	150	137	120

[back to top]

Number of Participants Achieving Mean Last 2 Hour Ambulatory Systolic and Diastolic Blood Pressure Reductions at Week 12

number of participants achieving mean last 2 hour ambulatory systolic and diastolic blood pressure reductions of; SBP reduction <= 15 mmHg, SBP reduction > 15 mmHg & <= 30 mmHg, SBP reduction > 30 mmHg & <= 45 mmHg, SBP reduction > 45 mmHg, DBP reduction <= 10 mmHg, DBP reduction > 10 mmHg & <= 15 mmHg, DBP reduction > 15 mmHg & <= 20 mmHg, DBP reduction > 20 mmHg at week 12 (NCT00654745)
Timeframe: week 0 - week 12

Intervention	participants (Number)
	mean last 2 hour SBP reduction =<15 mm Hg	mean last 2 hour SBP reduction >15 & =<30 mm Hg	mean last 2 hour SBP reduction >30 & =<45 mm Hg	mean last 2 hour SBP reduction >45 mm Hg	mean last 2 hour DBP reduction =<10 mm Hg	mean last 2 hour DBP reduction >10 & =<15 mm Hg	mean last 2 hour DBP reduction >15 & =<20 mm Hg	mean last 2 hour DBP reduction >20 mm Hg
Aml + Olm + Hctz	63	62	35	5	77	28	29	31

[back to top]

Number of Participants Achieving Mean Last 2 Hour Ambulatory Blood Pressure Thresholds at Week 12

number of participants achieving mean last 2 hour ambulatory blood pressure thresholds BP<135/85, BP<130/80, BP<125/75, BP<120/80, SBP<135, SBP<130, SBP<125, SBP<120, DBP<85, DBP<80, DBP<75 at week 12 (NCT00654745)
Timeframe: week 0 - week 12

Intervention	participants (Number)
	mean last 2 hour BP < 135/85	mean last 2 hour BP < 130/80	mean last 2 hour BP < 125/75	mean last 2 hour BP < 120/80	mean last 2 hour SBP < 135	mean last 2 hour SBP < 130	mean last 2 hour SBP < 125	mean last 2 hour SBP < 120	mean last 2 hour DBP < 85	mean last 2 hour DBP < 80	mean last 2 hour DBP < 75
Aml + Olm + Hctz	110	85	63	49	115	92	76	51	145	125	94

[back to top]

Number of Participants Achieving Mean Daytime Ambulatory Systolic and Diastolic Blood Pressure Reductions at Week 12

number of participants achieving mean daytime ambulatory systolic and diastolic blood pressure reductions of; SBP reduction <= 15 mmHg, SBP reduction > 15 mmHg & <= 30 mmHg, SBP reduction > 30 mmHg & <= 45 mmHg, SBP reduction > 45 mmHg, DBP reduction <= 10 mmHg, DBP reduction > 10 mmHg & <= 15 mmHg, DBP reduction > 15 mmHg & <= 20 mmHg, DBP reduction > 20 mmHg at week 12 (NCT00654745)
Timeframe: week 0 - week 12

Intervention	participants (Number)
	mean daytime SBP reduction =<15 mm Hg	mean daytime SBP reduction >15 & =<30 mm Hg	mean daytime SBP reduction >30 & =<45 mm Hg	mean daytime SBP reduction >45 mm Hg	mean daytime DBP reduction =<10 mm Hg	mean daytime DBP reduction >10 & =<15 mm Hg	mean daytime DBP reduction >15 & =<20 mm Hg	mean daytime DBP reduction >20 mm Hg
Aml + Olm + Hctz	47	84	31	3	68	41	33	23

[back to top]

Number of Participants Achieving Mean Daytime Ambulatory Blood Pressure Thresholds at Week 12

number of participants achieving mean daytime ambulatory blood pressure thresholds BP<135/85, BP<130/80, BP<125/75, BP<120/80, SBP<135, SBP<130, SBP<125, SBP<120, DBP<85, DBP<80, DBP<75 at week 12 (NCT00654745)
Timeframe: week 0 - week 12

Intervention	participants (Number)
	mean daytime BP < 135/85	mean daytime BP < 130/80	mean daytime BP < 125/75	mean daytime BP < 120/80	mean daytime SBP < 135	mean daytime SBP < 130	mean daytime SBP < 125	mean daytime SBP < 120	mean daytime DBP < 85	mean daytime DBP < 80	mean daytime DBP < 75
Aml + Olm + Hctz	116	83	48	42	118	94	67	42	151	124	91

[back to top]

Number of Participants Achieving Mean 24-hour Ambulatory Blood Pressure Thresholds at Week 12

number of participants achieving mean 24-hour ambulatory blood pressure thresholds BP<135/85, BP<130/80, BP<125/75, BP<120/80, SBP<135, SBP<130, SBP<125, SBP<120, DBP<85, DBP<80, DBP<75 at week 12 (NCT00654745)
Timeframe: week 0 - week 12

Intervention	participants (Number)
	mean 24-hour BP <135/85	mean 24-hour BP <130/80	mean 24-hour BP <125/75	mean 24-hour BP <120/80	mean 24-hour SBP <135	mean 24-hour SBP <130	mean 24-hour SBP <125	mean 24-hour SBP <120	mean 24-hour DBP <85	mean 24-hour DBP <80	mean 24-hour DBP <75
Aml + Olm + Hctz	140	116	76	59	140	120	92	59	158	146	121

[back to top]

Number of Participants Achieving Mean 24 Hour Ambulatory Systolic and Diastolic Blood Pressure Reductions at Week 12

number of participants achieving mean 24 hour ambulatory systolic and diastolic blood pressure reductions of; SBP reduction <= 15 mmHg, SBP reduction > 15 mmHg & <= 30 mmHg, SBP reduction > 30 mmHg & <= 45 mmHg, SBP reduction > 45 mmHg, DBP reduction <= 10 mmHg, DBP reduction > 10 mmHg & <= 15 mmHg, DBP reduction > 15 mmHg & <= 20 mmHg, DBP reduction > 20 mmHg at week 12 (NCT00654745)
Timeframe: week 0 - week 12

Intervention	participants (Number)
	mean 24-hour SBP reduction =<15 mm Hg	mean 24-hour SBP reduction >15 & =<30 mm Hg	mean 24-hour SBP reduction >30 & =<45 mm Hg	mean 24-hour SBP reduction >45 mm Hg	mean 24-hour DBP reduction =<10 mm Hg	mean 24-hour DBP reduction >10 & =<15 mm Hg	mean 24-hour DBP reduction >15 & =<20 mm Hg	mean 24-hour DBP reduction >20 mm Hg
Aml + Olm + Hctz	50	91	22	2	72	47	31	15

[back to top]

Change in Mean Seated Systolic Blood Pressure (SeSBP) From Week 0 (Baseline) After 3, 6, 9, 12, 15, and 18 Weeks

change in mean SeSBP from week 0 (baseline) to Weeks 3, 6, 9, 12, 15, and 18. (NCT00654745)
Timeframe: week 0 - weeks 3, 6, 9, 12, 15, 18

Intervention	mm Hg (Mean)
	week 3 mean SBP change from baseline	week 6 mean SBP change from baseline	week 9 mean SBP change from baseline	week 12 mean SBP change from baseline	week 15 mean SBP change from baseline	week 18 mean SBP change from baseline
Aml + Olm + Hctz	-10.3	-17.9	-20.0	-23.7	-28.5	-31.1

[back to top]

Change in Mean Seated Diastolic Blood Pressure (SeDBP) From Week 0 (Baseline) After 3, 6, 9, 12, 15, and 18 Weeks

change in mean SeDBP from week 0 (baseline) to Weeks 3, 6, 9, 12, 15, and 18. (NCT00654745)
Timeframe: week 0 - weeks 3, 6, 9, 12, 15, 18

Intervention	mm Hg (Mean)
	week 3 mean seDBP change from baseline	week 6 mean seDBP change from baseline	week 9 mean seDBP change from baseline	week 12 mean seDBP change from baseline	week 15 mean seDBP change from baseline	week 18 mean seDBP change from baseline
Aml + Olm + Hctz	-4.1	-8.2	-9.7	-11.2	-14.4	-15.1

[back to top]

Change From Week 0 (Baseline) in Mean ABPM SBP After 12 Weeks of Active Treatment

Daytime mean SBP, Nighttime mean SBP, Last 6 hour mean SBP, Last 4 hour mean SBP, Last 2 hour mean SBP (NCT00654745)
Timeframe: week 0 - week 12 (24-hour, Daytime, Nighttime, Last 6 hour, Last 4 hour, Last 2 hour)

Intervention	mm Hg (Mean)
	daytime mean SBP change from baseline	nighttime mean SBP change from baseline	last 6 hours mean SBP change from baseline	last 4 hours mean SBP change from baseline	last 2 hours mean SBP change from baseline
Aml + Olm + Hctz	-20.8	-18.5	-18.9	-19.1	-19.5

[back to top]

Change From Week 0 (Baseline) in Mean ABPM Diastolic Blood Pressure (DBP) After 12 Weeks of Active Treatment

24-hour mean DBP, Daytime mean DBP, Nighttime mean DBP, Last 6 hour mean DBP, Last 4 hour mean DBP, Last 2 hour mean DBP (NCT00654745)
Timeframe: week 0 - week 12 (24-hour, Daytime, Nighttime, Last 6 hour, Last 4 hour, Last 2 hour)

Intervention	mm Hg (Mean)
	24-hour mean DBP change from baseline	daytime mean DBP change from baseline	nighttime mean DBP change from baseline	last 6 hour mean DBP change from baseline	last 4 hour mean DBP change from baseline	last 2 hour mean DBP change from baseline
Aml + Olm + Hctz	-11.2	-11.7	-10.4	-10.9	-11.1	-11.5

[back to top]

Change From Week 0 (Baseline) in Mean 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Systolic Blood Pressure (SBP) After 12 Weeks of Active Treatment

Change from week 0 (baseline) in mean 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Systolic Blood Pressure (SBP) after 12 weeks of active treatment. change = week 12 - week 0. (NCT00654745)
Timeframe: week 0 - week 12

Intervention	mm Hg (Mean)
Aml + Olm + Hctz	-19.9

[back to top]

Number of Participants Achieving Mean Nighttime Ambulatory Systolic and Diastolic Blood Pressure Reductions at Week 12

number of participants achieving mean nighttime ambulatory systolic and diastolic blood pressure reductions of; SBP reduction <= 15 mmHg, SBP reduction > 15 mmHg & <= 30 mmHg, SBP reduction > 30 mmHg & <= 45 mmHg, SBP reduction > 45 mmHg, DBP reduction <= 10 mmHg, DBP reduction > 10 mmHg & <= 15 mmHg, DBP reduction > 15 mmHg & <= 20 mmHg, DBP reduction > 20 mmHg at week 12 (NCT00654745)
Timeframe: week 0 - week 12

Intervention	participants (Number)
	mean nighttime SBP reduction =<15 mm Hg	mean nighttime SBP reduction >15 & =<30 mm Hg	mean nighttime SBP reduction >30 & =<45 mm Hg	mean nighttime SBP reduction >45 mm Hg	mean nighttime DBP reduction =<10 mm Hg	mean nighttime SBP reduction >10 & =<15 mm Hg	mean nighttime SBP reduction >15 & =<20 mm Hg	mean nighttime DBP reduction >20 mm Hg
Aml + Olm + Hctz	60	79	21	5	80	41	21	23

[back to top]

Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 3

Intervention	participants (Number)
	mean seated SBP reduction =<15 mm Hg	mean seated SBP reduction >15 & =<30 mm Hg	mean seated SBP reduction >30 & =<45 mm Hg	mean seated SBP reduction >45 mm Hg	mean seated DBP reduction =<10 mm Hg	mean seated DBP reduction >10 & =<15 mm Hg	mean seated DBP reduction >15 & =<20 mm Hg	mean seated DBP reduction >20 mm Hg
Aml + Olm + Hctz	131	62	6	2	163	25	10	3

[back to top]

Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 6

Intervention	participants (Number)
	mean seated SBP reduction =<15 mm Hg	mean seated SBP reduction >15 & =<30 mm Hg	mean seated SBP reduction >30 & =<45 mm Hg	mean seated SBP reduction >45 mm Hg	mean seated DBP reduction =<10 mm Hg	mean seated DBP reduction >10 & =<15 mm Hg	mean seated DBP reduction >15 & =<20 mm Hg	mean seated DBP reduction >20 mm Hg
Aml + Olm + Hctz	69	90	31	2	120	33	24	15

[back to top]

Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 9

Intervention	participants (Number)
	mean seated SBP reduction =<15 mm Hg	mean seated SBP reduction >15 & =<30 mm Hg	mean seated SBP reduction >30 & =<45 mm Hg	mean seated SBP reduction >45 mm Hg	mean seated DBP reduction =<10 mm Hg	mean seated DBP reduction >10 & =<15 mm Hg	mean seated DBP reduction >15 & =<20 mm Hg	mean seated DBP reduction >20 mm Hg
Aml + Olm + Hctz	72	69	34	9	100	43	18	23

[back to top]

Number of Participants Achieving Seated Systolic and Diastolic Blood Pressure Thresholds at Week 12

number of participants achieving seated systolic and diastolic blood pressure thresholds BP<135/85, BP<130/80, BP<125/75, BP<120/80, SBP<135, SBP<130, SBP<125, SBP<120, DBP<85, DBP<80, DBP<75 at week 12 (NCT00654745)
Timeframe: week 0 - week 12

Intervention	participants (Number)
	mean BP < 135/85	mean BP < 130/80	mean BP < 125/75	mean BP < 120/80	mean SBP < 135	mean SBP < 130	mean SBP < 125	mean SBP < 120	mean DBP < 85	mean DBP < 80	mean DBP < 75
Aml + Olm + Hctz	86	61	33	28	93	70	46	28	134	105	74

[back to top]

Number of Participants Achieving Seated Systolic and Diastolic Blood Pressure Thresholds at Week 15

Intervention	participants (Number)
	mean BP < 135/85	mean BP < 130/80	mean BP < 125/75	mean BP < 120/80	mean SBP < 135	mean SBP < 130	mean SBP < 125	mean SBP < 120	mean DBP < 85	mean DBP < 80	mean DBP < 75
Aml + Olm + Hctz	114	83	51	45	116	95	69	48	153	122	96

[back to top]

Number of Participants Achieving Seated Systolic and Diastolic Blood Pressure Thresholds at Week 18

Intervention	participants (Number)
	mean BP < 135/85	mean BP < 130/80	mean BP < 125/75	mean BP < 120/80	mean SBP < 135	mean SBP < 130	mean SBP < 125	mean SBP < 120	mean DBP < 85	mean DBP < 80	mean DBP < 75
Aml + Olm + Hctz	117	87	56	49	123	101	74	51	147	128	94

[back to top]

Number of Participants Achieving Seated Systolic and Diastolic Blood Pressure Thresholds at Week 3

Intervention	participants (Number)
	mean BP < 135/85	mean BP < 130/80	mean BP < 125/75	mean BP < 120/80	mean SBP < 135	mean SBP < 130	mean SBP < 125	mean SBP < 120	mean DBP < 85	mean DBP < 80	mean DBP < 75
Aml + Olm + Hctz	31	10	4	2	41	17	9	2	99	58	29

[back to top]

Number of Participants Achieving Seated Systolic and Diastolic Blood Pressure Thresholds at Week 6

Intervention	participants (Number)
	mean BP < 135/85	mean BP < 130/80	mean BP < 125/75	mean BP < 120/80	mean SBP < 135	mean SBP < 130	mean SBP < 125	mean SBP < 120	mean DBP < 85	mean DBP < 80	mean DBP < 75
Aml + Olm + Hctz	61	36	18	13	73	48	31	14	127	91	48

[back to top]

Number of Participants Achieving Seated Systolic and Diastolic Blood Pressure Thresholds at Week 9

Intervention	participants (Number)
	mean BP < 135/85	mean BP < 130/80	mean BP < 125/75	mean BP < 120/80	mean SBP < 135	mean SBP < 130	mean SBP < 125	mean SBP < 120	mean DBP < 85	mean DBP < 80	mean DBP < 75
Aml + Olm + Hctz	76	47	25	19	82	61	41	20	132	95	64

[back to top]

Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 18

Intervention	participants (Number)
	mean seated SBP reduction =<15 mm Hg	mean seated SBP reduction >15 & =<30 mm Hg	mean seated SBP reduction >30 & =<45 mm Hg	mean seated SBP reduction >45 mm Hg	mean seated DBP reduction =<10 mm Hg	mean seated DBP reduction >10 & =<15 mm Hg	mean seated DBP reduction >15 & =<20 mm Hg	mean seated DBP reduction >20 mm Hg
Aml + Olm + Hctz	22	53	64	25	50	33	29	52

[back to top]

Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in nighttime (12am to 6am) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am. (NCT00696241)
Timeframe: Baseline and Week 6.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20 mg QD	-11.10
Azilsartan Medoxomil 40 mg QD	-12.39
Azilsartan Medoxomil 80 mg QD	-13.35
Olmesartan 40 mg QD	-12.13
Placebo QD	-0.97

[back to top]

Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in nighttime (12am to 6am) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am. (NCT00696241)
Timeframe: Baseline and Week 6.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20 mg QD	-6.98
Azilsartan Medoxomil 40 mg QD	-7.90
Azilsartan Medoxomil 80 mg QD	-7.79
Olmesartan 40 mg QD	-7.62
Placebo QD	-0.96

[back to top]

Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in 24-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing. (NCT00696241)
Timeframe: Baseline and Week 6.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20 mg QD	-12.15
Azilsartan Medoxomil 40 mg QD	-13.48
Azilsartan Medoxomil 80 mg QD	-14.62
Olmesartan 40 mg QD	-12.56
Placebo QD	-1.40

[back to top]

Change From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in 24-hour mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing. (NCT00696241)
Timeframe: Baseline and Week 6.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20 mg QD	-7.47
Azilsartan Medoxomil 40 mg QD	-8.38
Azilsartan Medoxomil 80 mg QD	-8.61
Olmesartan 40 mg QD	-7.74
Placebo QD	-0.69

[back to top]

Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring

The change in the 12-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing. (NCT00696241)
Timeframe: Baseline and Week 6.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20 mg QD	-12.72
Azilsartan Medoxomil 40 mg QD	-14.05
Azilsartan Medoxomil 80 mg QD	-15.18
Olmesartan 40 mg QD	-13.07
Placebo QD	-1.36

[back to top]

Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring

The change in the 12-hour mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing. (NCT00696241)
Timeframe: Baseline and Week 6.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20 mg QD	-7.72
Azilsartan Medoxomil 40 mg QD	-8.63
Azilsartan Medoxomil 80 mg QD	-8.88
Olmesartan 40 mg QD	-7.86
Placebo QD	-0.47

[back to top]

Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure

The change in mean trough clinic sitting systolic blood pressure measured at final visit or week 6 relative to baseline. (NCT00696241)
Timeframe: Baseline and Week 6.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20 mg QD	-14.28
Azilsartan Medoxomil 40 mg QD	-14.47
Azilsartan Medoxomil 80 mg QD	-17.58
Olmesartan 40 mg QD	-14.87
Placebo QD	-2.06

[back to top]

Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure

The change in mean trough clinic sitting diastolic blood pressure measured at final visit or week 6 relative to baseline. (NCT00696241)
Timeframe: Baseline and Week 6.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20 mg QD	-6.82
Azilsartan Medoxomil 40 mg QD	-6.86
Azilsartan Medoxomil 80 mg QD	-8.42
Olmesartan 40 mg QD	-6.91
Placebo QD	0.21

[back to top]

Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in daytime (6am to 10pm) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm. (NCT00696241)
Timeframe: Baseline and Week 6.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20 mg QD	-12.57
Azilsartan Medoxomil 40 mg QD	-13.75
Azilsartan Medoxomil 80 mg QD	-14.96
Olmesartan 40 mg QD	-12.73
Placebo QD	-1.54

[back to top]

Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in daytime (6am to 10pm) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm. (NCT00696241)
Timeframe: Baseline and Week 6.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20 mg QD	-7.71
Azilsartan Medoxomil 40 mg QD	-8.43
Azilsartan Medoxomil 80 mg QD	-8.87
Olmesartan 40 mg QD	-7.82
Placebo QD	-0.59

[back to top]

Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in trough mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing. (NCT00696241)
Timeframe: Baseline and Week 6.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20 mg QD	-12.15
Azilsartan Medoxomil 40 mg QD	-12.39
Azilsartan Medoxomil 80 mg QD	-13.42
Olmesartan 40 mg QD	-11.10
Placebo QD	-1.21

[back to top]

Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as < 90 mm Hg and/or Reduction From Baseline ≥ 10 mm Hg

Percentage of participants who achieve a clinic diastolic blood pressure response measured at week 6, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg. Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements. (NCT00696241)
Timeframe: Baseline and Week 6.

Intervention	percentage of participants (Number)
Azilsartan Medoxomil 20 mg QD	67.5
Azilsartan Medoxomil 40 mg QD	71.0
Azilsartan Medoxomil 80 mg QD	73.5
Olmesartan 40 mg QD	73.9
Placebo QD	47.9

[back to top]

Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as < 140 mm Hg and/or Reduction From Baseline ≥ 20 mm Hg

Percentage of participants who achieve a clinic systolic blood pressure response measured at week 6, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements. (NCT00696241)
Timeframe: Baseline and Week 6.

Intervention	percentage of participants (Number)
Azilsartan Medoxomil 20 mg QD	47.8
Azilsartan Medoxomil 40 mg QD	50.4
Azilsartan Medoxomil 80 mg QD	56.6
Olmesartan 40 mg QD	53.2
Placebo QD	17.1

[back to top]

Percentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response

Percentage of participants who achieve both a clinic diastolic and systolic blood pressure response measured at week 6, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg AND less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Diastolic and systolic blood pressure is based on the arithmetic mean of the 3 sitting blood pressure measurements. (NCT00696241)
Timeframe: Baseline and Week 6.

Intervention	percentage of participants (Number)
Azilsartan Medoxomil 20 mg QD	42.7
Azilsartan Medoxomil 40 mg QD	45.3
Azilsartan Medoxomil 80 mg QD	52.0
Olmesartan 40 mg QD	47.5
Placebo QD	14.3

[back to top]

Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in trough mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing. (NCT00696241)
Timeframe: Baseline and Week 6.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20 mg QD	-7.96
Azilsartan Medoxomil 40 mg QD	-7.93
Azilsartan Medoxomil 80 mg QD	-8.68
Olmesartan 40 mg QD	-7.56
Placebo QD	-1.12

[back to top]

Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as < 90 mm Hg and/or Reduction From Baseline ≥ 10 mm Hg

Intervention	percentage of participants (Number)
Azilsartan Medoxomil 40 mg QD	68.8
Azilsartan Medoxomil 80 mg QD	71.1
Valsartan 320 mg QD	63.8
Olmesartan 40 mg QD	68.2
Placebo QD	43.9

[back to top]

Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as < 140 mm Hg and/or Reduction From Baseline ≥ 20 mm Hg

Intervention	percentage of participants (Number)
Azilsartan Medoxomil 40 mg QD	56.5
Azilsartan Medoxomil 80 mg QD	57.8
Valsartan 320 mg QD	48.7
Olmesartan 40 mg QD	48.8
Placebo QD	22.3

[back to top]

Percentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response

Intervention	percentage of participants (Number)
Azilsartan Medoxomil 40 mg QD	49.1
Azilsartan Medoxomil 80 mg QD	52.6
Valsartan 320 mg QD	43.9
Olmesartan 40 mg QD	44.5
Placebo QD	18.2

[back to top]

Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 40 mg QD	-8.96
Azilsartan Medoxomil 80 mg QD	-9.80
Valsartan 320 mg QD	-7.23
Olmesartan 40 mg QD	-7.82
Placebo QD	0.01

[back to top]

Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure

The change in mean trough clinic sitting systolic blood pressure measured at final visit or week 6 relative to baseline. (NCT00696436)
Timeframe: Baseline and Week 6.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 40 mg QD	-6.97
Azilsartan Medoxomil 80 mg QD	-8.27
Valsartan 320 mg QD	-5.11
Olmesartan 40 mg QD	-6.10
Placebo QD	-0.76

[back to top]

Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure.

The change in mean trough clinic sitting systolic blood pressure measured at final visit or week 6 relative to baseline. (NCT00696436)
Timeframe: Baseline and Week 6.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 40 mg QD	-16.38
Azilsartan Medoxomil 80 mg QD	-16.74
Valsartan 320 mg QD	-11.31
Olmesartan 40 mg QD	-13.20
Placebo QD	-1.83

[back to top]

Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 40 mg QD	-9.16
Azilsartan Medoxomil 80 mg QD	-10.13
Valsartan 320 mg QD	-7.42
Olmesartan 40 mg QD	-7.82
Placebo QD	0.01

[back to top]

Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 40 mg QD	-14.03
Azilsartan Medoxomil 80 mg QD	-15.55
Valsartan 320 mg QD	-10.44
Olmesartan 40 mg QD	-12.23
Placebo QD	-0.10

[back to top]

Change From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 40 mg QD	-8.65
Azilsartan Medoxomil 80 mg QD	-9.43
Valsartan 320 mg QD	-7.09
Olmesartan 40 mg QD	-7.74
Placebo QD	-0.07

[back to top]

Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 40 mg QD	-13.42
Azilsartan Medoxomil 80 mg QD	-14.53
Valsartan 320 mg QD	-10.22
Olmesartan 40 mg QD	-11.99
Placebo QD	-0.25

[back to top]

Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 40 mg QD	-7.65
Azilsartan Medoxomil 80 mg QD	-8.54
Valsartan 320 mg QD	-6.26
Olmesartan 40 mg QD	-7.82
Placebo QD	0.10

[back to top]

Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 40 mg QD	-12.28
Azilsartan Medoxomil 80 mg QD	-13.32
Valsartan 320 mg QD	-9.66
Olmesartan 40 mg QD	-11.90
Placebo QD	-0.31

[back to top]

Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 40 mg QD	-8.69
Azilsartan Medoxomil 80 mg QD	-8.61
Valsartan 320 mg QD	-6.22
Olmesartan 40 mg QD	-8.25
Placebo QD	-0.69

[back to top]

Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 40 mg QD	-12.46
Azilsartan Medoxomil 80 mg QD	-13.38
Valsartan 320 mg QD	-9.14
Olmesartan 40 mg QD	-11.65
Placebo QD	-0.55

[back to top]

Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 40 mg QD	-13.73
Azilsartan Medoxomil 80 mg QD	-15.02
Valsartan 320 mg QD	-10.26
Olmesartan 40 mg QD	-12.16
Placebo QD	-0.11

[back to top]

Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks

Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. (NCT00791258)
Timeframe: Baseline to 12 weeks

Intervention	Percentage of participants (Number)
	24-hour mean systolic blood pressure <140 mmHg	24-hour mean systolic blood pressure <135 mmHg	24-hour mean systolic blood pressure <130 mmHg	24-hour mean systolic blood pressure <120 mmHg	24-hour mean diastolic blood pressure <90 mmHg	24-hour mean diastolic blood pressure <85 mmHg	24-hour mean diastolic blood pressure <80 mmHg	24-hour mean blood pressure <140/90 mmHg	24-hour mean blood pressure <135/95 mmHg	24-hour mean blood pressure <135/80 mmHg	24-hour mean blood pressure <130/80 mmHg	24-hour mean blood pressure <125/75 mmHg	24-hour mean blood pressure <120/80 mmHg	24-hour mean blood pressure <120/70 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	95.6	90.4	79.9	47.2	98.7	96.1	84.7	94.3	89.1	80.3	73.4	52.4	45.9	27.5

[back to top]

Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks

Intervention	Percentage of participants (Number)
	24-hour mean systolic blood pressure <140 mmHg	24-hour mean systolic blood pressure <135 mmHg	24-hour mean systolic blood pressure <130 mmHg	24-hour mean systolic blood pressure <120 mmHg	24-hour mean diastolic blood pressure <90 mmHg	24-hour mean diastolic blood pressure <85 mmHg	24-hour mean diastolic blood pressure <80 mmHg	24-hour mean blood pressure <140/90 mmHg	24-hour mean blood pressure <135/95 mmHg	24-hour mean blood pressure <135/80 mmHg	24-hour mean blood pressure <130/80 mmHg	24-hour mean blood pressure <125/75 mmHg	24-hour mean blood pressure <120/80 mmHg	24-hour mean blood pressure <120/70 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	99.5	97.5	94.5	70.4	100.0	97.5	93.0	99.5	96.0	92.5	90.5	75.4	70.4	55.3

[back to top]

Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks

Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Daytime is defined as 8AM - 4PM. (NCT00791258)
Timeframe: Baseline to 12 weeks

Intervention	Percentage of participants (Number)
	Daytime mean systolic blood pressure <140 mmHg	Daytime mean systolic blood pressure <135 mmHg	Daytime mean systolic blood pressure <130 mmHg	Daytime mean systolic blood pressure <120 mmHg	Daytime mean diastolic blood pressure <90 mmHg	Daytime mean diastolic blood pressure <85 mmHg	Daytime mean diastolic blood pressure <80 mmHg	Daytime mean blood pressure <140/90 mmHg	Daytime mean blood pressure <135/95 mmHg	Daytime mean blood pressure <135/80 mmHg	Daytime mean blood pressure <130/80 mmHg	Daytime mean blood pressure <125/75 mmHg	Daytime mean blood pressure <120/80 mmHg	Daytime mean blood pressure <120/70 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	88.2	79.9	66.4	28.8	95.6	83.0	65.5	86.9	72.9	61.1	53.3	31.9	27.9	13.1

[back to top]

Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks

Intervention	Percentage of participants (Number)
	Daytime mean systolic blood pressure <140 mmHg	Daytime mean systolic blood pressure <135 mmHg	Daytime mean systolic blood pressure <130 mmHg	Daytime mean systolic blood pressure <120 mmHg	Daytime mean diastolic blood pressure <90 mmHg	Daytime mean diastolic blood pressure <85 mmHg	Daytime mean diastolic blood pressure <80 mmHg	Daytime mean blood pressure <140/90 mmHg	Daytime mean blood pressure <135/95 mmHg	Daytime mean blood pressure <135/80 mmHg	Daytime mean blood pressure <130/80 mmHg	Daytime mean blood pressure <125/75 mmHg	Daytime mean blood pressure <120/80 mmHg	Daytime mean blood pressure <120/70 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	96.5	93.5	83.9	51.8	98.5	92.5	83.9	95.0	88.4	81.9	77.4	56.8	51.3	33.2

[back to top]

Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks

Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Nighttime is defined as 10p.m. - 6 a.m. (NCT00791258)
Timeframe: Baseline to 12 weeks

Intervention	Percentage of participants (Number)
	Nighttime mean systolic blood pressure <140 mmHg	Nighttime mean systolic blood pressure <135 mmHg	Nighttime mean systolic blood pressure <130 mmHg	Nighttime mean systolic blood pressure <120 mmHg	Nighttime mean diastolic blood pressure <90 mmHg	Nighttime mean diastolic blood pressure <85 mmHg	Nighttime mean diastolic blood pressure <80 mmHg	Nighttime mean blood pressure <140/90 mmHg	Nighttime mean blood pressure <135/95 mmHg	Nighttime mean blood pressure <135/80 mmHg	Nighttime mean blood pressure <130/80 mmHg	Nighttime mean blood pressure <125/75 mmHg	Nighttime mean blood pressure <120/80 mmHg	Nighttime mean blood pressure <120/70 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	97.8	94.3	92.6	74.7	99.6	98.3	94.8	97.4	93.4	90.8	89.1	77.7	74.2	62.0

[back to top]

Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks

Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Nighttime is defined as 10 p.m. - 6 a.m. (NCT00791258)
Timeframe: Baseline to 20 weeks

Intervention	Percentage of participants (Number)
	Nighttime mean systolic blood pressure <140 mmHg	Nighttime mean systolic blood pressure <135 mmHg	Nighttime mean systolic blood pressure <130 mmHg	Nighttime mean systolic blood pressure <120 mmHg	Nighttime mean diastolic blood pressure <90 mmHg	Nighttime mean diastolic blood pressure <85 mmHg	Nighttime mean diastolic blood pressure <80 mmHg	Nighttime mean blood pressure <140/90 mmHg	Nighttime mean blood pressure <135/95 mmHg	Nighttime mean blood pressure <135/80 mmHg	Nighttime mean blood pressure <130/80 mmHg	Nighttime mean blood pressure <125/75 mmHg	Nighttime mean blood pressure <120/80 mmHg	Nighttime mean blood pressure <120/70 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	99.5	99.5	97.5	86.4	99.5	98.5	96.0	99.0	98.5	96.0	95.0	88.9	85.9	78.9

[back to top]

Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks

(NCT00791258)
Timeframe: Baseline to 12 weeks

Intervention	Percentage of participants (Number)
	Systolic blood pressure <140 mmHg	Systolic blood pressure <135 mmHg	Systolic blood pressure <130 mmHg	Systolic blood pressure <120 mmHg	Diastolic blood pressure <90 mmHg	Diastolic blood pressure <85 mmHg	Diastolic blood pressure <80 mmHg	Blood pressure <140/90 mmHg	Blood pressure <135/80 mmHg	Blood pressure <130/80 mmHg	Blood pressure <120/80 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	88.5	75.2	62.0	33.6	94.7	83.2	61.1	86.7	55.8	49.6	29.2

[back to top]

Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks

(NCT00791258)
Timeframe: Baseline to 20 weeks

Intervention	Percentage of participants (Number)
	Systolic blood pressure <140 mmHg	Systolic blood pressure <135 mmHg	Systolic blood pressure <130 mmHg	Systolic blood pressure <120 mmHg	Diastolic blood pressure <90 mmHg	Diastolic blood pressure <85 mmHg	Diastolic blood pressure <80 mmHg	Blood pressure <140/90 mmHg	Blood pressure <135/80 mmHg	Blood pressure <130/80 mmHg	Blood pressure <120/80 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	93.8	87.6	79.7	47.8	98.2	89.4	77.0	92.9	74.3	69.9	43.4

[back to top]

Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks

(NCT00791258)
Timeframe: Baseline to 12 weeks

Intervention	Percentage of participants (Number)
	Systolic blood pressure <140 mmHg	Systolic blood pressure <135 mmHg	Systolic blood pressure <130 mmHg	Systolic blood pressure <120 mmHg	Diastolic blood pressure <90 mmHg	Diastolic blood pressure <85 mmHg	Diastolic blood pressure <80 mmHg	Blood pressure <140/90 mmHg	Blood pressure <135/80 mmHg	Blood pressure <130/80 mmHg	Blood pressure <120/80 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	73.5	59.0	47.9	18.8	86.3	72.7	48.7	68.4	40.2	34.2	16.2

[back to top]

Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks

(NCT00791258)
Timeframe: Baseline to 20 weeks

Intervention	Percentage of participants (Number)
	Systolic blood pressure <140 mmHg	Systolic blood pressure <135 mmHg	Systolic blood pressure <130 mmHg	Systolic blood pressure <120 mmHg	Diastolic blood pressure <90 mmHg	Diastolic blood pressure <85 mmHg	Diastolic blood pressure <80 mmHg	Blood pressure <140/90 mmHg	Blood pressure <135/80 mmHg	Blood pressure <130/80 mmHg	Blood pressure <120/80 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	89.7	83.8	69.2	41.0	91.5	85.5	69.2	85.5	64.1	59.8	36.8

[back to top]

Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 12 Weeks

(NCT00791258)
Timeframe: Baseline to 12 weeks

Intervention	Percentage of participants (Number)
	Systolic blood pressure <140 mmHg	Systolic blood pressure <135 mmHg	Systolic blood pressure <130 mmHg	Systolic blood pressure <120 mmHg	Diastolic blood pressure <90 mmHg	Diastolic blood pressure <85 mmHg	Diastolic blood pressure <80 mmHg	Blood pressure <140/90 mmHg	Blood pressure <135/80 mmHg	Blood pressure <130/80 mmHg	Blood pressure <120/80 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	92.8	82.5	78.3	51.2	94.6	86.8	71.7	88.6	67.5	65.1	48.2

[back to top]

Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 20 Weeks

(NCT00791258)
Timeframe: Baseline to 20 weeks

Intervention	Percentage of participants (Number)
	Systolic blood pressure <140 mmHg	Systolic blood pressure <135 mmHg	Systolic blood pressure <130 mmHg	Systolic blood pressure <120 mmHg	Diastolic blood pressure <90 mmHg	Diastolic blood pressure <85 mmHg	Diastolic blood pressure <80 mmHg	Blood pressure <140/90 mmHg	Blood pressure <135/80 mmHg	Blood pressure <130/80 mmHg	Blood pressure <120/80 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	92.8	82.5	78.3	51.2	94.6	86.8	71.7	88.6	67.5	65.1	48.2

[back to top]

Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks

(NCT00791258)
Timeframe: Baseline to 12 weeks

Intervention	Percentage of participants (Number)
	Systolic blood pressure <140 mmHg	Systolic blood pressure <135 mmHg	Systolic blood pressure <130 mmHg	Systolic blood pressure <120 mmHg	Diastolic blood pressure <90 mmHg	Diastolic blood pressure <85 mmHg	Diastolic blood pressure <80 mmHg	Blood pressure <140/90 mmHg	Blood pressure <135/80 mmHg	Blood pressure <130/80 mmHg	Blood pressure <120/80 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	100.0	90.0	75.0	25.0	100.0	95.0	75.0	100.0	70.0	65.0	20.0

[back to top]

Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks

(NCT00791258)
Timeframe: Baseline to 20 weeks

Intervention	Percentage of participants (Number)
	Systolic blood pressure <140 mmHg	Systolic blood pressure <135 mmHg	Systolic blood pressure <130 mmHg	Systolic blood pressure <120 mmHg	Diastolic blood pressure <90 mmHg	Diastolic blood pressure <85 mmHg	Diastolic blood pressure <80 mmHg	Blood pressure <140/90 mmHg	Blood pressure <135/80 mmHg	Blood pressure <130/80 mmHg	Blood pressure <120/80 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	100.0	100.0	95.0	45.0	100.0	95.0	95.0	100.0	95.0	95.0	40.0

[back to top]

Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 12 Weeks

(NCT00791258)
Timeframe: Baseline to 12 weeks

Intervention	Percentage of participants (Number)
	Systolic blood pressure <140 mmHg	Systolic blood pressure <135 mmHg	Systolic blood pressure <130 mmHg	Systolic blood pressure <120 mmHg	Diastolic blood pressure <90 mmHg	Diastolic blood pressure <85 mmHg	Diastolic blood pressure <80 mmHg	Blood pressure <140/90 mmHg	Blood pressure <135/80 mmHg	Blood pressure <130/80 mmHg	Blood pressure <120/80 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	81.3	69.3	53.0	31.5	94.4	80.6	64.3	78.5	52.7	43.5	27.9

[back to top]

Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 20 Weeks

(NCT00791258)
Timeframe: Baseline to 20 weeks

Intervention	Percentage of participants (Number)
	Systolic blood pressure <140 mmHg	Systolic blood pressure <135 mmHg	Systolic blood pressure <130 mmHg	Systolic blood pressure <120 mmHg	Diastolic blood pressure <90 mmHg	Diastolic blood pressure <85 mmHg	Diastolic blood pressure <80 mmHg	Blood pressure <140/90 mmHg	Blood pressure <135/80 mmHg	Blood pressure <130/80 mmHg	Blood pressure <120/80 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	91.5	84.5	71.4	47.4	98.2	89.8	78.5	90.5	71.0	61.5	44.5

[back to top]

Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks

(NCT00791258)
Timeframe: Baseline to 12 weeks

Intervention	Percentage of participants (Number)
	Systolic blood pressure <140 mmHg	Systolic blood pressure <135 mmHg	Systolic blood pressure <130 mmHg	Systolic blood pressure <120 mmHg	Diastolic blood pressure <90 mmHg	Diastolic blood pressure <85 mmHg	Diastolic blood pressure <80 mmHg	Blood pressure <140/90 mmHg	Blood pressure <135/80 mmHg	Blood pressure <130/80 mmHg	Blood pressure <120/80 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	80.8	69.2	56.0	26.1	89.7	76.9	59.0	76.1	52.6	46.2	23.1

[back to top]

Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks

(NCT00791258)
Timeframe: Baseline to 20 weeks

Intervention	Percentage of participants (Number)
	Systolic blood pressure <140 mmHg	Systolic blood pressure <135 mmHg	Systolic blood pressure <130 mmHg	Systolic blood pressure <120 mmHg	Diastolic blood pressure <90 mmHg	Diastolic blood pressure <85 mmHg	Diastolic blood pressure <80 mmHg	Blood pressure <140/90 mmHg	Blood pressure <135/80 mmHg	Blood pressure <130/80 mmHg	Blood pressure <120/80 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	92.3	87.2	79.5	47.4	96.6	89.3	74.8	90.6	70.1	65.0	44.0

[back to top]

Percentage of Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

Intervention	Percentage of Participants (Number)
	4 weeks: <140/90 mm Hg, N=975	4 weeks: <135/80 mm Hg, N=975	4 weeks: <130/80 mm Hg, N=975	4 weeks: <120/80 mm Hg, N=975	8 weeks: <140/90 mm Hg, N=929	8 weeks: <135/80 mm Hg, N=929	8 weeks: <130/80 mm Hg, N=929	8 weeks: <120/80 mm Hg, N=929	12 weeks: <140/90 mm Hg, N=865	12 weeks: <135/80 mm Hg, N=865	12 weeks: <130/80 mm Hg, N=865	12 weeks: <120/80 mm Hg, N=865	16 weeks: <140/90mm Hg, N=797	16 weeks: <135/80mm Hg, N=797	16 weeks: <130/80mm Hg, N=797	16 weeks: <120/80mm Hg, N=797	20 weeks: <140/90 mm Hg, N=745	20 weeks: <135/80 mm Hg, N=745	20 weeks: <130/80 mm Hg, N=745	20 weeks: <120/80 mm Hg, N=745
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	49.1	23.0	17.3	7.8	52.4	29.8	24.8	11.2	68.1	40.0	34.3	17.6	77.8	51.3	46.2	28.7	81.3	55.6	50.1	28.2

[back to top]

Percentage of Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

Intervention	Percentage of participants (Number)
	4 weeks: <90 mm Hg, N=975	4weeks: <85 mm Hg, N=975	4 weeks: <80 mm Hg, N=975	8 weeks: <90 mm Hg, N=929	8 weeks: <85 mm Hg, N=929	8 weeks: <80 mm Hg, N=929	12 weeks: <90 mm Hg, N=865	12 weeks: <85 mm Hg, N=865	12 weeks: <80 mm Hg, N=865	16 weeks: <90 mm Hg, N=797	16 weeks: <85 mm Hg, N=797	16 weeks: <80 mm Hg, N=797	20 weeks: <90 mm Hg, N=745	20 weeks: <85 mm Hg, N=745	20 weeks: <80 mm Hg, N=745
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	71.3	55.2	34.2	75.1	57.1	40.2	84.3	68.7	49.5	90.2	76.9	59.6	89.7	79.5	62.0

[back to top]

Percentage of Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

Intervention	Percentage of Participants (Number)
	4 weeks: ≤ 10 mm Hg, N=975	4 weeks: >10 and ≤ 15 mm Hg, N=975	4 weeks: >15 and ≤ 20 mm Hg, N=975	4 weeks: >20 mm Hg, N=975	8 weeks: ≤ 10 mm Hg, N=929	8 weeks: >10 and ≤ 15 mm Hg, N=929	8 weeks: >15 and ≤ 20 mm Hg, N=929	8 weeks: >20 mm Hg, N=929	12 weeks: ≤ 10 mm Hg, N=865	12 weeks: >10 and ≤ 15 mm Hg, N=865	12 weeks: >15 and ≤ 20 mm Hg, N=865	12 weeks: >20 mm Hg, N=865	16 weeks: ≤ 10 mm Hg, N=797	16 weeks: >10 and ≤ 15 mm Hg, N=797	16 weeks: >15 and ≤ 20 mm Hg, N=797	16 weeks: >20 mm Hg, N=797	20 weeks: ≤ 10 mm Hg, N=745	20 weeks: >10 and ≤ 15 mm Hg, N=745	20 weeks: >15 and ≤ 20 mm Hg, N=745	20 weeks: >20 mm Hg, N=745
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	61.3	21.0	10.5	7.2	54.7	20.7	14.1	10.6	43.8	24.1	15.8	16.3	30.4	22.8	21.5	25.4	31.4	19.9	22.6	26.2

[back to top]

Percentage of Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

Intervention	Percentage of Participants (Number)
	4 weeks: <140 mm Hg, N=975	4 weeks: <135 mm Hg, N=975	4 weeks: <130 mm Hg, N=975	4 weeks: <120 mm Hg, N=975	8 weeks: <140 mm Hg, N=929	8 weeks: <135 mm Hg, N=929	8 weeks: <130 mm Hg, N=929	8 weeks: <120 mm Hg, N=929	12 weeks: <140 mm Hg, N=865	12 weeks: <135 mm Hg, N=865	12 weeks: <130 mm Hg, N=865	12 weeks: <120 mm Hg, N=865	16 weeks: <140 mm Hg, N=797	16 weeks: <135 mm Hg, N=797	16 weeks: <130 mm Hg, N=797	16 weeks: <120 mm Hg, N=797	20 weeks: <140 mm Hg, N=745	20 weeks: <135 mm Hg, N=745	20 weeks: <130 mm Hg, N=745	20 weeks: <120 mm Hg, N=745
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	54.2	39.8	25.3	8.9	57.2	45.9	35.0	12.9	72.6	59.0	45.3	19.4	80.9	70.3	58.9	30.9	84.3	75.2	64.2	31.5

[back to top]

Percentage of Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

Intervention	Percentage of Participants (Number)
	4 weeks: ≤ 15 mm Hg, N=975	4 weeks: >15 and ≤ 30 mm Hg, N=975	4 weeks: >30 and ≤ 45 mm Hg, N=975	4 weeks: >45 mm Hg, N=975	8 weeks: ≤ 15 mm Hg, N=929	8 weeks: >15 and ≤ 30 mm Hg, N=929	8 weeks: >30 and ≤ 45 mm Hg, N=929	8 weeks: >45 mm Hg, N=929	12 weeks: ≤ 15 mm Hg, N=865	12 weeks: >15 and ≤ 30 mm Hg, N=865	12 weeks: >30 and ≤ 45 mm Hg, N=865	12 weeks: >45 mm Hg, N=865	16 weeks: ≤ 15 mm Hg, N=797	16 weeks: >15 and ≤ 30 mm Hg, N=797	16 weeks: >30 and ≤ 45 mm Hg, N=797	16 weeks: >45 mm Hg, N=797	20 weeks: ≤ 15 mm Hg, N=745	20 weeks: >15 and ≤ 30 mm Hg, N=745	20 weeks: >30 and ≤ 45 mm Hg, N=745	20 weeks: >45 mm Hg, N=745
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	51.4	36.6	10.5	1.5	45.8	37.7	14.3	2.3	30.5	43.1	22.4	3.9	23.2	35.9	32.0	8.9	20.4	36.2	34.0	9.4

[back to top]

Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

Intervention	Percentage of Participants (Number)
	4 weeks: <90 mm Hg, N=454	4 weeks: <85 mm Hg, N=454	4 weeks: <80 mm Hg, N=454	8 weeks: <90 mm Hg, N=457	8 weeks: <85 mm Hg, N=457	8 weeks: <80 mm Hg, N=457	12 weeks: <90 mm Hg, N=457	12 weeks: <85 mm Hg, N=457	12 weeks: <80 mm Hg, N=457	16 weeks: <90 mm Hg, N=457	16 weeks: <85 mm Hg, N=457	16 weeks: <80 mm Hg, N=457	20 weeks: <90 mm Hg, N=457	20 weeks: <85 mm Hg, N=457	20 weeks: <80 mm Hg, N=457
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	69.6	53.5	31.9	82.1	66.1	43.5	90.4	76.6	56.5	94.8	83.2	65.9	95.4	86.2	72.0

[back to top]

Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

Intervention	Percentage of Participants (Number)
	4 weeks: ≤ 10 mm Hg, N=453	4 weeks: >10 and ≤ 15 mm Hg, N=453	4 weeks: >15 and ≤ 20 mm Hg, N=453	4 weeks: >20 mm Hg, N=453	8 weeks: ≤ 10 mm Hg, N=431	8 weeks: >10 and ≤ 15 mm Hg, N=431	8 weeks: >15 and ≤ 20 mm Hg, N=431	8 weeks: >20 mm Hg, N=431	12 weeks: ≤ 10 mm Hg, N=402	12 weeks: >10 and ≤15 mm Hg, N=402	12 weeks: >15 and ≤ 20 mm Hg, N=402	12 weeks: >20 mm Hg, N=402	16 weeks: ≤ 10 mm Hg, N=371	16 weeks: >10 and ≤ 15 mm Hg, N=371	16 weeks: >15 and ≤ 20 mm Hg, N=371	16 weeks: >20 mm Hg, N=371	20 weeks: ≤ 10 mm Hg, N=356	20 weeks: >10 and ≤ 15 mm Hg, N=356	20 weeks: >15 and ≤ 20 mm Hg, N=356	20 weeks: >20 mm Hg, N=356
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	62.7	22.3	8.6	6.4	56.6	19.7	15.3	8.4	44.3	22.1	17.4	16.2	32.4	24.0	21.0	22.6	33.2	19.4	22.5	25.0

[back to top]

Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

Intervention	Percentage of Participants (Number)
	4 weeks: <140 mm Hg, N=454	4 weeks: <135 mm Hg, N=454	4 weeks: <130 mm Hg, N=454	4 weeks: <120 mm Hg, N=454	8 weeks: <140 mm Hg, N=457	8 weeks: <135 mm Hg, N=457	8 weeks: <130 mm Hg, N=457	8 weeks: <120 mm Hg, N=457	12 weeks: <140 mm Hg, N=457	12 weeks: <135 mm Hg, N=457	12 weeks: <130 mm Hg, N=457	12 weeks: <120 mm Hg, N=457	16 weeks: <140 mm Hg, N=457	16 weeks: <135 mm Hg, N=457	16 weeks: <130 mm Hg, N=457	16 weeks: <120 mm Hg, N=457	20 weeks: <140 mm Hg, N=457	20 weeks: <135 mm Hg, N=457	20 weeks: <130 mm Hg, N=457	20 weeks: <120 mm Hg, N=457
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	56.4	41.4	27.1	7.9	67.6	54.3	40.9	16.2	81.4	67.2	54.1	27.6	88.8	80.3	67.0	39.0	91.5	85.6	74.8	47.1

[back to top]

Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

Intervention	Percentage of Participants (Number)
	4 weeks: ≤ 15 mm Hg, N=453	4 weeks: >15 and ≤ 30 mm Hg, N=453	4 weeks: >30 and ≤ 45 mm Hg, N=453	4 weeks: >45 mm Hg, N=453	8 weeks: ≤ 15 mm Hg, N=431	8 weeks: >15 and ≤ 30 mm Hg, N=431	8 weeks: >30 and ≤ 45 mm Hg, N=431	8 weeks: >45 mm Hg, N=431	12 weeks: ≤ 15 mm Hg, N=402	12 weeks: >15 and ≤ 30 mm Hg, N=402	12 weeks: >30 and ≤ 45 mm Hg, N=402	12 weeks: >45 mm Hg, N=402	16 weeks: ≤ 15 mm Hg, N=371	16 weeks: >15 and ≤ 30 mm Hg, N=371	16 weeks: >30 and ≤ 45 mm Hg, N=371	16 weeks: >45 mm Hg, N=371	20 weeks: ≤ 15 mm Hg, N=356	20 weeks: >15 and ≤ 30 mm Hg, N=356	20 weeks: >30 and ≤ 45 mm Hg, N=356	20 weeks: >45 mm Hg, N=356
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	49.5	38.4	11.5	0.7	48.0	35.5	14.4	2.1	30.4	43.8	22.6	3.2	24.0	37.7	29.1	9.2	19.7	36.5	36.0	7.9

[back to top]

Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

Intervention	Percentage of Participants (Number)
	4 weeks: <90 mm Hg, N=190	4 weeks: <85 mm Hg, N=190	4 weeks: <80 mm Hg, N=190	8 weeks: <90 mm Hg, N=190	8 weeks: <85 mm Hg, N=190	8 weeks: <80 mm Hg, N=190	12 weeks: <90 mm Hg, N=190	12 weeks: <85 mm Hg, N=190	12 weeks: <80 mm Hg, N=190	16 weeks: <90 mm Hg, N=190	16 weeks: <85 mm Hg, N=190	16 weeks: <80 mm Hg, N=190	20 weeks: <90 mm Hg, N=190	20 weeks: <85 mm Hg, N=190	20 weeks: <80 mm Hg, N=190
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	75.8	64.2	39.0	85.8	72.6	51.1	94.2	83.2	63.7	97.9	89.0	70.5	99.0	90.5	76.8

[back to top]

Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

Intervention	Percentage of Participants (Number)
	4 weeks: ≤ 10 mm Hg, N=189	4 weeks: >10 and ≤ 15 mm Hg, N=189	4 weeks: >15 and ≤ 20 mm Hg, N=189	4 weeks: >20 mm Hg, N=189	8 weeks: ≤ 10 mm Hg, N=181	8 weeks: >10 and ≤ 15 mm Hg, N=181	8 weeks: >15 and ≤ 20 mm Hg, N=181	8 weeks: >20 mm Hg, N=181	12 weeks: ≤ 10 mm Hg, N=170	12 weeks: >10 and ≤15 mm Hg, N=170	12 weeks: >15 and ≤ 20 mm Hg, N=170	12 weeks: >20 mm Hg, N=170	16 weeks: ≤ 10 mm Hg, N=156	16 weeks: >10 and ≤ 15 mm Hg, N=156	16 weeks: >15 and ≤ 20 mm Hg, N=156	16 weeks: >20 mm Hg, N=156	20 weeks: ≤ 10 mm Hg, N=150	20 weeks: >10 and ≤ 15 mm Hg, N=150	20 weeks: >15 and ≤ 20 mm Hg, N=150	20 weeks: >20 mm Hg, N=150
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	67.7	16.9	11.6	3.7	60.8	20.4	14.9	3.9	41.2	32.4	12.9	13.5	32.7	26.9	21.8	18.6	37.3	18.0	26.0	18.7

[back to top]

Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

Intervention	Percentage of Participants (Number)
	4 weeks: <140 mm Hg, N=190	4 weeks: <135 mm Hg, N=190	4 weeks: <130 mm Hg, N=190	4 weeks: <120 mm Hg, N=190	8 weeks: <140 mm Hg, N=190	8 weeks: <135 mm Hg, N=190	8 weeks: <130 mm Hg, N=190	8 weeks: <120 mm Hg, N=190	12 weeks: <140 mm Hg, N=190	12 weeks: <135 mm Hg, N=190	12 weeks: <130 mm Hg, N=190	12 weeks: <120 mm Hg, N=190	16 weeks: <140 mm Hg, N=190	16 weeks: <135 mm Hg, N=190	16 weeks: <130 mm Hg, N=190	16 weeks: <120 mm Hg, N=190	20 weeks: <140 mm Hg, N=190	20 weeks: <135 mm Hg, N=190	20 weeks: <130 mm Hg, N=190	20 weeks: <120 mm Hg, N=190
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	54.7	41.1	26.3	10.0	69.0	56.3	42.6	15.8	81.6	69.5	57.9	30.0	87.9	79.0	69.0	39.5	91.1	84.2	75.3	48.4

[back to top]

Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

Intervention	Percentage of Participants (Number)
	4 weeks: ≤ 15 mm Hg, N=189	4 weeks: >15 and ≤ 30 mm Hg, N=189	4 weeks: >30 and ≤ 45 mm Hg, N=189	4 weeks: >45 mm Hg, N=189	8 weeks: ≤ 15 mm Hg, N=181	8 weeks: >15 and ≤ 30 mm Hg, N=181	8 weeks: >30 and ≤ 45 mm Hg, N=181	8 weeks: >45 mm Hg, N=181	12 weeks: ≤ 15 mm Hg, N=170	12 weeks: >15 and ≤ 30 mm Hg, N=170	12 weeks: >30 and ≤ 45 mm Hg, N=170	12 weeks: >45 mm Hg, N=170	16 weeks: ≤ 15 mm Hg, N=156	16 weeks: >15 and ≤ 30 mm Hg, N=156	16 weeks: >30 and ≤ 45 mm Hg, N=156	16 weeks: >45 mm Hg, N=156	20 weeks: ≤ 15 mm Hg, N=150	20 weeks: >15 and ≤ 30 mm Hg, N=150	20 weeks: >30 and ≤ 45 mm Hg, N=150	20 weeks: >45 mm Hg, N=150
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	56.1	36.0	7.9	0.0	54.1	34.3	11.6	0.0	35.3	38.2	22.9	3.5	28.2	40.4	26.3	5.1	26.0	40.0	26.7	7.3

[back to top]

The Percentage of Subjects Who Achieve BP Goal (<140/90 mmHg for Non-diabetics or <130/80 mmHg for Diabetics) From Baseline to 12 and 20 Weeks

(NCT00791258)
Timeframe: Baseline to 12 and 20 weeks

Intervention	Percentage of participants (Number)
	12 weeks	20 weeks
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	71.3	84.8

[back to top]

The Percentage of Patients Who Achieve Seated Systolic Blood Pressure Goal (<140 mm Hg for Non-diabetics and <130 mm Hg for Diabetics) From Baseline to 12 Weeks

(NCT00791258)
Timeframe: baseline to 12 weeks

Intervention	Percentage of participants (Number)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	75.8

[back to top]

The Percentage of Subjects Achieving Seated Diastolic BP Goal (<90 mmHg for Non-diabetics or < 80 mmHg for Subjects With Diabetes) From Baseline to 12 Weeks

(NCT00791258)
Timeframe: baseline to 12 weeks

Intervention	Percentage of participants (Number)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	84.3

[back to top]

Change From Baseline to Week 12 in Ambulatory Systolic and Diastolic Blood Pressure Values

Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Daytime is defined as 8 a.m. to 4 p.m. Nighttime is defined as 10 p.m. to 6 a.m. (NCT00791258)
Timeframe: Baseline to 12 weeks

Intervention	mm Hg (Mean)
	24-hour mean systolic blood pressure	Mean daytime systolic blood pressure	Mean nighttime systolic blood pressure	Systolic blood pressure - last 2 hours of dose	Systolic blood pressure - last 4 hours of dose	Systolic blood pressure - last 6 hours of dose	24-hour mean diastolic blood pressure	Mean daytime diastolic blood pressure	Mean nighttime diastolic blood pressure	Diastolic blood pressure - last 2 hours of dose	Diastolic blood pressure - last 4 hours of dose	Diastolic blood pressure - last 6 hours of dose
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	-14.8	-16.3	-12.5	-13.6	-13.0	-12.6	-9.4	-10.6	-7.6	-8.6	-8.0	-7.7

[back to top]

Change From Baseline to Week 20 in Ambulatory Systolic and Diastolic Blood Pressure Values

Intervention	mm Hg (Mean)
	24-hour mean systolic blood pressure	Mean daytime systolic blood pressure	Mean nighttime systolic blood pressure	Systolic blood pressure - last 2 hours of dose	Systolic blood pressure - last 4 hours of dose	Systolic blood pressure - last 6 hours of dose	24-hour mean diastolic blood pressure	Mean daytime diastolic blood pressure	Mean nighttime diastolic blood pressure	Diastolic blood pressure - last 2 hours of dose	Diastolic blood pressure - last 4 hours of dose	Diastolic blood pressure - last 6 hours of dose
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	-21.0	-23.2	-17.5	-19.6	-18.2	-17.9	-13.3	-15.0	-11.1	-12.3	-11.6	-11.3

[back to top]

Change in Mean Seated Diastolic Blood Pressure From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

Intervention	mm Hg (Mean)
	4 weeks, N=975	8 weeks, N=929	12 weeks, N=865	16 weeks, N=797	20 weeks, N=745
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	-8.1	-9.1	-11.9	-14.6	-14.5

[back to top]

Change in Mean Seated Systolic Blood Pressure From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

Intervention	mm Hg (Mean)
	4 weeks, N=975	8 weeks, N=929	12 weeks, N=865	16 weeks, N=797	20 weeks, N=745
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	-14.6	-16.6	-21.8	-26.0	-26.8

[back to top]

Percentage of African American/Black Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

Intervention	Percentage of Participants (Number)
	4 weeks: <140/90 mm Hg, N=230	4 weeks: <135/80 mm Hg, N=230	4 weeks: <130/80 mm Hg, N=230	4 weeks: <120/80 mm Hg, N=230	8 weeks: <140/90 mm Hg, N=231	8 weeks: <135/80 mm Hg, N=231	8 weeks: <130/80 mm Hg, N=232	8 weeks: <120/80 mm Hg, N=232	12 weeks: <140/90mm Hg, N=232	12 weeks: <135/80 mm Hg, N=232	12 weeks: <130/80 mm Hg, N=232	12 weeks: <120/80 mm Hg, N=232	16 weeks: <140/90 mm Hg, N=232	16 weeks: <135/80 mm Hg, N=232	16 weeks: <130/80 mm Hg, N=232	16 weeks: <120/80 mm Hg, N=232	20 weeks: <140/90 mm Hg, N=232	20 weeks: <135/80 mm Hg, N=232	20 weeks: <130/80 mm Hg, N=232	20 weeks: <120/80 mm Hg, N=232
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	45.7	14.8	10.4	3.9	55.0	23.8	20.8	10.4	68.5	38.4	35.8	16.4	80.6	49.1	47.4	30.6	86.6	57.8	55.2	39.7

[back to top]

Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

Intervention	Percentage of Participants (Number)
	4 weeks: <90 mm Hg, N=230	4 weeks: <85 mm Hg, N=230	4 weeks: <80 mm Hg, N=230	8 weeks: <90 mm Hg, N=231	8 weeks: <85 mm Hg, N=231	8 weeks: <80 mm Hg, N=231	12 weeks: <90 mm Hg, N=232	12 weeks: <85 mm Hg, N=232	12 weeks: <80 mm Hg, N=232	16 weeks: <90 mm Hg, N=232	16 weeks: <85 mm Hg, N=232	16 weeks: <80 mm Hg, N=232	20 weeks: <90 mm Hg, N=232	20 weeks: <85 mm Hg, N=232	20 weeks: <80 mm Hg, N=232
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	60.9	42.2	19.6	71.9	53.7	30.3	82.3	66.0	45.3	92.2	76.3	55.2	94.8	80.6	61.2

[back to top]

Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

Intervention	Percentage of Participants (Number)
	4 weeks: ≤ 10 mm Hg, N=230	4 weeks: >10 and ≤ 15 mm Hg, N=230	4 weeks: >15 and ≤ 20 mm Hg, N=230	4 weeks: >20 mm Hg, N=230	8 weeks: ≤ 10 mm Hg, N=220	8 weeks: >10 and ≤ 15 mm Hg, N=220	8 weeks: >15 and ≤ 20 mm Hg, N=220	8 weeks: >20 mm Hg, N=220	12 weeks: ≤ 10 mm Hg, N=208	12 weeks: >10 and ≤15 mm Hg, N=208	12 weeks: >15 and ≤ 20 mm Hg, N=208	12 weeks: >20 mm Hg, N=208	16 weeks: ≤ 10 mm Hg, N=199	16 weeks: >10 and ≤ 15 mm Hg, N=199	16 weeks: >15 and ≤ 20 mm Hg, N=199	16 weeks: >20 mm Hg, N=199	20 weeks: ≤ 10 mm Hg, N=189	20 weeks: >10 and ≤ 15 mm Hg, N=189	20 weeks: >15 and ≤ 20 mm Hg, N=189	20 weeks: >20 mm Hg, N=189
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	70.0	17.8	7.9	4.4	66.8	15.0	10.9	7.3	54.8	21.2	12.0	12.0	38.7	19.6	23.1	18.6	36.0	19.6	20.6	23.8

[back to top]

Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

Intervention	Percentage of Participants (Number)
	4 weeks: <140 mm Hg, N=230	4 weeks: <135 mm Hg, N=230	4 weeks: <130 mm Hg, N=230	4 weeks: <120 mm Hg, N=230	8 weeks: <140 mm Hg, N=231	8 weeks: <135 mm Hg, N=231	8 weeks: <130 mm Hg, N=231	8 weeks: <120 mm Hg, N=231	12 weeks: <140 mm Hg, N=232	12 weeks: <135 mm Hg, N=232	12 weeks: <130 mm Hg, N=232	12 weeks: <120 mm Hg, N=232	16 weeks: <140 mm Hg, N=232	16 weeks: <135 mm Hg, N=232	16 weeks: <130 mm Hg, N=232	16 weeks: <120 mm Hg, N=232	20 weeks: <140 mm Hg, N=232	20 weeks: <135 mm Hg, N=232	20 weeks: <130 mm Hg, N=232	20 weeks: <120 mm Hg, N=232
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	51.7	34.4	19.6	5.7	62.3	44.6	33.8	13.0	76.3	59.1	47.0	19.8	84.9	71.1	61.2	34.1	91.0	80.6	71.1	44.4

[back to top]

Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

Intervention	Percentage of Participants (Number)
	4 weeks: ≤ 15 mm Hg, N=230	4 weeks: >15 and ≤ 30 mm Hg, N=230	4 weeks: >30 and ≤ 45 mm Hg, N=230	4 weeks: >45 mm Hg, N=230	8 weeks: ≤ 15 mm Hg, N=220	8 weeks: >15 and ≤ 30 mm Hg, N=220	8 weeks: >30 and ≤ 45 mm Hg, N=220	8 weeks: >45 mm Hg, N=220	12 weeks: ≤ 15 mm Hg, N=208	12 weeks: >15 and ≤ 30 mm Hg, N=208	12 weeks: >30 and ≤ 45 mm Hg, N=208	12 weeks: >45 mm Hg, N=208	16 weeks: ≤ 15 mm Hg, N=199	16 weeks: >15 and ≤ 30 mm Hg, N=199	16 weeks: >30 and ≤ 45 mm Hg, N=199	16 weeks: >45 mm Hg, N=199	20 weeks: ≤ 15 mm Hg, N=189	20 weeks: >15 and ≤ 30 mm Hg, N=189	20 weeks: >30 and ≤ 45 mm Hg, N=189	20 weeks: >45 mm Hg, N=189
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	60.0	32.2	7.4	0.4	53.6	38.2	7.3	0.9	38.9	41.8	16.4	2.9	30.7	37.2	25.1	7.0	24.3	37.6	29.6	8.5

[back to top]

Percentage of Asain Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

Intervention	Percentage of Participants (Number)
	4 weeks: <90 mm Hg, N=128	4 weeks: <85 mm Hg, N=128	4 weeks: <80 mm Hg, N=128	8 weeks: <90 mm Hg, N=128	8 weeks: <85 mm Hg, N=128	8 weeks: <80 mm Hg, N=128	12 weeks: <90 mm Hg, N=128	12 weeks: <85 mm Hg, N=128	12 weeks: <80 mm Hg, N=128	16 weeks: <90 mm Hg, N=128	16 weeks: <85 mm Hg, N=128	16 weeks: <80 mm Hg, N=128	20 weeks: <90 mm Hg, N=128	20 weeks: <85 mm Hg, N=128	20 weeks: <80 mm Hg, N=128
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	83.6	69.5	45.3	89.1	79.7	60.2	95.3	87.5	71.1	96.9	93.0	82.0	96.9	93.0	85.2

[back to top]

Percentage of Asian Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

Intervention	Percentage of Participants (Number)
	4 weeks: ≤ 10 mm Hg, N=126	4 weeks: >10 and ≤ 15 mm Hg, N=126	4 weeks: >15 and ≤ 20 mm Hg, N=126	4 weeks: >20 mm Hg, N=126	8 weeks: ≤ 10 mm Hg, N=123	8 weeks: >10 and ≤ 15 mm Hg, N=123	8 weeks: >15 and ≤ 20 mm Hg, N=123	8 weeks: >20 mm Hg, N=123	12 weeks: ≤ 10 mm Hg, N=120	12 weeks: >10 and ≤15 mm Hg, N=120	12 weeks: >15 and ≤ 20 mm Hg, N=120	12 weeks: >20 mm Hg, N=120	16 weeks: ≤ 10 mm Hg, N=112	16 weeks: >10 and ≤ 15 mm Hg, N=112	16 weeks: >15 and ≤ 20 mm Hg, N=112	16 weeks: >20 mm Hg, N=112	20 weeks: ≤ 10 mm Hg, N=105	20 weeks: >10 and ≤ 15 mm Hg, N=105	20 weeks: >15 and ≤ 20 mm Hg, N=105	20 weeks: >20 mm Hg, N=105
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	47.6	26.2	13.5	12.7	38.2	24.4	22.0	15.5	33.3	25.8	19.2	21.7	27.7	17.0	20.5	34.8	36.2	16.2	18.1	29.5

[back to top]

Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

Intervention	Percentage of Participants (Number)
	4 weeks: <140 mm Hg, N=128	4 weeks: <135 mm Hg, N=128	4 weeks: <130 mm Hg, N=128	4 weeks: <120 mm Hg, N=128	8 weeks: <140 mm Hg, N=128	8 weeks: <135 mm Hg, N=128	8 weeks: <130 mm Hg, N=128	8 weeks: <120 mm Hg, N=128	12 weeks: <140 mm Hg, N=128	12 weeks: <135 mm Hg, N=128	12 weeks: <130 mm Hg, N=128	12 weeks: <120 mm Hg, N=128	16 weeks: <140 mm Hg, N=128	16 weeks: <135 mm Hg, N=128	16 weeks: <130 mm Hg, N=128	16 weeks: <120 mm Hg, N=128	20 weeks: <140 mm Hg, N=128	20 weeks: <135 mm Hg, N=128	20 weeks: <130 mm Hg, N=128	20 weeks: <120 mm Hg, N=128
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	64.8	51.6	35.2	11.7	76.6	67.2	51.6	25.0	89.1	78.9	66.4	38.3	95.3	89.8	81.3	47.7	97.7	93.0	85.9	51.6

[back to top]

Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

Intervention	Percentage of Participants (Number)
	4 weeks: ≤ 15 mm Hg, N=126	4 weeks: >15 and ≤ 30 mm Hg, N=126	4 weeks: >30 and ≤ 45 mm Hg, N=126	4 weeks: >45 mm Hg, N=126	8 weeks: ≤ 15 mm Hg, N=123	8 weeks: >15 and ≤ 30 mm Hg, N=123	8 weeks: >30 and ≤ 45 mm Hg, N=123	8 weeks: >45 mm Hg, N=123	12 weeks: ≤ 15 mm Hg, N=120	12 weeks: >15 and ≤ 30 mm Hg, N=120	12 weeks: >30 and ≤ 45 mm Hg, N=120	12 weeks: >45 mm Hg, N=120	16 weeks: ≤ 15 mm Hg, N=112	16 weeks: >15 and ≤ 30 mm Hg, N=112	16 weeks: >30 and ≤ 45 mm Hg, N=112	16 weeks: >45 mm Hg, N=112	20 weeks: ≤ 15 mm Hg, N=105	20 weeks: >15 and ≤ 30 mm Hg, N=105	20 weeks: >30 and ≤ 45 mm Hg, N=105	20 weeks: >45 mm Hg, N=105
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	43.7	38.1	15.9	2.4	40.7	35.8	22.0	1.6	28.3	39.2	27.5	5.0	20.5	36.6	31.3	11.6	29.5	28.6	33.3	8.6

[back to top]

Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

Intervention	Percentage of Participants (Number)
	4 weeks: <90 mm Hg, N=227	4 weeks: <85 mm Hg, N=227	4 weeks: <80 mm Hg, N=227	8 weeks: <90 mm Hg, N=227	8 weeks: <85 mm Hg, N=227	8 weeks: <80 mm Hg, N=227	12 weeks: <90 mm Hg, N=227	12 weeks: <85 mm Hg, N=227	12 weeks: <80 mm Hg, N=227	16 weeks: <90 mm Hg, N=227	16 weeks: <85 mm Hg, N=227	16 weeks: <80 mm Hg, N=227	20 weeks: <90 mm Hg, N=227	20 weeks: <85 mm Hg, N=227	20 weeks: <80 mm Hg, N=227
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	88.1	76.7	58.2	92.1	83.7	71.8	97.4	92.1	80.2	98.7	94.3	88.6	98.7	95.2	90.3

[back to top]

Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

Intervention	Percentage of Participants (Number)
	4 weeks: ≤ 10 mm Hg, N=224	4 weeks: >10 and ≤ 15 mm Hg, N=224	4 weeks: >15 and ≤ 20 mm Hg, N=224	4 weeks: >20 mm Hg, N=224	8 weeks: ≤ 10 mm Hg, N=217	8 weeks: >10 and ≤ 15 mm Hg, N=217	8 weeks: >15 and ≤ 20 mm Hg, N=217	8 weeks: >20 mm Hg, N=217	12 weeks: ≤ 10 mm Hg, N=199	12 weeks: >10 and ≤15 mm Hg, N=199	12 weeks: >15 and ≤ 20 mm Hg, N=199	12 weeks: >20 mm Hg, N=199	16 weeks: ≤ 10 mm Hg, N=179	16 weeks: >10 and ≤ 15 mm Hg, N=179	16 weeks: >15 and ≤ 20 mm Hg, N=179	16 weeks: >20 mm Hg, N=179	20 weeks: ≤ 10 mm Hg, N=166	20 weeks: >10 and ≤ 15 mm Hg, N=166	20 weeks: >15 and ≤ 20 mm Hg, N=166	20 weeks: >20 mm Hg, N=166
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	63.8	20.5	9.4	6.3	57.1	19.8	14.3	8.8	45.2	25.1	15.6	14.1	27.4	25.1	22.9	24.6	34.9	20.5	24.1	20.5

[back to top]

Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

Intervention	Percentage of Participants (Number)
	4 weeks: <140 mm Hg, N=227	4 weeks: <135 mm Hg, N=227	4 weeks: <130 mm Hg, N=227	4 weeks: <120 mm Hg, N=227	8 weeks: <140 mm Hg, N=227	8 weeks: <135 mm Hg, N=227	8 weeks: <130 mm Hg, N=227	8 weeks: <120 mm Hg, N=227	12 weeks: <140 mm Hg, N=227	12 weeks: <135 mm Hg, N=227	12 weeks: <130 mm Hg, N=227	12 weeks: <120 mm Hg, N=227	16 weeks: <140 mm Hg, N=227	16 weeks: <135 mm Hg, N=227	16 weeks: <130 mm Hg, N=227	16 weeks: <120 mm Hg, N=227	20 weeks: <140 mm Hg, N=227	20 weeks: <135 mm Hg, N=227	20 weeks: <130 mm Hg, N=227	20 weeks: <120 mm Hg, N=227
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	52.0	37.9	23.4	9.7	67.0	57.7	43.6	18.1	80.6	70.0	56.8	28.6	87.7	79.7	70.9	43.6	91.6	85.9	78.9	50.7

[back to top]

Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

Intervention	Percentage of Participants (Number)
	4 weeks: ≤ 15 mm Hg, N=224	4 weeks: >15 and ≤ 30 mm Hg, N=224	4 weeks: >30 and ≤ 45 mm Hg, N=224	4 weeks: >45 mm Hg, N=224	8 weeks: ≤ 15 mm Hg, N=217	8 weeks: >15 and ≤ 30 mm Hg, N=217	8 weeks: >30 and ≤ 45 mm Hg, N=217	8 weeks: >45 mm Hg, N=217	12 weeks: ≤ 15 mm Hg, N=199	12 weeks: >15 and ≤ 30 mm Hg, N=199	12 weeks: >30 and ≤ 45 mm Hg, N=199	12 weeks: >45 mm Hg, N=199	16 weeks: ≤ 15 mm Hg, N=179	16 weeks: >15 and ≤ 30 mm Hg, N=179	16 weeks: >30 and ≤ 45 mm Hg, N=179	16 weeks: >45 mm Hg, N=179	20 weeks: ≤ 15 mm Hg, N=166	20 weeks: >15 and ≤ 30 mm Hg, N=166	20 weeks: >30 and ≤ 45 mm Hg, N=166	20 weeks: >45 mm Hg, N=166
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	47.3	40.2	11.2	1.3	42.9	37.8	16.6	2.8	26.6	46.7	24.6	2.0	17.9	32.4	39.7	10.1	14.5	37.4	38.0	10.2

[back to top]

Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

Intervention	Percentage of Participants (Number)
	4 weeks: <90 mm Hg, N=98	4 weeks: <85 mm Hg, N=98	4 weeks: <80 mm Hg, N=98	8 weeks: <90 mm Hg, N=100	8 weeks: <85 mm Hg, N=100	8 weeks: <80 mm Hg, N=100	12 weeks: <90 mm Hg, N=100	12 weeks: <85 mm Hg, N=100	12 weeks: <80 mm Hg, N=100	16 weeks: <90 mm Hg, N=100	16 weeks: <85 mm Hg, N=100	16 weeks: <80 mm Hg, N=100	20 weeks: <90 mm Hg, N=100	20 weeks: <85 mm Hg, N=100	20 weeks: <80 mm Hg, N=100
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	66.3	53.1	34.7	85.0	70.0	48.0	92.0	78.0	62.0	96.0	90.0	75.0	96.0	90.0	75.0

[back to top]

Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

Intervention	Percentage of Participants (Number)
	4 weeks: ≤ 10 mm Hg, N=98	4 weeks: >10 and ≤ 15 mm Hg, N=98	4 weeks: >15 and ≤ 20 mm Hg, N=98	4 weeks: >20 mm Hg, N=98	8 weeks: ≤ 10 mm Hg, N=91	8 weeks: >10 and ≤ 15 mm Hg, N=91	8 weeks: >15 and ≤ 20 mm Hg, N=91	8 weeks: >20 mm Hg, N=91	12 weeks: ≤ 10 mm Hg, N=83	12 weeks: >10 and ≤15 mm Hg, N=83	12 weeks: >15 and ≤ 20 mm Hg, N=83	12 weeks: >20 mm Hg, N=83	16 weeks: ≤ 10 mm Hg, N=75	16 weeks: >10 and ≤ 15 mm Hg, N=75	16 weeks: >15 and ≤ 20 mm Hg, N=75	16 weeks: >20 mm Hg, N=75	20 weeks: ≤ 10 mm Hg, N=71	20 weeks: >10 and ≤ 15 mm Hg, N=71	20 weeks: >15 and ≤ 20 mm Hg, N=71	20 weeks: >20 mm Hg, N=71
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	65.3	16.3	8.2	10.2	52.8	18.7	14.3	14.3	41.0	20.5	14.5	24.1	30.7	25.3	16.0	28.0	31.0	12.7	26.8	29.6

[back to top]

Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

Intervention	Percentage of Participants (Number)
	4 weeks: <140 mm Hg, N=98	4 weeks: <135 mm Hg, N=98	4 weeks: <130 mm Hg, N=98	4 weeks: <120 mm Hg, N=98	8 weeks: <140 mm Hg, N=100	8 weeks: <135 mm Hg, N=100	8 weeks: <130 mm Hg, N=100	8 weeks: <120 mm Hg, N=100	12 weeks: <140 mm Hg, N=100	12 weeks: <135 mm Hg, N=100	12 weeks: <130 mm Hg, N=100	12 weeks: <120 mm Hg, N=100	16 weeks: <140 mm Hg, N=100	16 weeks: <135 mm Hg, N=100	16 weeks: <130 mm Hg, N=100	16 weeks: <120 mm Hg, N=100	20 weeks: <140 mm Hg, N=100	20 weeks: <135 mm Hg, N=100	20 weeks: <130 mm Hg, N=100	20 weeks: <120 mm Hg, N=100
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	55.1	39.8	31.6	10.2	64.0	51.0	41.0	15.0	77.0	67.0	54.0	30.0	84.0	77.0	66.0	37.0	88.0	83.0	72.0	41.0

[back to top]

Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

Intervention	Percentage of Participants (Number)
	4 weeks: ≤ 15 mm Hg, N=98	4 weeks: >15 and ≤ 30 mm Hg, N=98	4 weeks: >30 and ≤ 45 mm Hg, N=98	4 weeks: >45 mm Hg, N=98	8 weeks: ≤ 15 mm Hg, N=91	8 weeks: >15 and ≤ 30 mm Hg, N=91	8 weeks: >30 and ≤ 45 mm Hg, N=91	8 weeks: >45 mm Hg, N=91	12 weeks: ≤ 15 mm Hg, N=83	12 weeks: >15 and ≤ 30 mm Hg, N=83	12 weeks: >30 and ≤ 45 mm Hg, N=83	12 weeks: >45 mm Hg, N=83	16 weeks: ≤ 15 mm Hg, N=75	16 weeks: >15 and ≤ 30 mm Hg, N=75	16 weeks: >30 and ≤ 45 mm Hg, N=75	16 weeks: >45 mm Hg, N=75	20 weeks: ≤ 15 mm Hg, N=71	20 weeks: >15 and ≤ 30 mm Hg, N=71	20 weeks: >30 and ≤ 45 mm Hg, N=71	20 weeks: >45 mm Hg, N=71
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	50.0	37.8	7.1	5.1	42.9	44.0	9.9	3.3	31.3	36.1	25.3	7.2	22.7	36.0	34.7	6.7	23.9	33.8	33.8	8.5

[back to top]

Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

Intervention	Percentage of Participants (Number)
	4 weeks: <90 mm Hg, N=497	4 weeks: <85 mm Hg, N=497	4 weeks: <80 mm Hg, N=497	8 weeks: <90 mm Hg, N=497	8 weeks: <85 mm Hg, N=500	8 weeks: <80 mm Hg, N=500	12 weeks: <90 mm Hg, N=500	12 weeks: <85 mm Hg, N=500	12 weeks: <80 mm Hg, N=500	16 weeks: <90 mm Hg, N=500	16 weeks: <85 mm Hg, N=500	16 weeks: <80 mm Hg, N=500	20 weeks: <90 mm Hg, N=500	20 weeks: <85 mm Hg, N=500	20 weeks: <80 mm Hg, N=500
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	63.2	46.3	26.0	77.2	59.4	38.8	86.6	69.8	48.4	93.2	80.4	60.4	94.6	83.8	67.6

[back to top]

Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

Intervention	Percentage of Participants (Number)
	4 weeks: ≤ 10 mm Hg, N=495	4 weeks: >10 and ≤ 15 mm Hg, N=495	4 weeks: >15 and ≤ 20 mm Hg, N=495	4 weeks: >20 mm Hg, N=495	8 weeks: ≤ 10 mm Hg, N=468	8 weeks: >10 and ≤ 15 mm Hg, N=468	8 weeks: >15 and ≤ 20 mm Hg, N=468	8 weeks: >20 mm Hg, N=468	12 weeks: ≤ 10 mm Hg, N=436	12 weeks: >10 and ≤15 mm Hg, N=436	12 weeks: >15 and ≤ 20 mm Hg, N=436	12 weeks: >20 mm Hg, N=436	16 weeks: ≤ 10 mm Hg, N=400	16 weeks: >10 and ≤ 15 mm Hg, N=400	16 weeks: >15 and ≤ 20 mm Hg, N=400	16 weeks: >20 mm Hg, N=400	20 weeks: ≤ 10 mm Hg, N=379	20 weeks: >10 and ≤ 15 mm Hg, N=379	20 weeks: >15 and ≤ 20 mm Hg, N=379	20 weeks: >20 mm Hg, N=379
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	67.5	17.8	8.5	6.3	59.4	19.9	13.0	7.7	48.9	22.5	16.1	12.6	33.3	23.0	19.0	24.8	31.9	18.7	22.4	26.9

[back to top]

Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

Intervention	Percentage of Participants (Number)
	4 weeks: <140 mm Hg, N=497	4 weeks: <135 mm Hg, N=497	4 weeks: <130 mm Hg, N=497	4 weeks: <120 mm Hg, N=497	8 weeks: <140 mm Hg, N=500	8 weeks: <135 mm Hg, N=500	8 weeks: <130 mm Hg, N=500	8 weeks: <120 mm Hg, N=500	12 weeks: <140 mm Hg, N=500	12 weeks: <135 mm Hg, N=500	12 weeks: <130 mm Hg, N=500	12 weeks: <120 mm Hg, N=500	16 weeks: <140 mm Hg, N=500	16 weeks: <135 mm Hg, N=500	16 weeks: <130 mm Hg, N=500	16 weeks: <120 mm Hg, N=500	20 weeks: <140 mm Hg, N=500	20 weeks: <135 mm Hg, N=500	20 weeks: <130 mm Hg, N=500	20 weeks: <120 mm Hg, N=500
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	51.3	37.2	23.3	7.9	63.2	49.2	37.0	13.8	76.6	61.6	49.2	23.2	85.8	75.6	63.6	34.6	90.2	82.6	72.2	43.0

[back to top]

Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks

Intervention	Percentage of Participants (Number)
	4 weeks: ≤ 15 mm Hg, N=495	4 weeks: >15 and ≤ 30 mm Hg, N=495	4 weeks: >30 and ≤ 45 mm Hg, N=495	4 weeks: >45 mm Hg, N=495	8 weeks: ≤ 15 mm Hg, N=468	8 weeks: >15 and ≤ 30 mm Hg, N=468	8 weeks: >30 and ≤ 45 mm Hg, N=468	8 weeks: >45 mm Hg, N=468	12 weeks: ≤ 15 mm Hg, N=436	12 weeks: >15 and ≤ 30 mm Hg, N=436	12 weeks: >30 and ≤ 45 mm Hg, N=436	12 weeks: >45 mm Hg, N=436	16 weeks: ≤ 15 mm Hg, N=400	16 weeks: >15 and ≤ 30 mm Hg, N=400	16 weeks: >30 and ≤ 45 mm Hg, N=400	16 weeks: >45 mm Hg, N=400	20 weeks: ≤ 15 mm Hg, N=379	20 weeks: >15 and ≤ 30 mm Hg, N=379	20 weeks: >30 and ≤ 45 mm Hg, N=379	20 weeks: >45 mm Hg, N=379
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	56.0	35.2	8.5	0.4	52.4	35.9	10.3	1.5	37.8	42.4	17.4	2.5	27.8	36.0	27.5	8.8	20.6	37.5	33.3	8.7

[back to top]

Percentage of Participants Who Achieve a Clinic Diastolic AND Systolic Blood Pressure Response, Defined as <140/90 mm Hg for Participants Without Diabetes or Chronic Kidney Disease (CKD) or <130/80 mm Hg for Participants With Diabetes or CKD

Percentage of participants who achieve both a clinic diastolic blood pressure response, defined as <140/90 mm Hg for participants without diabetes or chronic kidney disease (CKD) or <130/80 mm Hg for participants with diabetes or CKD at each time frame relative to baseline. (NCT00846365)
Timeframe: Baseline, Week 2, Week 4, Week 6 and Week 8.

Intervention	percentage of participants (Number)
	Week 2 (n=343; n=334; n=345)	Week 4 (n=360; n=347; n=352)	Week 6 (n=362; n=350; n=353)	Week 8 (n=363; n=350; n=353)
Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD	51.3	58.1	68.8	69.4
Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD	48.5	61.4	65.4	68.9
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	35.9	44.6	55.5	54.7

[back to top]

Change From Baseline in Trough, Sitting, Clinic Diastolic Blood Pressure

The change in trough diastolic blood pressure measured at week 4 and week 8 relative to baseline. Diastolic blood pressure is the average of the 3 serial trough sitting diastolic blood pressure measurements. (NCT00846365)
Timeframe: Baseline, Week 4 and Week 8.

Intervention	mmHg (Least Squares Mean)
	Week 4 (n=360; n=347; n=352)	Week 8 (n=363; n=350; n=353)
Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD	-13.6	-16.1
Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD	-14.2	-16.5
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-10.4	-12.8

[back to top]

Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as Defined as <90 mm Hg for Participants Without Diabetes or CKD or <80 mm Hg for Participants With Diabetes or CKD

Percentage of participants who achieve a clinic diastolic blood pressure response, defined as defined as <90 mm Hg for participants without diabetes or CKD or <80 mm Hg for participants with diabetes or CKD at each time frame relative to baseline. (NCT00846365)
Timeframe: Baseline, Week 2, Week 4, Week 6 and Week 8.

Intervention	percentage of participants (Number)
	Week 2 (n=343; n=334; n=345)	Week 4 (n=360; n=347; n=352)	Week 6 (n=362; n=350; n=353)	Week 8 (n=363; n=350; n=353)
Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD	63.6	71.4	77.9	79.9
Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD	66.2	73.8	76.9	79.1
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	47.8	58.2	66.9	66.0

[back to top]

Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as <140 mm Hg for Participants Without Diabetes or CKD or <130 mm Hg for Participants With Diabetes or CKD

Percentage of participants who achieve a clinic systolic blood pressure response, defined as <140 mm Hg for participants without diabetes or CKD or <130 mm Hg for participants with diabetes or CKD at each time frame relative to baseline. (NCT00846365)
Timeframe: Baseline, Week 2, Week 4, Week 6 and Week 8.

Intervention	percentage of participants (Number)
	Week 2 (n=343; n=334; n=345)	Week 4 (n=360; n=347; n=352)	Week 6 (n=362; n=350; n=353)	Week 8 (n=363; n=350; n=353)
Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD	60.3	66.1	76.8	76.0
Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD	57.2	68.9	73.4	76.0
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	44.9	52.3	64.9	64.6

[back to top]

Change From Baseline in 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in the 0 to 24-hours-after-dosing mean diastolic blood pressure measured at Week 4 and Week 8 relative to baseline. . Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The mean consists of the average of measurements collected over the subsequent 24 hours. (NCT00846365)
Timeframe: Baseline, Week 4 and Week 8.

Intervention	mmHg (Least Squares Mean)
	Week 4 (n=223; n=227; n=219)	Week 8 (n=290; n=278; n=281)
Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD	-13.9	-15.1
Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD	-14.4	-16.4
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-10.5	-12.0

[back to top]

Change From Baseline in 12-hr Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in the 0 to 12 hours-after-dosing mean Systolic Blood Pressure measured at Week 4 and Week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night The mean consists of the average (arithmetic mean) of measurements collected at each time frame and includes all observations recorded over the subsequent 12 hours. (NCT00846365)
Timeframe: Baseline, Week 4 and Week 8.

Intervention	mmHg (Least Squares Mean)
	Week 4 (n=223; n=227; n=219)	Week 8 (n=290; n=278; n=281)
Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD	-25.0	-27.1
Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD	-25.5	-28.8
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-19.2	-21.1

[back to top]

Change From Baseline in 12-hr Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in the 0 to 12 hours-after-dosing mean diastolic blood pressure measured at Week 4 and Week 8 to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The mean consists of the average (arithmetic mean) of measurements collected at each time frame and includes all observations recorded over the subsequent 12 hours. (NCT00846365)
Timeframe: Baseline, Week 4 and Week 8.

Intervention	mmHg (Least Squares Mean)
	Week 4 (n=223; n=227; n=219)	Week 8 (n=290; n=278; n=281)
Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD	-14.4	-15.4
Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD	-14.8	-16.9
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-10.8	-12.1

[back to top]

Change From Baseline to Week 8 in Trough, Sitting, Clinic Systolic Blood Pressure.

The change in trough systolic blood pressure measured at week 8 or final visit relative to baseline. Systolic blood pressure is the average of the 3 serial trough sitting systolic blood pressure measurements. (NCT00846365)
Timeframe: Baseline and Week 8.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD	-37.6
Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD	-38.2
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-31.5

[back to top]

Change From Baseline to Week 4 in Trough, Sitting, Clinic Systolic Blood Pressure.

The change in trough systolic blood pressure measured at week 4 relative to baseline. Systolic blood pressure is the average of the 3 serial trough sitting systolic blood pressure measurements. (NCT00846365)
Timeframe: Baseline and Week 4.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD	-33.0
Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD	-34.1
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-26.9

[back to top]

Change From Baseline in 24-hour Mean Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring.

The change in the 24-hour mean systolic blood pressure at week4 and week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing. (NCT00846365)
Timeframe: Baseline, Week 4 and Week 8.

Intervention	mmHg (Least Squares Mean)
	Week 4 (n=223; n=227; n=219)	Week 8 (n=290; n=278; n=281)
Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD	-24.1	-26.4
Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD	-24.4	-27.9
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-18.4	-20.7

[back to top]

Change From Baseline in Daytime Mean (6am to 10pm) Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in the daytime, while awake (6am to 10pm) mean diastolic blood pressure measured at Week 4 and Week 8relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of measurements recorded between the hours of 6 AM (inclusive) and 10 PM (exclusive) included in the 24-hour mean calculations. (NCT00846365)
Timeframe: Baseline, Week 4 and Week 8.

Intervention	mmHg (Least Squares Mean)
	Week 4 (n=223; n=227; n=219)	Week 8 (n=290; n=278; n=281)
Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD	-14.2	-15.3
Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD	-14.7	-16.6
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-10.7	-12.1

[back to top]

Change From Baseline in Daytime Mean (6am to 10pm) Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in the daytime, while awake (6am to 10pm) mean systolic blood pressure measured at Week 4 and Week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night Daytime mean is the average of measurements recorded between the hours of 6 AM (inclusive) and 10 PM (exclusive) included in the 24-hour mean calculations. (NCT00846365)
Timeframe: Baseline, Week 4 and Week 8.

Intervention	mmHg (Least Squares Mean)
	Week 4 (n=223; n=227; n=219)	Week 8 (n=290; n=278; n=281)
Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD	-24.5	-26.7
Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD	-25.1	-28.4
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-18.9	-21.0

[back to top]

Change From Baseline in Nighttime Mean (12am to 6am) Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in the nighttime, while asleep (12am to 6am) mean diastolic blood pressure measured at Week 4 and Week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average (arithmetic mean) of measurements recorded between the hours of 12 AM (inclusive) and 6 AM (exclusive) included in the 24-hour mean calculations. (NCT00846365)
Timeframe: Baseline, Week 4 and Week 8.

Intervention	mmHg (Least Squares Mean)
	Week 4 (n=223; n=227; n=219)	Week 8 (n=290; n=278; n=281)
Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD	-13.4	-14.9
Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD	-13.3	-15.8
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-9.6	-11.8

[back to top]

Change From Baseline in Nighttime Mean (12am to 6am) Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring

The change in the nighttime, while asleep (12am to 6am) mean systolic blood pressure measured at Week 4 and Week 8 to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of measurements recorded between the hours of 12 AM (inclusive) and 6 AM (exclusive) included in the 24-hour mean calculations. (NCT00846365)
Timeframe: Baseline, Week 4 and Week 8.

Intervention	mmHg (Least Squares Mean)
	Week 4 (n=223; n=227; n=219)	Week 8 (n=290; n=278; n=281)
Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD	-22.3	-25.2
Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD	-21.9	-26.3
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-16.6	-19.7

[back to top]

Change From Baseline in Trough Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in trough systolic blood pressure measured at week 4 and week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Trough is the average of all measurements recorded from 22 to 24 hours after dosing. (NCT00846365)
Timeframe: Baseline, Week 4 and Week 8.

Intervention	mmHg (Least Squares Mean)
	Week 4 (n=223; n=227; n=219)	Week 8 (n=290; n=278; n=281)
Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD	-13.4	-14.6
Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD	-14.6	-15.9
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-10.9	-12.0

[back to top]

Change From Baseline in Trough Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

Intervention	mmHg (Least Squares Mean)
	Week 4 (n=223; n=227; n=219)	Week 8 (n=290; n=278; n=281)
Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD	-22.4	-24.9
Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD	-23.6	-26.8
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-17.4	-19.6

[back to top]

Mean Change of Sitting dBP From Baseline to Week 12

The difference in the sitting diastolic blood pressure (dBP) at trough, i.e. 24±2 hours after drug administration, from base line to Week 12. (NCT00857285)
Timeframe: Baseline to 12 weeks

Intervention	mmHg (Mean)
Olmesartan Medoxomil	-14.80
Losartan Potassium	-11.60

[back to top]

Percent of Patients With Drug-related Adverse Events (Laboratory Changes in Clinical Laboratory Values)

Drug-related, laboratory value change adverse events are adverse events(AEs) as determined by the Investigator that can not be denied to be related to the study drugs. The relationship between adverse events and drugs were determined by the Investigator based on his/her clinical judgement. Factors used in determining relatedness included, but are not limited to, the medical history of the participant, use of concomitant medication, and the time course from drug administration to AE occurence. (NCT00858702)
Timeframe: At week 8

Intervention	Percent of participants (Number)
Olmesartan Tablets and a Calcium Channel Blocker Tablet	1.9
Olmesartan Medoxomil Tablets and a Diuretic	44.2

[back to top]

Percentage of Patients With Drug-related Adverse Events (Subjective Symptoms/Objective Findings)

Drug-related adverse events are adverse events(AEs) as determined by the Investigator that can not be denied to be related to the study drugs. The relationship between adverse events and drugs were determined by the Investigator based on his/her clinical judgement. Factors used in determining relatedness included, but are not limited to, the medical history of the participant, use of concomitant medication, and the time course from drug administration to AE occurence. (NCT00858702)
Timeframe: At week 8

Intervention	Percent of participants (Number)
Olmesartan Tablets and a Calcium Channel Blocker Tablet	0
Olmesartan Medoxomil Tablets and a Diuretic	7.7

[back to top]

The Percentage of Patients Achieving Target Sitting Blood Pressure of Less Than 130/85

(NCT00858702)
Timeframe: Baseline to week 8

Intervention	Percent of participants (Number)
Olmesartan Tablets and a Calcium Channel Blocker Tablet	34.0
Olmesartan Medoxomil Tablets and a Diuretic	59.2

[back to top]

Number of Patients That Achieved a Blood Pressure Goal of Less Than 130/85 in Second Titrated Group (Olmesartan 40 mg + 25 mg Hydrochlorothiazide)

Number of patients that achieved a blood pressure goal of less than 130/85 in second titrated group (olmesartan 40 mg + 25 mg hydrochlorothiazide). If BP was > or = to 140/90 at 4,8, or 9 wks the participant went to next level of medication for an additional 4-9 weeks. (NCT00890591)
Timeframe: 4 to 9 weeks

Intervention	Participants (Number)
Olmesartan + Hydrochlorothiazide	41

[back to top]

Number of Patients That Achieved a Blood Pressure Goal of Less Than 130/85 in Third Titrated Group (Olmesartan + Hydrochorothiazide + Amlodipine)

Number of patients that achieved a blood pressure goal of less than 130/85 in third titrated group (olmesartan 40 mg + 25 mg hydrochlorothiazide + amlodipine 5 mg). This combination was maintained as long as the participant's blood pressure remained within predefined parameters. If not, participant discontinued for lack of efficacy. (NCT00890591)
Timeframe: 4 - 9 weeks

Intervention	Participants (Number)
Olmesartan + Hydrochlorothiazide + Amlodipine	12

[back to top]

Number of Patients That Achieved a Blood Pressure Goal of Less Than 130/85 (Olmesartan 20 mg Monotherapy)

Number of patients that achieved a blood pressure (BP) goal of less than 130/85 in the first group (olmesartan monotherapy 20 mg). If BP was > or = to 140/90 at 4,8, or 9 wks the participant went to next level for an additional 4-9 weeks at the next medication level (NCT00890591)
Timeframe: 4 - 9 wks of olmesartan monotherapy

Intervention	Participants (Number)
Olmesartan Monotherapy	38

[back to top]

Number of Patients That Achieved a Blood Pressure Goal of Less Than 130/85 in First Titrated Group (Olmesartan 20 mg + 12.5 mg Hydrochlorothiazide)

Number of patients that achieved a blood pressure goal of less than 130/85 in first titrated group (olmesartan 20 mg + 12.5 mg hydrochlorothiazide)If BP was > or = to 140/90 at 4,8, or 9 wks the participant went to next level of medication for an additional 4-9 weeks (NCT00890591)
Timeframe: 4 to 9 weeks on combination therapy

Intervention	Participants (Number)
Olmesartan + Hydrochlorothiazide	33

[back to top]

In Non-responders, the Change in Seated Systolic Blood Pressure Associated With the Triple Combinations OM/AML/HCTZ 40/10/12.5 and 40/10/25 mg.

Change in seated systolic blood pressure from the beginning to the end of Period 4. Three cuff blood pressure measurements were taken at each visit. (NCT00902538)
Timeframe: week 24 to week 32

Intervention	mm Hg (Least Squares Mean)
OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 12.5 (Non-responders)	-5.5
OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 25 (Non-responders)	-7.8

[back to top]

In Non-responders, the Change in Seated Diastolic Blood Pressure Associated With the Triple Combinations OM/AML/HCTZ 40/10/12.5 and 40/10/25 mg.

Change in seated diastolic blood pressure from the beginning to the end of Period 4. Three cuff blood pressure measurements were taken at each visit. (NCT00902538)
Timeframe: week 24 to week 32

Intervention	mm Hg (Least Squares Mean)
OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 12.5 (Non-responders)	-6.7
OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 25 (Non-responders)	-7.9

[back to top]

Change in 24-hour Diastolic Blood Pressure (DBP) Assessed by 24-hour Ambulatory Blood Pressure Measurement (ABPM).

Three cuff blood pressure measurements were taken at each visit. (NCT00902538)
Timeframe: Baseline (8 weeks) to 16 weeks

Intervention	mm Hg (Least Squares Mean)
Olmesartan(OLM) 40 Mg-Amlodipine(AML) 10 mg	-2.1
OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 12.5	-4.0
OLM 40-AML 10-HCTZ 25	-5.3

[back to top]

Change in 24-hour Systolic Blood Pressure Assessed by 24-hour Ambulatory Blood Pressure Measurement.

Three cuff blood pressure measurements were taken at each visit. (NCT00902538)
Timeframe: Baseline (8 weeks) to 16 weeks

Intervention	mm Hg (Least Squares Mean)
Olmesartan(OLM) 40 Mg-Amlodipine(AML) 10 mg	-1.9
OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 12.5	-5.1
OLM 40-AML 10-HCTZ 25	-6.6

[back to top]

Change in Seated Diastolic Blood Pressure (SeDBP) of the Triple Combinations OM/AML/HCTZ 40/10/12.5 and 40/10/25 mg vs. OM/AML 40/10 mg

Three cuff blood pressure measurements were taken at each visit. (NCT00902538)
Timeframe: baseline (8 weeks) to 16 weeks

Intervention	mm Hg (Least Squares Mean)
Olmesartan(OLM) 40 Mg-Amlodipine(AML) 10 mg	-6.1
OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 12.5	-7.1
OLM 40-AML 10-HCTZ 25	-8.9

[back to top]

Change in Seated Systolic Blood Pressure (SeSBP) of the Triple Combinations OM/AML/HCTZ 40/10/12.5 and 40/10/25 mg vs. OM/AML 40/10 mg

Three cuff blood pressure measurements were taken at each visit. (NCT00902538)
Timeframe: baseline (8 weeks) to week 16

Intervention	mm Hg (Least Squares Mean)
Olmesartan(OLM) 40 Mg-Amlodipine(AML) 10 mg	-6.9
OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 12.5	-8.6
OLM 40-AML 10-HCTZ 25	-10.5

[back to top]

In Non-responders, the Change in 24-hour Diastolic Blood Pressure Assessed by 24-hour Ambulatory Blood Pressure Measurement.

In non-responders, the change in 24-hour diastolic blood pressure assessed by 24-hour ambulatory blood pressure measurement from the beginning to the end of Period 4. (NCT00902538)
Timeframe: Week 16 to week 32

Intervention	mm Hg (Least Squares Mean)
OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 12.5	-2.2
OLM 40-AML 10-HCTZ 25	-4.4

[back to top]

Number of Subjects Achieving Blood Pressure (BP) Goal at Week 16.

Achieving blood pressure goal is defined as seated blood pressure <140/90 mm Hg; 130/80 mm Hg for participants with diabetes and/or other chronic renal and/or chronic cardiovascular disease. Three cuff blood pressure measurements were taken at each visit. (NCT00902538)
Timeframe: baseline (week 8) to week 16

Intervention	Participants (Number)
Olmesartan(OLM) 40 Mg-Amlodipine(AML) 10 mg	65
OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 12.5	79
OLM 40-AML 10-HCTZ 25	111

[back to top]

In Non-responders, the Number of Subject Meeting Their Blood Pressure Goals Associated With the Triple Combinations OM/AML/HCTZ 40/10/12.5 and 40/10/25 mg.

The number of non-responding participants who achieved their blood pressure goals at the end of Period 4. Achieving blood pressure goal is defined as seated blood pressure <140/90 mm Hg; 130/80 mm Hg for participants with diabetes and/or other chronic renal and/or chronic cardiovascular disease. Three cuff blood pressure measurements were taken at each visit. (NCT00902538)
Timeframe: week 24 to week 32

Intervention	Participants (Number)
OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 12.5 (Non-responders)	31
OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 25 (Non-responders)	89

[back to top]

In Non-responders, the Change in 24-hour Systolic Blood Pressure Assessed by 24-hour Ambulatory Blood Pressure Measurement.

In non-responders, the change in 24-hour systolic blood pressure assessed by 24-hour ambulatory blood pressure measurement from the beginning to the end of Period 4. (NCT00902538)
Timeframe: Week 16 to week 32

Intervention	mm Hg (Least Squares Mean)
OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 12.5	-0.4
OLM 40-AML 10-HCTZ 25	-4.3

[back to top]

Change in Seated Systolic Blood Pressure (SeDBP).

(NCT00923091)
Timeframe: Baseline to week 10

Intervention	mm Hg (Least Squares Mean)
Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg	-33.2
Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg	-33.7
Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/25mg	-35.3
Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/12.5mg	-35.5
Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/25mg	-36.2
Olmesartan/Amlodipine 20mg/5mg	-29.9
Olmesartan/Amlodipine 40mg/5mg	-30.4
Olmesartan/Amlodipine 40mg/10mg	-32.8

[back to top]

Change in Seated Systolic Blood Pressure From Week 18 to Week 22

(NCT00923091)
Timeframe: Week 18 to week 22

Intervention	mm Hg (Least Squares Mean)
Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg	-5.7
Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg	-6.5

[back to top]

Change in Seated Systolic Blood Pressure From Week 22 to Week 26

(NCT00923091)
Timeframe: Week 22 to week 26

Intervention	mm Hg (Least Squares Mean)
OLM/AML/HCTZ 40/5/12.5mg Nonresponders Randomized to 40/5/12.5	-4.5
OLM/AML/HCTZ40/5/12.5mg Nonresponders Randomized to 40/5/25	-6.7

[back to top]

Number of Subjects Reaching Blood Pressure Goal at Week 10

Blood pressure treatment goal was defined as blood pressure <140/90 mmHg or <130/80 mmHg for subjects with diabetes, chronic renal disease, or chronic cardiovascular disease. (NCT00923091)
Timeframe: baseline to week 10

Intervention	Participants (Number)
Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg	177
Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg	176
Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/25mg	197
Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/12.5mg	190
Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/25mg	179
Olmesartan/Amlodipine 20mg/5mg	144
Olmesartan/Amlodipine 40mg/5mg	155
Olmesartan/Amlodipine 40mg/10mg	166

[back to top]

Number of Subjects Reaching Blood Pressure Goal From Week 18 to Week 22

Intervention	Participants (Number)
Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg	63
Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg	137

[back to top]

Change in Seated Diastolic Blood Pressure From Week 18 to Week 22

(NCT00923091)
Timeframe: Week 18 to week 22

Intervention	mm Hg (Least Squares Mean)
Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg	-3.3
Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg	-4.1

[back to top]

Number of Subjects Reaching Blood Pressure Goal at Week 26

Intervention	Participants (Number)
OLM/AML/HCTZ 40/5/12.5mg Nonresponders Randomized to 40/5/12.5	29
OLM/AML/HCTZ 40/5/12.5mg Nonresponders Randomized to 40/5/25	47

[back to top]

Change in Seated Diastolic Blood Pressure From Week 22 to Week 26

(NCT00923091)
Timeframe: Week 22 to week 26

Intervention	mm Hg (Least Squares Mean)
OLM/AML/HCTZ 40/5/12.5mg Nonresponders Randomized to 40/5/12.5	-2.7
OLM/AML/HCTZ 40/5/12.5mg Nonresponders Randomized to 40/5/25	-3.8

[back to top]

Change in Seated Systolic Blood Pressure (SeDBP) During Open-Label Period VI (Titration Effect From OM/AML/HCTZ 40/5/25 to 40/10/25.

(NCT00923091)
Timeframe: Week 26 to week 54

Intervention	mm Hg (Mean)
OLM/AML/HCTZ 40/5/25 Titrated to 40/10/25	-11.9

[back to top]

Change in Seated Diastolic Blood Pressure (SeDBP).

Baseline blood pressure was defined as the average values obtained at the randomization visit and at the visit prior to randomization (NCT00923091)
Timeframe: Baseline to week 10

Intervention	mm HG (Least Squares Mean)
Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg	-22.5
Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg	-22.5
Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/25mg	-23.0
Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/12.5mg	-23.9
Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/25mg	-23.8
Olmesartan/Amlodipine 20mg/5mg	-20.5
Olmesartan/Amlodipine 40mg/5mg	-21.2
Olmesartan/Amlodipine 40mg/10mg	-22.1

[back to top]

Change From Baseline to Week 8 in Trough, Cuff, Seated Diastolic Blood Pressure (SDBP)

The change from baseline in trough SDBP at Week 8 as measured by the Omron monitor. Morning doses of study medication were taken after the exam on study visit days, therefore exam measurements were taken when medication levels were at its lowest ('the trough'). Following a 5-minute rest period, three separate blood pressure measurements were taken with a full 2-minute (not exceeding 5 minutes) interval between measurements, with the cuff fully deflated between measurements. The mean of the 3 seated blood pressure measurements constitute the blood pressure value for the visit. (NCT00949884)
Timeframe: Day 0, Week 8

Intervention	mmHg (Least Squares Mean)
Olmesartan	-9.8
Combined Olmesartan	-9.7
Losartan	-7.1

[back to top]

Change From Baseline to Week 4 in Trough, Cuff, Seated Systolic Blood Pressure (SSBP)

The change from baseline in trough SSBP at Week 4 as measured by the Omron monitor. Morning doses of study medication were taken after the exam on study visit days, therefore exam measurements were taken when medication levels were at its lowest ('the trough'). Following a 5-minute rest period, three separate blood pressure measurements were taken with a full 2-minute (not exceeding 5 minutes) interval between measurements, with the cuff fully deflated between measurements. The mean of the 3 seated blood pressure measurements constitute the blood pressure value for the visit. (NCT00949884)
Timeframe: Day 0, Week 4

Intervention	mmHg (Least Squares Mean)
Olmesartan	-12.3
Combined Olmesartan	-12.0
Losartan	-8.5

[back to top]

Change From Baseline to Week 4 in Trough, Cuff, Seated Diastolic Blood Pressure (SDBP)

The change from baseline in trough SDBP at Week 4 as measured by the Omron monitor. Morning doses of study medication were taken after the exam on study visit days, therefore exam measurements were taken when medication levels were at its lowest ('the trough'). Following a 5-minute rest period, three separate blood pressure measurements were taken with a full 2-minute (not exceeding 5 minutes) interval between measurements, with the cuff fully deflated between measurements. The mean of the 3 seated blood pressure measurements constitute the blood pressure value for the visit. (NCT00949884)
Timeframe: Day 0, Week 4

Intervention	mmHg (Least Squares Mean)
Olmesartan	-9.0
Combined Olmesartan	-8.8
Losartan	-6.2

[back to top]

Percentage of Participants Achieving Blood Pressure Goals at Week 4

"Percentage of participants who achieved the following goals:~Systolic blood pressure: <140 mmHg, <135 mmHg, <130 mmHg, <120 mmHg Diastolic blood pressure: <90 mmHg, <85 mmHg, <80 mmHg Blood pressure: <140/90 mmHg, <135/80 mmHg, <130/80 mmHg" (NCT00949884)
Timeframe: Week 4

Intervention	percentage of participants analyzed (Number)
	Systolic BP <140 mmHg	Systolic BP <135 mmHg	Systolic BP <130 mmHg	Systolic BP <120 mmHg	Diastolic BP <90 mmHg	Diastolic BP <85 mmHg	Diastolic BP <80 mmHg	Blood pressure <140/90 mmHg	Blood pressure <135/80 mmHg	Blood pressure <130/80 mmHg
Combined Olmesartan	36.7	27.1	16.5	3.5	38.8	23.9	10.4	26.5	7.6	5.9
Losartan	25.6	14.1	7.2	2.0	24.5	13.0	4.6	14.3	2.2	1.5
Olmesartan	37.9	28.1	16.8	3.1	39.6	24.2	10.6	27.3	7.4	5.5

[back to top]

Percentage of Participants Achieving Ambulatory Blood Pressure Goal of < 135/85 mmHg at Week 8

Participants from pre-selected sites had 24-hour ambulatory blood pressure readings collected. Daytime readings were results collected between 8am and 4pm. Nighttime readings were results collected between 10pm and 6am. (NCT00949884)
Timeframe: Week 8

Intervention	percentage of population (Number)
	Mean 24-hour	Mean Daytime	Mean Nighttime
Combined Olmesartan	58.5	32.1	77.4
Losartan	40.9	21.8	66.4
Olmesartan	59.2	32.7	76.5

[back to top]

Change From Baseline to Week 2 in Trough, Cuff, Seated Blood Pressure

The change from baseline in trough systolic and diastolic blood pressure at Week 2 as measured by the Omron monitor. Morning doses of study medication were taken after the exam, therefore exam measurements were taken when medication levels were at its lowest ('the trough'). Following a 5-minute rest period, three separate blood pressure measurements were taken with a full 2-minute (not exceeding 5 minutes) interval between measurements, with the cuff fully deflated between measurements. The mean of the 3 seated blood pressure measurements constitute the blood pressure value for the visit. (NCT00949884)
Timeframe: Baseline, Week 2

Intervention	mmHg (Least Squares Mean)
	Diastolic blood pressure	Systolic blood pressure
Olmesartan	-8.3	-11.9
Placebo Followed by Olmesartan	-4.0	-3.3

[back to top]

Change From Baseline in Mean Daytime (8am to 4pm) and Mean Nighttime (10pm to 6am) Ambulatory Blood Pressure at Week 8

In week 8, participants arrived at the site in the morning without having taken that day's dose of medication. Once the ambulatory blood pressure monitor (ABPM) had been applied, medication was taken and the participant wore the ABPM for a period of 24-hours. Daytime (8am to 4pm) and nighttime (10pm to 6am) systolic and diastolic blood pressure readings are summarized. (NCT00949884)
Timeframe: Baseline, Week 8

Intervention	mmHg (Least Squares Mean)
	Daytime systolic blood pressure	Daytime diastolic blood pressure	Nighttime systolic blood pressure	Nighttime diastolic blood pressure
Combined Olmesartan	-8.7	-6.1	-9.3	-6.1
Losartan	-5.2	-3.7	-6.3	-4.1
Olmesartan	-8.7	-6.2	-9.3	-6.2

[back to top]

Change From Baseline in Mean Ambulatory Blood Pressure During the Final 2, 4, and 6 Hours of the Dosing Interval at Week 8

In week 8, participants arrived at the site in the morning without having taken that day's dose of medication. Once the ambulatory blood pressure monitor (ABPM) had been applied, medication was taken and the participant wore the ABPM for a period of 24-hours. Systolic and diastolic blood pressure readings taken in the final 2, 4, and 6 hours of the 24-hour ABPM cycle are summarized. (NCT00949884)
Timeframe: Baseline, Week 8

Intervention	mmHg (Least Squares Mean)
	2 hour systolic blood pressure	2 hour diastolic blood pressure	4 hour systolic blood pressure	4 hour diastolic blood pressure	6 hour systolic blood pressure	6 hour diastolic blood pressure
Combined Olmesartan	-9.5	-6.0	-10.1	-6.7	-9.7	-6.5
Losartan	-7.2	-4.0	-6.9	-4.1	-6.5	-4.0
Olmesartan	-10.0	-6.3	-10.5	-7.1	-10.0	-6.8

[back to top]

Change From Baseline in Mean Ambulatory Blood Pressure During the Final 2, 4, and 6 Hours of the Dosing Interval at Week 4

In week 4, participants arrived at the site in the morning without having taken that day's dose of medication. Once the ambulatory blood pressure monitor (ABPM) had been applied, medication was taken and the participant wore the ABPM for a period of 24-hours. Systolic and diastolic blood pressure readings taken in the final 2, 4, and 6 hours of the 24-hour ABPM cycle are summarized. (NCT00949884)
Timeframe: Baseline, Week 4

Intervention	mmHg (Least Squares Mean)
	2 hour systolic blood pressure	2 hour diastolic blood pressure	4 hour systolic blood pressure	4 hour diastolic blood pressure	6 hour systolic blood pressure	6 hour diastolic blood pressure
Combined Olmesartan	-8.4	-5.6	-8.3	-5.6	-8.0	-5.4
Losartan	-6.8	-3.8	-6.5	-4.1	-6.2	-3.9
Olmesartan	-8.7	-5.8	-8.4	-5.8	-8.0	-5.5

[back to top]

Change From Baseline in Mean Daytime (8am to 4pm) and Mean Nighttime (10pm to 6am) Ambulatory Blood Pressure at Week 4

In week 4, participants arrived at the site in the morning without having taken that day's dose of medication. Once the ambulatory blood pressure monitor (ABPM) had been applied, medication was taken and the participant wore the ABPM for a period of 24-hours. Daytime (8am to 4pm) and nighttime (10pm to 6am) systolic and diastolic blood pressure readings are summarized. (NCT00949884)
Timeframe: Baseline, Week 4

Intervention	mmHg (Least Squares Mean)
	Daytime systolic blood pressure	Daytime diastolic blood pressure	Nighttime systolic blood pressure	Nighttime diastolic blood pressure
Combined Olmesartan	-7.5	-5.2	-6.8	-4.3
Losartan	-5.8	-3.5	-5.5	-3.4
Olmesartan	-7.6	-5.4	-6.7	-4.4

[back to top]

Percentage of Participants Achieving Blood Pressure Goals at Week 8

Intervention	percentage of participants analyzed (Number)
	Systolic BP <140 mmHg	Systolic BP <135 mmHg	Systolic BP <130 mmHg	Systolic BP <120 mmHg	Diastolic BP <90 mmHg	Diastolic BP <85 mmHg	Diastolic BP <80 mmHg	Blood pressure <140/90 mmHg	Blood pressure <135/80 mmHg	Blood pressure <130/80 mmHg	Blood pressure <120/80 mmHg
Combined Olmesartan	41.0	30.0	18.4	6.6	42.5	22.9	11.8	31.6	9.9	7.5	4.7
Losartan	28.9	20.4	13.1	3.8	30.5	15.5	6.6	19.5	4.9	4.5	2.3
Olmesartan	41.1	29.9	18.2	6.8	43.2	22.9	12.2	32.6	10.2	7.6	4.9

[back to top]

Change From Baseline in Mean 24-Hour Ambulatory Blood Pressure at Week 8

Intervention	mmHg (Least Squares Mean)
	Systolic blood pressure	Diastolic blood pressure
Combined Olmesartan	-9.2	-6.1
Losartan	-5.6	-3.6
Olmesartan	-9.1	-6.1

[back to top]

Change From Baseline in Mean 24-Hour Ambulatory Blood Pressure at Week 4

Intervention	mmHg (Least Squares Mean)
	Systolic blood pressure	Diastolic blood pressure
Combined Olmesartan	-7.3	-4.8
Losartan	-5.9	-3.7
Olmesartan	-7.3	-4.9

[back to top]

Incremental Change From Week 4 to Week 8 in Trough, Cuff, Seated Systolic Blood Pressure (SSBP)

The change from Week 4 in trough SSBP at Week 8 as measured by the Omron monitor. Morning doses of study medication were taken after the exam on study visit days, therefore exam measurements were taken when medication levels were at its lowest ('the trough'). Following a 5-minute rest period, three separate blood pressure measurements were taken with a full 2-minute (not exceeding 5 minutes) interval between measurements, with the cuff fully deflated between measurements. The mean of the 3 seated blood pressure measurements constitute the blood pressure value for the visit. (NCT00949884)
Timeframe: Week 4, Week 8

Intervention	mmHg (Least Squares Mean)
Olmesartan	-1.1
Combined Olmesartan	-1.4
Losartan	0.0

[back to top]

Incremental Change From Week 4 to Week 8 in Trough, Cuff, Seated Diastolic Blood Pressure (SDBP)

The change from Week 4 in trough SDBP at Week 8 as measured by the Omron monitor. Morning doses of study medication were taken after the exam on study visit days, therefore exam measurements were taken when medication levels were at its lowest ('the trough'). Following a 5-minute rest period, three separate blood pressure measurements were taken with a full 2-minute (not exceeding 5 minutes) interval between measurements, with the cuff fully deflated between measurements. The mean of the 3 seated blood pressure measurements constitute the blood pressure value for the visit. (NCT00949884)
Timeframe: Week 4, Week 8

Intervention	mmHg (Least Squares Mean)
Olmesartan	-0.8
Combined Olmesartan	-0.9
Losartan	0.0

[back to top]

Change From Baseline to Week 8 in Trough, Cuff, Seated Systolic Blood Pressure (SSBP)

The change from baseline in trough SSBP at Week 8 as measured by the Omron monitor. Morning doses of study medication were taken after the exam on study visit days, therefore exam measurements were taken when medication levels were at its lowest ('the trough'). Following a 5-minute rest period, three separate blood pressure measurements were taken with a full 2-minute (not exceeding 5 minutes) interval between measurements, with the cuff fully deflated between measurements. The mean of the 3 seated blood pressure measurements constitute the blood pressure value for the visit. (NCT00949884)
Timeframe: Day 0, Week 8

Intervention	mmHg (Least Squares Mean)
Olmesartan	-13.6
Combined Olmesartan	-13.6
Losartan	-9.7

[back to top]

Percentage of Participants With at Least 1 Adverse Event

An adverse event is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product without regard to causality. (NCT00996281)
Timeframe: From Week 0 (Day 1) to Week 52.

Intervention	percentage of participants (Number)
Azilsartan Medoxomil and Chlorthalidone	78.5
Olmesartan Medoxomil and Hydrochlorothiazide	76.4

[back to top]

Percentage of Participants With Serum Creatinine Elevations Greater Than 50% From Baseline and Greater Than the Upper Limit of Normal (ULN)

Serum creatinine was measured at every visit and evaluated as a laboratory parameter of special interest. The percentage of participants with creatinine increase ≥50% from Baseline and greater than ULN was summarized: - At any visit (includes transient and persistent elevations). - At the Final Visit (includes persistent elevations and participants whose first elevation may have been at the Final Visit). - At least 2 consecutive visits (includes only persistent elevations). (NCT00996281)
Timeframe: Baseline and Week 52

Intervention	percentage of participants (Number)
	At any postbaseline visit	at the Final Visit	≥2 consecutive elevations
Azilsartan Medoxomil and Chlorthalidone	14.2	5.9	5.1
Olmesartan Medoxomil and Hydrochlorothiazide	5.8	1.0	1.2

[back to top]

Change From Baseline in 24-hour Mean Diastolic Blood Pressure by Ambulatory Blood Pressure Monitoring.

The change in 24-hour mean diastolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing. (NCT01033071)
Timeframe: Baseline and Week 12.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD	-19.4
Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD	-20.7
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-16.2

[back to top]

Change From Baseline in 24-hour Mean Systolic Blood Pressure by Ambulatory Blood Pressure Monitoring.

The change in 24-hour mean systolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing. (NCT01033071)
Timeframe: Baseline and Week 12.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD	-33.9
Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD	-36.3
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-27.5

[back to top]

Change From Baseline in Mean Daytime (6 AM to 10 PM) Diastolic Blood Pressure by Ambulatory Blood Pressure Monitoring.

The change in daytime (6am to 10pm) mean diastolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 AM (inclusive) and 10 PM (exclusive). (NCT01033071)
Timeframe: Baseline and Week 12.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD	-20.1
Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD	-21.8
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-17.0

[back to top]

Change From Baseline in Mean Daytime (6 AM to 10 PM) Systolic Blood Pressure by Ambulatory Blood Pressure Monitoring.

The change in daytime (6am to 10pm) mean systolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 AM (inclusive) and 10 PM (exclusive). (NCT01033071)
Timeframe: Baseline and Week 12.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD	-35.3
Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD	-37.9
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-28.8

[back to top]

Change From Baseline in Mean Nighttime (12 AM to 6 AM) Diastolic Blood Pressure by Ambulatory Blood Pressure Monitoring.

The change in the mean nighttime (12am to 6am) diastolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Mean nighttime is the average (arithmetic mean) of measurements recorded between the hours of 12 AM (inclusive) and 6 AM (exclusive). (NCT01033071)
Timeframe: Baseline and Week 12.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD	-17.5
Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD	-18.0
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-14.0

[back to top]

Change From Baseline in Mean Nighttime (12 AM to 6 AM) Systolic Blood Pressure by Ambulatory Blood Pressure Monitoring.

The change in the mean nighttime (12am to 6am) systolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Mean nighttime is the average (arithmetic mean) of measurements recorded between the hours of 12 AM (inclusive) and 6 AM (exclusive). (NCT01033071)
Timeframe: Baseline and Week 12.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD	-29.6
Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD	-31.8
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-23.9

[back to top]

Change From Baseline in Mean Trough Diastolic Blood Pressure by Ambulatory Blood Pressure Monitoring.

The change in trough diastolic blood pressure measured at week 12 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Trough is the average of all measurements recorded from 22 to 24 hours after dosing. (NCT01033071)
Timeframe: Baseline and Week 12.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD	-19.8
Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD	-20.2
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-16.0

[back to top]

Change From Baseline in Mean Trough Systolic Blood Pressure by Ambulatory Blood Pressure Monitoring.

The change in trough systolic blood pressure measured at week 12 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Trough is the average of all measurements recorded from 22 to 24 hours after dosing. (NCT01033071)
Timeframe: Baseline and Week 12.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD	-32.9
Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD	-34.9
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-25.9

[back to top]

Change From Baseline in the Mean Diastolic Blood Pressure at 0 to 12 Hours After Dosing by Ambulatory Blood Pressure Monitoring.

The change in the mean 12 hour diastolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The mean consists of the average (arithmetic mean) of measurements. (NCT01033071)
Timeframe: Baseline and Week 12.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD	-20.4
Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD	-22.2
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-17.5

[back to top]

Change From Baseline in the Mean Systolic Blood Pressure at 0 to 12 Hours After Dosing by Ambulatory Blood Pressure Monitoring.

The change in the mean 12 hour systolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The mean consists of the average (arithmetic mean) of measurements. (NCT01033071)
Timeframe: Baseline and Week 12.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD	-36.2
Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD	-38.8
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-29.7

[back to top]

Change From Baseline in Trough, Sitting, Clinic Systolic Blood Pressure.

The change in sitting trough clinic systolic blood pressure measured at week 12 or final visit relative to baseline. Trough blood pressure is the average of the non-missing values of the 3 serial trough sitting systolic blood pressure measurements. (NCT01033071)
Timeframe: Baseline and Week 12.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD	-42.5
Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD	-44.0
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-37.1

[back to top]

Change From Baseline in the Mean Diastolic Blood Pressure During Each Hour of the 24-hour Ambulatory Blood Pressure Monitoring.

The change from baseline for each hour interval of the 24-hour ambulatory blood pressure monitoring measured at week 12 or final visit. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The mean consists of the average (arithmetic mean) of measurements collected at each hour. (NCT01033071)
Timeframe: Baseline and Week 12.

Intervention	mmHg (Least Squares Mean)
	0 to 1 Hour (n=232; n=212; n=237)	1 to 2 Hour (n=232; n=214; n=238)	2 to 3 Hour (n=232; n=214; n=238)	3 to 4 Hour (n=232; n=214; n=238)	4 to 5 Hour (n=232; n=214; n=238)	5 to 6 Hour (n=232; n=214; n=238)	6 to 7 Hour (n=232; n=214; n=238)	7 to 8 Hour (n=232; n=214; n=238)	8 to 9 Hour (n=232; n=214; n=238)	9 to 10 Hour (n=232; n=214; n=238)	10 to 11 Hour (n=232; n=214; n=238)	11 to 12 Hour (n=232; n=214; n=238)	12 to 13 Hour (n=232; n=214; n=238)	13 to 14 Hour (n=232; n=214; n=238)	14 to 15 Hour (n=232; n=214; n=238)	15 to 16 Hour (n=232; n=214; n=238)	16 to 17 Hour (n=232; n=214; n=238)	17 to 18 Hour (n=231; n=214; n=238)	18 to 19 Hour (n=232; n=214; n=238)	19 to 20 Hour (n=232; n=214; n=238)	20 to 21 Hour (n=232; n=214; n=238)	21 to 22 Hour (n=232; n=214; n=238)	22 to 23 Hour (n=232; n=214; n=238)	23 to 24 Hour (n=232; n=214; n=238)
Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD	-18.2	-18.8	-21.2	-20.8	-21.7	-20.9	-20.8	-20.5	-20.7	-21.0	-19.7	-19.3	-19.2	-19.6	-18.9	-17.8	-17.2	-16.6	-17.4	-17.8	-16.7	-17.8	-19.5	-20.2
Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD	-20.4	-20.9	-23.4	-23.7	-23.7	-23.6	-22.0	-21.9	-21.5	-21.9	-20.7	-21.2	-20.3	-19.5	-19.7	-18.6	-16.9	-17.1	-18.1	-18.5	-18.4	-18.5	-19.6	-21.0
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-15.2	-15.9	-17.7	-18.2	-17.9	-19.0	-18.0	-17.7	-17.9	-18.3	-16.7	-17.0	-16.0	-15.3	-15.4	-14.5	-13.9	-13.2	-14.3	-13.8	-13.9	-14.7	-15.6	-16.4

[back to top]

Change From Baseline in the Mean Systolic Blood Pressure During Each Hour of the 24-hour Ambulatory Blood Pressure Monitoring.

Intervention	mmHg (Least Squares Mean)
	0 to 1 Hour (n=232; n=212; n=237)	1 to 2 Hour (n=232; n=214; n=238)	2 to 3 Hour (n=232; n=214; n=238)	3 to 4 Hour (n=232; n=214; n=238)	4 to 5 Hour (n=232; n=214; n=238)	5 to 6 Hour (n=232; n=214; n=238)	6 to 7 Hour (n=232; n=214; n=238)	7 to 8 Hour (n=232; n=214; n=238)	8 to 9 Hour (n=232; n=214; n=238)	9 to 10 Hour (n=232; n=214; n=238)	10 to 11 Hour (n=232; n=214; n=238)	11 to 12 Hour (n=232; n=214; n=238)	12 to 13 Hour (n=232; n=214; n=238)	13 to 14 Hour (n=232; n=214; n=238)	14 to 15 Hour (n=232; n=214; n=238)	15 to 16 Hour (n=232; n=214; n=238)	16 to 17 Hour (n=232; n=214; n=238)	17 to 18 Hour (n=231; n=214; n=238)	18 to 19 Hour (n=232; n=214; n=238)	19 to 20 Hour (n=232; n=214; n=238)	20 to 21 Hour (n=232; n=214; n=238)	21 to 22 Hour (n=232; n=214; n=238)	22 to 23 Hour (n=232; n=214; n=238)	23 to 24 Hour (n=232; n=214; n=238)
Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD	-33.6	-33.4	-36.7	-36.6	-36.8	-37.2	-36.3	-37.2	-37.3	-36.9	-36.1	-35.2	-34.8	-34.1	-33.4	-30.9	-29.6	-28.5	-29.5	-29.7	-28.2	-30.6	-32.9	-33.1
Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD	-36.2	-36.4	-39.3	-40.3	-40.8	-41.2	-38.6	-38.5	-38.1	-38.0	-37.6	-38.2	-36.2	-35.3	-35.0	-32.9	-31.1	-30.8	-31.9	-32.5	-31.2	-32.8	-34.0	-35.8
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-26.8	-27.5	-30.0	-29.6	-30.1	-31.5	-29.8	-29.7	-30.5	-30.8	-29.4	-29.3	-27.7	-26.4	-26.2	-25.3	-24.5	-23.1	-24.3	-23.5	-23.0	-24.6	-25.9	-26.1

[back to top]

Change From Baseline in Trough, Sitting, Clinic Diastolic Blood Pressure.

The change in sitting trough clinic diastolic blood pressure measured at each week indicated relative to baseline. Trough blood pressure is the average (arithmetic mean) of the non-missing values of the 3 serial trough sitting systolic blood pressure measurements. (NCT01033071)
Timeframe: Baseline, Week 4, Week 8 and Week 12.

Intervention	mmHg (Least Squares Mean)
	Week 4 (n=343; n=330; n=352)	Week 8 (n=344; n=330; n=353)	Week 12 (n=344; n=330; n=354)
Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD	-14.9	-17.0	-18.8
Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD	-15.8	-17.7	-20.5
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-11.7	-13.9	-16.4

[back to top]

Change From Baseline in Trough, Sitting, Clinic Systolic Blood Pressure.

The change in sitting trough clinic systolic blood pressure measured at each week indicated relative to baseline. Trough blood pressure is the average of the non-missing values of the 3 serial trough sitting systolic blood pressure measurements. (NCT01033071)
Timeframe: Baseline, Week 4 and Week 8.

Intervention	mmHg (Least Squares Mean)
	Week 4 (n=343; n=330; n=352)	Week 8 (n=344; n=330; n=353)
Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD	-34.7	-39.1
Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD	-36.7	-39.4
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-29.7	-33.5

[back to top]

Percent of Participants Who Reached Target Clinic Systolic Blood Pressure of <140 mm Hg and/or Reduction of ≥20 mm Hg From Baseline and Target Clinic Diastolic Blood Pressure of <90 mm Hg and/or Reduction of ≥10 mm Hg From Baseline.

Percentage of participants who achieve both a clinic diastolic and systolic blood pressure response measured at each week indicated, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg AND less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Diastolic and systolic blood pressure is based on the arithmetic mean of the non-missing values of the 3 serial trough sitting blood pressure measurements. (NCT01033071)
Timeframe: Baseline, Week 4, Week 8 and Week 12.

Intervention	percent of participants (Number)
	Week 4 (n=343; n=330; n=352)	Week 8 (n=344; n=330; n=353)	Week 12 (n=344; n=330; n=354)
Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD	81.3	88.1	91.3
Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD	84.8	87.3	92.4
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	74.4	81.0	84.7

[back to top]

Percentage of Participants Who Reached Target Clinic Diastolic Blood Pressure of <90 mm Hg and/or Reduction of ≥10 mm Hg From Baseline.

Percentage of participants who achieve a clinic diastolic blood pressure response measured at each week indicated, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg. Diastolic blood pressure is the arithmetic mean of the non-missing values of the 3 serial trough sitting diastolic blood pressure measurements. (NCT01033071)
Timeframe: Baseline, Week 4, Week 8 and Week 12.

Intervention	percentage of participants (Number)
	Week 4 (n=343; n=330; n=352)	Week 8 (n=344; n=330; n=353)	Week 12 (n=344; n=330; n=354)
Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD	89.2	90.7	94.5
Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD	89.7	90.9	95.8
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	85.2	87.8	91.5

[back to top]

Percentage of Participants Who Reached Target Clinic Systolic Blood Pressure of <140 mm Hg and/or Reduction of ≥20 mm Hg From Baseline.

Percentage of participants who achieve a clinic systolic blood pressure response measured at each week indicated, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Systolic blood pressure is the arithmetic mean of the non-missing values of the 3serial trough sitting systolic blood pressure measurements. (NCT01033071)
Timeframe: Baseline, Week 4, Week 8 and Week 12.

Intervention	percentage of participants (Number)
	Week 4 (n=343; n=330; n=352)	Week 8 (n=344; n=330; n=353)	Week 12 (n=344; n=330; n=354)
Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD	87.8	93.3	93.0
Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD	90.0	92.4	94.2
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	79.8	85.6	89.3

[back to top]

Percentage of Participants Achieving JNC VII Recommended Blood Pressure Goal at Week 12 With LOCF

Based on JNC VII, the ultimate public health goal of antihypertensive therapy is to reduce cardiovascular and renal morbidity and mortality. The JNC VII recommended BP goal is <140/90 mmHg and <130/80 mmHg for participants with diabetes. (NCT01200407)
Timeframe: Baseline, Week 12

Intervention	percentage of participants (Number)
Normetec	70.5

[back to top]

Change From Baseline in SBP and DBP at Week 12 With Last Observation Carried Forward (LOCF)

(NCT01200407)
Timeframe: Baseline, Week 12

Intervention	millimeters of mercury (mmHg) (Mean)
	Baseline: SBP	Baseline: DBP	Change at Week 12: SBP LOCF	Change at Week12: DBP LOCF
Normetec	161.6	98.9	-35.8	-19.4

[back to top]

Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Weeks 4, 8 and 12 Without (w/o) LOCF

(NCT01200407)
Timeframe: Baseline, Week 4, Week 8, Week 12

Intervention	mmHg (Mean)
	Change at Week 4: SBP w/o LOCF	Change at Week 4: DBP w/o LOCF	Change and Week 8: SBP w/o LOCF	Change and Week 8: DBP w/o LOCF	Change and Week 12: SBP w/o LOCF	Change and Week 12: DBP w/o LOCF
Normetec	-24.7	-13.2	-33.0	-17.6	-36.3	-19.9

[back to top]

Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last study drug administration (Week 12) that were absent before treatment or that worsened relative to pre-treatment state. AEs included both SAEs and non-SAEs. (NCT01200407)
Timeframe: Baseline up to 28 days after last study drug administration (Week 12)

Intervention	participants (Number)
	Number of Participants with AEs	Number of Participants with SAEs
Normetec	6	0

[back to top]

Number of Participants With at Least 1 Adverse Event (AE)

An AE is any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have a causal relationship with this treatment. A serious AE is defined as any untoward medical occurrence that resulted in death, was life threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability or incapacity, led to a congenital anomaly/birth defect or was an important medical event that may have required intervention to prevent any of items above. (NCT01309828)
Timeframe: From the first dose of open-label study drug until 14 days (or 30 days for a serious adverse event) after the last dose of open- label study drug (up to 56 weeks).

Intervention	participants (Number)
	Adverse Events	Adverse Events Leading to Discontinuation	Serious Adverse Events	Serious Adverse Events Leading to Discontinuation	Death
Azilsartan Medoxomil + Chlorthalidone	68	17	8	5	0
Olmesartan Medoxomil + Hydrochlorothiazide	58	15	9	4	1

[back to top]

Percentage of Participants at Final Visit Who Achieved Target Diastolic Blood Pressure <80 mm Hg

Diastolic blood pressure is the arithmetic mean of the 3 serial sitting diastolic blood pressure measurements. Percentage of participants at Week 52 who achieved a sitting clinic diastolic blood pressure response, defined as less than 80 mm Hg. (NCT01309828)
Timeframe: Week 52

Intervention	percentage of participants (Number)
Azilsartan Medoxomil + Chlorthalidone	80.0
Olmesartan Medoxomil + Hydrochlorothiazide	87.8

[back to top]

Percentage of Participants at Final Visit Who Achieve Target Systolic Blood Pressure <130 mm Hg

Systolic blood pressure is the arithmetic mean of the 3 serial sitting systolic blood pressure measurements. Percentage of participants who achieve a sitting clinic systolic blood pressure response defined as less than 130 mm Hg at Week 52. (NCT01309828)
Timeframe: Week 52

Intervention	percentage of participants (Number)
Azilsartan Medoxomil + Chlorthalidone	69.3
Olmesartan Medoxomil + Hydrochlorothiazide	78.4

[back to top]

Percentage of Participants at Final Visit Who Achieved Both a Clinic Systolic and Diastolic Blood Pressure Response

Systolic/diastolic blood pressure is the arithmetic mean of the 3 serial sitting systolic/diastolic blood pressure measurements. Percentage of participants who achieved both a sitting clinic systolic and diastolic blood pressure response, defined as systolic blood pressure less than 130 mm Hg and diastolic blood pressure less than 80 mm Hg at Week 52. (NCT01309828)
Timeframe: Week 52

Intervention	percentage of participants (Number)
Azilsartan Medoxomil + Chlorthalidone	58.7
Olmesartan Medoxomil + Hydrochlorothiazide	73.0

[back to top]

Percentage of Participants Achieving a Successful msDBP Response

Successfull msDBP response was defined as <90 mmHg or ≥10 mmHg reduction from baseline. (NCT01599104)
Timeframe: 8 weeks

Intervention	Percentage of participants (Number)
LCZ696 200 mg	69.5
LCZ696 400 mg	70.1
Olmesartan 20 mg	60.7

[back to top]

Change From Baseline in Office Pulse Pressure

Office pulse pressure was calculated as msSBP minus msDBP. Sitting blood pressure (BP) measurement was performed at screening through the end of study at every visit. Four separate sitting BP were obtained with a full two-minute interval between measurement. The 4 measurements were summed and then averaged to calculate the mean BP value. The baseline PP value was subtracted from the week 8 PP value to determine the change from baseline in PP. (NCT01599104)
Timeframe: Baseline, 8 weeks

Intervention	mmHg (Least Squares Mean)
LCZ696 200 mg	-10.49
LCZ696 400 mg	-11.30
Olmesartan 20 mg	-7.34

[back to top]

Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)

Sitting BP measurements were performed at screening through the end of study at every visit. Four separate sitting BP were obtained with a full two-minute interval between measurements. The 4 measurements were summed and averaged, and then the baseline BP value was subtracted from the average value to get the change from baseline. (NCT01599104)
Timeframe: Baseline, 8 weeks

Intervention	mmHg (Least Squares Mean)
LCZ696 200 mg	-18.21
LCZ696 400 mg	-20.18
Olmesartan 20 mg	-13.20

[back to top]

Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)

Sitting BP measurement was performed at screening through the end of study at every visit. Four separate sitting BP were obtained with a full two-minute interval between measurement. The 4 measurements were summed and averaged, and then the baseline BP value was subtracted from the average value to get the change from baseline. (NCT01599104)
Timeframe: Baseline, 8 weeks

Intervention	mmHg (Least Squares Mean)
LCZ696 200 mg	-7.76
LCZ696 400 mg	-8.79
Olmesartan 20 mg	-5.91

[back to top]

Change From Baseline in Mean 24-hour Ambulatory SBP (maSBP) at Week 8

Ambulatory blood pressure monitoring (ABPM) over a 24-hour period was conducted at two time-points during the study in a subset of participants. (NCT01599104)
Timeframe: Baseline, 8 weeks

Intervention	mmHg (Least Squares Mean)
LCZ696 200 mg	-13.44
LCZ696 400 mg	-14.99
Olmesartan 20 mg	-8.78

[back to top]

Number of Patients With Adverse Events, Serious Adverse Events and Death

Participants were monitored for adverse events, serious adverse events and deaths throughout the study. (NCT01599104)
Timeframe: 8 weeks

Intervention	Participants (Number)
	Adverse Events (serious and non-serious)	Seroius Adverse Events	Deaths
LCZ696 200 mg	135	1	0
LCZ696 400 mg	136	1	0
Olmesartan 20 mg	152	7	0

[back to top]

Change From Baseline in Mean 24-hour Ambulatory DBP (maDBP) at Week 8

ABPM over a 24-hour period was conducted at two time-points during the study in a subset of participants. (NCT01599104)
Timeframe: Baseline, 8 weeks

Intervention	mmHg (Least Squares Mean)
LCZ696 200 mg	-7.65
LCZ696 400 mg	-8.44
Olmesartan 20 mg	-5.56

[back to top]

Change From Baseline in Mean 24-hour Ambulatory Pulse Pressure

Ambulatory pulse pressure was calculated as hourly ambulatory SBP minus hourly ambulatory DBP in a subset of participants. (NCT01599104)
Timeframe: Baseline, 8 weeks

Intervention	mmHg (Least Squares Mean)
LCZ696 200 mg	-5.79
LCZ696 400 mg	-6.57
Olmesartan 20 mg	-3.20

[back to top]

Percentage of Participants Achieving a Successful Response in Overall Blood Pressure Control at Week 8

A successful response in overall BP control rate was defined as msSBP < 140 mmHg and msDBP <90 mmHg. (NCT01599104)
Timeframe: 8 weeks

Intervention	Percentage of participants (Number)
LCZ696 200 mg	43.9
LCZ696 400 mg	46.5
Olmesartan 20 mg	32.9

[back to top]

Percentage of Participants Achieving a Successful msSBP Response

Successful msSBP response was defined as < 140 mmHg or ≥ 20 mmHg reduction from baseline. (NCT01599104)
Timeframe: 8 weeks

Intervention	Percentage of participants (Number)
LCZ696 200 mg	57.9
LCZ696 400 mg	63.1
Olmesartan 20 mg	42.9

[back to top]

Change From Baseline in maSBP and maDBP for Daytime/Nighttime

ABPM over a 24-hour period was conducted at two time-points during the study in a subset of participants. (NCT01599104)
Timeframe: Baseline, 8 weeks

Intervention	mmHg (Least Squares Mean)
	maSBP daytime	maSBP nighttime	maDBP daytime	maDBP nighttime
LCZ696 200 mg	-12.60	-15.13	-7.01	-8.82
LCZ696 400 mg	-14.44	-16.09	-8.00	-9.42
Olmesartan 20 mg	-7.87	-10.65	-4.95	-6.79

[back to top]

Change in Baseline in Mean 24 Hour Ambulatory Diastolic Blood Pressure (maDBP)

Intervention	mmHg (Least Squares Mean)
LCZ696	-6.95
Olmesartan	-4.47

[back to top]

Change From Baseline in maSBP and maDBP Lowering Based on Nocturnal BP Dipping (Dipper Versus Non-dipper) in Dippers

ABPM over a 24-hour period was conducted at two time-points during the study in a subset of participants. Readings were taken every 20 minutes over the 24 hour period in the non-dominant arm. A non-dipper was defined as a participant who, at baseline, had a mean nighttime ABPM (10 pm - 6 am) that did not drop ≥ 10% below his or her mean daytime ABPM (6 am - 10 pm). A negative change from baseline indicates improvement. (NCT01615198)
Timeframe: Baseline, 10 weeks

Intervention	mmHg (Mean)
	maSBP, hour 1 (n=58,66)	maSBP, hour 2 (n=62,66)	maSBP, hour 3 (n=62,68)	maSBP, hour 4 (n=62,68)	maSBP, hour 5 (n=61,67)	maSBP, hour 6 (n=62,68)	maSBP, hour 7 (n=62,68)	maSBP, hour 8 (n=62,67)	maSBP, hour 9 (n=62,68)	maSBP, hour 10 (n=62,68)	maSBP, hour 11 (n=62,68)	maSBP, hour 12 (n=62,68)	maSBP, hour 13 (n=62,68)	maSBP, hour 14 (n=62,68)	maSBP, hour 15 (n=62,67)	maSBP, hour 16 (n=62,68)	maSBP, hour 17 (n=62,68)	maSBP, hour 18 (n=61,68)	maSBP, hour 19 (n=62,68)	maSBP, hour 20 (n=62,68)	maSBP, hour 21 (n=62,67)	maSBP, hour 22 (n=62,68)	maSBP, hour 23 (n=60,66)	maSBP, hour 24 (n=57,67)	maDBP, hour 1 (n=58,66)	maDBP, hour 2 (n=62,66)	maDBP, hour 3 (n=62,68)	maDBP, hour 4 (n=62,68)	maDBP, hour 5 (n=61,67)	maDBP, hour 6 (n=62,68)	maDBP, hour 7 (n=62,68)	maDBP, hour 8 (n=62,67)	maDBP, hour 9 (n=62,68)	maDBP, hour 10 (n=62,68)	maDBP, hour 11 (n=62,68)	maDBP, hour 12 (n=62,68)	maDBP, hour 13 (n=-62,68)	maDBP, hour 14 (n=62,68)	maDBP, hour 15 (n=62,67)	maDBP, hour 16 (n=62,68)	maDBP, hour 17 (n=62,68)	maDBP, hour 18 (n=61,68)	maDBP, hour 19 (n=62,68)	maDBP, hour 20 (n=62,68)	maDBP, hour 21 (n=62,67)	maDBP, hour 22 (n=62,68)	maDBP, hour 23 (n=60,66)	maDBP, hour 24 (n=57,67)
LCZ696	-18.48	-20.75	-17.44	-16.90	-16.70	-18.11	-17.60	-15.81	-14.06	-15.55	-13.17	-12.36	-8.71	-7.10	-9.05	-9.90	-9.88	-11.19	-12.38	-15.18	-13.71	-19.28	-16.88	-17.28	-8.34	-9.13	-8.41	-7.35	-8.17	-8.39	-9.14	-7.50	-7.01	-7.83	-8.08	-7.38	-4.36	-2.70	-4.02	-4.84	-5.71	-5.36	-6.10	-6.75	-6.91	-10.22	-7.85	-7.83
Olmesartan	-14.15	-17.26	-12.65	-14.83	-16.16	-15.00	-14.74	-16.37	-13.55	-13.50	-13.32	-13.43	-10.84	-9.96	-8.68	-7.81	-5.49	-4.88	-6.69	-9.40	-9.04	-9.61	-10.54	-16.03	-7.30	-7.80	-8.21	-8.98	-8.35	-8.09	-7.35	-8.50	-6.65	-6.70	-6.65	-7.64	-7.16	-6.28	-3.05	-3.88	-3.74	-1.65	-3.42	-4.00	-4.40	-4.48	-5.11	-6.62

[back to top]

Change From Baseline in maSBP and maDBP Lowering Based on Nocturnal BP Dipping (Dipper Versus Non-dipper) Status in Non-dippers

Intervention	mmHg (Mean)
	maSBP, hour 1 (n=84,84)	maSBP, hour 2 (n=89,85)	maSBP, hour 3 (n=90,88)	maSBP, hour 4 (n=91,88)	maSBP, hour 5 (n=90,88)	maSBP, hour 6 (n=90,89)	maSBP, hour 7 (n=91,89)	maSBP, hour 8 (n=91,88)	maSBP, hour 9 (n=91,89)	maSBP, hour 10 (n=92,89)	maSBP, hour 11 (n=92,89)	maSBP, hour 12 (n=92,88)	maSBP, hour 13 (n=92,89)	maSBP, hour 14 (n=92,88)	maSBP, hour 15 (n=92,89)	maSBP, hour 16 (n=92,89)	maSBP, hour 17 (n=92,89)	maSBP, hour 18 (n=92,88)	maSBP, hour 19 (n=91,89)	maSBP, hour 20 (n=92,89)	maSBP, hour 21 (n=91,89)	maSBP, hour 22 (n=91,89)	maSBP, hour 23 (n=92,85)	maSBP, hour 24 (n=86,85)	msDBP, hour 1 (n=84,84)	msDBP, hour 2 (n=89,85)	msDBP, hour 3 (n=90,88)	msDBP, hour 4 (n=91,88)	msDBP, hour 5 (n=90,88)	msDBP, hour 6 (n=90,89)	msDBP, hour 7 (n=91,89)	msDBP, hour 8 (n=91,88)	msDBP, hour 9 (n=91,89)	msDBP, hour 10 (n=92,89)	msDBP, hour 11 (n=92,89)	msDBP, hour 12 (n=92,88)	msDBP, hour 13 (n=92,89)	msDBP, hour 14 (n=92,88)	msDBP, hour 15 (n=92,89)	msDBP, hour 16 (n=92,89)	msDBP, hour 17 (n=92,89)	msDBP, hour 18 (n=92,88)	msDBP, hour 19 (n=91,89)	msDBP, hour 20 (n=92,89)	msDBP, hour 21 (n=91,89)	msDBP, hour 22 (n=91,89)	msDBP, hour 23 (n=92,85)	msDBP, hour 24 (n=86,85)
LCZ696	-13.42	-15.60	-13.17	-13.93	-12.90	-12.96	-12.68	-12.65	-13.51	-12.96	-12.69	-13.82	-16.51	-19.39	-19.33	-17.95	-17.34	-16.45	-15.81	-15.33	-14.78	-13.99	-10.93	-14.19	-7.01	-7.39	-6.61	-7.08	-5.75	-7.06	-5.69	-6.13	-7.05	-5.28	-6.18	-6.36	-8.63	-9.68	-9.60	-8.48	-7.60	-8.60	-7.46	-6.21	-7.63	-6.97	-5.72	-6.57
Olmesartan	-9.53	-8.57	-6.33	-4.98	-4.68	-5.49	-6.64	-7.45	-7.81	-7.63	-6.89	-3.92	-5.49	-5.16	-5.92	-6.57	-12.03	-8.54	-9.33	-6.77	-7.10	-6.05	-8.48	-7.98	-4.59	-3.32	-3.77	-2.24	-1.53	-2.00	-1.70	-3.04	-3.62	-3.14	-3.18	-1.61	-2.41	-1.69	-2.85	-2.54	-5.44	-4.25	-3.93	-3.10	-2.81	-2.60	-2.12	-3.91

[back to top]

Change From Baseline in Mean Sitting Pulse Pressure

Pulse rate was with automated BP device after the 4th blood pressure measurement at each visit. (NCT01615198)
Timeframe: Baseline, 4 weeks, 10 weeks, 14 weeks

Intervention	mmHg (Least Squares Mean)
	week 4	week 10	week 14
LCZ696	-11.57	-14.21	-14.65
Olmesartan	-10.38	-9.76	-10.90

[back to top]

Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic Blood Pressure (msDBP)

Sitting BP measurements were performed at trough (immediately prior to dosing at the clinic). At study entry, BP was measured in both arms. The arm with the higher SBP reading was used for the 4 measurements at screening visit and the same arm was used at all subsequent visits. A negative change from baseline indicated improvement. (NCT01615198)
Timeframe: Baseline, 4 weeks, 14 weeks

Intervention	mmHg (Least Squares Mean)
	msSBP, week 4	msDBP, week 4	msSBP, week 14	msDBP, week 14
LCZ696	-17.64	-6.08	-22.53	-7.92
Olmesartan	-15.81	-5.58	-16.75	-5.97

[back to top]

Number of Participants Achieving Overall Blood Pressure Control in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic Blood Pressure (msDBP)

A successful response in overall BP control rate was defined as msSBP < 140 mmHg and msDBP <90 mmHg. (NCT01615198)
Timeframe: 4 weeks, 10 weeks, 14 weeks

Intervention	Participants (Number)
	4 weeks	10 weeks	14 weeks
LCZ696	140	175	173
Olmesartan	120	130	126

[back to top]

Number of Participants Achieving Successful Response in msSBP and msDBP

Blood pressure response in msSBP was defined as a mean sitting BP < 140 mmHg or a >=20 mmHg reduction from baseline. Blood pressure response in msDBP was defined as a mean sitting diastolic blood pressure, 90 mmHg or >=10 mmHg reduction from baseline. (NCT01615198)
Timeframe: 4 weeks,10 weeks, 14 weeks

Intervention	Participants (Number)
	msSBP, week 4	msSBP, week 10	msSBP, week 14	msDBP, week 4	msDBP, week 10	msDBP, week 14
LCZ696	162	208	205	264	275	268
Olmesartan	146	142	144	245	254	246

[back to top]

Number of Participants With Adverse Events, Serious Adverse Events and Death

Adverse event monitoring was conducted throughout the study. (NCT01615198)
Timeframe: 14 weeks

Intervention	Participants (Number)
	Adverse events (non-serious and serious)	Serious adverse events	Deaths
LCZ696	141	7	0
Olmesartan	113	2	0

[back to top]

Change From Baseline in Daytime and Nighttime maSBP/maDBP

Intervention	mmHg (Least Squares Mean)
	maSBP, daytime	maSBP, nighttime	maDBP, daytime	maDBP, nighttime
LCZ696	-14.32	-13.97	-7.04	-6.70
Olmesartan	-10.02	-7.68	-4.88	-3.61

[back to top]

Change From Baseline in Mean 24 Hour Ambulatory Systolic Blood Pressure (maSBP)

Intervention	mmHg (Least Squares Mean)
LCZ696	-14.23
Olmesartan	-9.14

[back to top]

Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)

Sitting BP measurements was performed at trough (immediately prior to dosing at the clinic). At study entry, BP was measured in both arms. The arm with the higher SBP reading was used for the 4 measurements at screening visit and the same arm was used at all subsequent visits. A negative change from baseline indicates improvement. (NCT01615198)
Timeframe: Baseline, 10 weeks

Intervention	mmHg (Least Squares Mean)
LCZ696	-8.58
Olmesartan	-6.49

[back to top]

Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)

Sitting BP measurements were performed at trough (immediately prior to dosing at the clinic). At study entry, BP was measured in both arms. The arm with the higher SBP reading was used for the 4 measurements at screening visit and the same arm was used at all subsequent visits. A negative change from baseline indicates improvement. (NCT01615198)
Timeframe: Baseline, 10 weeks

Intervention	mmHg (Least Squares Mean)
LCZ696	-22.71
Olmesartan	-16.11

[back to top]

Collagen Gene Expression in Skeletal Muscle (Change Over Time)

RNA extraction and quantification were determined using an RNeasy Mini Fibrous Kit and DNase I treatment (Qiagen, Valencia, CA, USA) in accordance to the manufacturer's directions for mRNA extraction. Quantitative real-time polymerase chain reaction (qRT-PCR) measured the expression of collagen III using an ABI PRISM 7900 Sequence Detection System instrument and TaqMan Universal PCR Master Mix according to the manufacturer's instructions (Applied Biosystems, Foster City, CA, USA). Relative gene expression levels were determined using the number of cycles necessary to reach threshold and results were normalized to cyclophilin B RNA levels. (NCT01684748)
Timeframe: Baseline testing to post-testing after 8-week intervention

Intervention	Arbitrary unit (AU) (Mean)
	Pre-Olmesartan medoxomil	Post-Olmesartan medoxomil
Olmesartan Medoxomil	1491	774

[back to top]

Insulin Sensitivity by Intravenous Glucose Tolerance Testing (Change Over Time)

Data collected from the intravenous glucose tolerance tests included blood concentrations of glucose and insulin. Glucose was measured immediately on a YSI glucose analyzer and insulin was measured via ELISA colormetric kits once all study samples were collected. To analyze changes in insulin sensitivity, the MINMOD software was used. The MINMOD software uses Bergman's minimal model to determine insulin sensitivity during an intravenous glucose tolerance test. Both glucose and insulin values were inserted at each timepoint collected (33 in total over the 3-hour protocol) and the software was run to generate the insulin sensitivity value at baseline and post-test. This information was then used to calculate the change of insulin sensitivity from baseline to post-testing after each 8-week intervention. (NCT01684748)
Timeframe: Baseline testing to post-testing after 8-week intervention

Intervention	mu/L/min (Mean)
Olmesartan Medoxomil	0.253
No Drug Intervention	-0.804

[back to top]

Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)

At the first study visit, the patient had his/her blood pressure (BP) measured in both arms; the arm in which the highest sitting SBP was found was used for all subsequent readings throughout the study. At each study visit, after the patient had been sitting for 5 minutes, DBP were measured 3 times using a standard mercury sphygmomanometer and appropriate size cuff. The repeat sitting measurements were made at 1- to 2-minute intervals and the mean of those 3 measurements was used as the average sitting office BP for that visit. (NCT01692301)
Timeframe: baseline, 12 weeks, and 52 weeks

Intervention	mmHg (Least Squares Mean)
	Baseline to week 12 (n=226, 222)	Baseline to week 52 (n=226,223)
LCZ696 (Sacubitril/Valsartan)	-7.86	-8.92
Olmesartan	-5.58	-7.85

[back to top]

Change From Baseline in Mean Central Aortic Systolic Pressure (CASP) at 12 Weeks

"Central aortic blood pressure was derived from peripheral pressure waveforms recorded noninvasively from the brachial artery using a cuff-based device. This technique uses the brachial pressure and a signal processing algorithm to transform brachial signals into central blood pressure (BP) waveforms. When the aortic pressure waveform was derived, key pulse wave analysis (PWA) parameters, such as CASP was calculated by the system software.~At the first study visit, the arm with the highest systolic blood pressure (SBP) was used for all subsequent PWA. Brachial PWA measurements were performed on the same arm that the office blood pressures were taken. Two pulse waveform measurements, meeting all quality control criteria were captured at baseline and at week 12 visits." (NCT01692301)
Timeframe: baseline, 12 weeks

Intervention	mmHg (Least Squares Mean)
LCZ696 (Sacubitril/Valsartan)	-12.57
Olmesartan	-8.90

[back to top]

Change From Baseline in Mean Central Aortic Systolic Pressure (CASP) at 52 Weeks

Intervention	mmHg (Least Squares Mean)
LCZ696 (Sacubitril/Valsartan)	-16.18
Olmesartan	-14.70

[back to top]

Change From Baseline in Mean 24-hour Ambulatory Pulse Pressure (maPP)

Mean 24 hour ambulatory pulse pressure was calculated as the difference between the mean 24 hour systolic and diastolic ambulatory blood pressure in corresponding visits i.e. baseline, week 12 and week 52. (NCT01692301)
Timeframe: Baseline, 12 weeks, and 52 weeks

Intervention	mmHg (Least Squares Mean)
	Baseline to Week 12 (n=164, 162 )	Baseline to week 52 (n=174, 176)
LCZ696 (Sacubitril/Valsartan)	-5.77	-5.26
Olmesartan	-3.69	-5.91

[back to top]

Change From Baseline in Mean 24-hour Diastolic Blood Pressure (maDBP)

An Ambulatory Blood Pressure Monitor (ABPM) measured a participant's blood pressure over a 24 hour period using an automated validated monitoring device at baseline, week 12 and at week 52 starting one day before each visit. The 24 hour maDBP was calculated by taking the mean of all ambulatory systolic blood pressure readings for the 24 hour period. (NCT01692301)
Timeframe: Baseline, 12 weeks, and 52 weeks

Intervention	mmHg (Least Squares Mean)
	Baseline to week 12 (n= 164, 162)	Baseline to week 52 (n= 174, 176)
LCZ696 (Sacubitril/Valsartan)	-7.44	-8.85
Olmesartan	-5.48	-8.44

[back to top]

Change From Baseline in Mean Sitting Pulse Pressure (msPP)

Mean sitting pulse pressure for each patient and visit was calculated as the difference between the calculated values of mean sitting systolic blood pressure and mean sitting diastolic blood pressure. (NCT01692301)
Timeframe: baseline, 12 weeks, and 52 weeks

Intervention	mmHg (Least Squares Mean)
	Baseline to week 12 (n=226,222)	Baseline to week 52 (n= 226, 223)
LCZ696 (Sacubitril/Valsartan)	-13.13	-15.02
Olmesartan	-8.86	-13.58

[back to top]

Change From Baseline in Mean 24-hour Systolic Blood Pressure (maSBP)

An Ambulatory Blood Pressure Monitor (ABPM) measured a participant's blood pressure over a 24 hour period using an automated validated monitoring device at baseline, week 12 and at week 52 starting one day before each visit. The 24 hour maSBP was calculated by taking the mean of all ambulatory systolic blood pressure readings for the 24 hour period. (NCT01692301)
Timeframe: Baseline, 12 weeks, and 52 weeks

Intervention	mmHg (Least Squares Mean)
	Baseline to week 12 (n= 164, 162)	Baseline to week 52 (n= 174, 176)
LCZ696 (Sacubitril/Valsartan)	-13.25	-14.15
Olmesartan	-9.14	-14.32

[back to top]

Change From Baseline in Mean Arterial Pressure (MAP)

Mean arterial pressure (MAP) was calculated from mean sitting systolic BP (msSBP) and mean sitting diastolic BP (msDBP) as (2 * msDBP + msSBP)/3. (NCT01692301)
Timeframe: baseline, 12 weeks, and 52 weeks

Intervention	mmHg (Least Squares Mean)
	Baseline to week 12 (n=226, 222)	Baseline to week 52 (n=226, 223)
LCZ696 (Sacubitril/Valsartan)	-12.19	-13.92
Olmesartan	-8.57	-12.38

[back to top]

Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)

At the first study visit, the patient had his/her blood pressure (BP) measured in both arms; the arm in which the highest sitting SBP was found was used for all subsequent readings throughout the study. At each study visit, after the patient had been sitting for 5 minutes, SBP were measured 3 times using a standard mercury sphygmomanometer and appropriate size cuff. The repeat sitting measurements were made at 1- to 2-minute intervals and the mean of those 3 measurements was used as the average sitting office BP for that visit. (NCT01692301)
Timeframe: baseline, 12 weeks, and 52 weeks

Intervention	mmHg (Least Squares Mean)
	Baseline to week 12 (n=226, 222)	Baseline to week 52 (n=226,223)
LCZ696 (Sacubitril/Valsartan)	-20.84	-23.91
Olmesartan	-14.57	-21.45

[back to top]

Change From Baseline in Mean Central Pulse (CPP) Pressure

(NCT01692301)
Timeframe: Baseline, 12 weeks, and 52 weeks

Intervention	mmHg (Least Squares Mean)
	Baseline to Week 12 (n = 207, 206)	Baseline to Week 52 (n = 209, 208)
LCZ696 (Sacubitril/Valsartan)	-6.41	-7.16
Olmesartan	-3.96	-6.65

[back to top]

Change From Baseline in Mean Pulse Wave Velocity (PWV)

"Pulse wave velocity recordings were performed on patient while in a supine, face-up position.~Tonometry was performed on the carotid simultaneously with the cuff inflation over the femoral artery. Two pulse wave velocity measures, meeting all quality control criteria were captured at baseline, week 12 and week 52." (NCT01692301)
Timeframe: baseline, 12 weeks, and 52 weeks

Intervention	meter/second (Least Squares Mean)
	Baseline to week 12 (n= 192, 196)	Baseline to week 52 ( n= 199, 199)
LCZ696 (Sacubitril/Valsartan)	-0.68	-0.83
Olmesartan	-0.57	0.77

[back to top]

Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers.

Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. Dippers were defined as participants who showed a decrease of at least 10% in maSBP during the night (10pm-6am) compared with the daytime level. A negative change from baseline indicates improvement (NCT01785472)
Timeframe: baseline, 8 weeks

Intervention	mmHg (Mean)
	Hour 1	Hour 2	Hour 3	Hour 4	Hour 5	Hour 6	Hour 7	Hour 8	Hour 9	Hour 10	Hour 11	Hour 12	Hour 13	Hour 14	Hour 15	Hour 16	Hour 17	Hour 18	Hour 19	Hour 20	Hour 21	Hour 22	Hour 23	Hour 24
LCZ696 200 mg	-7.93	-8.47	-9.24	-6.86	-5.27	-7.83	-7.15	-8.00	-8.88	-6.89	-5.22	-402	-6.84	-4.34	-4.53	-3.91	-6.68	-5.87	-5.32	-5.17	-6.97	-7.57	-6.12	-5.23
LCZ696 400 mg	-7.38	-10.19	-9.90	-8.65	-10.79	-11.47	-9.13	-8.90	-9.56	-8.14	-8.69	-7.39	-6.33	-6.73	-5.51	-7.20	-7.21	-6.94	-7.61	-10.45	-9.44	-11.37	-9.95	-8.62
Olmesartan 20 mg	-5.99	-10.49	-9.28	-9.80	-8.54	-5.55	-6.23	-7.44	-6.83	-7.07	-5.41	-5.64	-6.69	-3.97	-3.85	-2.60	-4.43	-6.36	-3.94	-3.06	-6.33	-6.61	-9.89	-7.19

[back to top]

Number of Patients Achieving Successful Blood Pressure Control

Successful blood pressure control is defined as msSBP <140 mmHg and msDBP <90 mmHg. (NCT01785472)
Timeframe: 8 weeks

Intervention	Number of participants (Number)
LCZ696 200 mg	256
LCZ696 400 mg	270
Olmesartan 20 mg	235

[back to top]

Change From Baseline in Office Pulse Pressure (msPP)

Four separate sitting BP measurements should be obtained with a full two minute interval between measurements. (NCT01785472)
Timeframe: baseline, 8 weeks

Intervention	mmHg (Least Squares Mean)
LCZ696 200 mg	-12.35
LCZ696 400 mg	-12.93
Olmesartan 20 mg	-11.25

[back to top]

Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) Between LCZ696 400 mg Versus Olmesartan 20 mg

Sitting BP measurements will be performed at screening through end of study at every visit. Four separate sitting BP measurements will be obtained with a full two minute interval between measurements (NCT01785472)
Timeframe: baseline, 8 weeks

Intervention	mmHg (Least Squares Mean)
LCZ696 400 mg	-21.67
Olmesartan 20 mg	-18.15

[back to top]

Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) Between LCZ696 200 mg Versus Olmesartan 20 mg

Intervention	mmHg (Least Squares Mean)
LCZ696 200 mg	-20.48
Olmesartan 20 mg	-18.15

[back to top]

Change From Baseline in Ambulatory Pulse Pressure

Ambulatory pulse pressure (PP) is calculated by hourly ambulatory SBP and hourly ambulatory DBP over a 24-hour period. (NCT01785472)
Timeframe: baseline, 8 weeks

Intervention	mmHg (Least Squares Mean)
LCZ696 200 mg	-5.78
LCZ696 400 mg	-5.98
Olmesartan 20 mg	-4.58

[back to top]

Number of Patients With Adverse Events, Serious Adverse Events, and Death as Assessment of Safety and Tolerability

Participants were monitored for adverse events, serious adverse events and deaths throughout the study. (NCT01785472)
Timeframe: baseline, 8 weeks

Intervention	Participants (Number)
	Adverse events (non-serious and serious	Serious adverse events	Deaths
LCZ696 200 mg	143	5	0
LCZ696 400 mg	132	3	0
Olmesartan 20 mg	134	6	0

[back to top]

Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers.

Intervention	mmHg (Mean)
	Hour 1	Hour 2	Hour 3	Hour 4	Hour 5	Hour 6	Hour 7	Hour 8	Hour 9	Hour 10	Hour 11	Hour 12	Hour 13	Hour 14	Hour 15	Hour 16	Hour 17	Hour 18	Hour 19	Hour 20	Hour 21	Hour 22	Hour 23	Hour 24
LCZ696 200 mg	-5.93	-5.41	-3.95	-3.68	-3.53	-4.10	-4.85	-6.07	-4.34	-5.53	-4.53	-5.43	-5.57	-6.18	-7.29	-7.68	-7.28	-8.38	-9.02	-8.92	-8.05	-7.16	-6.34	-5.86
LCZ696 400 mg	-6.57	-551	-4.20	-3.53	-3.14	-3.55	-3.31	-2.22	-4.78	-4.48	-4.10	-4.42	-5.01	-5.91	-5.95	-7.26	-7.84	-8.81	-8.77	-7.12	-7.24	-6.55	-5.19	-6.05
Olmesartan 20 mg	-4.57	-5.49	-4.44	-4.70	-3.81	-2.94	-2.71	-3.44	-4.54	-3.57	-5.51	-4.50	-6.04	-5.26	-7.52	-6.96	-6.14	-5.28	-5.20	-5.80	-6.49	-5.65	-6.26	-4.96

[back to top]

Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers.

Intervention	mmHg (Mean)
	Hour 1	Hour 2	Hour 3	Hour 4	Hour 5	Hour 6	Hour 7	Hour 8	Hour 9	Hour 10	Hour 11	Hour 12	Hour 13	Hour 14	Hour 15	Hour 16	Hour 17	Hour 18	Hour 19	Hour 20	Hour 21	Hour 22	Hour 23	Hour 24
LCZ696 200 mg	-13.22	-17.24	-14.99	-13.09	-11.19	-13.66	-11.74	-13.84	-16.33	-13.81	-12.98	-8.99	-12.46	-9.64	-7.73	-4.92	-10.20	-9.84	-8.94	-8.03	-9.47	-12.62	-9.23	-8.43
LCZ696 400 mg	-15.02	-18.11	-16.83	-16.37	-18.88	-19.19	-18.07	-16.12	-15.64	15.13	-15.93	-15.54	-13.28	-12.33	-10.12	-12.82	-12.43	-11.70	-12.20	-15.04	-14.33	-17.20	-16.63	-15.76
Olmesartan 20 mg	-9.07	-13.95	-14.51	-14.63	-14.64	-11.54	-11.74	-12.99	-13.33	-10.89	-7.66	-10.51	-11.49	-6.66	-7.81	-4.40	-7.19	-8.90	-5.76	-4.83	-9.97	-9.95	-14.09	-12.71

[back to top]

Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers.

Intervention	mmHg (Mean)
	Hour 1	Hour 2	Hour 3	Hour 4	Hour 5	Hour 6	Hour 7	Hour 8	Hour 9	Hour 10	Hour 11	Hour 12	Hour 13	Hour 14	Hour 15	Hour 16	Hour 17	Hour 18	Hour 19	Hour 20	Hour 21	Hour 22	Hour 23	Hour 24
LCZ696 200 mg	-11.29	-10.51	-10.03	-8.79	-7.84	-8.71	-9.07	-11.07	-10.31	-11.48	-10.01	-12.37	-13.49	-13.20	-14.01	-15.15	-14.00	-15.93	-16.45	-15.29	-14.10	-13.97	-11.91	-13.07
LCZ696 400 mg	-10.38	-11.07	-9.82	-5.77	-8.15	-7.77	-8.27	-8.30	-10.65	-10.68	-8.96	-11.55	10.64	-13.34	-11.95	-14.04	-14.71	-15.37	-16.04	-14.20	-15.26	-12.79	-9.55	-11.81
Olmesartan 20 mg	-9.37	-10.26	-9.10	-7.55	-6.40	-6.51	-6.93	-6.36	-8.70	-7.55	-9.49	-8.25	-9.82	-10.24	-12.62	-12.52	-11.71	-9.97	-10.37	-10.90	-10.52	-10.67	-10.77	-7.57

[back to top]

Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) Between LCZ696 200, and LCZ696 400 mg Versus Olmesartan 20 mg

Sitting BP measurements were performed at screening through the end of the study at every study visit. A negative change from baseline indicates improvement (NCT01785472)
Timeframe: baseline, 8 weeks

Intervention	mmHg (Mean)
LCZ696 200 mg	-8.10
LCZ696 400 mg	-8.80
Olmesartan 20 mg	-6.86

[back to top]

Change From Baseline in Mean 24-hour Ambulatory Blood Pressure

In this analysis, mean 24 hour ambulatory systolic blood pressure maSBP, mean 24 hour ambulatory diastolic blood pressure maDBP, daytime and nightime maSBP and maDBP will be reported. Ambulatory blood pressure monitoring over a 24 hour period will be conducted at two time points during the study. (NCT01785472)
Timeframe: baseline, 8 weeks

Intervention	mmHg (Least Squares Mean)
	maSBP	maDBP
LCZ696 200 mg	-12.07	-6.36
LCZ696 400 mg	-12.76	-6.82
Olmesartan 20 mg	-10.26	-5.61

[back to top]

Number of Responders

Responders are patients with msSBP response (<140 mmHg or ≥20 mmHg reduction from baseline) and msDBP response (<90 mmHg or ≥10 mmHg reduction from baseline) (NCT01785472)
Timeframe: baseline, 8 weeks

Intervention	Participants (Number)
LCZ696 200 mg	312
LCZ696 400 mg	314
Olmesartan 20 mg	290

[back to top]

Change From Baseline in Augmentation Index at 52 Weeks

Augmentation index (Alx) is the percentage of the central pulse pressure due to wave reflection. (NCT01870739)
Timeframe: Baseline, 52 weeks

Intervention	percent (Least Squares Mean)
Sacubitril/Valsartan (LCZ696)	-2.385
Olmesartan	-1.515

[back to top]

Change From Baseline in Augmentation Pressure at 52 Weeks

Augmentation pressure is the added pressure during systole due to wave reflection. (NCT01870739)
Timeframe: Baseline, 52 weeks

Intervention	mmHg (Least Squares Mean)
Sacubitril/Valsartan (LCZ696)	-2.443
Olmesartan	-1.437

[back to top]

Change From Baseline in Carotid-femoral Pulse Wave Velocity at 52 Weeks

For pulse wave velocity calculation, the pressure waveform at the femoral site (using a partially inflated custom blood pressure cuff) and the carotid site (using hand -held applanation tonometry) were measured simultaneously. Pulse wave analysis was performed on the central aortic pressure waveform as derived from the brachial pressure waveform recorded in a partially-inflated blood pressure cuff around the upper arm. (NCT01870739)
Timeframe: Baseline, 52 weeks

Intervention	meters per second (m/s) (Least Squares Mean)
Sacubitril/Valsartan (LCZ696)	-0.428
Olmesartan	-0.434

[back to top]

Change From Baseline in Distal Descending Aorta Distensibility at 52 Weeks

Cardiovascular magnetic resonance imaging (MRI) scans were obtained at baseline prior to randomization, at week 52 for the assessment of local aortic distensibility. Distal descending aorta distensibility was one of the 3 components for measuring local arota distensibility. (NCT01870739)
Timeframe: Baseline, 52 weeks

Intervention	10^(-3) x mmHg^(-1) (Least Squares Mean)
Sacubitril/Valsartan (LCZ696)	0.417
Olmesartan	0.498

[back to top]

Change From Baseline in Central Blood Pressure at 52 Weeks

Central blood pressure was determined by measuring central systolic blood pressure , diastolic blood pressure and pulse pressure. (NCT01870739)
Timeframe: Baseline, 52 weeks

Intervention	mmHg (Least Squares Mean)
	Central systolic blood pressure	Central diastolic blood pressure	Central pulse pressure
Olmesartan	-13.625	-10.432	-3.041
Sacubitril/Valsartan (LCZ696)	-16.655	-10.318	-6.539

[back to top]

Change From Baseline in Regional Aortic Pulse Wave Velocity at 52 Weeks

Cardiovascular magnetic resonance imaging (MRI) scans were obtained at baseline prior to randomization, at week 52 for the assessment of regional aortic pulse wave velocity. (NCT01870739)
Timeframe: Baseline, 52 weeks

Intervention	meters per second (m/s) (Least Squares Mean)
Sacubitril/Valsartan (LCZ696)	-2.086
Olmesartan	-1.085

[back to top]

Change From Baseline in Ascending Aorta Distensibility at 52 Week

Cardiovascular magnetic resonance imaging (MRI) scans were obtained at baseline prior to randomization, at week 52 for the assessment of local aortic distensibility. Ascending aorta distensibility was one of the 3 components for measuring local arota distensibility. (NCT01870739)
Timeframe: Baseline, 52 weeks

Intervention	10^(-3) x mmHg^(-1) (Least Squares Mean)
Sacubitril/Valsartan (LCZ696)	0.269
Olmesartan	0.330

[back to top]

Number of Patients With Reported Adverse Events, Serious Adverse Events and Death

This outcome measure summarizes patients with any adverse events, serious adverse events and death. (NCT01870739)
Timeframe: 12 weeks

,,,,,

Intervention	Patients (Number)
	Any Adverse events	Serious Adverse Events	Death
Initiation Dose : Sacubitril/Valsartan (LCZ696 200mg)	13	0	0
Initiation Dose: Olmesartan 20mg	16	2	0
Maintenance Dose: Olmesartan 40 mg	28	2	0
Maintenance Dose: Sacubitril/Valsartan (LCZ696 400mg)	21	0	0
Olmesartan 40mg +/- Amlodipine	38	5	0
Sacubitril/Valsartan (LCZ696 400mg) +/- Amlodipine	31	6	0

[back to top]

Change From Baseline in Local Aortic Strain at 52 Weeks

Cardiovascular magnetic resonance imaging (MRI) scans were obtained at baseline prior to randomization, at week 52 for the assessment of local aortic strain. Local aortic strain was measured by assessing ascending aorta strain, proximal descending aorta strain and distal descending aorta strain. (NCT01870739)
Timeframe: Baseline, 52 weeks

Intervention	percent (Least Squares Mean)
	Ascending Aorta Strain	Proximal Descending Aorta Strain	Distal Descending Aorta Strain
Olmesartan	0.453	-0.066	0.225
Sacubitril/Valsartan (LCZ696)	-0.830	-0.284	-1.092

[back to top]

Change From Baseline in Proximal Descending Aorta Distensibility at 52 Weeks

Cardiovascular magnetic resonance imaging (MRI) scans were obtained at baseline prior to randomization, at week 52 for the assessment of local aortic distensibility. Proximal descending aorta distensibility was one of the 3 components for measuring local arota distensibility. (NCT01870739)
Timeframe: Baseline, 52 weeks

Intervention	10^(-3) x mmHg^(-1) (Least Squares Mean)
Sacubitril/Valsartan (LCZ696)	0.510
Olmesartan	0.547

[back to top]

Number of Patients Achieving Successful Mean Sitting Diastolic Blood Pressure (msDBP) Response

Successful mean sitting diastolic blood pressure response is defined as msDBP <90 mmHg or a reduction ≥10 mmHg from baseline. (NCT01876368)
Timeframe: baseline, 8 weeks

Intervention	Participants (Number)
LCZ696 200 mg	137
Olmesartan 20 mg	115

[back to top]

Number of Patients Achieving Successful Mean Sitting Systolic Blood Pressure (msSBP) Control

Successful mean sitting systolic blood pressure control is defined as msSBP <140 mmHg (NCT01876368)
Timeframe: 8 weeks

Intervention	Participants (Number)
LCZ696 200 mg	84
Olmesartan 20 mg	58

[back to top]

Number of Patients Achieving Successful Mean Sitting Systolic Blood Pressure (msSBP) Response

Successful mean sitting systolic blood pressure response is defined as msSBP <140 mmHg or a reduction ≥ 20 mmHg from baseline. (NCT01876368)
Timeframe: baseline, 8 weeks

Intervention	Participants (Number)
LCZ696 200 mg	90
Olmesartan 20 mg	65

[back to top]

Number of Patients Achieving Successful Overall Blood Pressure Control

Successful overall blood pressure control is defined as both msSBP/msDBP <140/90 mmHg (NCT01876368)
Timeframe: 8 weeks

Intervention	Participants (Number)
LCZ696 200 mg	76
Olmesartan 20 mg	52

[back to top]

Number of Patients With Total Adverse Events, Serious Adverse Events and Death

Number of patients with total adverse events, serious adverse events and death were reported. (NCT01876368)
Timeframe: 8 weeks

Intervention	Number of participants (Number)
	Adverse events (serious and non-serious)	Serious Adverse Events	Deaths
LCZ696 200 mg	44	0	0
Olmesartan 20 mg	41	2	0

[back to top]

Change From Baseline in Mean 24-hour Ambulatory Diastolic Blood Pressure (maDBP)

Twenty-four hour mean ambulatory blood pressure measurements (ABPM) will be performed at baseline and at end of study (week 8). The 24-hour ABPM measurements are performed beginning 24 hours prior to baseline and week 8 visits. (NCT01876368)
Timeframe: baseline, 8 weeks

Intervention	mmHg (Least Squares Mean)
LCZ696 200 mg	-2.27
Olmesartan 20 mg	-0.35

[back to top]

Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)

Sitting blood pressure (BP) measurement will be taken at every visit from screening through end of study. For each participant at each visit, four separate sitting BP measurements will be obtained (with a full two minute interval between measurements) and averaged to obtain the mean (NCT01876368)
Timeframe: baseline, 8 weeks

Intervention	mmHg (Least Squares Mean)
LCZ696 200 mg	-14.21
Olmesartan 20 mg	-10.03

[back to top]

Change From Baseline in 24-hour Mean Ambulatory Systolic Blood Pressure (maSBP)

Twenty-four hour mean ambulatory blood pressure measurements (ABPM) will be performed at baseline and at end of study (week 8). The first 24-hour ABPM will be performed beginning at 24 hours prior to baseline visit and the second will be performed 24 hours prior to week 8 visit. (NCT01876368)
Timeframe: baseline, 8 weeks

Intervention	mmHg (Least Squares Mean)
LCZ696 200 mg	-4.26
Olmesartan 20 mg	-1.04

[back to top]

Change From Baseline in Office Pulse Pressure

Mean sitting pulse pressure (msPP) will be calculated at screening through end of study at every visit. Mean sitting pulse pressure is calculated as msSBP-msDBP. (NCT01876368)
Timeframe: baseline, 8 weeks

Intervention	mmHg (Least Squares Mean)
LCZ696 200 mg	-6.67
Olmesartan 20 mg	-5.54

[back to top]

Number of Patients Achieving Successful Mean Sitting Diastolic Blood Pressure (msDBP) Control

Successful mean sitting diastolic blood pressure control is defined as msDBP <90 mmHg (NCT01876368)
Timeframe: 8 weeks

Intervention	Participants (Number)
LCZ696 200 mg	133
Olmesartan 20 mg	112

[back to top]

Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)

Intervention	mmHg (Least Squares Mean)
LCZ696 200 mg	-7.52
Olmesartan 20 mg	-4.47

[back to top]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
ethylene dichloride ethylene dichloride: RN given refers to 1,2-isomer; structure given in first source. 1,2-dichloroethane : A member of the class of chloroethanes substituted by two chloro groups at positions 1 and 2.	2.05	1	0	chloroethanes	hepatotoxic agent; mutagen; non-polar solvent
gamma-aminobutyric acid gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.. gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.	2.25	1	0	amino acid zwitterion; gamma-amino acid; monocarboxylic acid	human metabolite; neurotransmitter; Saccharomyces cerevisiae metabolite; signalling molecule
aminolevulinic acid Aminolevulinic Acid: A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS.. 5-aminolevulinic acid : The simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used (in the form of the hydrochloride salt)in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp.	3.64	2	0	4-oxo monocarboxylic acid; amino acid zwitterion; delta-amino acid	antineoplastic agent; dermatologic drug; Escherichia coli metabolite; human metabolite; mouse metabolite; photosensitizing agent; plant metabolite; prodrug; Saccharomyces cerevisiae metabolite
ethylene glycol Ethylene Glycol: A colorless, odorless, viscous dihydroxy alcohol. It has a sweet taste, but is poisonous if ingested. Ethylene glycol is the most important glycol commercially available and is manufactured on a large scale in the United States. It is used as an antifreeze and coolant, in hydraulic fluids, and in the manufacture of low-freezing dynamites and resins.. ethanediol : Any diol that is ethane or substituted ethane carrying two hydroxy groups.. ethylene glycol : A 1,2-glycol compound produced via reaction of ethylene oxide with water.	2.05	1	0	ethanediol; glycol	metabolite; mouse metabolite; solvent; toxin
acetic acid Acetic Acid: Product of the oxidation of ethanol and of the destructive distillation of wood. It is used locally, occasionally internally, as a counterirritant and also as a reagent. (Stedman, 26th ed). acetic acid : A simple monocarboxylic acid containing two carbons.	2.21	1	0	monocarboxylic acid	antimicrobial food preservative; Daphnia magna metabolite; food acidity regulator; protic solvent
adenine [no description available]	2.31	1	0	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
quinacrine Quinacrine: An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.. quinacrine : A member of the class of acridines that is acridine substituted by a chloro group at position 6, a methoxy group at position 2 and a [5-(diethylamino)pentan-2-yl]nitrilo group at position 9.	2.04	1	0	acridines; aromatic ether; organochlorine compound; tertiary amino compound	antimalarial; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor
carbamates [no description available]	2.17	1	0	amino-acid anion
carnitine [no description available]	7.25	1	0	amino-acid betaine	human metabolite; mouse metabolite
choline [no description available]	2.03	1	0	cholines	allergen; Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; neurotransmitter; nutrient; plant metabolite; Saccharomyces cerevisiae metabolite
chlorine chloride : A halide anion formed when chlorine picks up an electron to form an an anion.	2.11	1	0	halide anion; monoatomic chlorine	cofactor; Escherichia coli metabolite; human metabolite
coumarin 2H-chromen-2-one: coumarin derivative	2.57	2	0	coumarins	fluorescent dye; human metabolite; plant metabolite
salicylic acid Scalp: The outer covering of the calvaria. It is composed of several layers: SKIN; subcutaneous connective tissue; the occipitofrontal muscle which includes the tendinous galea aponeurotica; loose connective tissue; and the pericranium (the PERIOSTEUM of the SKULL).	2.6	1	0	monohydroxybenzoic acid	algal metabolite; antifungal agent; antiinfective agent; EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor; keratolytic drug; plant hormone; plant metabolite
4-aminophenol 4-aminophenol: RN given refers to parent cpd. 4-aminophenol : An amino phenol (one of the three possible isomers) which has the single amino substituent located para to the phenolic -OH group.	2.05	1	0	aminophenol	allergen; metabolite
n(g),n(g')-dimethyl-l-arginine N,N-dimethylarginine: asymmetric dimethylarginine; do not confuse with N,N'-dimethylarginine	3.46	1	1	alpha-amino acid
aminocaproic acid Aminocaproic Acid: An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.. 6-aminohexanoic acid : An epsilon-amino acid comprising hexanoic acid carrying an amino substituent at position C-6. Used to control postoperative bleeding, and to treat overdose effects of the thrombolytic agents streptokinase and tissue plasminogen activator.	2.05	1	0	amino acid zwitterion; epsilon-amino acid; omega-amino fatty acid	antifibrinolytic drug; hematologic agent; metabolite
creatine [no description available]	2.03	1	0	glycine derivative; guanidines; zwitterion	geroprotector; human metabolite; mouse metabolite; neuroprotective agent; nutraceutical
lactic acid Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed). 2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.	2.05	1	0	2-hydroxy monocarboxylic acid	algal metabolite; Daphnia magna metabolite
hexachlorocyclohexane Lindane: An organochlorine insecticide made up of greater than 99% gamma-Hexachlorocyclohexane. It has been used as a pediculicide and scabicide, and shown to cause cancer.. beta-hexachlorocyclohexane : The beta-isomer of hexachlorocyclohexane.	2.05	1	0	chlorocyclohexane
glycine [no description available]	2.07	1	0	alpha-amino acid; amino acid zwitterion; proteinogenic amino acid; serine family amino acid	EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor; fundamental metabolite; hepatoprotective agent; micronutrient; neurotransmitter; NMDA receptor agonist; nutraceutical
thioctic acid Thioctic Acid: An octanoic acid bridged with two sulfurs so that it is sometimes also called a pentanoic acid in some naming schemes. It is biosynthesized by cleavage of LINOLEIC ACID and is a coenzyme of oxoglutarate dehydrogenase (KETOGLUTARATE DEHYDROGENASE COMPLEX). It is used in DIETARY SUPPLEMENTS.	2.6	1	0	dithiolanes; heterocyclic fatty acid; thia fatty acid	fundamental metabolite; geroprotector
inositol Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.. inositol : Any cyclohexane-1,2,3,4,5,6-hexol.. 1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.. muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.	2.05	1	0	cyclitol; hexol
melatonin [no description available]	7.47	2	0	acetamides; tryptamines	anticonvulsant; central nervous system depressant; geroprotector; hormone; human metabolite; immunological adjuvant; mouse metabolite; radical scavenger
niacinamide nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.	3.89	2	1	pyridine alkaloid; pyridinecarboxamide; vitamin B3	anti-inflammatory agent; antioxidant; cofactor; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; Escherichia coli metabolite; geroprotector; human urinary metabolite; metabolite; mouse metabolite; neuroprotective agent; Saccharomyces cerevisiae metabolite; Sir2 inhibitor
niacin Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.. vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).. nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.	2.47	2	0	pyridine alkaloid; pyridinemonocarboxylic acid; vitamin B3	antidote; antilipemic drug; EC 3.5.1.19 (nicotinamidase) inhibitor; Escherichia coli metabolite; human urinary metabolite; metabolite; mouse metabolite; plant metabolite; vasodilator agent
nitrates Nitrates: Inorganic or organic salts and esters of nitric acid. These compounds contain the NO3- radical.	2.94	1	0	monovalent inorganic anion; nitrogen oxoanion; reactive nitrogen species
nitrites Nitrites: Salts of nitrous acid or compounds containing the group NO2-. The inorganic nitrites of the type MNO2 (where M=metal) are all insoluble, except the alkali nitrites. The organic nitrites may be isomeric, but not identical with the corresponding nitro compounds. (Grant & Hackh's Chemical Dictionary, 5th ed)	3.73	3	0	monovalent inorganic anion; nitrogen oxoanion; reactive nitrogen species	human metabolite
1-octanol 1-Octanol: A colorless, slightly viscous liquid used as a defoaming or wetting agent. It is also used as a solvent for protective coatings, waxes, and oils, and as a raw material for plasticizers. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed). octan-1-ol : An octanol carrying the hydroxy group at position 1.	2.02	1	0	octanol; primary alcohol	antifungal agent; bacterial metabolite; fuel additive; kairomone; plant metabolite
picolinic acid picolinic acid: iron-chelating agent that inhibits DNA synthesis; may interfere with iron-dependent production of stable free organic radical which is essential for ribonucleotide reductase formation of deoxyribonucleotides; RN given refers to parent cpd; structure in Merck Index, 9th ed, #7206. picolinic acid : A pyridinemonocarboxylic acid in which the carboxy group is located at position 2. It is an intermediate in the metabolism of tryptophan.	2.6	1	0	pyridinemonocarboxylic acid	human metabolite; MALDI matrix material
1-propanol 1-Propanol: A colorless liquid made by oxidation of aliphatic hydrocarbons that is used as a solvent and chemical intermediate.. propan-1-ol : The parent member of the class of propan-1-ols that is propane in which a hydrogen of one of the methyl groups is replaced by a hydroxy group.	2.02	1	0	propan-1-ols; short-chain primary fatty alcohol	metabolite; protic solvent
pyrazinamide pyrazinecarboxamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis.	2.74	3	0	monocarboxylic acid amide; N-acylammonia; pyrazines	antitubercular agent; prodrug
pyrazinoic acid pyrazinoic acid: active metabolite of pyrazinamide; structure. pyrazine-2-carboxylic acid : The parent compound of the class of pyrazinecarboxylic acids, that is pyrazine bearing a single carboxy substituent. The active metabolite of the antitubercular drug pyrazinamide.	2.03	1	0	pyrazinecarboxylic acid	antitubercular agent; drug metabolite
pyridoxine 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol: structure in first source. vitamin B6 : Any member of the group of pyridines that exhibit biological activity against vitamin B6 deficiency. Vitamin B6 deficiency is associated with microcytic anemia, electroencephalographic abnormalities, dermatitis with cheilosis (scaling on the lips and cracks at the corners of the mouth) and glossitis (swollen tongue), depression and confusion, and weakened immune function. Vitamin B6 consists of the vitamers pyridoxine, pyridoxal, and pyridoxamine and their respective 5'-phosphate esters (and includes their corresponding ionized and salt forms).	2.05	1	0	hydroxymethylpyridine; methylpyridines; monohydroxypyridine; vitamin B6	cofactor; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
thiamine thiamine(1+) : A primary alcohol that is 1,3-thiazol-3-ium substituted by (4-amino-2-methylpyrimidin-5-yl)methyl, methyl and 2-hydroxyethyl groups at positions 3, 4 and 5, respectively.	2.54	2	0	primary alcohol; vitamin B1	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
uric acid Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.. uric acid : An oxopurine that is the final oxidation product of purine metabolism.. 6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.. 7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.	2.49	2	0	uric acid	Escherichia coli metabolite; human metabolite; mouse metabolite
urea pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.	2.46	2	0	isourea; monocarboxylic acid amide; one-carbon compound	Daphnia magna metabolite; Escherichia coli metabolite; fertilizer; flour treatment agent; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
2,4-dinitrophenol 2,4-Dinitrophenol: A toxic dye, chemically related to trinitrophenol (picric acid), used in biochemical studies of oxidative processes where it uncouples oxidative phosphorylation. It is also used as a metabolic stimulant. (Stedman, 26th ed). dinitrophenol : Members of the class of nitrophenol carrying two nitro substituents.. 2,4-dinitrophenol : A dinitrophenol having the nitro groups at the 2- and 4-positions.	2.05	1	0	dinitrophenol	allergen; antiseptic drug; bacterial xenobiotic metabolite; geroprotector; oxidative phosphorylation inhibitor
3-aminobenzamide [no description available]	2.6	1	0	benzamides; substituted aniline	EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
pleconaril WIN 63843: structure given in first source	2.6	1	0
4-(2-aminoethyl)benzenesulfonylfluoride [no description available]	2.6	1	0
phenytoin [no description available]	3.18	5	0	imidazolidine-2,4-dione	anticonvulsant; drug allergen; sodium channel blocker; teratogenic agent
8-(4-sulfophenyl)theophylline 8-(4-sulfophenyl)theophylline: adenosine antagonist	2.05	1	0
tacrine Tacrine: A cholinesterase inhibitor that crosses the blood-brain barrier. Tacrine has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders.. tacrine : A member of the class of acridines that is 1,2,3,4-tetrahydroacridine substituted by an amino group at position 9. It is used in the treatment of Alzheimer's disease.	2.76	3	0	acridines; aromatic amine	EC 3.1.1.7 (acetylcholinesterase) inhibitor
acetaminophen Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.. paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.	3.16	5	0	acetamides; phenols	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; cyclooxygenase 3 inhibitor; environmental contaminant; ferroptosis inducer; geroprotector; hepatotoxic agent; human blood serum metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
acetazolamide Acetazolamide: One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)	4.95	4	2	monocarboxylic acid amide; sulfonamide; thiadiazoles	anticonvulsant; diuretic; EC 4.2.1.1 (carbonic anhydrase) inhibitor
acetohexamide Acetohexamide: A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide.. acetohexamide : An N-sulfonylurea that is urea in which a hydrogen attached to one of the nitrogens is replaced by a p-acetylphenylsulfonyl group, while a hydrogen attached to the other nitrogen is replaced by a cyclohexyl group.	2.05	1	0	acetophenones; N-sulfonylurea	hypoglycemic agent; insulin secretagogue
albendazole [no description available]	2.05	1	0	aryl sulfide; benzimidazoles; benzimidazolylcarbamate fungicide; carbamate ester	anthelminthic drug; microtubule-destabilising agent; tubulin modulator
alendronate alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.	3.19	1	0	1,1-bis(phosphonic acid); primary amino compound	bone density conservation agent; EC 2.5.1.1 (dimethylallyltranstransferase) inhibitor
alosetron alosetron : A pyrido[4,3-b]indole compound having a 5-methyl-1H-imidazol-4-ylmethyl group at the 2-position.	2.03	1	0	imidazoles; pyridoindole	antiemetic; gastrointestinal drug; serotonergic antagonist
alprenolol Alprenolol: One of the ADRENERGIC BETA-ANTAGONISTS used as an antihypertensive, anti-anginal, and anti-arrhythmic agent.. alprenolol : A secondary alcohol that is propan-2-ol substituted by a 2-allylphenoxy group at position 1 and an isopropylamino group at position 3. It is a beta-adrenergic antagonist used as a antihypertensive, anti-arrhythmia and a sympatholytic agent.	2.58	2	0	secondary alcohol; secondary amino compound	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent
amantadine amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source	3.64	2	0	adamantanes; primary aliphatic amine	analgesic; antiparkinson drug; antiviral drug; dopaminergic agent; NMDA receptor antagonist; non-narcotic analgesic
aminoglutethimide Aminoglutethimide: An aromatase inhibitor that is used in the treatment of advanced BREAST CANCER.. aminoglutethimide : A dicarboximide that is a six-membered cyclic compound having ethyl and 4-aminophenyl substituents at the 3-position.	2.05	1	0	dicarboximide; piperidones; substituted aniline	adrenergic agent; anticonvulsant; antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
p-aminohippuric acid p-Aminohippuric Acid: The glycine amide of 4-aminobenzoic acid. Its sodium salt is used as a diagnostic aid to measure effective renal plasma flow (ERPF) and excretory capacity.. p-aminohippurate : A hippurate that is the conjugate base of p-aminohippuric acid, arising from deprotonation of the carboxy group.. p-aminohippuric acid : An N-acylglycine that is the 4-amino derivative of hippuric acid; used as a diagnostic agent in the measurement of renal plasma flow.	3.55	2	0	N-acylglycine	Daphnia magna metabolite
theophylline [no description available]	2.97	4	0	dimethylxanthine	adenosine receptor antagonist; anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; drug metabolite; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; fungal metabolite; human blood serum metabolite; immunomodulator; muscle relaxant; vasodilator agent
2-aminothiazole 2-aminothiazole: RN given refers to parent cpd; structure. 1,3-thiazol-2-amine : A primary amino compound that is 1,3-thiazole substituted by an amino group at position 2.	2.6	1	0	1,3-thiazoles; primary amino compound
amiodarone Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.. amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.	2.74	3	0	1-benzofurans; aromatic ketone; organoiodine compound; tertiary amino compound	cardiovascular drug
amitriptyline Amitriptyline: Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines.. amitriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(dimethylamino)propylidene group at position 5.	2.49	2	0	carbotricyclic compound; tertiary amine	adrenergic uptake inhibitor; antidepressant; environmental contaminant; tropomyosin-related kinase B receptor agonist; xenobiotic
amlodipine Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.. amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.	16.68	103	51	dihydropyridine; ethyl ester; methyl ester; monochlorobenzenes; primary amino compound	antihypertensive agent; calcium channel blocker; vasodilator agent
amodiaquine Amodiaquine: A 4-aminoquinoline compound with anti-inflammatory properties.. amodiaquine : A quinoline having a chloro group at the 7-position and an aryl amino group at the 4-position.	2.81	3	0	aminoquinoline; organochlorine compound; phenols; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; drug allergen; EC 2.1.1.8 (histamine N-methyltransferase) inhibitor; non-steroidal anti-inflammatory drug; prodrug
amoxapine Amoxapine: The N-demethylated derivative of the antipsychotic agent LOXAPINE that works by blocking the reuptake of norepinephrine, serotonin, or both; it also blocks dopamine receptors. Amoxapine is used for the treatment of depression.. amoxapine : A dibenzooxazepine compound having a chloro substituent at the 2-position and a piperazin-1-yl group at the 11-position.	2.05	1	0	dibenzooxazepine	adrenergic uptake inhibitor; antidepressant; dopaminergic antagonist; geroprotector; serotonin uptake inhibitor
amsacrine Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.. amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.	2.07	1	0	acridines; aromatic ether; sulfonamide	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
anastrozole [no description available]	2.03	1	0	nitrile; triazoles	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
antipyrine Antipyrine: An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29). antipyrine : A pyrazolone derivative that is 1,2-dihydropyrazol-3-one substituted with methyl groups at N-1 and C-5 and with a phenyl group at N-2.	2.08	1	0	pyrazolone	antipyretic; cyclooxygenase 3 inhibitor; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
acetovanillone apocynin : An aromatic ketone that is 1-phenylethanone substituted by a hydroxy group at position 4 and a methoxy group at position 3.	2.04	1	0	acetophenones; aromatic ketone; methyl ketone	antirheumatic drug; EC 1.6.3.1. [NAD(P)H oxidase (H2O2-forming)] inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; peripheral nervous system drug; plant metabolite
aspirin Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5). acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.. acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.	8.21	5	0	benzoic acids; phenyl acetates; salicylates	anticoagulant; antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; EC 1.1.1.188 (prostaglandin-F synthase) inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; plant activator; platelet aggregation inhibitor; prostaglandin antagonist; teratogenic agent
astemizole Astemizole: Antihistamine drug now withdrawn from the market in many countries because of rare but potentially fatal side effects.. astemizole : A piperidine compound having a 2-(4-methoxyphenyl)ethyl group at the 1-position and an N-[(4-fluorobenzyl)benzimidazol-2-yl]amino group at the 4-position.	2.47	2	0	benzimidazoles; piperidines	anti-allergic agent; anticoronaviral agent; H1-receptor antagonist
atenolol Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.. atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.	4.53	5	1	ethanolamines; monocarboxylic acid amide; propanolamine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; sympatholytic agent; xenobiotic
azathioprine Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed). azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.	2.47	2	0	aryl sulfide; C-nitro compound; imidazoles; thiopurine	antimetabolite; antineoplastic agent; carcinogenic agent; DNA synthesis inhibitor; hepatotoxic agent; immunosuppressive agent; prodrug
baclofen [no description available]	2.6	1	0	amino acid zwitterion; gamma-amino acid; monocarboxylic acid; monochlorobenzenes; primary amino compound	central nervous system depressant; GABA agonist; muscle relaxant
benzamide benzamide : An aromatic amide that consists of benzene bearing a single carboxamido substituent. The parent of the class of benzamides.	2.6	1	0	benzamides
benzbromarone Benzbromarone: Uricosuric that acts by increasing uric acid clearance. It is used in the treatment of gout.. benzbromarone : 1-Benzofuran substituted at C-2 and C-3 by an ethyl group and a 3,5-dibromo-4-hydroxybenzoyl group respectively. An inhibitor of CYP2C9, it is used as an anti-gout medication.	3.16	5	0	1-benzofurans; aromatic ketone	uricosuric drug
bepridil Bepridil: A long-acting calcium-blocking agent with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist.. bepridil : A tertiary amine in which the substituents on nitrogen are benzyl, phenyl and 3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl.	2.48	2	0	pyrrolidines; tertiary amine	anti-arrhythmia drug; antihypertensive agent; calcium channel blocker; vasodilator agent
bicalutamide bicalutamide: approved for treatment of advanced prostate cancer. N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide : A member of the class of (trifluoromethyl)benzenes that is 4-amino-2-(trifluoromethyl)benzonitrile in which one of the amino hydrogens is substituted by a 3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanoyl group.. bicalutamide : A racemate comprising of equal amounts of (R)-bicalutamide and (S)-bicalutamide. It is an oral non-steroidal antiandrogen used in the treatment of prostate cancer and hirsutism.	2.05	1	0	(trifluoromethyl)benzenes; monocarboxylic acid amide; monofluorobenzenes; nitrile; sulfone; tertiary alcohol
bisindolylmaleimide i bisindolylmaleimide I: a bis(indolyl)maleimide	2.46	2	0
bisoprolol Bisoprolol: A cardioselective beta-1 adrenergic blocker. It is effective in the management of HYPERTENSION and ANGINA PECTORIS.	2.17	1	0	secondary alcohol; secondary amine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent
bithionol Bithionol: Halogenated anti-infective agent that is used against trematode and cestode infestations.. bithionol : An aryl sulfide that is diphenyl sulfide in which each phenyl group is substituted at position 2 by hydroxy and at positions 3 and 5 by chlorine. A fungicide and anthelmintic, it was used in various topical drug products for the treatment of liver flukes, but withdrawn after being shown to be a potent photosensitizer with the potential to cause serious skin disorders.	2.05	1	0	aryl sulfide; bridged diphenyl antifungal drug; bridged diphenyl fungicide; dichlorobenzene; organochlorine pesticide; polyphenol	antifungal agrochemical; antiplatyhelmintic drug
bumetanide [no description available]	3.84	3	0	amino acid; benzoic acids; sulfonamide	diuretic; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor
bupivacaine Bupivacaine: A widely used local anesthetic agent.. 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide : A piperidinecarboxamide obtained by formal condensation of the carboxy group of N-butylpipecolic acid with the amino group of 2,6-dimethylaniline.. bupivacaine : A racemate composed of equimolar amounts of dextrobupivacaine and levobupivacaine. Used (in the form of its hydrochloride hydrate) as a local anaesthetic.	2.05	1	0	aromatic amide; piperidinecarboxamide; tertiary amino compound
buspirone Buspirone: An anxiolytic agent and serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the BENZODIAZAPINES, but it has an efficacy comparable to DIAZEPAM.. buspirone : An azaspiro compound that is 8-azaspiro[4.5]decane-7,9-dione substituted at the nitrogen atom by a 4-(piperazin-1-yl)butyl group which in turn is substituted by a pyrimidin-2-yl group at the N(4) position.	2.47	2	0	azaspiro compound; N-alkylpiperazine; N-arylpiperazine; organic heteropolycyclic compound; piperidones; pyrimidines	anxiolytic drug; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; sedative; serotonergic agonist
busulfan [no description available]	2.74	3	0	methanesulfonate ester	alkylating agent; antineoplastic agent; carcinogenic agent; insect sterilant; teratogenic agent
caffeine [no description available]	2.97	4	0	purine alkaloid; trimethylxanthine	adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic
verapamil Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.	4.08	4	0	aromatic ether; nitrile; polyether; tertiary amino compound
camostat camostat : A benzoate ester resulting from the formal condensation of the carboxy group of 4-guanidinobenzoic acid with the hydroxy group of 2-(dimethylamino)-2-oxoethyl (4-hydroxyphenyl)acetate. It is a potent inhibitor of the human transmembrane protease serine 2 (TMPRSS2) and its mesylate salt is currently under investigation for its effectiveness in COVID-19 patients.	2.6	1	0	benzoate ester; carboxylic ester; diester; guanidines; tertiary carboxamide	anti-inflammatory agent; anticoronaviral agent; antifibrinolytic drug; antihypertensive agent; antineoplastic agent; antiviral agent; serine protease inhibitor
camphor, (+-)-isomer [no description available]	2.6	1	0	bornane monoterpenoid; cyclic monoterpene ketone	plant metabolite
candesartan cilexetil candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects	4.92	6	0	biphenyls
candesartan candesartan: a nonpeptide angiotensin II receptor antagonist. candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.	10.38	39	13	benzimidazolecarboxylic acid; biphenylyltetrazole	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
carbamazepine Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.. carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.	3.16	5	0	dibenzoazepine; ureas	analgesic; anticonvulsant; antimanic drug; drug allergen; EC 3.5.1.98 (histone deacetylase) inhibitor; environmental contaminant; glutamate transporter activator; mitogen; non-narcotic analgesic; sodium channel blocker; xenobiotic
carmustine Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed). carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.	2.07	1	0	N-nitrosoureas; organochlorine compound	alkylating agent; antineoplastic agent
celecoxib [no description available]	3.85	3	0	organofluorine compound; pyrazoles; sulfonamide; toluenes	cyclooxygenase 2 inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug
cetirizine Cetirizine: A potent second-generation histamine H1 antagonist that is effective in the treatment of allergic rhinitis, chronic urticaria, and pollen-induced asthma. Unlike many traditional antihistamines, it does not cause drowsiness or anticholinergic side effects.. cetirizine : A member of the class of piperazines that is piperazine in which the hydrogens attached to nitrogen are replaced by a (4-chlorophenyl)(phenyl)methyl and a 2-(carboxymethoxy)ethyl group respectively.	3.15	1	0	ether; monocarboxylic acid; monochlorobenzenes; piperazines	anti-allergic agent; environmental contaminant; H1-receptor antagonist; xenobiotic
cetylpyridinium Cetylpyridinium: Cationic bactericidal surfactant used as a topical antiseptic for skin, wounds, mucous membranes, instruments, etc.; and also as a component in mouthwash and lozenges.	2.6	1	0	pyridinium ion
chlorambucil Chlorambucil: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed). chlorambucil : A monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia.	2.03	1	0	aromatic amine; monocarboxylic acid; nitrogen mustard; organochlorine compound; tertiary amino compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent
chloroquine Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.	2.07	1	0	aminoquinoline; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; autophagy inhibitor; dermatologic drug
chloroxylenol chloroxylenol: topical antiseptic; RN given refers to parent cpd; structure. 4-chloro-3,5-dimethylphenol : A member of the class of phenols that is 3,5-xylenol which is substituted at position 4 by chlorine. It is bactericidal against most Gram-positive bacteria but less effective against Staphylococci and Gram-negative bacteria, and often inactive against Pseudomonas species. It is ineffective against bacterial spores.	2.6	1	0	monochlorobenzenes; phenols	antiseptic drug; disinfectant; molluscicide
chlorpromazine Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.. chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.	3.18	5	0	organochlorine compound; phenothiazines; tertiary amine	anticoronaviral agent; antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; phenothiazine antipsychotic drug
chlorpropamide Chlorpropamide: A sulfonylurea hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. (From Martindale, The Extra Pharmacopoeia, 30th ed, p277). chlorpropamide : An N-sulfonylurea that is urea in which a hydrogen attached to one of the nitrogens is substituted by 4-chlorobenzenesulfonyl group and a hydrogen attached to the other nitrogen is substituted by propyl group. Chlorpropamide is a hypoglycaemic agent used in the treatment of type 2 (non-insulin-dependent) diabetes mellitus not responding to dietary modification.	2.47	2	0	monochlorobenzenes; N-sulfonylurea	hypoglycemic agent; insulin secretagogue
chlorthalidone Chlorthalidone: A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic.	6.93	5	3	isoindoles; monochlorobenzenes; sulfonamide
chlorzoxazone Chlorzoxazone: A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202). chlorzoxazone : A member of the class of 1,3-benzoxazoles that is 1,3-benzoxazol-2-ol in which the hydrogen atom at position 5 is substituted by chlorine. A centrally acting muscle relaxant with sedative properties, it is used for the symptomatic treatment of painful muscle spasm.	2.47	2	0	1,3-benzoxazoles; heteroaryl hydroxy compound; organochlorine compound	muscle relaxant; sedative
ciclopirox [no description available]	2.05	1	0	cyclic hydroxamic acid; hydroxypyridone antifungal drug; pyridone	antibacterial agent; antiseborrheic
ciglitazone ciglitazone: structure given in second source; PPAR agonist used for type II diabetes. ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.	2.05	1	0	aromatic ether; thiazolidinone	antineoplastic agent; insulin-sensitizing drug
cilostazol [no description available]	2.07	1	0	lactam; tetrazoles	anticoagulant; bronchodilator agent; EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor; fibrin modulating drug; neuroprotective agent; platelet aggregation inhibitor; vasodilator agent
cimetidine Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.. cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.	4.25	5	0	aliphatic sulfide; guanidines; imidazoles; nitrile	adjuvant; analgesic; anti-ulcer drug; H2-receptor antagonist; P450 inhibitor
ciprofibrate [no description available]	2.54	2	0	cyclopropanes; monocarboxylic acid; organochlorine compound	antilipemic drug
ciprofloxacin Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.	3.84	3	0	aminoquinoline; cyclopropanes; fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone; zwitterion	antibacterial drug; antiinfective agent; antimicrobial agent; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; environmental contaminant; topoisomerase IV inhibitor; xenobiotic
cisapride Cisapride: A substituted benzamide used for its prokinetic properties. It is used in the management of gastroesophageal reflux disease, functional dyspepsia, and other disorders associated with impaired gastrointestinal motility. (Martindale The Extra Pharmacopoeia, 31st ed). cisapride : The amide resulting from formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with cis-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-amine. It has been used (as its monohydrate or as its tartrate) for the treatment of gastro-oesophageal reflux disease and for non-ulcer dyspepsia, but its propensity to cause cardiac arrhythmias resulted in its complete withdrawal from many countries, including the U.K., and restrictions on its use elsewhere.	2.47	2	0	benzamides
citalopram Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.. citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.. 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.	2.05	1	0	2-benzofurans; cyclic ether; nitrile; organofluorine compound; tertiary amino compound
clofibrate angiokapsul: contains clofibrate & insoitolnicotinate	2.74	3	0	aromatic ether; ethyl ester; monochlorobenzenes	anticholesteremic drug; antilipemic drug; geroprotector; PPARalpha agonist
clomiphene [no description available]	2.05	1	0	tertiary amine	estrogen antagonist; estrogen receptor modulator
clomipramine Clomipramine: A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine.. clomipramine : A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine which is substituted by chlorine at position 3 and in which the hydrogen attached to the nitrogen is replaced by a 3-(dimethylamino)propyl group. One of the more sedating tricyclic antidepressants, it is used as the hydrochloride salt for the treatment of depression as well as obsessive-compulsive disorder and phobias.	2.54	2	0	dibenzoazepine	anticoronaviral agent; antidepressant; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; serotonergic antagonist; serotonergic drug; serotonin uptake inhibitor
clonazepam Clonazepam: An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of GAMMA-AMINOBUTYRIC ACID receptor responses.. clonazepam : 1,3-Dihydro-2H-1,4-benzodiazepin-2-one in which the hydrogens at positions 5 and 7 are substituted by 2-chlorophenyl and nitro groups, respectively. It is used in the treatment of all types of epilepsy and seizures, as well as myoclonus and associated abnormal movements, and panic disorders. However, its use can be limited by the development of tolerance and by sedation.	2.03	1	0	1,4-benzodiazepinone; monochlorobenzenes	anticonvulsant; anxiolytic drug; GABA modulator
clonidine Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.. clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.	2.03	1	0	clonidine; imidazoline
clotrimazole [no description available]	2.47	2	0	conazole antifungal drug; imidazole antifungal drug; imidazoles; monochlorobenzenes	antiinfective agent; environmental contaminant; xenobiotic
cromolyn cromoglycic acid : A dicarboxylic acid that is the bis-chromone derivative of glycerol. It is effective as a mast cell stabilizer.	2.47	2	0	chromones; dicarboxylic acid	anti-asthmatic drug; calcium channel blocker
danthron danthron: structure. chrysazin : A dihydroxyanthraquinone that is anthracene-9,10-dione substituted by hydroxy groups at positions 1 and 8.	2.6	1	0	dihydroxyanthraquinone	apoptosis inducer; plant metabolite
dapsone [no description available]	2.74	3	0	substituted aniline; sulfone	anti-inflammatory drug; antiinfective agent; antimalarial; leprostatic drug
deferiprone Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.. deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.	2.6	1	0	4-pyridones	iron chelator; protective agent
desipramine Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.. desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.	2.47	2	0	dibenzoazepine; secondary amino compound	adrenergic uptake inhibitor; alpha-adrenergic antagonist; antidepressant; cholinergic antagonist; drug allergen; EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; serotonin uptake inhibitor
diazepam Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.. diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5.	2.03	1	0	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; environmental contaminant; sedative; xenobiotic
diclofenac Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.. diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.	4.26	5	0	amino acid; aromatic amine; dichlorobenzene; monocarboxylic acid; secondary amino compound	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
diethylcarbamazine Diethylcarbamazine: An anthelmintic used primarily as the citrate in the treatment of filariasis, particularly infestations with Wucheria bancrofti or Loa loa.	2.05	1	0	N-carbamoylpiperazine; N-methylpiperazine
diflunisal Diflunisal: A salicylate derivative and anti-inflammatory analgesic with actions and side effects similar to those of ASPIRIN.. diflunisal : An organofluorine compound comprising salicylic acid having a 2,4-difluorophenyl group at the 5-position.	2.45	2	0	monohydroxybenzoic acid; organofluorine compound	non-narcotic analgesic; non-steroidal anti-inflammatory drug
dimercaprol Dimercaprol: An anti-gas warfare agent that is effective against Lewisite (dichloro(2-chlorovinyl)arsine) and formerly known as British Anti-Lewisite or BAL. It acts as a chelating agent and is used in the treatment of arsenic, gold, and other heavy metal poisoning.. dimercaprol : A dithiol that is propane-1,2-dithiol in which one of the methyl hydrogens is replaced by a hydroxy group. a chelating agent originally developed during World War II as an experimental antidote against the arsenic-based poison gas Lewisite, it has been used clinically since 1949 for the treatment of poisoning by arsenic, mercury and gold. It can also be used for treatment of poisoning by antimony, bismuth and possibly thallium, and (with sodium calcium edetate) in cases of acute leaad poisoning. Administration is by (painful) intramuscular injection of a suspension of dimercaprol in peanut oil, typically every 4 hours for 2-10 days depending on the toxicity. In the past, dimercaprol was also used for the treatment of Wilson's disease, a severely debilitating genetic disorder in which the body tends to retain copper, with resultant liver and brain injury.	2.05	1	0	dithiol; primary alcohol	chelator
diphenhydramine Diphenhydramine: A histamine H1 antagonist used as an antiemetic, antitussive, for dermatoses and pruritus, for hypersensitivity reactions, as a hypnotic, an antiparkinson, and as an ingredient in common cold preparations. It has some undesired antimuscarinic and sedative effects.. diphenhydramine : An ether that is the benzhydryl ether of 2-(dimethylamino)ethanol. It is a H1-receptor antagonist used as a antipruritic and antitussive drug.. antitussive : An agent that suppresses cough. Antitussives have a central or a peripheral action on the cough reflex, or a combination of both. Compare with expectorants, which are considered to increase the volume of secretions in the respiratory tract, so facilitating their removal by ciliary action and coughing, and mucolytics, which decrease the viscosity of mucus, facilitating its removal by ciliary action and expectoration.	2.75	3	0	ether; tertiary amino compound	anti-allergic agent; antidyskinesia agent; antiemetic; antiparkinson drug; antipruritic drug; antitussive; H1-receptor antagonist; local anaesthetic; muscarinic antagonist; oneirogen; sedative
dipyridamole Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752). dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.	2.54	2	0	piperidines; pyrimidopyrimidine; tertiary amino compound; tetrol	adenosine phosphodiesterase inhibitor; EC 3.5.4.4 (adenosine deaminase) inhibitor; platelet aggregation inhibitor; vasodilator agent
disopyramide Disopyramide: A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.. disopyramide : A monocarboxylic acid amide that is butanamide substituted by a diisopropylamino group at position 4, a phenyl group at position 2 and a pyridin-2-yl group at position 2. It is used as a anti-arrhythmia drug.	3.15	1	0	monocarboxylic acid amide; pyridines; tertiary amino compound	anti-arrhythmia drug
disulfiram [no description available]	2.8	3	0	organic disulfide; organosulfur acaricide	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor; EC 3.1.1.1 (carboxylesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; ferroptosis inducer; fungicide; NF-kappaB inhibitor
valproic acid Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.. valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.	3.33	6	0	branched-chain fatty acid; branched-chain saturated fatty acid	anticonvulsant; antimanic drug; EC 3.5.1.98 (histone deacetylase) inhibitor; GABA agent; neuroprotective agent; psychotropic drug; teratogenic agent
domperidone Domperidone: A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.. domperidone : 1-[3-(Piperidin-1-yl)propyl]-1,3-dihydro-2H-benzimidazol-2-one in which the 4-position of the piperidine ring is substituted by a 5-chloro-1,3-dihydro-2H-benzimidazol-2-on-1-yl group. A dopamine antagonist, it is used as an antiemetic for the short-term treatment of nausea and vomiting, and to control gastrointestinal effects of dopaminergic drugs given in the management of parkinsonism. The free base is used in oral suspensions, while the maleate salt is used in tablet preparations.	2.03	1	0	benzimidazoles; heteroarylpiperidine	antiemetic; dopaminergic antagonist
donepezil Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.. donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.. 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.	2.76	3	0	aromatic ether; indanones; piperidines; racemate	EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; nootropic agent
doxazosin Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.. doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.	2.79	3	0	aromatic amine; benzodioxine; monocarboxylic acid amide; N-acylpiperazine; N-arylpiperazine; quinazolines	alpha-adrenergic antagonist; antihyperplasia drug; antihypertensive agent; antineoplastic agent; vasodilator agent
ebselen ebselen : A benzoselenazole that is 1,2-benzoselenazol-3-one carrying an additional phenyl substituent at position 2. Acts as a mimic of glutathione peroxidase.	2.6	1	0	benzoselenazole	anti-inflammatory drug; antibacterial agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antioxidant; apoptosis inducer; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; EC 3.1.3.25 (inositol-phosphate phosphatase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; EC 3.5.4.1 (cytosine deaminase) inhibitor; EC 5.1.3.2 (UDP-glucose 4-epimerase) inhibitor; enzyme mimic; ferroptosis inhibitor; genotoxin; hepatoprotective agent; neuroprotective agent; radical scavenger
erythrosine Fluoresceins: A family of spiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one derivatives. These are used as dyes, as indicators for various metals, and as fluorescent labels in immunoassays.	2.05	1	0
ethosuximide Ethosuximide: An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.. ethosuximide : A dicarboximide that is pyrrolidine-2,5-dione in which the hydrogens at position 3 are substituted by one methyl and one ethyl group. An antiepileptic, it is used in the treatment of absence seizures and may be used for myoclonic seizures, but is ineffective against tonic-clonic seizures.	2.05	1	0	dicarboximide; pyrrolidinone	anticonvulsant; geroprotector; T-type calcium channel blocker
etidronate Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.. etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.	2.57	2	0	1,1-bis(phosphonic acid)	antineoplastic agent; bone density conservation agent; chelator
2-hexyloxybenzamide 2-hexyloxybenzamide: structure	2.6	1	0	aromatic ether; benzamides	antifungal agent
brl 42810 [no description available]	2.52	2	0	2-aminopurines; acetate ester	antiviral drug; prodrug
carbonyl cyanide p-trifluoromethoxyphenylhydrazone Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone: A proton ionophore that is commonly used as an uncoupling agent in biochemical studies.. carbonyl cyanide p-trifluoromethoxyphenylhydrazone : A hydrazone that is hydrazonomalononitrile in which one of the hydrazine hydrogens is substituted by a p-trifluoromethoxyphenyl group.	2.05	1	0	aromatic ether; hydrazone; nitrile; organofluorine compound	ATP synthase inhibitor; geroprotector; ionophore
felbamate Felbamate: A PEGylated phenylcarbamate derivative that acts as an antagonist of NMDA RECEPTORS. It is used as an anticonvulsant, primarily for the treatment of SEIZURES in severe refractory EPILEPSY.. felbamate : The bis(carbamate ester) of 2-phenylpropane-1,3-diol. An anticonvulsant, it is used in the treatment of epilepsy.	2.47	2	0	carbamate ester	anticonvulsant; neuroprotective agent
fenofibrate Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE	2.47	2	0	aromatic ether; chlorobenzophenone; isopropyl ester; monochlorobenzenes	antilipemic drug; environmental contaminant; geroprotector; xenobiotic
fexofenadine fexofenadine: a second generation antihistamine; metabolite of the antihistaminic drug terfenadine; structure in first source; RN refers to HCl. fexofenadine : A piperidine-based anti-histamine compound.	3.85	3	0	piperidines; tertiary amine	anti-allergic agent; H1-receptor antagonist
fipexide fipexide: regulates dopaminergic systems at macromolecular level	2.05	1	0	benzodioxoles
flecainide Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.. flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).	2.08	1	0	aromatic ether; monocarboxylic acid amide; organofluorine compound; piperidines	anti-arrhythmia drug
fluconazole Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.. fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.	2.47	2	0	conazole antifungal drug; difluorobenzene; tertiary alcohol; triazole antifungal drug	environmental contaminant; P450 inhibitor; xenobiotic
flucytosine Flucytosine: A fluorinated cytosine analog that is used as an antifungal agent.. flucytosine : An organofluorine compound that is cytosine that is substituted at position 5 by a fluorine. A prodrug for the antifungal 5-fluorouracil, it is used for the treatment of systemic fungal infections.	2.45	2	0	aminopyrimidine; nucleoside analogue; organofluorine compound; pyrimidine antifungal drug; pyrimidone	prodrug
flufenamic acid Flufenamic Acid: An anthranilic acid derivative with analgesic, anti-inflammatory, and antipyretic properties. It is used in musculoskeletal and joint disorders and administered by mouth and topically. (From Martindale, The Extra Pharmacopoeia, 30th ed, p16). flufenamic acid : An aromatic amino acid consisting of anthranilic acid carrying an N-(trifluoromethyl)phenyl substituent. An analgesic and anti-inflammatory, it is used in rheumatic disorders.	2.05	1	0	aromatic amino acid; organofluorine compound	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
fluphenazine [no description available]	2.52	2	0	N-alkylpiperazine; organofluorine compound; phenothiazines	anticoronaviral agent; dopaminergic antagonist; phenothiazine antipsychotic drug
flumazenil Flumazenil: A potent benzodiazepine receptor antagonist. Since it reverses the sedative and other actions of benzodiazepines, it has been suggested as an antidote to benzodiazepine overdoses.. flumazenil : An organic heterotricyclic compound that is 5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted at positions 3, 5, 6, and 8 by ethoxycarbonyl, methyl, oxo, and fluoro groups, respectively. It is used as an antidote to benzodiazepine overdose.	2.05	1	0	ethyl ester; imidazobenzodiazepine; organofluorine compound	antidote to benzodiazepine poisoning; GABA antagonist
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	2.54	2	0	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
fluoxetine Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.. fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.. N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.	2.98	4	0	(trifluoromethyl)benzenes; aromatic ether; secondary amino compound
flurbiprofen Flurbiprofen: An anti-inflammatory analgesic and antipyretic of the phenylalkynoic acid series. It has been shown to reduce bone resorption in periodontal disease by inhibiting CARBONIC ANHYDRASE.. flurbiprofen : A monocarboxylic acid that is a 2-fluoro-[1,1'-biphenyl-4-yl] moiety linked to C-2 of propionic acid. A non-steroidal anti-inflammatory, analgesic and antipyretic, it is used as a pre-operative anti-miotic as well as orally for arthritis or dental pain.	2.05	1	0	fluorobiphenyl; monocarboxylic acid	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
fluspirilene Fluspirilene: A long-acting injectable antipsychotic agent used for chronic schizophrenia.	2.05	1	0	diarylmethane
flutamide Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.	2.98	4	0	(trifluoromethyl)benzenes; monocarboxylic acid amide	androgen antagonist; antineoplastic agent
foscarnet Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.. phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.	2.05	1	0	carboxylic acid; one-carbon compound; phosphonic acids	antiviral drug; geroprotector; HIV-1 reverse transcriptase inhibitor; sodium-dependent Pi-transporter inhibitor
furosemide Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.. furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.	4.26	5	0	chlorobenzoic acid; furans; sulfonamide	environmental contaminant; loop diuretic; xenobiotic
gabapentin Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.. gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.	2.45	2	0	gamma-amino acid	anticonvulsant; calcium channel blocker; environmental contaminant; xenobiotic
gabexate Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.	2.6	1	0	benzoate ester
gemfibrozil [no description available]	2.05	1	0	aromatic ether	antilipemic drug
glafenine Glafenine: An anthranilic acid derivative with analgesic properties used for the relief of all types of pain.. glafenine : A carboxylic ester that is 2,3-dihydroxypropyl anthranilate in which the amino group is substituted by a 7-chloroquinolin-4-yl group. A non-steroidal anti-inflammatory drug, glafenine and its hydrochloride salt were used for the relief of all types of pain, but high incidence of anaphylactic reactions resulted in their withdrawal from the market.	2.47	2	0	aminoquinoline; carboxylic ester; glycol; organochlorine compound; secondary amino compound	inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
gliclazide Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.	2.05	1	0	N-sulfonylurea	hypoglycemic agent; insulin secretagogue; radical scavenger
glimepiride glimepiride: structure given in first source	2.45	2	0	sulfonamide
glipizide Glipizide: An oral hypoglycemic agent which is rapidly absorbed and completely metabolized.. glipizide : An N-sulfonylurea that is glyburide in which the (5-chloro-2-methoxybenzoyl group is replaced by a (5-methylpyrazin-2-yl)carbonyl group. An oral hypoglycemic agent, it is used in the treatment of type 2 diabetes mellitus.	2.03	1	0	aromatic amide; monocarboxylic acid amide; N-sulfonylurea; pyrazines	EC 2.7.1.33 (pantothenate kinase) inhibitor; hypoglycemic agent; insulin secretagogue
glutaral Glutaral: One of the protein CROSS-LINKING REAGENTS that is used as a disinfectant for sterilization of heat-sensitive equipment and as a laboratory reagent, especially as a fixative.. glutaraldehyde : A dialdehyde comprised of pentane with aldehyde functions at C-1 and C-5.	2.6	1	0	dialdehyde	cross-linking reagent; disinfectant; fixative
glutethimide Glutethimide: A hypnotic and sedative. Its use has been largely superseded by other drugs.	2.05	1	0	piperidines
glyburide Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide. glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.	3.55	2	0	monochlorobenzenes; N-sulfonylurea	anti-arrhythmia drug; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor; hypoglycemic agent
granisetron [no description available]	2.03	1	0	aromatic amide; indazoles
guaifenesin Guaifenesin: An expectorant that also has some muscle relaxing action. It is used in many cough preparations.	2.07	1	0	methoxybenzenes
1-(5-isoquinolinesulfonyl)-2-methylpiperazine 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.. 1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.	2.46	2	0	isoquinolines; N-sulfonylpiperazine	EC 2.7.11.13 (protein kinase C) inhibitor
fasudil fasudil: intracellular calcium antagonist; structure in first source. fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.	2.79	3	0	isoquinolines; N-sulfonyldiazepane	antihypertensive agent; calcium channel blocker; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; geroprotector; neuroprotective agent; nootropic agent; vasodilator agent
haloperidol Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279). haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.	2.79	3	0	aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol	antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist
hexachlorophene Hexachlorophene: A chlorinated bisphenol antiseptic with a bacteriostatic action against Gram-positive organisms, but much less effective against Gram-negative organisms. It is mainly used in soaps and creams and is an ingredient of various preparations used for skin disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p797). hexachlorophene : An organochlorine compound that is diphenylmethane in which each of the phenyl groups is substituted by chlorines at positions 2, 3, and 5, and by a hydroxy group at position 6. An antiseptic that is effective against Gram-positive organisms, it is used in soaps and creams for the treatment of various skin disorders. It is also used in agriculture as an acaricide and fungicide, but is not approved for such use within the European Union.	2.05	1	0	bridged diphenyl fungicide; polyphenol; trichlorobenzene	acaricide; antibacterial agent; antifungal agrochemical; antiseptic drug
miltefosine miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin. miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.	2.6	1	0	phosphocholines; phospholipid	anti-inflammatory agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antiprotozoal drug; apoptosis inducer; immunomodulator; protein kinase inhibitor
hexylresorcinol [no description available]	2.6	1	0	resorcinols
beta-thujaplicin beta-thujaplicin: structure. beta-thujaplicin : A monoterpenoid that is cyclohepta-2,4,6-trien-1-one substituted by a hydroxy group at position 2 and an isopropyl group at position 4. Isolated from Thuja plicata and Chamaecyparis obtusa, it exhibits antimicrobial activities.	2.6	1	0	cyclic ketone; enol; monoterpenoid	antibacterial agent; antifungal agent; antineoplastic agent; antiplasmodial drug; plant metabolite
hycanthone Hycanthone: Potentially toxic, but effective antischistosomal agent, it is a metabolite of LUCANTHONE.. hycanthone : A thioxanthen-9-one compound having a hydroxymethyl substituent at the 1-position and a 2-[(diethylamino)ethyl]amino substituent at the 4-position. It was formerly used (particularly as the monomethanesulfonic acid salt) as a schistosomicide for individual or mass treatement of infection with Schistosoma haematobium and S. mansoni, but due to its toxicity and concern about possible carcinogenicity, it has been replaced by other drugs such as praziquantel.	2.8	3	0	thioxanthenes	mutagen; schistosomicide drug
hydralazine Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.. hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.	4.07	14	0	azaarene; hydrazines; ortho-fused heteroarene; phthalazines	antihypertensive agent; vasodilator agent
hydrochlorothiazide Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.. hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.	15.31	65	29	benzothiadiazine; organochlorine compound; sulfonamide	antihypertensive agent; diuretic; environmental contaminant; xenobiotic
hydroxyurea [no description available]	2.54	2	0	one-carbon compound; ureas	antimetabolite; antimitotic; antineoplastic agent; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; genotoxin; immunomodulator; radical scavenger; teratogenic agent
hydroxyzine Hydroxyzine: A histamine H1 receptor antagonist that is effective in the treatment of chronic urticaria, dermatitis, and histamine-mediated pruritus. Unlike its major metabolite CETIRIZINE, it does cause drowsiness. It is also effective as an antiemetic, for relief of anxiety and tension, and as a sedative.. hydroxyzine : A N-alkylpiperazine that is piperzine in which the nitrogens atoms are substituted by 2-(2-hydroxyethoxy)ethyl and (4-chlorophenyl)(phenyl)methyl groups respectively.	2.07	1	0	hydroxyether; monochlorobenzenes; N-alkylpiperazine	anticoronaviral agent; antipruritic drug; anxiolytic drug; dermatologic drug; H1-receptor antagonist
ibuprofen Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine	3.2	5	0	monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; radical scavenger; xenobiotic
phenelzine Phenelzine: One of the MONOAMINE OXIDASE INHIBITORS used to treat DEPRESSION; PHOBIC DISORDERS; and PANIC.	2.47	2	0	primary amine
lidocaine Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.. lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.	2.05	1	0	benzenes; monocarboxylic acid amide; tertiary amino compound	anti-arrhythmia drug; drug allergen; environmental contaminant; local anaesthetic; xenobiotic
ifosfamide [no description available]	2.05	1	0	ifosfamides	alkylating agent; antineoplastic agent; environmental contaminant; immunosuppressive agent; xenobiotic
imipramine Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.. imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.	2.98	4	0	dibenzoazepine	adrenergic uptake inhibitor; antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
amrinone Amrinone: A positive inotropic cardiotonic (CARDIOTONIC AGENTS) with vasodilator properties, phosphodiesterase 3 inhibitory activity, and the ability to stimulate calcium ion influx into the cardiac cell.. amrinone : A 3,4'-bipyridine substituted at positions 5 and 6 by an amino group and a keto function respectively. A pyridine phosphodiesterase 3 inhibitor, it is a drug that may improve the prognosis in patients with congestive heart failure.	2.05	1	0	bipyridines	EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
indomethacin Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.	8.22	5	0	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic
iproniazid [no description available]	2.47	2	0	carbohydrazide; pyridines
avapro Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.. irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.	9.39	26	7	azaspiro compound; biphenylyltetrazole	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
isocarboxazid Isocarboxazid: An MAO inhibitor that is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in the treatment of panic disorder and the phobic disorders. (From AMA, Drug Evaluations Annual, 1994, p311)	2.05	1	0	benzenes
isoniazid Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.. hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).	2.47	2	0	carbohydrazide	antitubercular agent; drug allergen
isoproterenol Isoproterenol: Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.. isoprenaline : A secondary amino compound that is noradrenaline in which one of the hydrogens attached to the nitrogen is replaced by an isopropyl group. A sympathomimetic acting almost exclusively on beta-adrenergic receptors, it is used (mainly as the hydrochloride salt) as a bronghodilator and heart stimulant for the management of a variety of cardiac disorders.	2.57	2	0	catechols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; sympathomimetic agent
itraconazole [no description available]	2.52	2	0	piperazines
ketoconazole 1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.	2.76	3	0	dichlorobenzene; dioxolane; ether; imidazoles; N-acylpiperazine; N-arylpiperazine
ketoprofen Ketoprofen: An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis.. ketoprofen : An oxo monocarboxylic acid that consists of propionic acid substituted by a 3-benzoylphenyl group at position 2.	2.47	2	0	benzophenones; oxo monocarboxylic acid	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-steroidal anti-inflammatory drug; xenobiotic
ketotifen Ketotifen: A cycloheptathiophene blocker of histamine H1 receptors and release of inflammatory mediators. It has been proposed for the treatment of asthma, rhinitis, skin allergies, and anaphylaxis.. ketotifen : An organic heterotricyclic compound that is 4,9-dihydro-10H-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one which is substituted at position 4 by a 1-methylpiperidin-4-ylidene group. A blocker of histamine H1 receptors with a stabilising action on mast cells, it is used (usually as its hydrogen fumarate salt) for the treatment of asthma, where it may take several weeks to exert its full effect.	2.05	1	0	cyclic ketone; olefinic compound; organic heterotricyclic compound; organosulfur heterocyclic compound; piperidines; tertiary amino compound	anti-asthmatic drug; H1-receptor antagonist
kojic acid [no description available]	2.6	1	0	4-pyranones; enol; primary alcohol	Aspergillus metabolite; EC 1.10.3.1 (catechol oxidase) inhibitor; EC 1.10.3.2 (laccase) inhibitor; EC 1.13.11.24 (quercetin 2,3-dioxygenase) inhibitor; EC 1.14.18.1 (tyrosinase) inhibitor; EC 1.4.3.3 (D-amino-acid oxidase) inhibitor; NF-kappaB inhibitor; skin lightening agent
kynurenic acid Kynurenic Acid: A broad-spectrum excitatory amino acid antagonist used as a research tool.. kynurenic acid : A quinolinemonocarboxylic acid that is quinoline-2-carboxylic acid substituted by a hydroxy group at C-4.	2.21	1	0	monohydroxyquinoline; quinolinemonocarboxylic acid	G-protein-coupled receptor agonist; human metabolite; neuroprotective agent; nicotinic antagonist; NMDA receptor antagonist; Saccharomyces cerevisiae metabolite
labetalol Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.. labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.. 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.	2.47	2	0	benzamides; benzenes; phenols; primary carboxamide; salicylamides; secondary alcohol; secondary amino compound
lamotrigine [no description available]	2.07	1	0	1,2,4-triazines; dichlorobenzene; primary arylamine	anticonvulsant; antidepressant; antimanic drug; calcium channel blocker; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; excitatory amino acid antagonist; geroprotector; non-narcotic analgesic; xenobiotic
lansoprazole Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.	2.46	2	0	benzimidazoles; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
lapachol lapachol : A hydroxy-1,4-naphthoquinone that is 1,4-naphthoquinone substituted by hydroxy and 3-methylbut-2-en-1-yl groups at positions 2 and 3, respectively. It is a natural compound that exhibits antibacterial and anticancer properties, first isolated in 1882 from the bark of Tabebuia avellanedae.	2.6	1	0
leflunomide Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.. leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.	2.05	1	0	(trifluoromethyl)benzenes; isoxazoles; monocarboxylic acid amide	antineoplastic agent; antiparasitic agent; EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; hepatotoxic agent; immunosuppressive agent; non-steroidal anti-inflammatory drug; prodrug; pyrimidine synthesis inhibitor; tyrosine kinase inhibitor
letrozole [no description available]	2.03	1	0	nitrile; triazoles	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
loperamide Loperamide: One of the long-acting synthetic ANTIDIARRHEALS; it is not significantly absorbed from the gut, and has no effect on the adrenergic system or central nervous system, but may antagonize histamine and interfere with acetylcholine release locally.. loperamide : A synthetic piperidine derivative, effective against diarrhoea resulting from gastroenteritis or inflammatory bowel disease.	3.64	2	0	monocarboxylic acid amide; monochlorobenzenes; piperidines; tertiary alcohol	anticoronaviral agent; antidiarrhoeal drug; mu-opioid receptor agonist
loratadine Loratadine: A second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (HISTAMINE H1 ANTAGONISTS) it lacks central nervous system depressing effects such as drowsiness.. loratadine : A benzocycloheptapyridine that is 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine substituted by a chloro group at position 8 and a 1-(ethoxycarbonyl)piperidin-4-ylidene group at position 11. It is a H1-receptor antagonist commonly employed in the treatment of allergic disorders.	2.6	1	0	benzocycloheptapyridine; ethyl ester; N-acylpiperidine; organochlorine compound; tertiary carboxamide	anti-allergic agent; cholinergic antagonist; geroprotector; H1-receptor antagonist
losartan Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.. losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position	10.11	39	7	biphenylyltetrazole; imidazoles	angiotensin receptor antagonist; anti-arrhythmia drug; antihypertensive agent; endothelin receptor antagonist
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source	2.03	1	0	chromones; morpholines; organochlorine compound	autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector
4-(dimethylamino)-n-(7-(hydroxyamino)-7-oxoheptyl)benzamide 4-(dimethylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)benzamide: structure in first source. 4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]benzamide : A benzamide resulting from the formal condensation of the carboxy group of 4-(dimethylamino)benzoic acid with the amino group of 7-amino-N-hydroxyheptanamide. It is a potent inhibitor of histone deacetylases and induces cell cycle arrest and apoptosis in several human cancer cell lines.	2.6	1	0	benzamides; hydroxamic acid; secondary carboxamide; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
mafenide Mafenide: A sulfonamide that inhibits the enzyme CARBONIC ANHYDRASE and is used as a topical anti-bacterial agent, especially in burn therapy.	2.6	1	0	aromatic amine
manidipine [no description available]	5.05	3	3	diarylmethane
maprotiline Maprotiline: A bridged-ring tetracyclic antidepressant that is both mechanistically and functionally similar to the tricyclic antidepressants, including side effects associated with its use.	2.47	2	0	anthracenes
mebendazole Mebendazole: A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.. mebendazole : A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a benzoyl group at position 5.	2.05	1	0	aromatic ketone; benzimidazoles; carbamate ester	antinematodal drug; microtubule-destabilising agent; tubulin modulator
mecamylamine Mecamylamine: A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.	2.07	1	0	primary aliphatic amine
meclizine Meclizine: A histamine H1 antagonist used in the treatment of motion sickness, vertigo, and nausea during pregnancy and radiation sickness.	2.07	1	0	diarylmethane
meclofenamate sodium anhydrous [no description available]	2.05	1	0	organic sodium salt
mefenamic acid Mefenamic Acid: A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.. mefenamic acid : An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,3-dimethylphenyl group. Although classed as a non-steroidal anti-inflammatory drug, its anti-inflammatory properties are considered to be minor. It is used to relieve mild to moderate pain, including headaches, dental pain, osteoarthritis and rheumatoid arthritis.	2.76	3	0	aminobenzoic acid; secondary amino compound	analgesic; antipyretic; antirheumatic drug; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-steroidal anti-inflammatory drug; xenobiotic
memantine [no description available]	2.05	1	0	adamantanes; primary aliphatic amine	antidepressant; antiparkinson drug; dopaminergic agent; neuroprotective agent; NMDA receptor antagonist
vitamin k 3 Vitamin K 3: A synthetic naphthoquinone without the isoprenoid side chain and biological activity, but can be converted to active vitamin K2, menaquinone, after alkylation in vivo.	2.05	1	0	1,4-naphthoquinones; vitamin K	angiogenesis inhibitor; antineoplastic agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; human urinary metabolite; nutraceutical
meperidine Meperidine: A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration.. pethidine : A piperidinecarboxylate ester that is piperidine which is substituted by a methyl group at position 1 and by phenyl and ethoxycarbonyl groups at position 4. It is an analgesic which is used for the treatment of moderate to severe pain, including postoperative pain and labour pain.	2.07	1	0	ethyl ester; piperidinecarboxylate ester; tertiary amino compound	antispasmodic drug; kappa-opioid receptor agonist; mu-opioid receptor agonist; opioid analgesic
mephenytoin Mephenytoin: An anticonvulsant effective in tonic-clonic epilepsy (EPILEPSY, TONIC-CLONIC). It may cause blood dyscrasias.. mephenytoin : An imidazolidine-2,4-dione (hydantoin) in which the imidazolidine nucleus carries a methyl group at N-3 and has ethyl and phenyl substituents at C-5. An anticonvulsant, it is no longer available in the USA or the UK but is still studied largely because of its interesting hydroxylation polymorphism.	2.08	1	0	imidazolidine-2,4-dione	anticonvulsant
mepivacaine Mepivacaine: A local anesthetic that is chemically related to BUPIVACAINE but pharmacologically related to LIDOCAINE. It is indicated for infiltration, nerve block, and epidural anesthesia. Mepivacaine is effective topically only in large doses and therefore should not be used by this route. (From AMA Drug Evaluations, 1994, p168). mepivacaine : A piperidinecarboxamide in which N-methylpipecolic acid and 2,6-dimethylaniline have combined to form the amide bond. It is used as a local amide-type anaesthetic.	2.07	1	0	piperidinecarboxamide	drug allergen; local anaesthetic
meprobamate Meprobamate: A carbamate with hypnotic, sedative, and some muscle relaxant properties, although in therapeutic doses reduction of anxiety rather than a direct effect may be responsible for muscle relaxation. Meprobamate has been reported to have anticonvulsant actions against petit mal seizures, but not against grand mal seizures (which may be exacerbated). It is used in the treatment of ANXIETY DISORDERS, and also for the short-term management of INSOMNIA but has largely been superseded by the BENZODIAZEPINES. (From Martindale, The Extra Pharmacopoeia, 30th ed, p603)	2.05	1	0	organic molecular entity
metformin Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289). metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.	3.86	3	0	guanidines	environmental contaminant; geroprotector; hypoglycemic agent; xenobiotic
methapyrilene Methapyrilene: Histamine H1 antagonist with sedative action used as a hypnotic and in allergies.. methapyrilene : A member of the class of ethylenediamine derivatives that is ethylenediamine in which one of the nitrogens is substituted by two methyl groups, and the other nitrogen is substituted by a 2-pyridyl group and a (2-thienyl)methyl group.	2.05	1	0	ethylenediamine derivative	anti-allergic agent; carcinogenic agent; H1-receptor antagonist; sedative
methazolamide Methazolamide: A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma.	2.6	1	0	sulfonamide; thiadiazoles
methocarbamol Methocarbamol: A centrally acting muscle relaxant whose mode of action has not been established. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1206). methocarbamol : A racemate comprising equimolar amounts of (R)- and (S)-methocarbamol. A centrally acting skeletal muscle relaxant, it is used as an adjunct in the short-term symptomatic treatment of painful muscle spasm. The (R)-enantiomer is more active than the (S)-enantiomer.. 2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate : A carbamate ester that is glycerol in which one of the primary alcohol groups has been converted to its 2-methoxyphenyl ether while the other has been converted to the corresponding carbamate ester.	2.57	2	0	aromatic ether; carbamate ester; secondary alcohol
nocodazole [no description available]	2.05	1	0	aromatic ketone; benzimidazoles; carbamate ester; thiophenes	antimitotic; antineoplastic agent; microtubule-destabilising agent; tubulin modulator
methylphenidate Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.. methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.. methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.	2.05	1	0	beta-amino acid ester; methyl ester; piperidines
metoclopramide Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.. metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.	2.03	1	0	benzamides; monochlorobenzenes; substituted aniline; tertiary amino compound	antiemetic; dopaminergic antagonist; environmental contaminant; gastrointestinal drug; xenobiotic
metolazone Metolazone: A quinazoline-sulfonamide derived DIURETIC that functions by inhibiting SODIUM CHLORIDE SYMPORTERS.. metolazone : A quinazoline that consists of 1,2,3,4-tetrahydroquinazolin-4-one bearing additional methyl, 2-tolyl, sulfamyl and chloro substituents at positions 2, 3, 6 and 7 respectively. A quinazoline diuretic, with properties similar to thiazide diuretics.	2.05	1	0	organochlorine compound; quinazolines; sulfonamide	antihypertensive agent; diuretic; ion transport inhibitor
metoprolol Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.. metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.	8.09	4	0	aromatic ether; propanolamine; secondary alcohol; secondary amino compound	antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; geroprotector; xenobiotic
metronidazole Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.. metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.	2.05	1	0	C-nitro compound; imidazoles; primary alcohol	antiamoebic agent; antibacterial drug; antimicrobial agent; antiparasitic agent; antitrichomonal drug; environmental contaminant; prodrug; radiosensitizing agent; xenobiotic
mexiletine Mexiletine: Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties.. mexiletine : An aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol.	2.08	1	0	aromatic ether; primary amino compound	anti-arrhythmia drug
mianserin Mianserin: A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.. mianserin : A dibenzoazepine (specifically 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine) methyl-substituted on N-2. Closely related to (and now mostly superseded by) the tetracyclic antidepressant mirtazapinean, it is an atypical antidepressant used in the treatment of depression throughout Europe and elsewhere.	2.05	1	0	dibenzoazepine	adrenergic uptake inhibitor; alpha-adrenergic antagonist; antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; geroprotector; H1-receptor antagonist; histamine agonist; sedative; serotonergic antagonist
miconazole Miconazole: An imidazole antifungal agent that is used topically and by intravenous infusion.. 1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]imidazole : A member of the class of imidazoles that is 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethanol in which the hydroxyl hydrogen is replaced by a 2,4-dichlorobenzyl group.. miconazole : A racemate composed of equimolar amounts of (R)- and (S)-miconazole. Used (as its nitrate salt) to treat skin infections such as athlete's foot, jock itch, ringworm and other fungal skin infections. It inhibits the synthesis of ergosterol, a critical component of fungal cell membranes.	2.05	1	0	dichlorobenzene; ether; imidazoles
midazolam Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.. midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.	2.03	1	0	imidazobenzodiazepine; monofluorobenzenes; organochlorine compound	anticonvulsant; antineoplastic agent; anxiolytic drug; apoptosis inducer; central nervous system depressant; GABAA receptor agonist; general anaesthetic; muscle relaxant; sedative
midodrine Midodrine: An ethanolamine derivative that is an adrenergic alpha-1 agonist. It is used as a vasoconstrictor agent in the treatment of HYPOTENSION.. midodrine : An aromatic ether that is 1,4-dimethoxybenzene which is substituted at position 2 by a 2-(glycylamino)-1-hydroxyethyl group. A direct-acting sympathomimetic with selective alpha-adrenergic agonist activity, it is used (generally as its hydrochloride salt) as a peripheral vasoconstrictor in the treatment of certain hypotensive states. The main active moiety is its major metabolite, deglymidodrine.	2.07	1	0	amino acid amide; aromatic ether; secondary alcohol	alpha-adrenergic agonist; prodrug; sympathomimetic agent; vasoconstrictor agent
milrinone [no description available]	2.03	1	0	bipyridines; nitrile; pyridone	cardiotonic drug; EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor; platelet aggregation inhibitor; vasodilator agent
minoxidil Minoxidil: A potent direct-acting peripheral vasodilator (VASODILATOR AGENTS) that reduces peripheral resistance and produces a fall in BLOOD PRESSURE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p371). minoxidil : A pyrimidine N-oxide that is pyrimidine-2,4-diamine 3-oxide substituted by a piperidin-1-yl group at position 6.	2.07	1	0	dialkylarylamine; tertiary amino compound
mitoxantrone Mitoxantrone: An anthracenedione-derived antineoplastic agent.. mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.	3.64	2	0	dihydroxyanthraquinone	analgesic; antineoplastic agent
modafinil Modafinil: A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.. modafinil : A racemate comprising equimolar amounts of armodafinil and (S)-modafinil. A central nervous system stimulant, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. The optical enantiomers of modafinil have similar pharmacological actions in animals.. 2-[(diphenylmethyl)sulfinyl]acetamide : A sulfoxide that is dimethylsulfoxide in which two hydrogens attached to one of the methyl groups are replaced by phenyl groups, while one hydrogen attached to the other methyl group is replaced by a carbamoyl (aminocarbonyl) group.	2.07	1	0	monocarboxylic acid amide; sulfoxide
entinostat [no description available]	2.6	1	0	benzamides; carbamate ester; primary amino compound; pyridines; substituted aniline	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
ethylmaleimide Ethylmaleimide: A sulfhydryl reagent that is widely used in experimental biochemical studies.	2.6	1	0	maleimides	anticoronaviral agent; EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor; EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor; EC 2.7.1.1 (hexokinase) inhibitor
nabumetone Nabumetone: A butanone non-steroidal anti-inflammatory drug and cyclooxygenase-2 (COX2) inhibitor that is used in the management of pain associated with OSTEOARTHRITIS and RHEUMATOID ARTHRITIS.. nabumetone : A methyl ketone that is 2-butanone in which one of the methyl hydrogens at position 4 is replaced by a 6-methoxy-2-naphthyl group. A prodrug that is converted to the active metabolite, 6-methoxy-2-naphthylacetic acid, following oral administration. It is shown to have a slightly lower risk of gastrointestinal side effects than most other non-steroidal anti-inflammatory drugs.	2.6	1	0	methoxynaphthalene; methyl ketone	cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug
nafamostat nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic	2.6	1	0	benzoic acids; guanidines
nalidixic acid [no description available]	2.05	1	0	1,8-naphthyridine derivative; monocarboxylic acid; quinolone antibiotic	antibacterial drug; antimicrobial agent; DNA synthesis inhibitor
naratriptan naratriptan: structure given in first source	2.03	1	0	heteroarylpiperidine; sulfonamide; tryptamines	serotonergic agonist; vasoconstrictor agent
nefazodone nefazodone: may be useful as an opiate adjunct	2.47	2	0	aromatic ether; monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; triazoles	alpha-adrenergic antagonist; analgesic; antidepressant; serotonergic antagonist; serotonin uptake inhibitor
nevirapine Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.. nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.	3	4	0	cyclopropanes; dipyridodiazepine	antiviral drug; HIV-1 reverse transcriptase inhibitor
nicardipine Nicardipine: A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents.. nicardipine : A racemate comprising equimolar amounts of (R)- and (S)-nicardipine. It is a calcium channel blocker which is used to treat hypertension.. 2-[benzyl(methyl)amino]ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine substituted by a methyl, {2-[benzyl(methyl)amino]ethoxy}carbonyl, 3-nitrophenyl, methoxycarbonyl and methyl groups at positions 2, 3, 4, 5 and 6, respectively.	2.47	2	0	benzenes; C-nitro compound; diester; dihydropyridine; methyl ester; tertiary amino compound
nifedipine Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.	8.56	8	0	C-nitro compound; dihydropyridine; methyl ester	calcium channel blocker; human metabolite; tocolytic agent; vasodilator agent
nilutamide [no description available]	2.07	1	0	(trifluoromethyl)benzenes; C-nitro compound; imidazolidinone	androgen antagonist; antineoplastic agent
nimesulide nimesulide: structure. nimesulide : An aromatic ether having phenyl and 2-methylsulfonamido-5-nitrophenyl as the two aryl groups.	2.47	2	0	aromatic ether; C-nitro compound; sulfonamide	cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
nimodipine Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.. nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.	2.75	3	0	2-methoxyethyl ester; C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; isopropyl ester	antihypertensive agent; calcium channel blocker; cardiovascular drug; vasodilator agent
nisoldipine Nisoldipine: A dihydropyridine calcium channel antagonist that acts as a potent arterial vasodilator and antihypertensive agent. It is also effective in patients with cardiac failure and angina.. nisoldipine : A racemate consisting of equimolar amounts of (R)- and (S)-nisoldipine. A calcium channel blocker, it is used in the treatment of hypertension and angina pectoris.. methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a methoxycarbonyl group at position 3, an o-nitrophenyl group at position 4, and an isobutoxycarbonyl group at position 5. The racemate, a calcium channel blocker, is used in the treatment of hypertension and angina pectoris.	9.14	3	1	C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; methyl ester
nitrazepam Nitrazepam: A benzodiazepine derivative used as an anticonvulsant and hypnotic.. nitrazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one which is substituted at positions 5 and 7 by phenyl and nitro groups, respectively. It is used as a hypnotic for the short-term management of insomnia and for the treatment of epileptic spasms in infants (West's syndrome).	2.03	1	0	1,4-benzodiazepinone; C-nitro compound	anticonvulsant; antispasmodic drug; drug metabolite; GABA modulator; sedative
nitroglycerin Nitroglycerin: A volatile vasodilator which relieves ANGINA PECTORIS by stimulating GUANYLATE CYCLASE and lowering cytosolic calcium. It is also sometimes used for TOCOLYSIS and explosives.. nitroglycerol : A nitrate ester that is glycerol in which nitro group(s) replace the hydrogen(s) attached to one or more of the hydroxy groups.. nitroglycerin : A nitroglycerol that is glycerol in which the hydrogen atoms of all three hydroxy groups are replaced by nitro groups. It acts as a prodrug, releasing nitric oxide to open blood vessels and so alleviate heart pain.	2.02	1	0	nitroglycerol	explosive; muscle relaxant; nitric oxide donor; prodrug; tocolytic agent; vasodilator agent; xenobiotic
nizatidine [no description available]	2.03	1	0	1,3-thiazoles; C-nitro compound; carboxamidine; organic sulfide; tertiary amino compound	anti-ulcer drug; cholinergic drug; H2-receptor antagonist
nomifensine Nomifensine: An isoquinoline derivative that prevents dopamine reuptake into synaptosomes. The maleate was formerly used in the treatment of depression. It was withdrawn worldwide in 1986 due to the risk of acute hemolytic anemia with intravascular hemolysis resulting from its use. In some cases, renal failure also developed. (From Martindale, The Extra Pharmacopoeia, 30th ed, p266). nomifensine : An N-methylated tetrahydroisoquinoline carrying phenyl and amino substituents at positions C-4 and C-8, respectively.	2.05	1	0	isoquinolines	dopamine uptake inhibitor
norfloxacin Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.. norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.	2.08	1	0	fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antibacterial drug; DNA synthesis inhibitor; environmental contaminant; xenobiotic
ofloxacin Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.. 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.. ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.	2.07	1	0	3-oxo monocarboxylic acid; N-arylpiperazine; N-methylpiperazine; organofluorine compound; oxazinoquinoline
omeprazole Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.. omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.. 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.	2.82	3	0	aromatic ether; benzimidazoles; pyridines; sulfoxide
orphenadrine Orphenadrine: A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm.. orphenadrine : A tertiary amino compound which is the phenyl-o-tolylmethyl ether of 2-(dimethylamino)ethanol.	2.07	1	0	ether; tertiary amino compound	antidyskinesia agent; antiparkinson drug; H1-receptor antagonist; muscarinic antagonist; muscle relaxant; NMDA receptor antagonist; parasympatholytic
osalmide osalmide: structure	2.6	1	0	organic molecular entity
oxaprozin Oxaprozin: An oxazole-propionic acid derivative, cyclooxygenase inhibitor, and non-steroidal anti-inflammatory drug that is used in the treatment of pain and inflammation associated with of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; and ARTHRITIS, JUVENILE.. oxaprozin : A monocarboxylic acid that is a propionic acid derivative having a 4,5-diphenyl-1,3-oxazol-2-yl substituent at position 3. It is non-steroidal anti-inflammatory drug commonly used to relieve the pain and inflammatory responses associated with osteoarthritis and rheumatoid arthritis.	2.05	1	0	1,3-oxazoles; monocarboxylic acid	analgesic; non-steroidal anti-inflammatory drug
oxethazaine [no description available]	2.6	1	0	amino acid amide
oxibendazole oxibendazole: structure	2.05	1	0	benzimidazoles; carbamate ester
oxybutynin oxybutynin: RN given refers to parent cpd. oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.	2.07	1	0	acetylenic compound; carboxylic ester; racemate; tertiary alcohol; tertiary amino compound	antispasmodic drug; calcium channel blocker; local anaesthetic; muscarinic antagonist; muscle relaxant; parasympatholytic
oxyphenbutazone Oxyphenbutazone: A non-steroidal anti-inflammatory drug. Oxyphenbutazone eyedrops have been used abroad in the management of postoperative ocular inflammation, superficial eye injuries, and episcleritis. (From AMA, Drug Evaluations Annual, 1994, p2000) It had been used by mouth in rheumatic disorders such as ankylosing spondylitis, osteoarthritis, and rheumatoid arthritis but such use is no longer considered justified owing to the risk of severe hematological adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p27). oxyphenbutazone : A metabolite of phenylbutazone obtained by hydroxylation at position 4 of one of the phenyl rings. Commonly used (as its hydrate) to treat pain, swelling and stiffness associated with arthritis and gout, it was withdrawn from the market 1984 following association with blood dyscrasis and Stevens-Johnson syndrome.	2.07	1	0	phenols; pyrazolidines	antimicrobial agent; antineoplastic agent; antipyretic; drug metabolite; gout suppressant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic metabolite
aminosalicylic acid Aminosalicylic Acid: An antitubercular agent often administered in association with ISONIAZID. The sodium salt of the drug is better tolerated than the free acid.. 4-aminosalicylic acid : An aminobenzoic acid that is salicylic acid substituted by an amino group at position 4.	2.47	2	0	aminobenzoic acid; phenols	antitubercular agent
palmidrol palmidrol: a cannabinoid receptor-inactive eCB-related molecule used as prophylactic in helping to prevent respiratory viral infection. palmitoyl ethanolamide : An N-(long-chain-acyl)ethanolamine that is the ethanolamide of palmitic (hexadecanoic) acid.	2.6	1	0	endocannabinoid; N-(long-chain-acyl)ethanolamine; N-(saturated fatty acyl)ethanolamine	anti-inflammatory drug; anticonvulsant; antihypertensive agent; neuroprotective agent
pamidronate [no description available]	2.47	2	0	phosphonoacetic acid
pantoprazole Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.. pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.	2.03	1	0	aromatic ether; benzimidazoles; organofluorine compound; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; environmental contaminant; xenobiotic
papaverine Papaverine: An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels.. papaverine : A benzylisoquinoline alkaloid that is isoquinoline substituted by methoxy groups at positions 6 and 7 and a 3,4-dimethoxybenzyl group at position 1. It has been isolated from Papaver somniferum.	2.6	1	0	benzylisoquinoline alkaloid; dimethoxybenzene; isoquinolines	antispasmodic drug; vasodilator agent
4-dichlorobenzene dichlorobenzene : Any member of the class of chlorobenzenes carrying two chloro groups at unspecified positions.. 1,4-dichlorobenzene : A dichlorobenzene carrying chloro groups at positions 1 and 4.	2.05	1	0	dichlorobenzene	insecticide
pargyline Pargyline: A monoamine oxidase inhibitor with antihypertensive properties.	2.05	1	0	aromatic amine
pemoline Pemoline: A central nervous system stimulant used in fatigue and depressive states and to treat hyperkinetic disorders in children.. pemoline : A member of the class of 1,3-oxazoles that is 1,3-oxazol-4(5H)-one which is substituted by an amino group at position 2 and by a phenyl group at position 5. A central nervous system stimulant, it was used to treat hyperactivity disorders in children, but withdrawn from use following reports of serious hepatotoxicity.	2.05	1	0	1,3-oxazoles	central nervous system stimulant
pentoxifylline [no description available]	2.6	1	0	oxopurine
perhexiline Perhexiline: 2-(2,2-Dicyclohexylethyl)piperidine. Coronary vasodilator used especially for angina of effort. It may cause neuropathy and hepatitis.	2.8	3	0	piperidines	cardiovascular drug
perphenazine Perphenazine: An antipsychotic phenothiazine derivative with actions and uses similar to those of CHLORPROMAZINE.. perphenazine : A phenothiazine derivative in which the phenothiazine tricycle carries a chloro substituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at N-10.	2.08	1	0	N-(2-hydroxyethyl)piperazine; N-alkylpiperazine; organochlorine compound; phenothiazines	antiemetic; dopaminergic antagonist; phenothiazine antipsychotic drug
phenacetin Saridon: contains phenacetin, caffeine, propyphenazone & pyrithyldione	2.47	2	0	acetamides; aromatic ether	cyclooxygenase 3 inhibitor; non-narcotic analgesic; peripheral nervous system drug
phenazopyridine Phenazopyridine: A local anesthetic that has been used in urinary tract disorders. Its use is limited by problems with toxicity (primarily blood disorders) and potential carcinogenicity.. phenazopyridine : A diaminopyridine that is 2,6-diaminopyridine substituted at position 3 by a phenylazo group. A local anesthetic that has topical analgesic effect on mucosa lining of the urinary tract. Its use is limited by problems with toxicity (primarily blood disorders) and potential carcinogenicity.	2.6	1	0	diaminopyridine; monoazo compound	anticoronaviral agent; carcinogenic agent; local anaesthetic; non-narcotic analgesic
phenobarbital Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.. phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.	2.46	2	0	barbiturates	anticonvulsant; drug allergen; excitatory amino acid antagonist; sedative
phenoxybenzamine Phenoxybenzamine: An alpha-adrenergic antagonist with long duration of action. It has been used to treat hypertension and as a peripheral vasodilator.	2.07	1	0	aromatic amine
phentermine Phentermine: A central nervous system stimulant and sympathomimetic with actions and uses similar to those of DEXTROAMPHETAMINE. It has been used most frequently in the treatment of obesity.	2.07	1	0	primary amine	adrenergic agent; appetite depressant; central nervous system drug; central nervous system stimulant; dopaminergic agent; sympathomimetic agent
4-phenylbutyric acid 4-phenylbutyric acid: RN refers to the parent cpd. 4-phenylbutyric acid : A monocarboxylic acid the structure of which is that of butyric acid substituted with a phenyl group at C-4. It is a histone deacetylase inhibitor that displays anticancer activity. It inhibits cell proliferation, invasion and migration and induces apoptosis in glioma cells. It also inhibits protein isoprenylation, depletes plasma glutamine, increases production of foetal haemoglobin through transcriptional activation of the gamma-globin gene and affects hPPARgamma activation.	2.6	1	0	monocarboxylic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor; prodrug
phenylbutazone Phenylbutazone: A butyl-diphenyl-pyrazolidinedione that has anti-inflammatory, antipyretic, and analgesic activities. It has been used in ANKYLOSING SPONDYLITIS; RHEUMATOID ARTHRITIS; and REACTIVE ARTHRITIS.. phenylbutazone : A member of the class of pyrazolidines that is 1,2-diphenylpyrazolidine-3,5-dione carrying a butyl group at the 4-position.	2.47	2	0	pyrazolidines	antirheumatic drug; EC 1.1.1.184 [carbonyl reductase (NADPH)] inhibitor; metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; peripheral nervous system drug
phenylmethylsulfonyl fluoride Phenylmethylsulfonyl Fluoride: An enzyme inhibitor that inactivates IRC-50 arvin, subtilisin, and the fatty acid synthetase complex.. phenylmethanesulfonyl fluoride : An acyl fluoride with phenylmethanesulfonyl as the acyl group.	2.6	1	0	acyl fluoride	serine proteinase inhibitor
pilsicainide pilsicainide: structure given in first source. pilsicainide : A secondary carboxamide resulting from the formal condensation of the amino group of 2,6-dimethylaniline with the carboxy group of (tetrahydro-1H-pyrrolizin-7a(5H)-yl)acetic acid. It is a sodium channel blocker which is used as an antiarrhythmic drug for the management of atrial tachyarrhythmias in Japan.	3.15	1	0	organic heterobicyclic compound; secondary carboxamide	anti-arrhythmia drug; sodium channel blocker
pimobendan pimobendan: produces arterial & venous dilatation in dogs; structure given in first source	2.6	1	0	benzimidazoles; pyridazinone	cardiotonic drug; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; vasodilator agent
pinacidil Pinacidil: A guanidine that opens POTASSIUM CHANNELS producing direct peripheral vasodilatation of the ARTERIOLES. It reduces BLOOD PRESSURE and peripheral resistance and produces fluid retention. (Martindale The Extra Pharmacopoeia, 31st ed)	2.05	1	0	pyridines
pindolol Pindolol: A moderately lipophilic beta blocker (ADRENERGIC BETA-ANTAGONISTS). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638). pindolol : A member of the class of indols which is the 2-hydroxy-3-(isopropylamino)propyl ether derivative of 1H-indol-4-ol.	3.56	2	0	indoles; secondary amine	antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist; serotonergic antagonist; vasodilator agent
pioglitazone Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.. pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.	8.18	5	0	aromatic ether; pyridines; thiazolidinediones	antidepressant; cardioprotective agent; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; geroprotector; hypoglycemic agent; insulin-sensitizing drug; PPARgamma agonist; xenobiotic
pj-34 PJ34 : A member of the class of phenanthridines that is 5,6-dihydrophenanthridine substituted at positions 2 and 6 by (N,N-dimethylglycyl)amino and oxo groups, respectively. It is a potent inhibitor of poly(ADP-ribose) polymerases PARP1 and PARP2 (IC50 of 110 nM and 86 nM, respectively) and exhibits anti-cancer, cardioprotective and neuroprotective properties.	2.6	1	0	phenanthridines; secondary carboxamide; tertiary amino compound	angiogenesis inhibitor; anti-inflammatory agent; antiatherosclerotic agent; antineoplastic agent; apoptosis inducer; cardioprotective agent; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; neuroprotective agent
ag 1879 3-(4-chlorophenyl)-1-(1,1-dimethylethyl)-1H-pyrazolo(3,4-d)pyrimidin-4-amine: Fyn kinase inhibitor	2.03	1	0	aromatic amine; monochlorobenzenes; pyrazolopyrimidine	beta-adrenergic antagonist; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; geroprotector
praziquantel azinox: Russian drug	2.54	2	0	isoquinolines
prazosin Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.. prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.	2.46	2	0	aromatic ether; furans; monocarboxylic acid amide; piperazines; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
primidone Primidone: A barbiturate derivative that acts as a GABA modulator and anti-epileptic agent. It is partly metabolized to PHENOBARBITAL in the body and owes some of its actions to this metabolite.. primidone : A pyrimidone that is dihydropyrimidine-4,6(1H,5H)-dione substituted by an ethyl and a phenyl group at position 5. It is used as an anticonvulsant for treatment of various types of seizures.	2.45	2	0	pyrimidone	anticonvulsant; environmental contaminant; xenobiotic
probenecid Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.. probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.	4.09	4	0	benzoic acids; sulfonamide	uricosuric drug
probucol Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).. probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.	2.81	3	0	dithioketal; polyphenol	anti-inflammatory drug; anticholesteremic drug; antilipemic drug; antioxidant; cardiovascular drug
procainamide Procainamide: A class Ia antiarrhythmic drug that is structurally-related to PROCAINE.. procainamide : A benzamide that is 4-aminobenzamide substituted on the amide N by a 2-(diethylamino)ethyl group. It is a pharmaceutical antiarrhythmic agent used for the medical treatment of cardiac arrhythmias.	3.84	3	0	benzamides	anti-arrhythmia drug; platelet aggregation inhibitor; sodium channel blocker
prochlorperazine Prochlorperazine: A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612). prochlorperazine : A member of the class of phenothiazines that is 10H-phenothiazine having a chloro substituent at the 2-position and a 3-(4-methylpiperazin-1-yl)propyl group at the N-10 position.	2.07	1	0	N-alkylpiperazine; N-methylpiperazine; organochlorine compound; phenothiazines	alpha-adrenergic antagonist; antiemetic; cholinergic antagonist; dopamine receptor D2 antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; first generation antipsychotic
promazine Promazine: A phenothiazine with actions similar to CHLORPROMAZINE but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic.. promazine : A phenothiazine deriative in which the phenothiazine tricycle has a 3-(dimethylaminopropyl) group at the N-10 position.	2.6	1	0	phenothiazines; tertiary amine	antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; muscarinic antagonist; phenothiazine antipsychotic drug; serotonergic antagonist
promethazine Promethazine: A phenothiazine derivative with histamine H1-blocking, antimuscarinic, and sedative properties. It is used as an antiallergic, in pruritus, for motion sickness and sedation, and also in animals.. promethazine : A tertiary amine that is a substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropan-2-amine moiety.	2.6	1	0	phenothiazines; tertiary amine	anti-allergic agent; anticoronaviral agent; antiemetic; antipruritic drug; H1-receptor antagonist; local anaesthetic; sedative
propafenone Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.. propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.	2.08	1	0	aromatic ketone; secondary alcohol; secondary amino compound	anti-arrhythmia drug
propofol Propofol: An intravenous anesthetic agent which has the advantage of a very rapid onset after infusion or bolus injection plus a very short recovery period of a couple of minutes. (From Smith and Reynard, Textbook of Pharmacology, 1992, 1st ed, p206). Propofol has been used as ANTICONVULSANTS and ANTIEMETICS.. propofol : A phenol resulting from the formal substitution of the hydrogen at the 2 position of 1,3-diisopropylbenzene by a hydroxy group.	2.05	1	0	phenols	anticonvulsant; antiemetic; intravenous anaesthetic; radical scavenger; sedative
propranolol Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.. propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.	3.19	5	0	naphthalenes; propanolamine; secondary amine	anti-arrhythmia drug; antihypertensive agent; anxiolytic drug; beta-adrenergic antagonist; environmental contaminant; human blood serum metabolite; vasodilator agent; xenobiotic
protriptyline Protriptyline: Tricyclic antidepressant similar in action and side effects to IMIPRAMINE. It may produce excitation.	2.03	1	0	carbotricyclic compound	antidepressant
pyridostigmine [no description available]	2.07	1	0	pyridinium ion
pyrilamine Pyrilamine: A histamine H1 antagonist. It has mild hypnotic properties and some local anesthetic action and is used for allergies (including skin eruptions) both parenterally and locally. It is a common ingredient of cold remedies.. mepyramine : An ethylenediamine derivative that is ethylenediamine in which one of the amino nitrogens is substituted by two methyl groups and the remaining amino nitrogen is substituted by a 4-methoxybenzyl and a pyridin-2-yl group.	2.07	1	0	aromatic ether; ethylenediamine derivative	H1-receptor antagonist
pyrimethamine Maloprim: contains above 2 cpds	2.05	1	0	aminopyrimidine; monochlorobenzenes	antimalarial; antiprotozoal drug; EC 1.5.1.3 (dihydrofolate reductase) inhibitor
raloxifene raloxifene : A member of the class of 1-benzothiophenes that is 1-benzothiophene in which the hydrogens at positions 2, 3, and 6 have been replaced by p-hydroxyphenyl, p-[2-(piperidin-1-yl)ethoxy]benzoyl, and hydroxy groups, respectively.	2.74	3	0	1-benzothiophenes; aromatic ketone; N-oxyethylpiperidine; phenols	bone density conservation agent; estrogen antagonist; estrogen receptor modulator
ranitidine [no description available]	4.08	4	0	aralkylamine
riluzole Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.	2.05	1	0	benzothiazoles
rimantadine Rimantadine: An RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza.	2.6	1	0	alkylamine
risperidone Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.. risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.	2.45	2	0	1,2-benzoxazoles; heteroarylpiperidine; organofluorine compound; pyridopyrimidine	alpha-adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; psychotropic drug; second generation antipsychotic; serotonergic antagonist
rizatriptan rizatriptan: structure given in first source; RN given refers to benzoate	2.03	1	0	tryptamines	anti-inflammatory drug; serotonergic agonist; vasoconstrictor agent
rofecoxib [no description available]	2.03	1	0	butenolide; sulfone	analgesic; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
rolipram [no description available]	2.6	1	0	pyrrolidin-2-ones	antidepressant; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
ropinirole [no description available]	2.03	1	0	indolones; tertiary amine	antidyskinesia agent; antiparkinson drug; central nervous system drug; dopamine agonist
saccharin Saccharin: Flavoring agent and non-nutritive sweetener.. saccharin : A 1,2-benzisothiazole having a keto-group at the 3-position and two oxo substituents at the 1-position. It is used as an artificial sweetening agent.	2.03	1	0	1,2-benzisothiazole; N-sulfonylcarboxamide	environmental contaminant; sweetening agent; xenobiotic
scriptaid scriptide: provokes translocation of GLUT4 to increase glucose uptake; structure in first source	2.6	1	0	isoquinolines
sebacic acid sebacic acid : An alpha,omega-dicarboxylic acid that is the 1,8-dicarboxy derivative of octane.	2.6	1	0	alpha,omega-dicarboxylic acid; dicarboxylic fatty acid	human metabolite; plant metabolite
risedronic acid Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.	2.52	2	0	pyridines
sotalol Sotalol: An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.. sotalol : A sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is substituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias.	2.07	1	0	ethanolamines; secondary alcohol; secondary amino compound; sulfonamide	anti-arrhythmia drug; beta-adrenergic antagonist; environmental contaminant; xenobiotic
fenofibrate [no description available]	2.6	1	0	benzochromenone; delta-lactone; naphtho-alpha-pyrone	platelet aggregation inhibitor; Sir2 inhibitor
imatinib [no description available]	3.96	3	0	aromatic amine; benzamides; N-methylpiperazine; pyridines; pyrimidines	antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
sulfabenzamide sulfabenzamide : A sulfonamide containing a benzamido substituent on nitrogen. An antibacterial/antimicrobial, it is often used in conjunction with sulfathiazole and sulfacetamide as a topical, intravaginal antibacterial preparation.	2.05	1	0	benzenes; sulfonamide antibiotic; sulfonamide	antibacterial drug; antimicrobial drug
sulfamethizole Sulfamethizole: A sulfathiazole antibacterial agent.. sulfamethizole : A sulfonamide consisting of a 1,3,4-thiadiazole nucleus with a methyl substituent at C-5 and a 4-aminobenzenesulfonamido group at C-2.	2.05	1	0	sulfonamide antibiotic; sulfonamide; thiadiazoles	antiinfective agent; antimicrobial agent; drug allergen; EC 2.5.1.15 (dihydropteroate synthase) inhibitor
sulfamethoxazole Sulfamethoxazole: A bacteriostatic antibacterial agent that interferes with folic acid synthesis in susceptible bacteria. Its broad spectrum of activity has been limited by the development of resistance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p208). sulfamethoxazole : An isoxazole (1,2-oxazole) compound having a methyl substituent at the 5-position and a 4-aminobenzenesulfonamido group at the 3-position.	2.06	1	0	isoxazoles; substituted aniline; sulfonamide antibiotic; sulfonamide	antibacterial agent; antiinfective agent; antimicrobial agent; drug allergen; EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; epitope; P450 inhibitor; xenobiotic
sulfanilamide [no description available]	2.05	1	0	substituted aniline; sulfonamide antibiotic; sulfonamide	antibacterial agent; drug allergen; EC 4.2.1.1 (carbonic anhydrase) inhibitor
sulfaphenazole Sulfaphenazole: A sulfonilamide anti-infective agent.. sulfaphenazole : A sulfonamide that is sulfanilamide in which the sulfonamide nitrogen is substituted by a 1-phenyl-1H-pyrazol-5-yl group. It is a selective inhibitor of cytochrome P450 (CYP) 2C9 isozyme, and antibacterial agent.	2.48	2	0	primary amino compound; pyrazoles; substituted aniline; sulfonamide antibiotic; sulfonamide	antibacterial drug; EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor; EC 1.14.13.67 (quinine 3-monooxygenase) inhibitor; P450 inhibitor
sulfasalazine Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907). sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.	2.76	3	0
sulfinpyrazone Sulfinpyrazone: A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.	2.05	1	0	pyrazolidines; sulfoxide	uricosuric drug
sulfobromophthalein Sulfobromophthalein: A phenolphthalein that is used as a diagnostic aid in hepatic function determination.	2.48	2	0	2-benzofurans; organobromine compound; organosulfonic acid; phenols	dye
sulpiride Sulpiride: A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed). sulpiride : A member of the class of benzamides obtained from formal condensation between the carboxy group of 2-methoxy-5-sulfamoylbenzoic acid and the primary amino group of (1-ethylpyrrolidin-2-yl)methylamine.	2.48	2	0	benzamides; N-alkylpyrrolidine; sulfonamide	antidepressant; antiemetic; antipsychotic agent; dopaminergic antagonist
sumatriptan Sumatriptan: A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.. sumatriptan : A sulfonamide that consists of N,N-dimethyltryptamine bearing an additional (N-methylsulfamoyl)methyl substituent at position 5. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used (in the form of its succinate salt) for the acute treatment of migraine with or without aura in adults.	2.05	1	0	sulfonamide; tryptamines	serotonergic agonist; vasoconstrictor agent
suprofen Suprofen: An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It inhibits prostaglandin synthesis and has been proposed as an anti-arthritic.. suprofen : An aromatic ketone that is thiophene substituted at C-2 by a 4-(1-carboxyethyl)benzoyl group.	2.6	1	0	aromatic ketone; monocarboxylic acid; thiophenes	antirheumatic drug; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; peripheral nervous system drug
gatifloxacin Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.. gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.	2.05	1	0	N-arylpiperazine; organofluorine compound; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antiinfective agent; antimicrobial agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
telenzepine telenzepine: structure given in first source	2.45	2	0	benzodiazepine
temozolomide [no description available]	2.05	1	0	imidazotetrazine; monocarboxylic acid amide; triazene derivative	alkylating agent; antineoplastic agent; prodrug
terazosin Terazosin: induces decreased blood pressure; used in the treatment of benign prostatic hyperplasia	2.48	2	0	furans; piperazines; primary amino compound; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; antineoplastic agent
terfenadine Terfenadine: A selective histamine H1-receptor antagonist devoid of central nervous system depressant activity. The drug was used for ALLERGY but withdrawn due to causing LONG QT SYNDROME.	2.05	1	0	diarylmethane
tetraethylammonium Tetraethylammonium: A potassium-selective ion channel blocker. (From J Gen Phys 1994;104(1):173-90)	3.15	1	0	quaternary ammonium ion
thalidomide Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.. thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.. 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.	2.6	1	0	phthalimides; piperidones
ticlopidine Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.. ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.	3.19	5	0	monochlorobenzenes; thienopyridine	anticoagulant; fibrin modulating drug; hematologic agent; P2Y12 receptor antagonist; platelet aggregation inhibitor
tolazamide Tolazamide: A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE.. tolazamide : An N-sulfonylurea that is 1-tosylurea in which a hydrogen attached to the nitrogen at position 3 is replaced by an azepan-1-yl group. A hypoglycemic agent, it is used for the treatment of type 2 diabetes mellitus.	2.05	1	0	N-sulfonylurea	hypoglycemic agent; potassium channel blocker
tolbutamide Tolbutamide: A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290). tolbutamide : An N-sulfonylurea that consists of 1-butylurea having a tosyl group attached at the 3-position.	2.45	2	0	N-sulfonylurea	human metabolite; hypoglycemic agent; insulin secretagogue; potassium channel blocker
tolmetin Tolmetin: A non-steroidal anti-inflammatory agent (ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL) similar in mode of action to INDOMETHACIN.. tolmetin : A monocarboxylic acid that is (1-methylpyrrol-2-yl)acetic acid substituted at position 5 on the pyrrole ring by a 4-methylbenzoyl group. Used in the form of its sodium salt dihydrate as a nonselective nonsteroidal anti-inflammatory drug.	2.05	1	0	aromatic ketone; monocarboxylic acid; pyrroles	EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug
ultram 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol : A tertiary alcohol that is cyclohexanol substituted at positions 1 and 2 by 3-methoxyphenyl and dimethylaminomethyl groups respectively.	2.03	1	0	aromatic ether; tertiary alcohol; tertiary amino compound
triamterene Triamterene: A pteridinetriamine compound that inhibits SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS.. triamterene : Pteridine substituted at positions 2, 4 and 7 with amino groups and at position 6 with a phenyl group. A sodium channel blocker, it is used as a diuretic in the treatment of hypertension and oedema.	2.52	2	0	pteridines	diuretic; sodium channel blocker
triazolam Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.	2.03	1	0	triazolobenzodiazepine	sedative
trichlormethiazide Trichlormethiazide: A thiazide diuretic with properties similar to those of HYDROCHLOROTHIAZIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830). trichlormethiazide : A benzothiadiazine, hydrogenated at positions 2, 3 and 4 and substituted with an aminosulfonyl group at C-7, a chloro substituent at C-6 and a dichloromethyl group at C-3 and with S-1 as an S,S-dioxide. A sulfonamide antibiotic, it is used as a diuretic to treat oedema (including that associated with heart failure) and hypertension.	8.87	2	1	benzothiadiazine; sulfonamide antibiotic	antihypertensive agent; diuretic
trifluoperazine [no description available]	2.54	2	0	N-alkylpiperazine; N-methylpiperazine; organofluorine compound; phenothiazines	antiemetic; calmodulin antagonist; dopaminergic antagonist; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor; phenothiazine antipsychotic drug
triflupromazine Triflupromazine: A phenothiazine used as an antipsychotic agent and as an antiemetic.. triflupromazine : A member of the class of phenothiazines that is 10H-phenothiazine having a trifluoromethyl subsitituent at the 2-position and a 3-(dimethylamino)propyl group at the N-10 position.	2.6	1	0	organofluorine compound; phenothiazines; tertiary amine	anticoronaviral agent; antiemetic; dopaminergic antagonist; first generation antipsychotic
trigonelline trigonelline: in hydra among other organisms; RN given refers to hydroxide inner salt; structure. N-methylnicotinic acid : A pyridinium ion consisting of nicotinic acid having a methyl substituent on the pyridine nitrogen.. N-methylnicotinate : An iminium betaine that is the conjugate base of N-methylnicotinic acid, arising from deprotonation of the carboxy group.	2.6	1	0	alkaloid; iminium betaine	food component; human urinary metabolite; plant metabolite
trimethadione Trimethadione: An anticonvulsant effective in absence seizures, but generally reserved for refractory cases because of its toxicity. (From AMA Drug Evaluations Annual, 1994, p378). trimethadione : An oxazolidinone that is 1,3-oxazolidine-2,4-dione substituted by methyl groups at positions 3, 5 and 5. It is an antiepileptic agent.	2.05	1	0	oxazolidinone	anticonvulsant; geroprotector
trimethobenzamide trimethobenzamide: major descriptor (64-84); on-line search BENZAMIDES (64-84); Index Medicus search TRIMETHOBENZAMIDE (64-84); RN given refers to parent cpd. trimethobenzamide : The amide obtained by formal condensation of 3,4,5-trihydroxybenzoic acid with 4-[2-(N,N-dimethylamino)ethoxy]benzylamine. It is used to prevent nausea and vomitting in humans.	2.6	1	0	benzamides; tertiary amino compound	antiemetic
trimethoprim Trimethoprim: A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.. trimethoprim : An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge.	3.18	5	0	aminopyrimidine; methoxybenzenes	antibacterial drug; diuretic; drug allergen; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; environmental contaminant; xenobiotic
troglitazone Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.	2.47	2	0	chromanes; thiazolidinone	anticoagulant; anticonvulsant; antineoplastic agent; antioxidant; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; hypoglycemic agent; platelet aggregation inhibitor; vasodilator agent
tyrphostin a9 [no description available]	2.6	1	0	alkylbenzene	geroprotector
delavirdine Delavirdine: A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.. delavirdine : The amide resulting from the formal condensation of 5-[(methylsulfonyl)amino]-1H-indole-2-carboxylic acid and 4-amino group of 1-[3-(isopropylamino)pyridin-2-yl]piperazine, delavirdine is a non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. Viral resistance emerges rapidly when delavirdine is used alone, so it is therefore used (as the methanesulfonic acid salt) with other antiretrovirals for combination therapy of HIV infection.	3.88	3	0	aminopyridine; indolecarboxamide; N-acylpiperazine; sulfonamide	antiviral drug; HIV-1 reverse transcriptase inhibitor
venlafaxine venlafaxine : A tertiary amino compound that is N,N-dimethylethanamine substituted at position 1 by a 1-hydroxycyclohexyl and 4-methoxyphenyl group.	2.07	1	0	cyclohexanols; monomethoxybenzene; tertiary alcohol; tertiary amino compound	adrenergic uptake inhibitor; analgesic; antidepressant; dopamine uptake inhibitor; environmental contaminant; serotonin uptake inhibitor; xenobiotic
vesnarinone [no description available]	2.6	1	0	organic molecular entity
ici 204,219 zafirlukast: a leukotriene D4 receptor antagonist	2.76	3	0	carbamate ester; indoles; N-sulfonylcarboxamide	anti-asthmatic agent; leukotriene antagonist
zaleplon zaleplon: an azabicyclo(4.3.0)nonane; a nonbenzodiazepine; one of the so-called of Z drugs (zopiclone, eszopiclone, zolpidem, and zaleplon) for which there is some correlation with tumors; a hypnotic with less marked effect on psychomotor functions compared to lorazepam. zaleplon : A pyrazolo[1,5-a]pyrimidine having a nitrile group at position 3 and a 3-(N-ethylacetamido)phenyl substituent at the 7-position.	2.03	1	0	nitrile; pyrazolopyrimidine	anticonvulsant; anxiolytic drug; central nervous system depressant; sedative
zolpidem Zolpidem: An imidazopyridine derivative and short-acting GABA-A receptor agonist that is used for the treatment of INSOMNIA.. zolpidem : An imidazo[1,2-a]pyridine compound having a 4-tolyl group at the 2-position, an N,N-dimethylcarbamoylmethyl group at the 3-position and a methyl substituent at the 6-position.	2.97	4	0	imidazopyridine	central nervous system depressant; GABA agonist; sedative
zomepirac zomepirac: RN given refers to parent cpd; structure	2.76	3	0	aromatic ketone; monocarboxylic acid; monochlorobenzenes; pyrroles	cardiovascular drug; non-steroidal anti-inflammatory drug
mitomycin Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.. mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.	2.07	1	0	mitomycin	alkylating agent; antineoplastic agent
oxyphenonium Oxyphenonium: A quaternary ammonium anticholinergic agent with peripheral side effects similar to those of ATROPINE. It is used as an adjunct in the treatment of gastric and duodenal ulcer, and to relieve visceral spasms. The drug has also been used in the form of eye drops for mydriatic effect.	2.05	1	0	acylcholine
prednisolone Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.. prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.	3.56	2	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; drug metabolite; environmental contaminant; immunosuppressive agent; xenobiotic
estriol hormonin: estrogen replacement; each tablet contains 600 ug micronized 17beta-estradiol, 270 ug estriol and 1.4 mg estrone. chlorapatite : A phosphate mineral with the formula Ca5(PO4)3Cl.	2.07	1	0	16alpha-hydroxy steroid; 17beta-hydroxy steroid; 3-hydroxy steroid	estrogen; human metabolite; human xenobiotic metabolite; mouse metabolite
reserpine Reserpine: An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.. reserpine : An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria.	2.07	1	0	alkaloid ester; methyl ester; yohimban alkaloid	adrenergic uptake inhibitor; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; first generation antipsychotic; plant metabolite; xenobiotic
cephaloridine Cephaloridine: A cephalosporin antibiotic.. cefaloridine : A cephalosporin compound having pyridinium-1-ylmethyl and 2-thienylacetamido side-groups. A first-generation semisynthetic derivative of cephalosporin C.	2.05	1	0	beta-lactam antibiotic allergen; cephalosporin; semisynthetic derivative	antibacterial drug
sorbitol D-glucitol : The D-enantiomer of glucitol (also known as D-sorbitol).	2.05	1	0	glucitol	cathartic; Escherichia coli metabolite; food humectant; human metabolite; laxative; metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite; sweetening agent
alloxan Alloxan: Acidic compound formed by oxidation of URIC ACID. It is isolated as an efflorescent crystalline hydrate.. alloxan : A member of the class of pyrimidones, the structure of which is that of perhydropyrimidine substituted at C-2, -4, -5 and -6 by oxo groups.	2.08	1	0	pyrimidone	hyperglycemic agent; metabolite
floxuridine Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.. floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.	2.47	2	0	nucleoside analogue; organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; radiosensitizing agent
isoproterenol hydrochloride [no description available]	2.05	1	0	catechols
hydroxyproline Hydroxyproline: A hydroxylated form of the imino acid proline. A deficiency in ASCORBIC ACID can result in impaired hydroxyproline formation.. hydroxyproline : A proline derivative that is proline substituted by at least one hydroxy group.	2.75	3	0	4-hydroxyproline; L-alpha-amino acid zwitterion	human metabolite; mouse metabolite; plant metabolite
spironolactone Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827). spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.	4.67	8	0	3-oxo-Delta(4) steroid; oxaspiro compound; steroid lactone; thioester	aldosterone antagonist; antihypertensive agent; diuretic; environmental contaminant; xenobiotic
aldosterone [no description available]	8.43	17	5	11beta-hydroxy steroid; 18-oxo steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid hormone; mineralocorticoid; primary alpha-hydroxy ketone; steroid aldehyde	human metabolite; mouse metabolite
prednisone Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.. prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.	2.74	3	0	11-oxo steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; immunosuppressive agent; prodrug
estrone Hydroxyestrones: Estrone derivatives substituted with one or more hydroxyl groups in any position. They are important metabolites of estrone and other estrogens.	4.41	6	0	17-oxo steroid; 3-hydroxy steroid; phenolic steroid; phenols	antineoplastic agent; bone density conservation agent; estrogen; human metabolite; mouse metabolite
promazine hydrochloride [no description available]	2.05	1	0	hydrochloride
penicillin g Penicillin G: A penicillin derivative commonly used in the form of its sodium or potassium salts in the treatment of a variety of infections. It is effective against most gram-positive bacteria and against gram-negative cocci. It has also been used as an experimental convulsant because of its actions on GAMMA-AMINOBUTYRIC ACID mediated synaptic transmission.. benzylpenicillin : A penicillin in which the substituent at position 6 of the penam ring is a phenylacetamido group.	2.44	2	0	penicillin allergen; penicillin	antibacterial drug; drug allergen; epitope
idoxuridine [no description available]	2.54	2	0	organoiodine compound; pyrimidine 2'-deoxyribonucleoside	antiviral drug; DNA synthesis inhibitor
metaraminol Metaraminol: A sympathomimetic agent that acts predominantly at alpha-1 adrenergic receptors. It has been used primarily as a vasoconstrictor in the treatment of HYPOTENSION.. metaraminol : A member of the class of phenylethanolamines that is 2-amino-1-phenylethanol substituted by a methyl group at position 2 and a phenolic hydroxy group at position 1. A sympathomimetic agent , it is used in the treatment of hypotension.	2.07	1	0	phenylethanolamines	alpha-adrenergic agonist; sympathomimetic agent; vasoconstrictor agent
pilocarpine Pilocarpine: A slowly hydrolyzed muscarinic agonist with no nicotinic effects. Pilocarpine is used as a miotic and in the treatment of glaucoma.. (+)-pilocarpine : The (+)-enantiomer of pilocarpine.	2.05	1	0	pilocarpine	antiglaucoma drug
triiodothyronine Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.. 3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism.	2.47	2	0	2-halophenol; amino acid zwitterion; iodophenol; iodothyronine	human metabolite; mouse metabolite; thyroid hormone
carbon tetrachloride Carbon Tetrachloride: A solvent for oils, fats, lacquers, varnishes, rubber waxes, and resins, and a starting material in the manufacturing of organic compounds. Poisoning by inhalation, ingestion or skin absorption is possible and may be fatal. (Merck Index, 11th ed). tetrachloromethane : A chlorocarbon that is methane in which all the hydrogens have been replaced by chloro groups.	2.81	3	0	chlorocarbon; chloromethanes	hepatotoxic agent; refrigerant
serine Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.. serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.	2.04	1	0	L-alpha-amino acid; proteinogenic amino acid; serine family amino acid; serine zwitterion; serine	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
chloramphenicol Amphenicol: Chloramphenicol and its derivatives.	2.52	2	0	C-nitro compound; carboxamide; diol; organochlorine compound	antibacterial drug; antimicrobial agent; Escherichia coli metabolite; geroprotector; Mycoplasma genitalium metabolite; protein synthesis inhibitor
lysine Lysine: An essential amino acid. It is often added to animal feed.. lysine : A diamino acid that is caproic (hexanoic) acid bearing two amino substituents at positions 2 and 6.. L-lysine : An L-alpha-amino acid; the L-isomer of lysine.	2.52	2	0	aspartate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; lysine; organic molecular entity; proteinogenic amino acid	algal metabolite; anticonvulsant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
physostigmine Physostigmine: A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity.	2.45	2	0	carbamate ester; indole alkaloid	antidote to curare poisoning; EC 3.1.1.8 (cholinesterase) inhibitor; miotic
sucrose Saccharum: A plant genus of the family POACEAE widely cultivated in the tropics for the sweet cane that is processed into sugar.	7.11	1	0	glycosyl glycoside	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; osmolyte; Saccharomyces cerevisiae metabolite; sweetening agent
ethinyl estradiol Ethinyl Estradiol: A semisynthetic alkylated ESTRADIOL with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally, and is often used as the estrogenic component in ORAL CONTRACEPTIVES.. 17alpha-ethynylestradiol : A 3-hydroxy steroid that is estradiol substituted by a ethynyl group at position 17. It is a xenoestrogen synthesized from estradiol and has been shown to exhibit high estrogenic potency on oral administration.	2.97	4	0	17-hydroxy steroid; 3-hydroxy steroid; terminal acetylenic compound	xenoestrogen
aminopyrine Aminopyrine: A pyrazolone with analgesic, anti-inflammatory, and antipyretic properties but has risk of AGRANULOCYTOSIS. A breath test with 13C-labeled aminopyrine has been used as a non-invasive measure of CYTOCHROME P-450 metabolic activity in LIVER FUNCTION TESTS.. aminophenazone : A pyrazolone that is 1,2-dihydro-3H-pyrazol-3-one substituted by a dimethylamino group at position 4, methyl groups at positions 1 and 5 and a phenyl group at position 2. It exhibits analgesic, anti-inflammatory, and antipyretic properties.	2.47	2	0	pyrazolone; tertiary amino compound	antipyretic; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
promethazine hydrochloride [no description available]	2.05	1	0	hydrochloride	anti-allergic agent; anticoronaviral agent; antiemetic; antipruritic drug; geroprotector; H1-receptor antagonist; local anaesthetic; sedative
adenosine diphosphate Adenosine Diphosphate: Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position.	2.05	1	0	adenosine 5'-phosphate; purine ribonucleoside 5'-diphosphate	fundamental metabolite; human metabolite
levodopa Levodopa: The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.. L-dopa : An optically active form of dopa having L-configuration. Used to treat the stiffness, tremors, spasms, and poor muscle control of Parkinson's disease	2.05	1	0	amino acid zwitterion; dopa; L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	allelochemical; antidyskinesia agent; antiparkinson drug; dopaminergic agent; hapten; human metabolite; mouse metabolite; neurotoxin; plant growth retardant; plant metabolite; prodrug
edetic acid Edetic Acid: A chelating agent that sequesters a variety of polyvalent cations such as CALCIUM. It is used in pharmaceutical manufacturing and as a food additive.	2.43	2	0	ethylenediamine derivative; polyamino carboxylic acid; tetracarboxylic acid	anticoagulant; antidote; chelator; copper chelator; geroprotector
phenylethyl alcohol Phenylethyl Alcohol: An antimicrobial, antiseptic, and disinfectant that is used also as an aromatic essence and preservative in pharmaceutics and perfumery.. 2-phenylethanol : A primary alcohol that is ethanol substituted by a phenyl group at position 2.	2.6	1	0	benzenes; primary alcohol	Aspergillus metabolite; fragrance; plant growth retardant; plant metabolite; Saccharomyces cerevisiae metabolite
tyrosine Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring.	2.08	1	0	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; proteinogenic amino acid; tyrosine	EC 1.3.1.43 (arogenate dehydrogenase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
acetylcholine chloride acetylcholine chloride : The chloride salt of acetylcholine, and a parasympatomimetic drug.	2.05	1	0	quaternary ammonium salt
methoxamine hydrochloride [no description available]	2.05	1	0	dimethoxybenzene
cloxacillin Cloxacillin: A semi-synthetic antibiotic that is a chlorinated derivative of OXACILLIN.. cloxacillin : A semisynthetic penicillin antibiotic carrying a 3-(2-chlorophenyl)-5-methylisoxazole-4-carboxamido group at position 6.	2.03	1	0	penicillin allergen; penicillin; semisynthetic derivative	antibacterial agent; antibacterial drug
zoxazolamine Zoxazolamine: A uricosuric and muscle relaxant. Zoxazolamine acts centrally as a muscle relaxant, but the mechanism of its action is not understood.	2.57	2	0	benzoxazole
leucine Leucine: An essential branched-chain amino acid important for hemoglobin formation.. leucine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isobutyl group.	2.46	2	0	amino acid zwitterion; L-alpha-amino acid; leucine; proteinogenic amino acid; pyruvate family amino acid	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
dimethylnitrosamine Dimethylnitrosamine: A nitrosamine derivative with alkylating, carcinogenic, and mutagenic properties. It causes serious liver damage and is a hepatocarcinogen in rodents.	2.05	1	0	nitrosamine	geroprotector; mutagen
lactose Lactose: A disaccharide of GLUCOSE and GALACTOSE in human and cow milk. It is used in pharmacy for tablets, in medicine as a nutrient, and in industry.. lactose : A glycosylglucose disaccharide, found most notably in milk, that consists of D-galactose and D-glucose fragments bonded through a beta-1->4 glycosidic linkage. The glucose fragment can be in either the alpha- or beta-pyranose form, whereas the galactose fragment can only have the beta-pyranose form.. beta-lactose : The beta-anomer of lactose.	2.05	1	0	lactose
primaquine phosphate [no description available]	2.05	1	0
methionine Methionine: A sulfur-containing essential L-amino acid that is important in many body functions.. methionine : A sulfur-containing amino acid that is butyric acid bearing an amino substituent at position 2 and a methylthio substituent at position 4.	2.44	2	0	aspartate family amino acid; L-alpha-amino acid; methionine zwitterion; methionine; proteinogenic amino acid	antidote to paracetamol poisoning; human metabolite; micronutrient; mouse metabolite; nutraceutical
desoxycorticosterone Desoxycorticosterone: A steroid metabolite that is the 11-deoxy derivative of CORTICOSTERONE and the 21-hydroxy derivative of PROGESTERONE	3.54	2	0	20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; mineralocorticoid; primary alpha-hydroxy ketone	human metabolite; mouse metabolite
colchicine (S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.	3.86	3	0	alkaloid; colchicine	anti-inflammatory agent; gout suppressant; mutagen
gallamine triethiodide Gallamine Triethiodide: A synthetic nondepolarizing blocking drug. The actions of gallamine triethiodide are similar to those of TUBOCURARINE, but this agent blocks the cardiac vagus and may cause sinus tachycardia and, occasionally, hypertension and increased cardiac output. It should be used cautiously in patients at risk from increased heart rate but may be preferred for patients with bradycardia. (From AMA Drug Evaluations Annual, 1992, p198)	2.05	1	0
uracil mustard Uracil Mustard: Nitrogen mustard derivative of URACIL. It is a alkylating antineoplastic agent that is used in lymphatic malignancies, and causes mainly gastrointestinal and bone marrow damage.	2.05	1	0	aminouracil; nitrogen mustard
cycloheximide Cycloheximide: Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis.. cycloheximide : A dicarboximide that is 4-(2-hydroxyethyl)piperidine-2,6-dione in which one of the hydrogens attached to the carbon bearing the hydroxy group is replaced by a 3,5-dimethyl-2-oxocyclohexyl group. It is an antibiotic produced by the bacterium Streptomyces griseus.	2.6	1	0	antibiotic fungicide; cyclic ketone; dicarboximide; piperidine antibiotic; piperidones; secondary alcohol	anticoronaviral agent; bacterial metabolite; ferroptosis inhibitor; neuroprotective agent; protein synthesis inhibitor
ficusin Ficusin: A naturally occurring furocoumarin, found in PSORALEA. After photoactivation with UV radiation, it binds DNA via single and double-stranded cross-linking.. psoralen : The simplest member of the class of psoralens that is 7H-furo[3,2-g]chromene having a keto group at position 7. It has been found in plants like Psoralea corylifolia and Ficus salicifolia.	2.6	1	0	psoralens	plant metabolite
egtazic acid Egtazic Acid: A chelating agent relatively more specific for calcium and less toxic than EDETIC ACID.. ethylene glycol bis(2-aminoethyl)tetraacetic acid : A diether that is ethylene glycol in which the hydrogens of the hydroxy groups have been replaced by 2-[bis(carboxymethyl)amino]ethyl group respectively.	2.05	1	0	diether; tertiary amino compound; tetracarboxylic acid	chelator
chloroform Chloroform: A commonly used laboratory solvent. It was previously used as an anesthetic, but was banned from use in the U.S. due to its suspected carcinogenicity.. chloroform : A one-carbon compound that is methane in which three of the hydrogens are replaced by chlorines.	2.05	1	0	chloromethanes; one-carbon compound	carcinogenic agent; central nervous system drug; inhalation anaesthetic; non-polar solvent; refrigerant
norethindrone Norethindrone: A synthetic progestational hormone with actions similar to those of PROGESTERONE but functioning as a more potent inhibitor of ovulation. It has weak estrogenic and androgenic properties. The hormone has been used in treating amenorrhea, functional uterine bleeding, endometriosis, and for CONTRACEPTION.. norethisterone : A 17beta-hydroxy steroid that is testosterone in which the hydrogen at position 17 is replaced by an ethynyl group and in which the methyl group attached to position 10 is replaced by hydrogen.	2.45	2	0	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; terminal acetylenic compound; tertiary alcohol	progestin; synthetic oral contraceptive
tubercidin Tubercidin: An antibiotic purine ribonucleoside that readily substitutes for adenosine in the biological system, but its incorporation into DNA and RNA has an inhibitory effect on the metabolism of these nucleic acids.. tubercidin : An N-glycosylpyrrolopyrimidine that is adenosine in which the in the 5-membered ring that is not attached to the ribose moiety is replaced by a carbon. Tubercidin is produced in the culture broth of Streptomyces tubericidus.	2.6	1	0	antibiotic antifungal agent; N-glycosylpyrrolopyrimidine; ribonucleoside	antimetabolite; antineoplastic agent; bacterial metabolite
cytarabine [no description available]	2.07	1	0	beta-D-arabinoside; monosaccharide derivative; pyrimidine nucleoside	antimetabolite; antineoplastic agent; antiviral agent; immunosuppressive agent
trifluridine Trifluridine: An antiviral derivative of THYMIDINE used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to HERPES SIMPLEX virus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p557). trifluridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-trifluoromethyluracil as the nucleobase. An antiviral drug used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis.	2.6	1	0	nucleoside analogue; organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; EC 2.1.1.45 (thymidylate synthase) inhibitor
medroxyprogesterone acetate [no description available]	2.05	1	0	20-oxo steroid; 3-oxo-Delta(4) steroid; acetate ester; corticosteroid; steroid ester	adjuvant; androgen; antineoplastic agent; antioxidant; female contraceptive drug; inhibitor; progestin; synthetic oral contraceptive
sulfobromophthalein sodium bromosulfophthalein sodium : An organic sodium salt that is the disodium salt of bromosulfophthalein.. bromosulfophthalein : An organosulfonic acid that consists of phthalide bearing four bromo substituents at positions 4, 5, 6 and 7 as well as two 4-hydroxy-3-sulfophenyl groups both located at position 1.	3.15	1	0	organic sodium salt	dye
valine Valine: A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.. valine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isopropyl group.. L-valine : The L-enantiomer of valine.	12.4	42	13	L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid; pyruvate family amino acid; valine	algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
mestranol [no description available]	2.47	2	0	17beta-hydroxy steroid; aromatic ether; terminal acetylenic compound	prodrug; xenoestrogen
arginine Arginine: An essential amino acid that is physiologically active in the L-form.. arginine : An alpha-amino acid that is glycine in which the alpha-is substituted by a 3-guanidinopropyl group.	4.13	3	1	arginine; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	biomarker; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical
propane Propane: A three carbon alkane with the formula H3CCH2CH3.	3.46	1	1	alkane; gas molecular entity	food propellant
acetonitrile acetonitrile: RN given refers to unlabeled cpd. acetonitrile : A nitrile that is hydrogen cyanide in which the hydrogen has been replaced by a methyl group.	2.05	1	0	aliphatic nitrile; volatile organic compound	EC 3.5.1.4 (amidase) inhibitor; NMR chemical shift reference compound; polar aprotic solvent
phencyclidine Phencyclidine: A hallucinogen formerly used as a veterinary anesthetic, and briefly as a general anesthetic for humans. Phencyclidine is similar to KETAMINE in structure and in many of its effects. Like ketamine, it can produce a dissociative state. It exerts its pharmacological action through inhibition of NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE). As a drug of abuse, it is known as PCP and Angel Dust.. phencyclidine : A member of the class of piperidines that is piperidine in which the nitrogen is substituted with a 1-phenylcyclohexyl group. Formerly used as an anaesthetic agent, it exhibits both hallucinogenic and neurotoxic effects.	2.03	1	0	benzenes; piperidines	anaesthetic; neurotoxin; NMDA receptor antagonist; psychotropic drug
tromethamine Tromethamine: An organic amine proton acceptor. It is used in the synthesis of surface-active agents and pharmaceuticals; as an emulsifying agent for cosmetic creams and lotions, mineral oil and paraffin wax emulsions, as a biological buffer, and used as an alkalizer. (From Merck, 11th ed; Martindale, The Extra Pharmacopoeia, 30th ed, p1424)	2.05	1	0	primary amino compound; triol	buffer
isoprene isoprene: used in manufacture of ''synthetic'' rubber, butyl rubber; copolymer in production of elastomers; structure. isoprene : A hemiterpene with the formula CH2=C(CH3)CH=CH2; the monomer of natural rubber and a common structure motif to the isoprenoids, a large class of other naturally occurring compounds.	2.6	1	0	alkadiene; hemiterpene; volatile organic compound	plant metabolite
trichloroethylene Trichloroethylene: A highly volatile inhalation anesthetic used mainly in short surgical procedures where light anesthesia with good analgesia is required. It is also used as an industrial solvent. Prolonged exposure to high concentrations of the vapor can lead to cardiotoxicity and neurological impairment.. triol : A chemical compound containing three hydroxy groups.	2.05	1	0	chloroethenes	inhalation anaesthetic; mouse metabolite
taurocholic acid Taurocholic Acid: The product of conjugation of cholic acid with taurine. Its sodium salt is the chief ingredient of the bile of carnivorous animals. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as a cholagogue and cholerectic.. taurocholate : An organosulfonate oxoanion that is the conjugate base of taurocholic acid.. taurocholic acid : A bile acid taurine conjugate of cholic acid that usually occurs as the sodium salt of bile in mammals.	3.15	1	0	amino sulfonic acid; bile acid taurine conjugate	human metabolite
cyclizine Cyclizine: A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935). cyclizine : An N-alkylpiperazine in which one nitrogen of the piperazine ring is substituted by a methyl group, while the other is substituted by a diphenylmethyl group.	2.05	1	0	N-alkylpiperazine	antiemetic; central nervous system depressant; cholinergic antagonist; H1-receptor antagonist; local anaesthetic
methylprednisolone Methylprednisolone: A PREDNISOLONE derivative with similar anti-inflammatory action.. 6alpha-methylprednisolone : The 6alpha-stereoisomer of 6-methylprednisolone.	2.46	2	0	6-methylprednisolone; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antiemetic; environmental contaminant; neuroprotective agent; xenobiotic
rotenone Derris: A plant genus of the family FABACEAE. The root is a source of rotenoids (ROTENONE) and flavonoids. Some species of Pongamia have been reclassified to this genus and some to MILLETTIA. Some species of Deguelia have been reclassified to this genus.. rotenoid : Members of the class of tetrahydrochromenochromene that consists of a cis-fused tetrahydrochromeno[3,4-b]chromene skeleton and its substituted derivatives. The term was originally restricted to natural products, but is now also used to describe semi-synthetic and fully synthetic compounds.	2.05	1	0	organic heteropentacyclic compound; rotenones	antineoplastic agent; metabolite; mitochondrial NADH:ubiquinone reductase inhibitor; phytogenic insecticide; piscicide; toxin
9,10-anthraquinone 9,10-anthraquinone : An anthraquinone that is anthracene in which positions 9 and 10 have been oxidised to carbonyls.	2.6	1	0	anthraquinone
diquat Diquat: A contact herbicide used also to produce desiccation and defoliation. (From Merck Index, 11th ed). diquat : The organic cation formed formally by addition of an ethylene bridge between the nitrogen atoms of 2,2'-bipyridine. Most often available as the dibromide.	2.05	1	0	organic cation	defoliant; herbicide
salicylanilide salicylanilide: RN given refers to parent cpd. salicylanilide : An amide of salicylic acid and of aniline; it is therefore both a salicylamide and an anilide.	2.6	1	0	benzanilide fungicide; salicylamides; salicylanilides
isosorbide dinitrate Isosorbide Dinitrate: A vasodilator used in the treatment of ANGINA PECTORIS. Its actions are similar to NITROGLYCERIN but with a slower onset of action.	2.52	2	0	glucitol derivative; nitrate ester	nitric oxide donor; vasodilator agent
gramine gramine : An aminoalkylindole that is indole carrying a dimethylaminomethyl substituent at postion 3.	2.6	1	0	aminoalkylindole; indole alkaloid; tertiary amino compound	antibacterial agent; antiviral agent; plant metabolite; serotonergic antagonist
aminacrine Aminacrine: A highly fluorescent anti-infective dye used clinically as a topical antiseptic and experimentally as a mutagen, due to its interaction with DNA. It is also used as an intracellular pH indicator.. 9-aminoacridine : An aminoacridine that is acridine in which the hydrogen at position 9 is replaced by an amino group. A fluorescent dyd and topical antiseptic agent, it is used (usually as the hydrochloride salt) in eye drops for the treatment of superficial eye infections.	2.6	1	0	aminoacridines; primary amino compound	acid-base indicator; antiinfective agent; antiseptic drug; fluorescent dye; MALDI matrix material; mutagen
phenothiazine 10H-phenothiazine : The 10H-tautomer of phenothiazine.	2.05	1	0	phenothiazine	ferroptosis inhibitor; plant metabolite; radical scavenger
2-bromophenol bromophenol : A halophenol that is any phenol containing one or more covalently bonded bromine atoms.	2.05	1	0	bromophenol	marine metabolite
methyl gallate methyl gallate: has both immunosuppressive and phytogenic antineoplastic activities; isolated from Acer saccharinum. methyl 3,4,5-trihydroxybenzoate : A gallate ester obtained by the formal condensation of gallic acid with methanol. It exhibits anti-oxidant, anti-tumor, anti-microbial and anti-inflammatory properties.	2.6	1	0	gallate ester	anti-inflammatory agent; antioxidant; plant metabolite
pyridostigmine bromide Pyridostigmine Bromide: A cholinesterase inhibitor with a slightly longer duration of action than NEOSTIGMINE. It is used in the treatment of myasthenia gravis and to reverse the actions of muscle relaxants.	2.05	1	0	pyridinium salt
4,4'-diaminodiphenylmethane 4,4'-diaminodiphenylmethane: RN given refers to parent cpd; structure. 4,4'-diaminodiphenylmethane : An aromatic amine that is diphenylmethane substituted at the 4-position of each benzene ring by an amino group.	2.05	1	0	aromatic amine	allergen; carcinogenic agent
boric acid [no description available]	2.43	2	0	boric acids	astringent
monobenzone monobenzone: structure. monobenzone : The monobenzyl ether of hydroquinone. It is used as a topical drug for medical depigmentation.	2.6	1	0	benzyl ether	allergen; dermatologic drug; melanin synthesis inhibitor
phenylisothiocyanate phenylisothiocyanate: structure. phenyl isothiocyanate : An isothiocyanate having a phenyl group attached to the nitrogen; used for amino acid sequencing in the Edman degradation.	2.05	1	0	isothiocyanate	allergen; reagent
4-bromophenol 4-bromophenol : A bromophenol containing only hydroxy and bromo substituents that are para to one another.	2.05	1	0	bromophenol	human urinary metabolite; human xenobiotic metabolite; marine metabolite; mouse metabolite; persistent organic pollutant; rat metabolite
2-bromoethylamine [no description available]	2.05	1	0
allyl alcohol allyl alcohol: structure. allylic alcohol : An alcohol where the hydroxy group is attached to a saturated carbon atom adjacent to a double bond (R groups may be H, organyl, etc.).. allyl alcohol : A propenol in which the C=C bond connects C-2 and C-3. It is has been found in garlic (Allium sativum). Formerly used as a herbicide for the control of various grass and weed seeds.	2.05	1	0	primary allylic alcohol; propenol	antibacterial agent; fungicide; herbicide; insecticide; plant metabolite
bromobenzene [no description available]	2.05	1	0	bromoarene; bromobenzenes; volatile organic compound	hepatotoxic agent; mouse metabolite; non-polar solvent
n-pentanoic acid n-pentanoic acid: RN given refers to unlabeled parent cpd. valeric acid : A straight-chain saturated fatty acid containing five carbon atoms.	2.05	1	0	short-chain fatty acid; straight-chain saturated fatty acid	plant metabolite
pyrroles 1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.	2.79	3	0	pyrrole; secondary amine
thiophenes Thiophenes: A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur.. thiophenes : Compounds containing at least one thiophene ring.	2.76	3	0	mancude organic heteromonocyclic parent; monocyclic heteroarene; thiophenes; volatile organic compound	non-polar solvent
imipramine hydrochloride [no description available]	2.05	1	0	hydrochloride	antidepressant
neostigmine bromide neostigmine bromide : The bromide salt of neostigmine.	2.07	1	0	bromide salt
mephobarbital Mephobarbital: A barbiturate that is metabolized to PHENOBARBITAL. It has been used for similar purposes, especially in EPILEPSY, but there is no evidence mephobarbital offers any advantage over PHENOBARBITAL.. mephobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at N-1 by a methyl group and at C-5 by ethyl and phenyl groups.	2.05	1	0	barbiturates	anticonvulsant
linalyl acetate linalyl acetate: structure in first source; RN refers to cpd without isomeric designation. linalyl acetate : A racemate comprising equimolar amounts of (R)- and (S)-linalyl acetate. It forms a principal component of the essential oils from bergamot and lavender.. 3,7-dimethylocta-1,6-dien-3-yl acetate : A monoterpenoid that is the acetate ester of linalool. It forms a principal component of the essential oils from bergamot and lavender.	7.17	1	0	acetate ester; monoterpenoid
edrophonium chloride edrophonium chloride : The chloride salt of edrophonium. A reversible inhibitor of cholinesterase with a rapid onset (30-60 seconds after injection) but a short duration of action (5-15 minutes), it is used in myasthenia gravis both diagnostically and to distinguish between under- or over-treatment with other anticholinesterases. It has also been used for the reversal of neuromuscular blockade in anaesthesia, and for the management of poisoning due to tetrodotoxin, a neuromuscular blocking toxin found in puffer fish and other marine animals.	2.05	1	0	chloride salt; quaternary ammonium salt	antidote; diagnostic agent; EC 3.1.1.8 (cholinesterase) inhibitor
pyrazolanthrone pyrazolanthrone: JNK (c-Jun N-terminal kinase) inhibitor; structure in first source. anthra[1,9-cd]pyrazol-6(2H)-one : A member of the class of anthrapyrazoles that is anthra[1,9-cd]pyrazole substituted at position 6 by an oxo group. An inhibitor of c-Jun N-terminal kinase.	2.11	1	0	anthrapyrazole; aromatic ketone; cyclic ketone	antineoplastic agent; c-Jun N-terminal kinase inhibitor; geroprotector
di-n-pentyl phthalate dipentyl phthalate : A phthalate ester that is the dipentyl ester of benzene-1,2-dicarboxylic acid.	2.05	1	0	diester; phthalate ester	plasticiser
cinchophen cinchophen: was heading 1963-94; ACIPHENOCHINOLIUM was see CHINOPHEN 1978-94; use QUINOLINES to search CINCHOPHEN 1966-94	2.05	1	0	quinolines
phenazopyridine hydrochloride phenazopyridine hydrochloride : A hydrochloride obtained by combining phenazopyridine with one equivalent of hydrochloric acid. A local anesthetic that has topical analgesic effect on mucosa lining of the urinary tract. Its use is limited by problems with toxicity (primarily blood disorders) and potential carcinogenicity.	2.05	1	0	hydrochloride	carcinogenic agent; local anaesthetic; non-narcotic analgesic
tetrracaine hydrochloride leocaine: a crystal beta-modification of the beta-dimethylaminoethyl ether of n-butylaminobenzoic acid hydrochloride	2.05	1	0	benzoate ester
diphenhydramine hydrochloride Antitussive Agents: Agents that suppress cough. They act centrally on the medullary cough center. EXPECTORANTS, also used in the treatment of cough, act locally.. diphenhydramine hydrochloride : The hydrochloride salt of diphenhydramine.	2.05	1	0	hydrochloride; organoammonium salt	anti-allergic agent; antiemetic; antiparkinson drug; antipruritic drug; H1-receptor antagonist; local anaesthetic; muscarinic antagonist; sedative
ditiocarb Ditiocarb: A chelating agent that has been used to mobilize toxic metals from the tissues of humans and experimental animals. It is the main metabolite of DISULFIRAM.. diethyldithiocarbamic acid : A member of the class of dithiocarbamic acids that is diethylcarbamic acid in which both of the oxygens are replaced by sulfur.	2.6	1	0	dithiocarbamic acids	chelator; copper chelator
fluocortolone Fluocortolone: A glucocorticoid with anti-inflammatory activity used topically for various skin disorders.	2.03	1	0	21-hydroxy steroid
catechin Catechin: An antioxidant flavonoid, occurring especially in woody plants as both (+)-catechin and (-)-epicatechin (cis) forms.. catechin : Members of the class of hydroxyflavan that have a flavan-3-ol skeleton and its substituted derivatives.. rac-catechin : A racemate comprising equimolar amounts of (+)- and (-)-catechin. (+)-catechin : The (+)-enantiomer of catechin and a polyphenolic antioxidant plant metabolite.	2.6	1	0	catechin	antioxidant; plant metabolite
tripelennamine hydrochloride [no description available]	2.05	1	0
oxazoles Oxazoles: Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions.. 1,3-oxazole : A five-membered monocyclic heteroarene that is an analogue of cyclopentadiene with O in place of CH2 at position 1 and N in place of CH at position 3.. oxazole : An azole based on a five-membered heterocyclic aromatic skeleton containing one N and one O atom.	2.04	1	0	1,3-oxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
ethynodiol diacetate Ethynodiol Diacetate: A synthetic progestational hormone used alone or in combination with estrogens as an oral contraceptive (CONTRACEPTIVES, ORAL).	2.05	1	0	steroid ester; terminal acetylenic compound	contraceptive drug; estrogen receptor modulator; synthetic oral contraceptive
calcium gluconate [no description available]	2.06	1	0	calcium salt	nutraceutical
hydrazine diamine : Any polyamine that contains two amino groups.	2.05	1	0	azane; hydrazines	EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor
monocrotaline Monocrotaline: A pyrrolizidine alkaloid and a toxic plant constituent that poisons livestock and humans through the ingestion of contaminated grains and other foods. The alkaloid causes pulmonary artery hypertension, right ventricular hypertrophy, and pathological changes in the pulmonary vasculature. Significant attenuation of the cardiopulmonary changes are noted after oral magnesium treatment.	2.05	1	0	pyrrolizidine alkaloid
azacitidine Azacitidine: A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.. 5-azacytidine : An N-glycosyl-1,3,5-triazine that is 4-amino-1,3,5-triazin-2(1H)-one substituted by a beta-D-ribofuranosyl residue via an N-glycosidic linkage. An antineoplastic agent, it is used in the treatment of myeloid leukaemia.	2.54	2	0	N-glycosyl-1,3,5-triazine; nucleoside analogue	antineoplastic agent
pseudoephedrine hydrochloride pseudoephedrine hydrochloride : A hydrochloride that is the monohydrochloride salt of pseudoephedrine.	2.05	1	0	hydrochloride	plant metabolite
procarbazine hydrochloride procarbazine hydrochloride : A hydrochloride obtained by combining procarbazine with one equivalent of hydrochloric acid. An antineoplastic chemotherapy drug used for treatment of Hodgkin's lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands.	2.05	1	0	hydrochloride	antineoplastic agent
betamethasone Betamethasone: A glucocorticoid given orally, parenterally, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. Its lack of mineralocorticoid properties makes betamethasone particularly suitable for treating cerebral edema and congenital adrenal hyperplasia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p724)	2.05	1	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	anti-asthmatic agent; anti-inflammatory drug; immunosuppressive agent
cyproterone acetate [no description available]	2.05	1	0	20-oxo steroid; 3-oxo-Delta(4) steroid; acetate ester; chlorinated steroid; steroid ester	androgen antagonist; geroprotector; progestin
lithocholic acid Lithocholic Acid: A bile acid formed from chenodeoxycholate by bacterial action, usually conjugated with glycine or taurine. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as cholagogue and choleretic.. lithocholic acid : A monohydroxy-5beta-cholanic acid with a alpha-hydroxy substituent at position 3. It is a bile acid obtained from chenodeoxycholic acid by bacterial action.. lithocholate : A bile acid anion that is the conjugate base of lithocholic acid.	2.05	1	0	bile acid; C24-steroid; monohydroxy-5beta-cholanic acid	geroprotector; human metabolite; mouse metabolite
fluorobenzenes Fluorobenzenes: Derivatives of BENZENE that contain FLUORINE.. monofluorobenzene : The simplest member of the class of monofluorobenzenes that is benzene carrying a single fluoro substituent.. fluorobenzenes : Any fluoroarene that is a benzene or a substituted benzene carrying at least one fluoro group.	6.66	5	4	monofluorobenzenes	NMR chemical shift reference compound
glycyrrhetinic acid [no description available]	2.07	1	0	cyclic terpene ketone; hydroxy monocarboxylic acid; pentacyclic triterpenoid	immunomodulator; plant metabolite
chenodeoxycholic acid Chenodeoxycholic Acid: A bile acid, usually conjugated with either glycine or taurine. It acts as a detergent to solubilize fats for intestinal absorption and is reabsorbed by the small intestine. It is used as cholagogue, a choleretic laxative, and to prevent or dissolve gallstones.. chenodeoxycholic acid : A dihydroxy-5beta-cholanic acid that is (5beta)-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 7 respectively.. chenodeoxycholate : Conjugate base of chenodeoxycholic acid; major species at pH 7.3.	2.05	1	0	bile acid; C24-steroid; dihydroxy-5beta-cholanic acid	human metabolite; mouse metabolite
lucanthone Lucanthone: One of the SCHISTOSOMICIDES, it has been replaced largely by HYCANTHONE and more recently PRAZIQUANTEL. (From Martindale The Extrapharmacopoeia, 30th ed., p46). lucanthone : A thioxanthen-9-one compound having a methyl substituent at the 1-position and a 2-[(diethylamino)ethyl]amino substituent at the 4-position. Formerly used for the treatment of schistosomiasis. It is a prodrug, being metabolised to hycanthone.	2.6	1	0	thioxanthenes	adjuvant; antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; mutagen; photosensitizing agent; prodrug; schistosomicide drug
cepharanthine cepharanthine: isoquinoline alkaloid from tubers of STEPHANIA; stimulates recovery of immunologic function in lymphatic system after administration of antineoplastic agents or x-irradiation. cepharanthine : A bisbenzylisoquinoline alkaloid from tubers of Stephania; stimulates recovery of immunologic function in lymphatic system after administration of antineoplastic agents or x-irradiation.	2.6	1	0	bisbenzylisoquinoline alkaloid; isoquinolines
aloe emodin aloe emodin: structure distinct from emodin; this does not mean emodin from aloe. Aloe emodin : A dihydroxyanthraquinone that is chrysazin carrying a hydroxymethyl group at position 3. It has been isolated from plant species of the genus Aloe.	2.6	1	0	aromatic primary alcohol; dihydroxyanthraquinone	antineoplastic agent; plant metabolite
chrysophanic acid chrysophanic acid: RN given refers to parent cpd; structure in Merck, 9th ed, #2260. chrysophanol : A trihydroxyanthraquinone that is chrysazin with a methyl substituent at C-3. It has been isolated from Aloe vera and exhibits antiviral and anti-inflammatory activity.	2.6	1	0	dihydroxyanthraquinone	anti-inflammatory agent; antiviral agent; plant metabolite
emetine Emetine: The principal alkaloid of ipecac, from the ground roots of Uragoga (or Cephaelis) ipecacuanha or U. acuminata, of the Rubiaceae. It is used as an amebicide in many different preparations and may cause serious cardiac, hepatic, or renal damage and violent diarrhea and vomiting. Emetine inhibits protein synthesis in EUKARYOTIC CELLS but not PROKARYOTIC CELLS.. emetine : A pyridoisoquinoline comprising emetam having methoxy substituents at the 6'-, 7'-, 10- and 11-positions. It is an antiprotozoal agent and emetic. It inhibits SARS-CoV2, Zika and Ebola virus replication and displays antimalarial, antineoplastic and antiamoebic properties.	2.6	1	0	isoquinoline alkaloid; pyridoisoquinoline	antiamoebic agent; anticoronaviral agent; antiinfective agent; antimalarial; antineoplastic agent; antiprotozoal drug; antiviral agent; autophagy inhibitor; emetic; expectorant; plant metabolite; protein synthesis inhibitor
osthol osthol: from Cnidium monnieri and Angelica pubescens (both Apiaceae); structure given in first source	2.6	1	0	botanical anti-fungal agent; coumarins	metabolite
flavanone flavanone: RN given refers to cpd with unspecified isomeric designation; structure in first source. flavanone : The simplest member of the class of flavanones that consists of flavan bearing an oxo substituent at position 4.	2.6	1	0	flavanones
phloretic acid phloretic acid: structure. N-hydroxysuccinimide ester : An ester of N-hydroxysuccinimide.. phloretic acid : A hydroxy monocarboxylic acid consisting of propionic acid having a 4-hydroxyphenyl group at the 3-position.	2.6	1	0	hydroxy monocarboxylic acid	plant metabolite
oleanolic acid [no description available]	2.6	1	0	hydroxy monocarboxylic acid; pentacyclic triterpenoid	plant metabolite
angelicin angelicin: used as tranquillizer; sedative; or anticonvulsant; structure	2.6	1	0	furanocoumarin
diperodon diperodon: RN given refers to parent cpd; structure given in first source	2.6	1	0	carbamate ester
methamphetamine Methamphetamine: A central nervous system stimulant and sympathomimetic with actions and uses similar to DEXTROAMPHETAMINE. The smokable form is a drug of abuse and is referred to as crank, crystal, crystal meth, ice, and speed.. methamphetamine : A member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent.	2.07	1	0	amphetamines; secondary amine	central nervous system stimulant; environmental contaminant; neurotoxin; psychotropic drug; xenobiotic
malondialdehyde Malondialdehyde: The dialdehyde of malonic acid.. malonaldehyde : A dialdehyde that is propane substituted by two oxo groups at the terminal carbon atoms respectively. A biomarker of oxidative damage to lipids caused by smoking, it exists in vivo mainly in the enol form.	3.36	6	0	dialdehyde	biomarker
amitriptyline hydrochloride [no description available]	2.05	1	0	organic tricyclic compound
1-naphthylisothiocyanate 1-Naphthylisothiocyanate: A tool for the study of liver damage which causes bile stasis and hyperbilirubinemia acutely and bile duct hyperplasia and biliary cirrhosis chronically, with changes in hepatocyte function. It may cause skin and kidney damage.	2.05	1	0	isothiocyanate	insecticide
isoxsuprine hydrochloride [no description available]	2.05	1	0	alkylbenzene
betaine hydrochloride [no description available]	2.05	1	0
megestrol acetate [no description available]	2.6	1	0	20-oxo steroid; 3-oxo-Delta(4) steroid; acetate ester; steroid ester	antineoplastic agent; appetite enhancer; contraceptive drug; progestin; synthetic oral contraceptive
acetylcysteine N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.	2.79	3	0	acetylcysteine; L-cysteine derivative; N-acetyl-L-amino acid	antidote to paracetamol poisoning; antiinfective agent; antioxidant; antiviral drug; ferroptosis inhibitor; geroprotector; human metabolite; mucolytic; radical scavenger; vulnerary
3-hydroxyacetanilide metacetamol : A derivative of phenol which has an acetamido substituent located meta to the phenolic -OH group. It is a non-toxic regioisomer of paracetamol with analgesic properties, but has never been marketed as a drug.	2.05	1	0	acetamides; phenols	non-narcotic analgesic
methoxyacetic acid methoxyacetic acid: RN given refers to parent cpd. methoxyacetic acid : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by a methoxy group.	2.05	1	0	ether; monocarboxylic acid	antineoplastic agent; apoptosis inducer; human xenobiotic metabolite; mutagen
Berberine chloride (TN) [no description available]	3.15	1	0	organic molecular entity
phendimetrazine phendimetrazine: minor descriptor (66-86); file maintained to MORPHOLINES (66-86); on-line & INDEX MEDICUS search MORPHOLINES (66-86); RN given refers to parent cpd without isomeric designation	2.07	1	0
benzydamine Benzydamine: A benzyl-indazole having analgesic, antipyretic, and anti-inflammatory effects. It is used to reduce post-surgical and post-traumatic pain and edema and to promote healing. It is also used topically in treatment of RHEUMATIC DISEASES and INFLAMMATION of the mouth and throat.. benzydamine : A member of the class of indazoles carrying benzyl and 3-(dimethylamino)propyl groups at positions 1 and 3 respectively. A locally-acting nonsteroidal anti-inflammatory drug that also exhibits local anaesthetic and analgesic properties.	2.08	1	0	aromatic ether; indazoles; tertiary amino compound	analgesic; central nervous system stimulant; hallucinogen; local anaesthetic; non-steroidal anti-inflammatory drug
erythromycin Erythromycin: A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.. erythromycin : Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus).. erythromycin A : An erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively.	3.16	5	0	cyclic ketone; erythromycin
dehydroepiandrosterone sulfate Dehydroepiandrosterone Sulfate: The circulating form of a major C19 steroid produced primarily by the ADRENAL CORTEX. DHEA sulfate serves as a precursor for TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE.. dehydroepiandrosterone sulfate : A steroid sulfate that is the 3-sulfooxy derivative of dehydroepiandrosterone.	3.58	2	0	17-oxo steroid; steroid sulfate	EC 2.7.1.33 (pantothenate kinase) inhibitor; human metabolite; mouse metabolite
hydroxychloroquine sulfate [no description available]	2.6	1	0
levonorgestrel Levonorgestrel: A synthetic progestational hormone with actions similar to those of PROGESTERONE and about twice as potent as its racemic or (+-)-isomer (NORGESTREL). It is used for contraception, control of menstrual disorders, and treatment of endometriosis.	2.03	1	0	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; terminal acetylenic compound	contraceptive drug; female contraceptive drug; progestin; synthetic oral contraceptive
vinblastine [no description available]	3.15	1	0
1-methylpyridinium 1-methylpyridinium: RN given refers to parent cpd	3.15	1	0	methylpyridines
cyproheptadine hydrochloride (anhydrous) cyproheptadine hydrochloride (anhydrous) : The hydrochloride salt of cyproheptadine. Note that the drug named cyproheptadine hydrochloride generally refers to cyproheptadine hydrochloride sesquihydrate.	2.05	1	0	hydrochloride
canrenone Canrenone: A synthetic pregnadiene compound with anti-aldosterone activity.	2.25	1	0	steroid lactone
estradiol valerate [no description available]	2.03	1	0	steroid ester
ethambutol Ethambutol: An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863). ethambutol : An ethylenediamine derivative that is ethane-1,2-diamine in which one hydrogen attached to each of the nitrogens is sutstituted by a 1-hydroxybutan-2-yl group (S,S-configuration). It is a bacteriostatic antimycobacterial drug, effective against Mycobacterium tuberculosis and some other mycobacteria. It is used (as the dihydrochloride salt) in combination with other antituberculous drugs in the treatment of pulmonary and extrapulmonary tuberculosis; resistant strains of M. tuberculosis are readily produced if ethambutol is used alone.	2.52	2	0	ethanolamines; ethylenediamine derivative	antitubercular agent; environmental contaminant; xenobiotic
metformin hydrochloride metformin hydrochloride : A hydrochloride resulting from the reaction of metformin with one molar equivalent of hydrogen chloride.	2.6	1	0	hydrochloride	environmental contaminant; hypoglycemic agent; xenobiotic
antimycin a [no description available]	2.6	1	0	benzamides; formamides; macrodiolide; phenols	antifungal agent; mitochondrial respiratory-chain inhibitor; piscicide
vancomycin Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.	2.05	1	0	glycopeptide	antibacterial drug; antimicrobial agent; bacterial metabolite
ibufenac ibufenac: used in the treatment of rheumatism; also possesses antipyretic properties; minor descriptor (75-84); on-line & Index Medicus search PHENYLACETATES (75-84); RN given refers to parent cpd. ibufenac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by a 4-isobutylphenyl group. Although it was shown to be effective in treatment of rheumatoid arthritis, the clinical use of ibufenac was discontinued due to hepatotoxic side-effects.	2.05	1	0	monocarboxylic acid	EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; hepatotoxic agent; non-narcotic analgesic; non-steroidal anti-inflammatory drug
5,5'-dimethyl-2,2'-bipyridyl 5,5'-dimethyl-2,2'-bipyridyl: structure in first source	2.6	1	0	bipyridines
dichlorobenzyl alcohol 2,4-dichlorobenzyl alcohol : A member of the class of benzyl alcohols that is benzyl alcohol in which the hydrogens at positions 2 and 4 are replaced by chlorines.	2.6	1	0	benzyl alcohols; dichlorobenzene	antiseptic drug
paraquat Paraquat: A poisonous dipyridilium compound used as contact herbicide. Contact with concentrated solutions causes irritation of the skin, cracking and shedding of the nails, and delayed healing of cuts and wounds.. paraquat : An organic cation that consists of 4,4'-bipyridine bearing two N-methyl substituents loctated at the 1- and 1'-positions.	2.05	1	0	organic cation	geroprotector; herbicide
dronabinol Dronabinol: A psychoactive compound extracted from the resin of Cannabis sativa (marihuana, hashish). The isomer delta-9-tetrahydrocannabinol (THC) is considered the most active form, producing characteristic mood and perceptual changes associated with this compound.. Delta(9)-tetrahydrocannabinol : A diterpenoid that is 6a,7,8,10a-tetrahydro-6H-benzo[c]chromene substituted at position 1 by a hydroxy group, positions 6, 6 and 9 by methyl groups and at position 3 by a pentyl group. The principal psychoactive constituent of the cannabis plant, it is used for treatment of anorexia associated with AIDS as well as nausea and vomiting associated with cancer chemotherapy.	2.03	1	0	benzochromene; diterpenoid; phytocannabinoid; polyketide	cannabinoid receptor agonist; epitope; hallucinogen; metabolite; non-narcotic analgesic
amiloride Amiloride: A pyrazine compound inhibiting SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with DIURETICS to spare POTASSIUM loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705). amiloride : A member of the class of pyrazines resulting from the formal monoacylation of guanidine with the carboxy group of 3,5-diamino-6-chloropyrazine-2-carboxylic acid.	3.15	1	0	aromatic amine; guanidines; organochlorine compound; pyrazines	diuretic; sodium channel blocker
buthiazide buthiazide: 3-isobutyl analog of hydrochlorothiazide; structure	2.05	1	0	benzothiadiazine
pimozide Pimozide: A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to HALOPERIDOL for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug Evaluations Annual, 1994, p403). pimozide : A member of the class of benzimidazoles that is 1,3-dihydro-2H-benzimidazol-2-one in which one of the nitrogens is substituted by a piperidin-4-yl group, which in turn is substituted on the nitrogen by a 4,4-bis(p-fluorophenyl)butyl group.	2.45	2	0	benzimidazoles; heteroarylpiperidine; organofluorine compound	antidyskinesia agent; dopaminergic antagonist; first generation antipsychotic; H1-receptor antagonist; serotonergic antagonist
azetidyl-2-carboxylic acid azetidyl-2-carboxylic acid: a proline analog (with 4-membered ring in place of 5); a toxic non-protein amino acid that is misincorporated into protein in place of proline; induces nonfunctional heat-shock proteins; inhibits acquired thermotolerance; RN given refers to (L)-isomer; found in beets and Liliaceae. (S)-azetidine-2-carboxylic acid : The (S)-enantiomer of azetidine-2-carboxylic acid.. azetidinecarboxylic acid : A member of the class of azetidines that is azetidine substituted by at least one carboxy group at unspecified position.	11.46	45	17	azetidine-2-carboxylic acid
sulfadoxine Sulfadoxine: A long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections.. sulfadoxine : A sulfonamide consisting of pyrimidine having methoxy substituents at the 5- and 6-positions and a 4-aminobenzenesulfonamido group at the 4-position. In combination with the antiprotozoal pyrimethamine (CHEBI:8673) it is used as an antimalarial.	2.07	1	0	pyrimidines; sulfonamide	antibacterial drug; antimalarial
stavudine Stavudine: A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.. stavudine : A nucleoside analogue obtained by formal dehydration across positions 2 and 3 of thymidine. An inhibitor of HIV-1 reverse transcriptase	3	4	0	dihydrofuran; nucleoside analogue; organic molecular entity	antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
fluorescein-5-isothiocyanate Fluorescein-5-isothiocyanate: Fluorescent probe capable of being conjugated to tissue and proteins. It is used as a label in fluorescent antibody staining procedures as well as protein- and amino acid-binding techniques.. fluorescein 5-isothiocyanate : The 5-isomer of fluorescein isothiocyanate. Acts as a fluorescent probe capable of being conjugated to tissue and proteins; used as a label in fluorescent antibody staining procedures as well as protein- and amino acid-binding techniques.	2	1	0	fluorescein isothiocyanate
streptomycin [no description available]	2.05	1	0	antibiotic antifungal drug; antibiotic fungicide; streptomycins	antibacterial drug; antifungal agrochemical; antimicrobial agent; antimicrobial drug; bacterial metabolite; protein synthesis inhibitor
dideoxyadenosine Dideoxyadenosine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is an inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal side effect is nephrotoxicity. In vivo, dideoxyadenosine is rapidly metabolized to DIDANOSINE (ddI) by enzymatic deamination; ddI is then converted to dideoxyinosine monophosphate and ultimately to dideoxyadenosine triphosphate, the putative active metabolite.	2.6	1	0	adenosines; purine 2',3'-dideoxyribonucleoside	EC 3.5.4.4 (adenosine deaminase) inhibitor; EC 4.6.1.1 (adenylate cyclase) inhibitor
clonidine hydrochloride [no description available]	2.05	1	0	dichlorobenzene
cladribine [no description available]	2.05	1	0	organochlorine compound; purine 2'-deoxyribonucleoside	antineoplastic agent; immunosuppressive agent
beclomethasone [no description available]	2.07	1	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; chlorinated steroid; corticosteroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	anti-asthmatic drug; anti-inflammatory drug
fructosamine Fructosamine: An amino sugar formed when glucose non-enzymatically reacts with the N-terminal amino group of proteins. The fructose moiety is derived from glucose by the classical Amadori rearrangement.	2.05	1	0
ethylene dimethanesulfonate ethylene dimethanesulfonate: antispermatogenic agent; structure	2.05	1	0
floxacillin Floxacillin: Antibiotic analog of CLOXACILLIN.. flucloxacillin : A penicillin compound having a 6beta-[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazole-4-carboxamido] side-chain.	2.03	1	0	penicillin allergen; penicillin	antibacterial drug
mexiletine hydrochloride mexiletine hydrochloride : A hydrochloride composed of equimolar amounts of mexiletine and hydrogen chloride.	2.05	1	0	hydrochloride	anti-arrhythmia drug
beclomethasone dipropionate beclomethasone dipropionate : A steroid ester comprising beclomethasone having propionyl groups at the 17- and 21-positions.	2.05	1	0	11beta-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid; chlorinated steroid; corticosteroid; enone; glucocorticoid; propanoate ester; steroid ester	anti-arrhythmia drug; anti-asthmatic drug; anti-inflammatory drug; prodrug
vidarabine adenine arabinoside : A purine nucleoside in which adenine is attached to arabinofuranose via a beta-N(9)-glycosidic bond.	2.54	2	0	beta-D-arabinoside; purine nucleoside	antineoplastic agent; bacterial metabolite; nucleoside antibiotic
levomethadone levomethadone : A 6-(dimethylamino)-4,4-diphenylheptan-3-one that has (R)-configuration. It is the active enantiomer of methadone and its hydrochloride salt is used to treat adults who are addicted to drugs such as heroin and morphine.	2.03	1	0	6-(dimethylamino)-4,4-diphenylheptan-3-one	antitussive; mu-opioid receptor agonist; NMDA receptor antagonist; opioid analgesic
3-deazaadenosine 3-deazaadenosine: RN given refers to parent cpd.	2.6	1	0
phenylethylmalonamide Phenylethylmalonamide: A metabolite of primidone.	2.03	1	0	amine
metoclopramide hydrochloride metoclopramide hydrochloride : A hydrate that is the monohydrate form of metoclopramide monohydrochloride.	2.05	1	0
zalcitabine Zalcitabine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.. zalcitabine : A pyrimidine 2',3'-dideoxyribonucleoside compound having cytosine as the nucleobase.	3.89	3	0	pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor
ferrous sulfate ferrous sulfate: Ferro-Gradumet is ferrous sulfate in controlled release form; RN given refers to Fe(+2)[1:1] salt. iron(2+) sulfate (anhydrous) : A compound of iron and sulfate in which the ratio of iron(2+) to sulfate ions is 1:1. Various hydrates occur naturally - most commonly the heptahydrate, which loses water to form the tetrahydrate at 57degreeC and the monohydrate at 65degreeC.	3.19	1	0	iron molecular entity; metal sulfate	reducing agent
deuterium Deuterium: The stable isotope of hydrogen. It has one neutron and one proton in the nucleus.	2.15	1	0	dihydrogen
ancitabine Ancitabine: Congener of CYTARABINE that is metabolized to cytarabine and thereby maintains a more constant antineoplastic action.. ancitabine : An organic heterotricyclic compound resulting from the formal condensation of the oxo group of cytidine to the 2' position with loss of water to give the corresponding cyclic ether. A prodrug, it is metabolised to the antineoplastic agent cytarabine, so is used to maintain a more constant antineoplastic action.	2.6	1	0	diol; organic heterotricyclic compound	antimetabolite; antineoplastic agent; prodrug
chloropyramine chloropyramine: RN given refers to parent cpd; structure	2.6	1	0	aminopyridine
carbendazim carbendazim: carcinogen when combined with sodium nitrite; principle metabolite of thiophanate methyl & benomyl; structure. carbendazim : A member of the class of benzimidazoles that is 2-aminobenzimidazole in which the primary amino group is substituted by a methoxycarbonyl group. A fungicide, carbendazim controls Ascomycetes, Fungi Imperfecti, and Basidiomycetes on a wide variety of crops, including bananas, cereals, cotton, fruits, grapes, mushrooms, ornamentals, peanuts, sugarbeet, soybeans, tobacco, and vegetables.	2.05	1	0	benzimidazole fungicide; benzimidazoles; benzimidazolylcarbamate fungicide; carbamate ester	antifungal agrochemical; antinematodal drug; metabolite; microtubule-destabilising agent
ethionine L-ethionine : An S-ethylhomocysteine that has S-configuration at the chiral centre.	2.05	1	0	S-ethylhomocysteine	antimetabolite; carcinogenic agent
metopimazine metopimazine: RN given refers to parent cpd; structure	2.03	1	0	phenothiazines
selegiline Selegiline: A selective, irreversible inhibitor of Type B monoamine oxidase that is used for the treatment of newly diagnosed patients with PARKINSON DISEASE, and for the treatment of depressive disorders. The compound without isomeric designation is Deprenyl.	2.07	1	0	selegiline; terminal acetylenic compound	geroprotector
levamisole Levamisole: An antihelminthic drug that has been tried experimentally in rheumatic disorders where it apparently restores the immune response by increasing macrophage chemotaxis and T-lymphocyte function. Paradoxically, this immune enhancement appears to be beneficial in rheumatoid arthritis where dermatitis, leukopenia, and thrombocytopenia, and nausea and vomiting have been reported as side effects. (From Smith and Reynard, Textbook of Pharmacology, 1991, p435-6). levamisole : A 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole that has S configuration. It is used (generally as the monohydrochloride salt) to treat parasitic worm infections in pigs, sheep and cattle and was formerly used in humans as an adjuvant to chemotherapy for the treatment of various cancers. It is also widely used as an adulterant to coccaine.	2.6	1	0	6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole	antinematodal drug; antirheumatic drug; EC 3.1.3.1 (alkaline phosphatase) inhibitor; immunological adjuvant; immunomodulator
clemastine Clemastine: A histamine H1 antagonist used as the hydrogen fumarate in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness.. clemastine : 2-[(2R)-1-Methylpyrrolidin-2-yl]ethanol in which the hydrogen of the hydroxy group is substituted by a 1-(4-chlorophenyl)-1-phenylethyl group (R configuration). An antihistamine with antimuscarinic and moderate sedative properties, it is used as its fumarate salt for the symptomatic relief of allergic conditions such as rhinitis, urticaria, conjunctivitis and in pruritic (severe itching) skin conditions.	2.07	1	0	monochlorobenzenes; N-alkylpyrrolidine	anti-allergic agent; antipruritic drug; H1-receptor antagonist; muscarinic antagonist
cephalexin Cephalexin: A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms.. cephalexin : A semisynthetic first-generation cephalosporin antibiotic having methyl and beta-(2R)-2-amino-2-phenylacetamido groups at the 3- and 7- of the cephem skeleton, respectively. It is effective against both Gram-negative and Gram-positive organisms, and is used for treatment of infections of the skin, respiratory tract and urinary tract.	3.55	2	0	beta-lactam antibiotic allergen; cephalosporin; semisynthetic derivative	antibacterial drug
isosorbide-5-mononitrate isosorbide-5-mononitrate: for prevention of angina pectoris; structure given in first source; a Russian drug	2.25	1	0	glucitol derivative; nitrate ester	nitric oxide donor; vasodilator agent
n'-nitrosonornicotine N'-nitrosonornicotine: structure; a potent carcinogen in laboratory animals	2.6	1	0	pyridines; pyrrolidines
danazol Danazol: A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders.	2.47	2	0	17beta-hydroxy steroid; terminal acetylenic compound	anti-estrogen; estrogen antagonist; geroprotector
metergoline Metergoline: A dopamine agonist and serotonin antagonist. It has been used similarly to BROMOCRIPTINE as a dopamine agonist and also for MIGRAINE DISORDERS therapy.. metergoline : An ergoline alkaloid that is the N-benzyloxycarbonyl derivative of lysergamine. A 5-HT2 antagonist. Also 5-HT1 antagonist and 5-HT1D ligand. Has moderate affinity for 5-HT6 and high affinity for 5-HT7.	2.03	1	0	carbamate ester; ergoline alkaloid	dopamine agonist; geroprotector; serotonergic antagonist
daunorubicin Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.. anthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.. daunorubicin : A natural product found in Actinomadura roseola.	2.81	3	0	aminoglycoside antibiotic; anthracycline; p-quinones; tetracenequinones	antineoplastic agent; bacterial metabolite
disopyramide phosphate [no description available]	2.05	1	0	organoammonium phosphate
carbimazole Carbimazole: An imidazole antithyroid agent. Carbimazole is metabolized to METHIMAZOLE, which is responsible for the antithyroid activity.. carbimazole : A member of the class of imidazoles that is methimazole in which the nitrogen bearing a hydrogen is converted into its ethoxycarbonyl derivative. A prodrug for methimazol, carbimazole is used for the treatment of hyperthyroidism.	2.07	1	0	1,3-dihydroimidazole-2-thiones; carbamate ester	antithyroid drug; prodrug
bromocriptine Bromocriptine: A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion.	2.03	1	0	indole alkaloid	antidyskinesia agent; antiparkinson drug; dopamine agonist; hormone antagonist
triamcinolone Triamcinolone: A glucocorticoid given, as the free alcohol or in esterified form, orally, intramuscularly, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. (From Martindale, The Extra Pharmacopoeia, 30th ed, p739). triamcinolone : A C21-steroid hormone that is 1,4-pregnadiene-3,20-dione carrying four hydroxy substituents at positions 11beta, 16alpha, 17alpha and 21 as well as a fluoro substituent at position 9. Used in the form of its 16,17-acetonide to treat various skin infections.	2.48	2	0	11beta-hydroxy steroid; 16alpha-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid hormone; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	anti-allergic agent; anti-inflammatory drug
ursodeoxycholic acid Ursodeoxycholic Acid: An epimer of chenodeoxycholic acid. It is a mammalian bile acid found first in the bear and is apparently either a precursor or a product of chenodeoxycholate. Its administration changes the composition of bile and may dissolve gallstones. It is used as a cholagogue and choleretic.. ursodeoxycholic acid : A bile acid found in the bile of bears (Ursidae) as a conjugate with taurine. Used therapeutically, it prevents the synthesis and absorption of cholesterol and can lead to the dissolution of gallstones.. ursodeoxycholate : A bile acid anion that is the conjugate base of ursodeoxycholic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.	2.05	1	0	bile acid; C24-steroid; dihydroxy-5beta-cholanic acid	human metabolite; mouse metabolite
butylated hydroxytoluene 2,6-di-tert-butyl-4-methylphenol : A member of the class of phenols that is 4-methylphenol substituted by tert-butyl groups at positions 2 and 6.	2.47	2	0	phenols	antioxidant; ferroptosis inhibitor; food additive; geroprotector
glutamic acid Glutamic Acid: A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.. glutamic acid : An alpha-amino acid that is glutaric acid bearing a single amino substituent at position 2.	2.02	1	0	glutamic acid; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; ferroptosis inducer; micronutrient; mouse metabolite; neurotransmitter; nutraceutical
cefazolin Cefazolin: A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.. cefazolin : A first-generation cephalosporin compound having [(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl and (1H-tetrazol-1-ylacetyl)amino side-groups at positions 3 and 7 respectively.	2.03	1	0	beta-lactam antibiotic allergen; cephalosporin; tetrazoles; thiadiazoles	antibacterial drug
amoxicillin Amoxicillin: A broad-spectrum semisynthetic antibiotic similar to AMPICILLIN except that its resistance to gastric acid permits higher serum levels with oral administration.. amoxicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-(4-hydroxyphenyl)acetamido group.	2.76	3	0	penicillin allergen; penicillin	antibacterial drug
timolol (S)-timolol (anhydrous) : The (S)-(-) (more active) enantiomer of timolol. A beta-adrenergic antagonist, both the hemihydrate and the maleate salt are used in the mangement of glaucoma, hypertension, angina pectoris and myocardial infarction, and for the prevention of migraine.	2	1	0	timolol	anti-arrhythmia drug; antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist
moricizine hydrochloride moricizine hydrochloride : A hydrochloride salt obtained from equimola amounts of moricizine and hydrogen chloride.	2.05	1	0	hydrochloride	anti-arrhythmia drug
zidovudine Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.	4.27	5	0	azide; pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor
pirprofen pirprofen: anti-inflammatory agent used in therapy of rheumatoid arthritis; prostaglandin synthetase inhibitor; more potent than indomethacin; structure	2.47	2	0	pyrroline
serentil mesoridazine besylate : The benzenesulfonate salt of mesoridazine prepared using equimolar amounts of mesoridazine and benzenesulfonic acid.	2.05	1	0	organosulfonate salt	dopaminergic antagonist; first generation antipsychotic
tobramycin Tobramycin: An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the PSEUDOMONAS species. It is a 10% component of the antibiotic complex, NEBRAMYCIN, produced by the same species.. tobramycin : A amino cyclitol glycoside that is kanamycin B lacking the 3-hydroxy substituent from the 2,6-diaminoglucose ring.	2.05	1	0	amino cyclitol glycoside	antibacterial agent; antimicrobial agent; toxin
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	4.37	3	0	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
etoposide [no description available]	3.85	3	0	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
propafenone hydrochloride propafenone hydrochloride : A hydrochloride that is the monohydrochloride salt of propafenone. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used in the management of supraventricular and ventricular arrhythmias.	2.05	1	0	hydrochloride	anti-arrhythmia drug
ribavirin Rebetron: Rebetron is tradename	2.78	3	0	1-ribosyltriazole; aromatic amide; monocarboxylic acid amide; primary carboxamide	anticoronaviral agent; antiinfective agent; antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
carbidopa [no description available]	2.05	1	0	catechols; hydrate; hydrazines; monocarboxylic acid	antidyskinesia agent; antiparkinson drug; dopaminergic agent; EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor
cephradine Cephradine: A semi-synthetic cephalosporin antibiotic.. cephradine : A first-generation cephalosporin antibiotic with a methyl substituent at position 3, and a (2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetamido substituent at position 7, of the cephem skeleton.	2.05	1	0	beta-lactam antibiotic allergen; cephalosporin	antibacterial drug
ticrynafen Ticrynafen: A novel diuretic with uricosuric action. It has been proposed as an antihypertensive agent.. tienilic acid : An aromatic ketone that is 2,3-dichlorophenoxyacetic acid in which the hydrogen at position 4 on the benzene ring is replaced by a thiophenecarbonyl group. A loop diuretic used to treat hypertension, it was withdrawn from the market in 1982 due to links with hepatitis.	2.98	4	0	aromatic ether; aromatic ketone; dichlorobenzene; monocarboxylic acid; thiophenes	antihypertensive agent; hepatotoxic agent; loop diuretic
methyldopa Methyldopa: An alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent.. alpha-methyl-L-dopa : A derivative of L-tyrosine having a methyl group at the alpha-position and an additional hydroxy group at the 3-position on the phenyl ring.	2.47	2	0	L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	alpha-adrenergic agonist; antihypertensive agent; hapten; peripheral nervous system drug; sympatholytic agent
pyridoxal phosphate [no description available]	2.6	1	0	pyridinecarbaldehyde
bezafibrate [no description available]	2.05	1	0	aromatic ether; monocarboxylic acid amide; monocarboxylic acid; monochlorobenzenes	antilipemic drug; environmental contaminant; geroprotector; xenobiotic
sq-11725 Nadolol: A non-selective beta-adrenergic antagonist with a long half-life, used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension. Nadolol is also used for MIGRAINE DISORDERS and for tremor.. nadolol : Nadolol is a diastereoisomeric mixture consisting of equimolar amounts of the four possible 2,3-cis-isomers of 5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol.	2.05	1	0
diltiazem Diltiazem: A benzothiazepine derivative with vasodilating action due to its antagonism of the actions of CALCIUM ion on membrane functions.. diltiazem : A 5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate in which both stereocentres have S configuration. A calcium-channel blocker and vasodilator, it is used as the hydrochloride in the management of angina pectoris and hypertension.	2.75	3	0	5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate	antihypertensive agent; calcium channel blocker; vasodilator agent
ng-nitroarginine methyl ester NG-Nitroarginine Methyl Ester: A non-selective inhibitor of nitric oxide synthase. It has been used experimentally to induce hypertension.	3.29	6	0	alpha-amino acid ester; L-arginine derivative; methyl ester; N-nitro compound	EC 1.14.13.39 (nitric oxide synthase) inhibitor
dexibuprofen dexibuprofen: structure in first source	2.03	1	0	ibuprofen	non-narcotic analgesic; non-steroidal anti-inflammatory drug
benoxaprofen benoxaprofen: RN given refers to parent cpd; structure. benoxaprofen : A monocarboxylic acid that is propionic acid substituted at position 2 by a 2-(4-chlorophenyl)-1,3-benzoxazol-5-yl group. It was used as a non-steroidal anti-inflammatory drug until 1982 when it was withdrawn from the market due to adverse side-effects including liver necrosis, photosensitivity, and carcinogenicity in animals.	2.05	1	0	1,3-benzoxazoles; monocarboxylic acid; monochlorobenzenes	antipsoriatic; antipyretic; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; hepatotoxic agent; nephrotoxin; non-narcotic analgesic; non-steroidal anti-inflammatory drug; protein kinase C agonist
permethrin hemoglobin Atlanta-Coventry: Leu replaced by Pro at beta75 and Leu deleted at beta141	2.05	1	0	cyclopropanecarboxylate ester; cyclopropanes	agrochemical; ectoparasiticide; pyrethroid ester acaricide; pyrethroid ester insecticide; scabicide
flecainide acetate flecainide acetate : An acetate salt obtained by combining flecainide with one molar equivalent of acetic acid. An antiarrhythmic agent used to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).	2.05	1	0	acetate salt	anti-arrhythmia drug
nicardipine hydrochloride [no description available]	2.05	1	0	dihydropyridine	geroprotector
nitazoxanide nitazoxanide: a 5-nitrothiazolyl derivative used for a broad range of intestinal parasitic infections including CRYPTOSPORIDIUM and GIARDIA; it is a redox-active nitrothiazolyl-salicylamide prodrug	2.6	1	0	benzamides; carboxylic ester
torsemide Torsemide: A pyridine and sulfonamide derivative that acts as a sodium-potassium chloride symporter inhibitor (loop diuretic). It is used for the treatment of EDEMA associated with CONGESTIVE HEART FAILURE; CHRONIC RENAL INSUFFICIENCY; and LIVER DISEASES. It is also used for the management of HYPERTENSION.. torasemide : An N-sulfonylurea obtained by formal condensation of [(3-methylphenyl)amino]pyridine-3-sulfonic acid with the free amino group of N-isopropylurea. It is a potent loop diuretic used for the treatment of hypertension and edema in patients with congestive heart failure.	2.46	2	0	aminopyridine; N-sulfonylurea; secondary amino compound	antihypertensive agent; loop diuretic
epirubicin Epirubicin: An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.	2.05	1	0	aminoglycoside; anthracycline antibiotic; anthracycline; deoxy hexoside; monosaccharide derivative; p-quinones; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	antimicrobial agent; antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
cefmetazole Cefmetazole: A semisynthetic cephamycin antibiotic with a broad spectrum of activity against both gram-positive and gram-negative microorganisms. It has a high rate of efficacy in many types of infection and to date no severe side effects have been noted.. cefmetazole : A second-generation cephalosporin antibiotic having N(1)-methyltetrazol-5-ylthiomethyl, {[(cyanomethyl)sulfanyl]acetyl}amino and methoxy side-groups at positions 3, 7beta and 7alpha respectively of the parent cephem bicyclic structure.	2.07	1	0	cephalosporin	antibacterial drug
indacrinone indacrinone: polyvalent saluretic; RN given refers to parent cpd without isomeric designation; structure	2.05	1	0
idarubicin Idarubicin: An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA.	2.03	1	0	anthracycline antibiotic; deoxy hexoside; monosaccharide derivative
paroxetine Paroxetine: A serotonin uptake inhibitor that is effective in the treatment of depression.. paroxetine : A benzodioxole that consists of piperidine bearing 1,3-benzodioxol-5-yloxy)methyl and 4-fluorophenyl substituents at positions 3 and 4 respectively; the (3S,4R)-diastereomer. Highly potent and selective 5-HT uptake inhibitor that binds with high affinity to the serotonin transporter (Ki = 0.05 nM). Ki values are 1.1, 350 and 1100 nM for inhibition of [3H]-5-HT, [3H]-l-NA and [3H]-DA uptake respectively. Displays minimal affinity for alpha1-, alpha2- or beta-adrenoceptors, 5-HT2A, 5-HT1A, D2 or H1 receptors at concentrations below 1000 nM, however displays weak affinity for muscarinic ACh receptors (Ki = 42 nM). Antidepressant and anxiolytic in vivo.	2.47	2	0	aromatic ether; benzodioxoles; organofluorine compound; piperidines	antidepressant; anxiolytic drug; hepatotoxic agent; P450 inhibitor; serotonin uptake inhibitor
captopril Captopril: A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin.. captopril : A L-proline derivative in which L-proline is substituted on nitrogen with a (2S)-2-methyl-3-sulfanylpropanoyl group. It is used as an anti-hypertensive ACE inhibitor drug.	9.96	11	0	alkanethiol; L-proline derivative; N-acylpyrrolidine; pyrrolidinemonocarboxylic acid	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
cefoperazone Cefoperazone: Semisynthetic broad-spectrum cephalosporin with a tetrazolyl moiety that is resistant to beta-lactamase. It may be used to treat Pseudomonas infections.. cefoperazone : A semi-synthetic parenteral cephalosporin with a tetrazolyl moiety that confers beta-lactamase resistance.	2.48	2	0	cephalosporin	antibacterial drug
oltipraz oltipraz : A 1,2-dithiole that is 3H-1,2-dithiole-3-thione substituted at positions 4 and 5 by methyl and pyrazin-2-yl groups respectively.	2.6	1	0	1,2-dithiole; pyrazines	angiogenesis modulating agent; antimutagen; antineoplastic agent; antioxidant; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor; neurotoxin; protective agent; schistosomicide drug
butoconazole nitrate butoconazole nitrate : An organic nitrate salt obtained by reaction of equimolar amounts of butaconazole and nitric acid. An antifungal agent, it is used in gynaecology for treatment of vulvovaginal infections caused by Candida species, particularly Candida albicans.	2.05	1	0	aryl sulfide; conazole antifungal drug; imidazole antifungal drug; imidazoles; organic nitrate salt
endralazine BQ 22-708: RN given refers to parent cpd	2.03	1	0	benzamides
cefadroxil anhydrous Cefadroxil: Long-acting, broad-spectrum, water-soluble, CEPHALEXIN derivative.. cefadroxil : A cephalosporin bearing methyl and (2R)-2-amino-2-(4-hydroxyphenyl)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton.	3.56	2	0	cephalosporin	antibacterial drug
fiacitabine fiacitabine: anti-herpes virus agent which also inhibits growth of certain human tumor cell lines in vitro.	2.6	1	0
fialuridine [no description available]	2.05	1	0
cefaclor anhydrous Cefaclor: Semisynthetic, broad-spectrum antibiotic derivative of CEPHALEXIN.. cefaclor : A cephalosporin bearing chloro and (R)-2-amino-2-phenylacetamido groups at positions 3 and 7, respectively, of the cephem skeleton.	3.55	2	0	cephalosporin	antibacterial drug; drug allergen
mitoxantrone hydrochloride [no description available]	2.05	1	0	hydrochloride	antineoplastic agent
pirazolac [no description available]	2.03	1	0
cefotetan Cefotetan: A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms.. cefotetan : A semi-synthetic second-generation cephamycin antibiotic with [(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl, methoxy and {[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl}amino groups at the 3, 7alpha, and 7beta positions, respectively, of the cephem skeleton. It is resistant to a wide range of beta-lactamases and is active against a broad spectrum of aerobic and anaerobic Gram-positive and Gram-negative microorganisms.	2.05	1	0
lovastatin Lovastatin: A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver.. lovastatin : A fatty acid ester that is mevastatin carrying an additional methyl group on the carbobicyclic skeleton. It is used in as an anticholesteremic drug and has been found in fungal species such as Aspergillus terreus and Pleurotus ostreatus (oyster mushroom).	2.74	3	0	delta-lactone; fatty acid ester; hexahydronaphthalenes; polyketide; statin (naturally occurring)	anticholesteremic drug; antineoplastic agent; Aspergillus metabolite; prodrug
tolrestat tolrestat: RN & structure given in first source	2.05	1	0	naphthalenes	EC 1.1.1.21 (aldehyde reductase) inhibitor
enoximone Enoximone: A selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. It is used in patients with CONGESTIVE HEART FAILURE.	2.03	1	0	aromatic ketone
simvastatin Simvastatin: A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL.. simvastatin : A member of the class of hexahydronaphthalenes that is lovastatin in which the 2-methylbutyrate ester moiety has been replaced by a 2,2-dimethylbutyrate ester group. It is used as a cholesterol-lowering and anti-cardiovascular disease drug.	2.74	3	0	delta-lactone; fatty acid ester; hexahydronaphthalenes; statin (semi-synthetic)	EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor; EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor; ferroptosis inducer; geroprotector; prodrug
remoxipride Remoxipride: An antipsychotic agent that is specific for dopamine D2 receptors. It has been shown to be effective in the treatment of schizophrenia.	2.07	1	0	dimethoxybenzene
pravastatin Pravastatin: An antilipemic fungal metabolite isolated from cultures of Nocardia autotrophica. It acts as a competitive inhibitor of HMG CoA reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES).. pravastatin : A carboxylic ester resulting from the formal condensation of (S)-2-methylbutyric acid with the hydroxy group adjacent to the ring junction of (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6,8-dihydroxy-2-methyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid. Derived from microbial transformation of mevastatin, pravastatin is a reversible inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA). The sodium salt is used for lowering cholesterol and preventing cardiovascular disease. It is one of the lower potency statins, but has the advantage of fewer side effects compared with lovastatin and simvastatin.	6.61	15	1	3-hydroxy carboxylic acid; carbobicyclic compound; carboxylic ester; hydroxy monocarboxylic acid; secondary alcohol; statin (semi-synthetic)	anticholesteremic drug; environmental contaminant; metabolite; xenobiotic
bambuterol bambuterol: selective inhibitor of butyrylcholinesterase & acetylcholinesterase. bambuterol : A carbamate ester that is terbutaline in which both of the phenolic hydroxy groups have been protected as the corresponding N,N-dimethylcarbamates. A long acting beta-adrenoceptor agonist used in the treatment of asthma, it is a prodrug for terbutaline.	2.05	1	0	carbamate ester; phenylethanolamines	anti-asthmatic drug; beta-adrenergic agonist; bronchodilator agent; EC 3.1.1.7 (acetylcholinesterase) inhibitor; prodrug; sympathomimetic agent; tocolytic agent
atomoxetine atomoxetine : A secondary amino compound having methyl and 3-(2-methylphenoxy)-3-phenylpropan-1-yl substituents.	2.45	2	0	aromatic ether; secondary amino compound; toluenes	adrenergic uptake inhibitor; antidepressant; environmental contaminant; xenobiotic
quinapril Quinapril: A tetrahydroisoquinoline derivative and ANGIOTENSIN CONVERTING ENZYME inhibitor that is used in the treatment of HYPERTENSION and HEART FAILURE.. quinapril : A member of the class of isoquinolines that is (3S)-2-L-alanyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid in which the alpha-amino group of the alanyl residue has been substituted by a 1-ethoxycarbonyl-4-phenylbutan-2-yl group (the all-S isomer). A prodrug for quinaprilat (by hydrolysis of the ethyl ester to the corresponding carboxylic acid), it is used as an angiotensin-converting enzyme inhibitor (ACE inhibitor) used (generally as the hydrochloride salt) for the treatment of hypertension and congestive heart failure.	2.05	1	0	dicarboxylic acid monoester; ethyl ester; isoquinolines; tertiary carboxamide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
alpidem [no description available]	2.47	2	0	imidazoles
eproxindine eproxindine: structure given in first source	2.03	1	0
(S)-nomifensine (S)-nomifensine : The S enantiomer of nomifensine.	2.03	1	0	nomifensine
ranolazine Ranolazine: An acetanilide and piperazine derivative that functions as a SODIUM CHANNEL BLOCKER and prevents the release of enzymes during MYOCARDIAL ISCHEMIA. It is used in the treatment of ANGINA PECTORIS.. N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide : An aromatic amide obtained by formal condensation of the carboxy group of 2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetic acid with the amino group of 2,6-dimethylaniline.. ranolazine : A racemate comprising equal amounts of (R)- and (S)-ranolazine. Used for treatment of chronic angina.	2.6	1	0	aromatic amide; monocarboxylic acid amide; monomethoxybenzene; N-alkylpiperazine; secondary alcohol
brequinar brequinar : A quinolinemonocarboxylic acid that is quinoline substituted by 2'-fluoro[1,1'-biphenyl]-4-yl, methyl, carboxy and fluoro groups at positions 2, 3, 4, and 6, respectively. It is an inhibitor of dihydroorotate dehydrogenase, an enzyme that is required for de novo pyrimidine biosynthesis. The compound exhibits antineoplastic and antiviral properties.	2.6	1	0	biphenyls; monocarboxylic acid; monofluorobenzenes; quinolinemonocarboxylic acid	anticoronaviral agent; antimetabolite; antineoplastic agent; antiviral agent; EC 1.3.5.2 [dihydroorotate dehydrogenase (quinone)] inhibitor; immunosuppressive agent; pyrimidine synthesis inhibitor
finasteride Finasteride: An orally active 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE inhibitor. It is used as a surgical alternative for treatment of benign PROSTATIC HYPERPLASIA.. finasteride : An aza-steroid that is a synthetic drug for the treatment of benign prostatic hyperplasia.	2.07	1	0	3-oxo steroid; aza-steroid; delta-lactam	androgen antagonist; antihyperplasia drug; EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor
imiquimod Imiquimod: A topically-applied aminoquinoline immune modulator that induces interferon production. It is used in the treatment of external genital and perianal warts, superficial CARCINOMA, BASAL CELL; and ACTINIC KERATOSIS.. imiquimod : An imidazoquinoline fused [4,5-c] carrying isobutyl and amino substituents at N-1 and C-4 respectively. A prescription medication, it acts as an immune response modifier and is used to treat genital warts, superficial basal cell carcinoma, and actinic keratosis.	2.6	1	0	imidazoquinoline	antineoplastic agent; interferon inducer
temafloxacin temafloxacin: structure given in first source. temafloxacin : A racemate comprising equimolar amounts of (R)- and (S)-temafloxacin. Both enantiomers both exhibit similar pharmacological profiles. Temafloxacin was briefly used (either as the free base or as the hydrochloride salt) as an antibacterial drug but was withdrawn worldwide in 1992 following reports of serious side effects, including severe hypoglycaemia, haemolytic anaemia, liver and kidney dysfunction, anaphylaxis, and death.. 1-(2,4-difluorophenyl)-6-fluoro-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid : A quinolone that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted at positions 1, 6, and 7 by 2,4-difluorophenyl, fluorine, and 3-methylpiperazin-1-yl groups, respectively.	2.05	1	0	amino acid; monocarboxylic acid; N-arylpiperazine; organofluorine compound; quinolone antibiotic; quinolone; secondary amino compound; tertiary amino compound
(2S)-2-[[oxo-(4-propan-2-ylcyclohexyl)methyl]amino]-3-phenylpropanoic acid [no description available]	2.03	1	0	phenylalanine derivative
clinafloxacin clinafloxacin: structure given in first source; RN given is for monoHCl	2.05	1	0	quinolines
adefovir adefovir: inhibitor of African swine fever virus. adefovir(1-) : A organophosphonate oxoanion obtained by removal of a proton from the phosphonate group of adefovir, a nucleoside reverse transcriptase inhibitor. It is the major microspecies at pH 7.3 (according to Marvin v 6.2.0.).. adefovir : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens has been replaced by a 2-(6-amino-9H-purin-9-yl)ethoxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(t-butoxycarbonyloxymethyl) ester (dipivoxil ester) prodrug is used to treat chronic hepatitis B viral infection.	3.64	2	0	6-aminopurines; ether; phosphonic acids	antiviral drug; DNA synthesis inhibitor; drug metabolite; HIV-1 reverse transcriptase inhibitor; nephrotoxic agent
zileuton [no description available]	2.47	2	0	1-benzothiophenes; ureas	anti-asthmatic drug; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; ferroptosis inhibitor; leukotriene antagonist; non-steroidal anti-inflammatory drug
clopidogrel Clopidogrel: A ticlopidine analog and platelet purinergic P2Y receptor antagonist that inhibits adenosine diphosphate-mediated PLATELET AGGREGATION. It is used to prevent THROMBOEMBOLISM in patients with ARTERIAL OCCLUSIVE DISEASES; MYOCARDIAL INFARCTION; STROKE; or ATRIAL FIBRILLATION.. clopidogrel : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group, the methylene hydrogen of which is replaced by a methoxycarbonyl group (the S enantiomer). A P2Y12 receptor antagonist, it is used to inhibit blood clots and prevent heart attacks.	2.06	1	0	methyl ester; monochlorobenzenes; thienopyridine	anticoagulant; P2Y12 receptor antagonist; platelet aggregation inhibitor
cidofovir anhydrous Cidofovir: An acyclic nucleoside phosphonate that acts as a competitive inhibitor of viral DNA polymerases. It is used in the treatment of RETINITIS caused by CYTOMEGALOVIRUS INFECTIONS and may also be useful for treating HERPESVIRUS INFECTIONS.. cidofovir anhydrous : Cytosine substituted at the 1 position by a 3-hydroxy-2-(phosphonomethoxy)propyl group (S configuration). A nucleoside analogue, it is an injectable antiviral used for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients.	3.64	2	0	phosphonic acids; pyrimidone	anti-HIV agent; antineoplastic agent; antiviral drug; photosensitizing agent
tiagabine Tiagabine: A nipecotic acid derivative that acts as a GABA uptake inhibitor and anticonvulsant agent. It is used in the treatment of EPILEPSY, for refractory PARTIAL SEIZURES.. tiagabine : A piperidinemonocarboxylic acid that is (R)-nipecotic acid in which the hydrogen attached to the nitrogen has been replaced by a 1,1-bis(3-methyl-2-thienyl)but-1-en-4-yl group. A GABA reuptake inhibitor, it is used (generally as the hydrochloride salt) for the treatment of epilepsy.	2.03	1	0	beta-amino acid; piperidinemonocarboxylic acid; tertiary amino compound; thiophenes	anticonvulsant; GABA reuptake inhibitor
mibefradil Mibefradil: A benzimidazoyl-substituted tetraline that selectively binds and inhibits CALCIUM CHANNELS, T-TYPE.	2.47	2	0	tetralins	T-type calcium channel blocker
topotecan Topotecan: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.. topotecan : A pyranoindolizinoquinoline used as an antineoplastic agent. It is a derivative of camptothecin and works by binding to the topoisomerase I-DNA complex and preventing religation of these 328 single strand breaks.	3.84	3	0	pyranoindolizinoquinoline	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor
bromfenac bromfenac: bromfenac sodium is the active cpd; structure in first source. bromfenac : Amfenac in which the the hydrogen at the 4 position of the benzoyl group is substituted by bromine. It is used for the management of ocular pain and treatment of postoperative inflammation in patients who have undergone cataract extraction. It was withdrawn from the US market in 1998, following concerns over off-label abuse and hepatic failure.	2.47	2	0	aromatic amino acid; benzophenones; organobromine compound; substituted aniline	non-narcotic analgesic; non-steroidal anti-inflammatory drug
celgosivir celgosivir: inhibits glycoprotein processing & the growth of HIVs	2.6	1	0
gemcitabine gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.	2.6	1	0	organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; environmental contaminant; immunosuppressive agent; photosensitizing agent; prodrug; radiosensitizing agent; xenobiotic
dup 532 DuP 532: angiotensin I receptor antagonist	3.15	1	0
atorvastatin [no description available]	3.32	6	0	aromatic amide; dihydroxy monocarboxylic acid; monofluorobenzenes; pyrroles; statin (synthetic)	environmental contaminant; xenobiotic
lamivudine [no description available]	4.09	4	0	monothioacetal; nucleoside analogue; oxacycle; primary alcohol	allergen; anti-HBV agent; antiviral drug; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor; HIV-1 reverse transcriptase inhibitor; prodrug
irinotecan [no description available]	3.15	1	0	carbamate ester; delta-lactone; N-acylpiperidine; pyranoindolizinoquinoline; ring assembly; tertiary alcohol; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 5.99.1.2 (DNA topoisomerase) inhibitor; prodrug
valsartan Valsartan: A tetrazole derivative and ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to treat HYPERTENSION.. valsartan : A monocarboxylic acid amide consisting of L-valine in which the amino hydrogens have been replaced by a pentanoyl and a [2'-(1H-tetrazol-5-yl)biphenyl]-4-yl]methyl group. It exhibits antihypertensive activity.	14.95	72	24	biphenylyltetrazole; monocarboxylic acid amide; monocarboxylic acid	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
ziprasidone ziprasidone: a benzisothiazoylpiperazine derivative; has combined dopamine and serotonin receptor antagonist activity; structurally related to tiospirone. ziprasidone : A piperazine compound having 1,2-benzothiazol-3-yl- and 2-(6-chloro-1,3-dihydro-2-oxindol-5-yl)ethyl substituents attached to the nitrogen atoms.	2.03	1	0	1,2-benzisothiazole; indolones; organochlorine compound; piperazines	antipsychotic agent; dopaminergic antagonist; histamine antagonist; muscarinic antagonist; psychotropic drug; serotonergic antagonist
zanamivir Zanamivir: A guanido-neuraminic acid that is used to inhibit NEURAMINIDASE.	2.6	1	0	guanidines	antiviral agent; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor
zolmitriptan zolmitriptan: an antimigraine compound; a serotonin (5HT)-1D receptor agonist. zolmitriptan : A member of the class of tryptamines that is N,N-dimethyltryptamine in which the hydrogen at position 5 of the indole ring has been replaced by a [(4S)-2-oxo-1,3-oxazolidin-4-yl]methyl group. A serotonin 5-HT1 B and D receptor agonist, it is used for the treatment of migraine.	2.03	1	0	oxazolidinone; tryptamines	anti-inflammatory drug; serotonergic agonist; vasoconstrictor agent
adefovir dipivoxil bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine: structure given in first source. adefovir pivoxil : An organic phosphonate that is the dipivoxil ester of adefovir. A prodrug for adefovir, an HIV-1 reverse transcriptase inhibitor, adefovir pivoxil is used to treat chronic hepatitis B viral infection.	2.6	1	0	6-aminopurines; carbonate ester; ether; organic phosphonate	antiviral drug; DNA synthesis inhibitor; HIV-1 reverse transcriptase inhibitor; nephrotoxic agent; prodrug
emtricitabine Emtricitabine: A deoxycytidine analog and REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B viruses. It is used to treat HIV INFECTIONS.. emtricitabine : An organofluorine compound that is 5-fluorocytosine substituted at the 1 position by a 2-(hydroxymethyl)-1,3-oxathiolan-5-yl group (2R,5S configuration). It is used in combination therapy for the treatment of HIV-1 infection.	3.88	3	0	monothioacetal; nucleoside analogue; organofluorine compound; pyrimidone	antiviral drug; HIV-1 reverse transcriptase inhibitor
tasosartan tasosartan: angiotensin II antagonist; structure given in first source	3.56	2	0	biphenyls
saquinavir monomethanesulfonate [no description available]	2.05	1	0	organic molecular entity
adenosine quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit	4.14	3	1	adenosines; purines D-ribonucleoside	analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent
octyl gallate [no description available]	2.6	1	0	gallate ester	food antioxidant; hypoglycemic agent; plant metabolite
allyl formate [no description available]	2.05	1	0
pipothiazine pipothiazine: was heading 1975-94 (see under PHENOTHIAZINE TRANQUILIZERS 1975-90); use PHENOTHIAZINES to search PIPOTHIAZINE 1975-94; a member of the family of phenothiazine tranquilizers	2.03	1	0
desferrioxamine b mesylate desferrioxamine B mesylate : A methanesulfonate salt obtained by reaction of desferrioxamine B with one molar equivalent of methanesulfonic acid. It is an iron-chelating medicine used to remove excess iron from the body. It binds to iron in the blood, which is then passed out in the urine.	2.05	1	0	methanesulfonate salt	antidote; ferroptosis inhibitor; iron chelator
bupropion hydrochloride [no description available]	2.05	1	0	aromatic ketone
diltiazem hydrochloride Carex: fluoride (1.8%) containing varnish; no further information available 8/91. diltiazem hydrochloride : A hydrochloride salt resulting from the reaction of equimolar amounts of diltiazem and hydrogen chloride. A calcium-channel blocker and vasodilator, it is used in the management of angina pectoris and hypertension.	2.05	1	0	hydrochloride	antihypertensive agent; calcium channel blocker; vasodilator agent
trazodone hydrochloride Triticum: A plant genus of the family POACEAE that is the source of EDIBLE GRAIN. A hybrid with rye (SECALE CEREALE) is called TRITICALE. The seed is ground into FLOUR and used to make BREAD, and is the source of WHEAT GERM AGGLUTININS.. trazodone hydrochloride : A hydrochloride salt prepared from equimolar amounts of trazodone and hydrogen chloride.	2.05	1	0	hydrochloride	adrenergic antagonist; antidepressant; H1-receptor antagonist; sedative; serotonin uptake inhibitor
trovafloxacin trovafloxacin: a trifluoronaphthyridone derivative of 7-(3-azabicyclo(3.1.0)hexyl)naphthyridone; has antineoplastic activity. trovafloxacin : A 1,8-naphthyridine derivative that is 4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid bearing additional 2,4-difluorophenyl, fluoro and 6-amino-3-azabicyclo[3.1.0]hex-3-yl substituents at positions 1, 6 and 7 respectively. A broad-spectrum antibiotic that was withdrawn from the market due to risk of liver failure.	2.05	1	0
verapamil hydrochloride verapamil hydrochloride : A racemate comprising equimolar amounts of dexverapamil hydrochloride and (S)-verapamil hydrochloride.	2.05	1	0
ciprofloxacin hydrochloride anhydrous [no description available]	2.05	1	0	hydrochloride	antibacterial drug; antiinfective agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; topoisomerase IV inhibitor
efavirenz efavirenz: HIV-1 reverse transcriptase inhibitor. efavirenz : 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection.	3.64	2	0	acetylenic compound; benzoxazine; cyclopropanes; organochlorine compound; organofluorine compound	antiviral drug; HIV-1 reverse transcriptase inhibitor
nelfinavir Nelfinavir: A potent HIV protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children.. nelfinavir : An aryl sulfide that is used (as its mesylate salt) for treatment of HIV and also exhibits some anticancer properties.	2.6	1	0	aryl sulfide; benzamides; organic heterobicyclic compound; phenols; secondary alcohol; tertiary amino compound	antineoplastic agent; HIV protease inhibitor
amantadine hydrochloride [no description available]	2.05	1	0	hydrochloride	antiviral agent; dopamine agonist; NMDA receptor antagonist
glucose, (beta-d)-isomer beta-D-glucose : D-Glucopyranose with beta configuration at the anomeric centre.. (1->4)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->4) linkages.. (1->3)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->3) linkages.	2.13	1	0	D-glucopyranose	epitope; mouse metabolite
betulinic acid [no description available]	2.6	1	0	hydroxy monocarboxylic acid; pentacyclic triterpenoid	anti-HIV agent; anti-inflammatory agent; antimalarial; antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; plant metabolite
arctigenin arctigenin: precursor to catechols; in many plants	2.6	1	0	lignan
baicalin [no description available]	2.6	1	0	dihydroxyflavone; glucosiduronic acid; glycosyloxyflavone; monosaccharide derivative	antiatherosclerotic agent; antibacterial agent; anticoronaviral agent; antineoplastic agent; antioxidant; cardioprotective agent; EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; ferroptosis inhibitor; neuroprotective agent; non-steroidal anti-inflammatory drug; plant metabolite; prodrug
plerixafor plerixafor: a bicyclam derivate, highly potent & selective inhibitor of HIV-1 & HIV-2. plerixafor : An azamacrocycle consisting of two cyclam rings connected by a 1,4-phenylenebis(methylene) linker. It is a CXCR4 chemokine receptor antagonist and a hematopoietic stem cell mobilizer. It is used in combination with grulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the perpheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.	2.6	1	0	azacycloalkane; azamacrocycle; benzenes; crown amine; secondary amino compound; tertiary amino compound	anti-HIV agent; antineoplastic agent; C-X-C chemokine receptor type 4 antagonist; immunological adjuvant
amprenavir [no description available]	2.6	1	0	carbamate ester; sulfonamide; tetrahydrofuryl ester	antiviral drug; HIV protease inhibitor
oseltamivir Oseltamivir: An acetamido cyclohexene that is a structural homolog of SIALIC ACID and inhibits NEURAMINIDASE.. oseltamivir : A cyclohexenecarboxylate ester that is the ethyl ester of oseltamivir acid. An antiviral prodrug (it is hydrolysed to the active free carboxylic acid in the liver), it is used to slow the spread of influenza.	2.52	2	0	acetamides; amino acid ester; cyclohexenecarboxylate ester; primary amino compound	antiviral drug; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor; environmental contaminant; prodrug; xenobiotic
epigallocatechin gallate epigallocatechin gallate: a steroid 5alpha-reductase inhibitor and antimutagen in green tea (Camellia sinensis). (-)-epigallocatechin 3-gallate : A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (-)-epigallocatechin.	2.6	1	0	flavans; gallate ester; polyphenol	antineoplastic agent; antioxidant; apoptosis inducer; geroprotector; Hsp90 inhibitor; neuroprotective agent; plant metabolite
fluorexon fluorexon: structure	2.05	1	0	xanthene dye	fluorochrome
1,2,3,4,6-pentakis-O-galloyl-beta-D-glucose pentagalloylglucose: pentahydroxy gallic acid ester of glucose; a phytogenic antineoplastic agent and antibacterial agent. 1,2,3,4,6-pentakis-O-galloyl-beta-D-glucose : A galloyl-beta-D-glucose compound having five galloyl groups in the 1-, 2-, 3-, 4- and 6-positions.	2.6	1	0	gallate ester; galloyl beta-D-glucose	anti-inflammatory agent; antineoplastic agent; geroprotector; hepatoprotective agent; plant metabolite; radiation protective agent; radical scavenger
cephalotaxine [no description available]	2.6	1	0	benzazepine alkaloid fundamental parent; benzazepine alkaloid; cyclic acetal; enol ether; organic heteropentacyclic compound; secondary alcohol; tertiary amino compound
dobutamine hydrochloride dobutamine hydrochloride : The hydrochloride salt of dobutamine. A beta1-adrenergic receptor agonist that has cardiac stimulant action without evoking vasoconstriction or tachycardia, it is used to increase the contractility of the heart in the management of acute heart failure.	2.05	1	0	hydrochloride	beta-adrenergic agonist; cardiotonic drug; sympathomimetic agent
desipramine hydrochloride desipramine hydrochloride : The hydrochloride salt of desipramine.	2.6	1	0	hydrochloride	drug allergen
mefloquine hydrochloride [no description available]	2.6	1	0	hydrochloride
iopamidol Iopamidol: A non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiological procedures.. iopamidol : A benzenedicarboxamide compound having N-substituted carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and a (2S)-2-hydroxypropanamido group at the 5-position.	2.05	1	0	benzenedicarboxamide; organoiodine compound; pentol	environmental contaminant; radioopaque medium; xenobiotic
sulconazole, mononitrate, (+-)-isomer [no description available]	2.05	1	0	conazole antifungal drug; imidazole antifungal drug; organic nitrate salt
aloxistatin aloxistatin: a membrane-permeable cysteine protease inhibitor. aloxistatin : An L-leucine derivative that is the amide obtained by formal condensation of the carboxy group of (2S,3S)-3-(ethoxycarbonyl)oxirane-2-carboxylic acid with the amino group of N-(3-methylbutyl)-L-leucinamide.	2.52	2	0	epoxide; ethyl ester; L-leucine derivative; monocarboxylic acid amide	anticoronaviral agent; cathepsin B inhibitor
propazole propazole: RN given refers to parent cpd; structure	2.6	1	0	benzimidazoles
lercanidipine [no description available]	2.51	2	0	diarylmethane
prulifloxacin prulifloxacin: structure given in first source	2.6	1	0	fluoroquinolone antibiotic; quinolone antibiotic
azelnidipine azelnidipine: structure given in first source	11.46	45	17	isopropyl ester
repaglinide [no description available]	3.86	3	0	piperidines
telmisartan Telmisartan: A biphenyl compound and benzimidazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION.. telmisartan : A member of the class of benzimidazoles used widely in the treatment of hypertension.	11.3	41	12	benzimidazoles; biphenyls; carboxybiphenyl	angiotensin receptor antagonist; antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; environmental contaminant; xenobiotic
bergenin bergenin: RN refers to (2R-(2alpha,3beta,4alpha,4aalpha,10bbeta))-isomer; structure	2.6	1	0	trihydroxybenzoic acid	metabolite
dexfenfluramine Dexfenfluramine: The S-isomer of FENFLURAMINE. It is a serotonin agonist and is used as an anorectic. Unlike fenfluramine, it does not possess any catecholamine agonist activity.. (S)-fenfluramine : The S-enantiomer of fenfluramine. It stimulates the release of serotonin and selectively inhibits its reuptake, but unlike fenfluramine it does not possess catecholamine agonist activity. It was formerly given by mouth as the hydrochloride in the treatment of obesity, but, like fenfluramine, was withdrawn wolrdwide following reports of valvular heart defects.	2.03	1	0	fenfluramine	appetite depressant; serotonergic agonist; serotonin uptake inhibitor
trimethobenzamide monohydrochloride [no description available]	2.05	1	0
amiloride hydrochloride amiloride hydrochloride dihydrate : A hydrate that is the dihydrate of amiloride hydrochloride.	2.05	1	0	hydrate	diuretic; sodium channel blocker
econazole nitrate econazole nitrate : A racemate composed of equimolar amounts of (R)- and (S)-econazole nitrate. Used to treat skin infections such as athlete's foot, jock itch, ringworm and other fungal skin infections.	2.05	1	0
sertraline Sertraline: A selective serotonin uptake inhibitor that is used in the treatment of depression.. sertraline : A member of the class of tetralins that is tetralin which is substituted at positions 1 and 4 by a methylamino and a 3,4-dichlorophenyl group, respectively (the S,S diastereoisomer). A selective serotonin-reuptake inhibitor (SSRI), it is administered orally as the hydrochloride salt as an antidepressant for the treatment of depression, obsessive-compulsive disorder, panic disorder and post-traumatic stress disorder.	2.76	3	0	dichlorobenzene; secondary amino compound; tetralins	antidepressant; serotonin uptake inhibitor
lomefloxacin hydrochloride lomefloxacin hydrochloride : The hydrochloride salt of lomefloxacin. It is administered by mouth to treat bacterial infections including bronchitis and urinary tract infections. It is also used topically as eye drops for the treatment of bacterial conjunctivitis, and as ear drops for the treatment of otitis externa and otitis media.	2.05	1	0	hydrochloride	antimicrobial agent; antitubercular agent; photosensitizing agent
zoledronic acid Zoledronic Acid: An imidobisphosphonate inhibitor of BONE RESORPTION that is used for the treatment of malignancy-related HYPERCALCEMIA; OSTEITIS DEFORMANS; and OSTEOPOROSIS.. zoledronic acid : An imidazole compound having a 2,2-bis(phosphono)-2-hydroxyethane-1-yl substituent at the 1-position.	2.6	1	0	1,1-bis(phosphonic acid); imidazoles	bone density conservation agent
artemisinin (+)-artemisinin : A sesquiterpene lactone obtained from sweet wormwood, Artemisia annua, which is used as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.	2.6	1	0	organic peroxide; sesquiterpene lactone	antimalarial; plant metabolite
brinzolamide brinzolamide: an antiglaucoma agent	2.6	1	0	sulfonamide; thienothiazine	antiglaucoma drug; EC 4.2.1.1 (carbonic anhydrase) inhibitor
flunoxaprofen flunoxaprofen: structure given in first source. flunoxaprofen : A monocarboxylic acid that is propionic acid substituted at position 2 by a 2-(4-chlorophenyl)-1,3-benzoxazol-5-yl group (the S-enantiomer). Although it was shown to be effective in treatment of rheumatoid arthritis and osteoarthritis, the clinical use of flunoxaprofen was discontinued due to possible hepatotoxic side-effects.	2.05	1	0	1,3-benzoxazoles; monocarboxylic acid; organofluorine compound	antirheumatic drug; hepatotoxic agent; non-steroidal anti-inflammatory drug; protein kinase C agonist
tianeptine tianeptine: structure given in first source. tianeptine : A racemate comprising of equimolar amounts of (R)- and (S)-tianeptine. It is an atypical antidepressant used in Europe to treat patients who respond poorly to selective serotonin reuptake inhibitors (SSRIs).. 7-[(3-chloro-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid : A member of the class of dibenzothiazepines that is 3-chloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide substituted by a (6-carboxyhexyl)amino group at position 11.. (S)-tianeptine : The S-enantiomer of tianeptine.	2.05	1	0	dibenzothiazepine; monocarboxylic acid; organochlorine compound
drospirenone drospirenone: a progestational compound with antimineralocorticoid and antiandrogenic activity; structure given in first source	2.03	1	0	3-oxo-Delta(4) steroid; steroid lactone	aldosterone antagonist; contraceptive drug; progestin
fenflumizole fenflumizole: structure in first source	2.03	1	0
biphenyl-2-carboxylic acid biphenyl-2-carboxylic acid: structure in first source	2.25	1	0
dipropylacetamide dipropylacetamide: structure. valpromide : A fatty amide derived from valproic acid.	2.6	1	0	fatty amide	geroprotector; metabolite; teratogenic agent
oxprenolol hydrochloride [no description available]	2.6	1	0
uk 68798 [no description available]	2.07	1	0	aromatic ether; sulfonamide; tertiary amino compound	anti-arrhythmia drug; potassium channel blocker
loperamide hydrochloride loperamide hydrochloride : A hydrochloride obtained by combining loperamide with one equivalent of hydrochloric acid. Used for treatment of diarrhoea resulting from gastroenteritis or inflammatory bowel disease.	2.05	1	0	hydrochloride	anticoronaviral agent; antidiarrhoeal drug; mu-opioid receptor agonist
opipramol hydrochloride [no description available]	2.6	1	0
moroxydine [no description available]	2.6	1	0	biguanides
bufuralol bufuralol: RN given refers to cpd without isomeric designation; structure	2.08	1	0	benzofurans
prednisolone phosphate prednisolone phosphate: RN given refers to (11 beta)-isomer. prednisolone phosphate : A synthetic glucocorticoid resulting from the formal condensation of the 21-hydroxy group of prednisolone with one of the hydroxy groups of phosphoric acid. It is a prodrug for prednisolone that is activated in vivo by phosphatases.	2.03	1	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid; glucocorticoid; steroid phosphate; tertiary alpha-hydroxy ketone	anti-inflammatory agent; antineoplastic agent; glucocorticoid receptor agonist; prodrug
(S)-flurbiprofen [no description available]	2.03	1	0	flurbiprofen
thioxolone tioxolone : A 1,3-benzoxathiole having a hydroxy substituent at the 6-position.	2.6	1	0	benzoxathiole	antiseborrheic
gr 117289 GR 117289: angiotensin AT1 receptor antagonist; structure given in first source. zolasartan : A member of the class of 1-benzofurans that is 3-bromo-1-benzofuran which is substituted by a 2-(1H-tetrazol-5-yl)phenyl group at position 2 and by a (2-butyl-5-carboxy-4-chloro-1H-imidazol-1-yl)methyl group at position 5. It is an angiotensin II receptor type 1 (AT1) antagonist and was in clinical trials for the treatment of hypertension (now discontinued).	3.15	1	0	1-benzofurans; biaryl; imidazolyl carboxylic acid; monocarboxylic acid; organobromine compound; organochlorine compound; tetrazoles	angiotensin receptor antagonist; antihypertensive agent
ubenimex ubenimex: growth inhibitor	3.15	1	0
honokiol [no description available]	2.76	2	0	biphenyls
nobiletin nobiletin : A methoxyflavone that is flavone substituted by methoxy groups at positions 5, 6, 7, 8, 3' and 4' respectively.	2.6	1	0	methoxyflavone	antineoplastic agent; plant metabolite
lycorine lycorine: from bulbs of LYCORIS & other plants; RN given refers to (1 alpha,2 beta)-isomer; structure in Merck Index, 9th ed, #5444. lycorine : An indolizidine alkaloid that is 3,12-didehydrogalanthan substituted by hydroxy groups at positions and 2 and a methylenedioxy group across positions 9 and 10. Isolated from Crinum asiaticum, it has been shown to exhibit antimalarial activity.	2.6	1	0	indolizidine alkaloid	anticoronaviral agent; antimalarial; plant metabolite; protein synthesis inhibitor
leupeptin [no description available]	2.6	1	0	aldehyde; tripeptide	bacterial metabolite; calpain inhibitor; cathepsin B inhibitor; EC 3.4.21.4 (trypsin) inhibitor; serine protease inhibitor
grepafloxacin grepafloxacin: structure in first source	2.05	1	0	fluoroquinolone antibiotic; quinolines; quinolone antibiotic
tetrandrine tetrandrine: a bisbenzylisoquinoline that exhibits antifibrogenic activity	2.6	1	0	bisbenzylisoquinoline alkaloid; isoquinolines
calpeptin [no description available]	2.6	1	0	amino acid amide
fangchinoline [no description available]	2.6	1	0	aromatic ether; bisbenzylisoquinoline alkaloid; macrocycle	anti-HIV-1 agent; anti-inflammatory agent; antineoplastic agent; antioxidant; neuroprotective agent; plant metabolite
maslinic acid (2Alpha,3beta)-2,3-dihydroxyolean-12-en-28-oic acid: from Luehea divaricata and Agrimonia eupatoria	2.6	1	0	dihydroxy monocarboxylic acid; pentacyclic triterpenoid	anti-inflammatory agent; antineoplastic agent; antioxidant; plant metabolite
2-naphthylisothiocyanate [no description available]	2.05	1	0
atovaquone Atovaquone: A hydroxynaphthoquinone that has antimicrobial activity and is being used in antimalarial protocols.. atovaquone : A naphthoquinone compound having a 4-(4-chlorophenyl)cyclohexyl group at the 2-position and a hydroxy substituent at the 3-position.	2.52	2	0	hydroxy-1,2-naphthoquinone
eletriptan eletriptan: 5-HT(1B/1D) receptor agonist; structure in first source. eletriptan : An N-alkylpyrrolidine, that is N-methylpyrrolidine in which the pro-R hydrogen at position 2 is replaced by a {5-[2-(phenylsulfonyl)ethyl]-1H-indol-3-yl}methyl group.	2.46	2	0	indoles; N-alkylpyrrolidine; sulfone	non-steroidal anti-inflammatory drug; serotonergic agonist; vasoconstrictor agent
rosiglitazone [no description available]	2.76	3	0	aminopyridine; thiazolidinediones	EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; insulin-sensitizing drug
flunisolide flunisolide: flunisolide HFA is a formulation of flunisolide using hydrofluoroalkane (HFA) as propellant in place of chlorofluorocarbon (CFC) ones	2.46	2	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; cyclic ketal; fluorinated steroid; primary alpha-hydroxy ketone	anti-asthmatic drug; anti-inflammatory drug; immunosuppressive agent
chloroquine diphosphate [no description available]	2.05	1	0
orphenadrine citrate orphenadrine citrate : A citrate salt which comprises equimolar amounts of orphenadrine and citric acid.	2.05	1	0	citrate salt	H1-receptor antagonist; muscarinic antagonist; muscle relaxant; NMDA receptor antagonist; parasympatholytic
ketorolac tromethamine Ketorolac Tromethamine: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is a non-steroidal anti-inflammatory agent used for analgesia for postoperative pain and inhibits cyclooxygenase activity.. ketorolac tromethamine : An organoammonium salt resulting from the mixture of equimolar amounts of ketorolac and tromethamine (tris). It has potent non-sedating analgesic and moderate anti-inflammatory effects. It is used in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis.	2.05	1	0	organoammonium salt	analgesic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor
clarithromycin Clarithromycin: A semisynthetic macrolide antibiotic derived from ERYTHROMYCIN that is active against a variety of microorganisms. It can inhibit PROTEIN SYNTHESIS in BACTERIA by reversibly binding to the 50S ribosomal subunits. This inhibits the translocation of aminoacyl transfer-RNA and prevents peptide chain elongation.. clarithromycin : The 6-O-methyl ether of erythromycin A, clarithromycin is a macrolide antibiotic used in the treatment of respiratory-tract, skin and soft-tissue infections. It is also used to eradicate Helicobacter pylori in the treatment of peptic ulcer disease. It prevents bacteria from growing by interfering with their protein synthesis.	2.74	3	0	macrolide antibiotic	antibacterial drug; environmental contaminant; protein synthesis inhibitor; xenobiotic
loganin [no description available]	2.6	1	0	beta-D-glucoside; cyclopentapyran; enoate ester; iridoid monoterpenoid; methyl ester; monosaccharide derivative; secondary alcohol	anti-inflammatory agent; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.2.1.20 (alpha-glucosidase) inhibitor; EC 3.4.23.46 (memapsin 2) inhibitor; neuroprotective agent; plant metabolite
n-(3,5-dichlorophenyl)succinimide N-(3,5-dichlorophenyl)succinimide: nephrotoxic; post-treatment enhanced induction of renal cell tumors in rats by dimethylnitrosamine, pre-treatment inhibited induction of tumors, & alone caused interstitial nephritis but no tumors	2.05	1	0	pyrrolidines
fibrinogen Fibrinogen: Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products.. D-iditol : The D-enantiomer of iditol.	8.43	1	1	iditol	fungal metabolite
moexipril [no description available]	2.52	2	0	peptide
phentolamine mesylate [no description available]	2.05	1	0
aucubin [no description available]	2.6	1	0	organic molecular entity	metabolite
oxybutynin hydrochloride [no description available]	2.05	1	0	hydrochloride
catalpol [no description available]	2.6	1	0	organic molecular entity	metabolite
cordium bepridil hydrochloride monohydrate : The hydrochloride monohydrate of bepridril.	2.05	1	0	hydrate; hydrochloride
lekoptin (S)-verapamil : A 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile that has S configuration.	2.52	2	0	2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile
tarenflurbil tarenflurbil: R-enantiomer of flurbiprofen but not a COX inhibitor; modulates NF-kB, gamma-secretase, amyloid beta-protein;	2.03	1	0	flurbiprofen
zofenopril zofenopril: structure given in first source; SQ 26900 refers to K salt & SQ 26991 to Ca salt. zofenopril : A proline derivative that is 4-(phenylsulfanyl)-L-proline in which the amine proton is replaced by a (2S)-3-(benzoylsulfanyl)-2-methylpropanoyl group. A prodrug for zofenoprilat.	3.85	3	0	aryl sulfide; L-proline derivative; N-acyl-L-amino acid; thioester	anticonvulsant; apoptosis inhibitor; cardioprotective agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug; vasodilator agent
lopinavir [no description available]	3.15	1	0	amphetamines; dicarboxylic acid diamide	anticoronaviral agent; antiviral drug; HIV protease inhibitor
glycylsarcosine glycylsarcosine : A dipeptide obtained by formal condensation of the carboxy group of glycine with the amino group of sarcosine.	3.15	1	0	dipeptide zwitterion; dipeptide
n-methyladenosine N-methyladenosine: is a inhibitor of cell differentiation. N(6)-methyladenosine : A methyladenosine compound with one methyl group attached to N(6) of the adenine nucleobase.	2.6	1	0	methyladenosine
1,2-bis(2-aminophenoxy)ethane-n,n,n',n'-tetraacetic acid 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid: structure in first source	2.05	1	0	polyamino carboxylic acid; tetracarboxylic acid	chelator
u 73122 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione: structure given in first source. U-73122 : An aza-steroid that is 3-O-methyl-17beta-estradiol in which the 17beta-hydroxy group is replaced by a 6-(maleimid-1-yl)hexylamino group. An inibitor of phospholipase C.	2.04	1	0	aromatic ether; aza-steroid; maleimides	EC 3.1.4.11 (phosphoinositide phospholipase C) inhibitor
1,4-dihydropyridine [no description available]	3.43	1	1
bosentan anhydrous Bosentan: A sulfonamide and pyrimidine derivative that acts as a dual endothelin receptor antagonist used to manage PULMONARY HYPERTENSION and SYSTEMIC SCLEROSIS.	2.45	2	0	primary alcohol; pyrimidines; sulfonamide	antihypertensive agent; endothelin receptor antagonist
sivelestat sivelestat: inhibitor of neutrophil elastase; structure given in first source	2.6	1	0	N-acylglycine; pivalate ester
pyronaridine [no description available]	2.6	1	0	aminoquinoline
perindopril Perindopril: An angiotensin-converting enzyme inhibitor. It is used in patients with hypertension and heart failure.. perindopril : An alpha-amino acid ester that is the ethyl ester of N-{(2S)-1-[(2S,3aS,7aS)-2-carboxyoctahydro-1H-indol-1-yl]-1-oxopropan-2-yl}-L-norvaline	7.44	7	4	alpha-amino acid ester; dicarboxylic acid monoester; ethyl ester; organic heterobicyclic compound	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
geniposide [no description available]	2.6	1	0	terpene glycoside
daidzin daidzin: a potent, selective, and reversible inhibitor of human mitochondrial aldehyde dehydrogenase. daidzein 7-O-beta-D-glucoside : A glycosyloxyisoflavone that is daidzein attached to a beta-D-glucopyranosyl residue at position 7 via a glycosidic linkage. It is used in the treatment of alcohol dependency (antidipsotropic).	2.6	1	0	7-hydroxyisoflavones 7-O-beta-D-glucoside; hydroxyisoflavone; monosaccharide derivative	plant metabolite
exp3174 losartan carboxylic acid: structure given in first source. losartan carboxylic acid : A biphenylyltetrazole that is losartan with the hydroxymethyl group at position 5 on the imidazole ring replaced with a carboxylic acid.	4.06	4	0	biphenylyltetrazole; imidazoles; organochlorine compound	metabolite
deoxyglucose Deoxyglucose: 2-Deoxy-D-arabino-hexose. An antimetabolite of glucose with antiviral activity.. deoxyglucose : A deoxyhexose comprising glucose having at least one hydroxy group replaced by hydrogen.	2.73	3	0
ibuprofen, (r)-isomer [no description available]	2.03	1	0	ibuprofen
pd 123177 PD 123177: nonpeptide angiotensin AII-2 inhibitor	2	1	0	diarylmethane
sophocarpine [no description available]	2.6	1	0
marimastat marimastat: a matrix metalloproteinase inhibitor active in patients with advanced carcinoma of the pancreas, prostate, or ovary. marimastat : A secondary carboxamide resulting from the foraml condensation of the carboxy group of (2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoic acid with the alpha-amino group of N,3-dimethyl-L-valinamide.	2.6	1	0	hydroxamic acid; secondary carboxamide	antineoplastic agent; matrix metalloproteinase inhibitor
elacridar Elacridar: inhibitor of MDR1 PROTEIN; structure given in first source	2.6	1	0
pramipexole Pramipexole: A benzothiazole derivative and dopamine agonist with antioxidant properties that is used in the treatment of PARKINSON DISEASE and RESTLESS LEGS SYNDROME.. pramipexole : A member of the class of benzothiazoles that is 4,5,6,7-tetrahydro-1,3-benzothiazole in which the hydrogens at the 2 and 6-pro-S-positions are substituted by amino and propylamino groups, respectively.	3.55	2	0	benzothiazoles; diamine	antidyskinesia agent; antiparkinson drug; dopamine agonist; radical scavenger
celastrol [no description available]	2.6	1	0	monocarboxylic acid; pentacyclic triterpenoid	anti-inflammatory drug; antineoplastic agent; antioxidant; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; Hsp90 inhibitor; metabolite
imatinib mesylate imatinib methanesulfonate : A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.	2.17	1	0	methanesulfonate salt	anticoronaviral agent; antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
almotriptan almotriptan : An indole compound having a 2-(dimethylamino)ethyl group at the 3-position and a (pyrrolidin-1-ylsulfonyl)methyl group at the 5-position.	2.03	1	0	indoles; sulfonamide; tertiary amine	non-steroidal anti-inflammatory drug; serotonergic agonist; vasoconstrictor agent
gefitinib [no description available]	2.45	2	0	aromatic ether; monochlorobenzenes; monofluorobenzenes; morpholines; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist
n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine N-(N-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine: inhibits calcium-activated neutral protease; see also record for E-64; RN given refers to (2-S-(2alpha,3beta)(R*)-isomer)	2.6	1	0	leucine derivative
n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine: structure given in first source; a selective A(3) adenosine receptor agonist. 3-iodobenzyl-5'-N-methylcarboxamidoadenosine : A derivative of adenosine in which the 5'-hydroxymethyl group is replaced by N-ethylcarboxamido and one of the hydrogens of the exocyclic amino function is substituted by a 3-iodobenzyl group.	3.23	1	0	adenosines; monocarboxylic acid amide; organoiodine compound	adenosine A3 receptor agonist
cgp 42112a CGP 42112A: a hexapeptide analog of angiotensin II; activation of Receptor, Angiotensin, Type 2 results in vasodilation. CGP-42112A : A hexapeptide consisting of L-tyrosine, L-lysine, L-histidine, L-proline and L-isoleucine amino acid residues coupled in sequence and in which the amino group of the L-tyrosyl residue is substituted by a (pyridin-3-ylcarbonyl)nitrilo group and in which the L-lysyl side chain amino group is substituted by a {N(2)-[(benzyloxy)carbonyl]-L-arginyl}nitrilo group. It is a potent angiotensin II receptor type 2 (AT2 receptor) agonist.	2.03	1	0	benzyl ester; oligopeptide; pyridinecarboxamide	angiotensin receptor agonist; anti-inflammatory agent; antineoplastic agent; neuroprotective agent; vasodilator agent
angiotensin ii, des-phe(8)- Ile(5)-angiotensin II (1-7) : An angiotensin compound consisting of the linear heptapeptide sequence L-Asp-L-Arg-L-Val-L-Tyr-L-Ile-L-His-L-Pro.	4.49	8	0	amino acid zwitterion; angiotensin	vasodilator agent
2-chloro-n(6)cyclopentyladenosine 2-chloro-N(6)cyclopentyladenosine: highly selective agonist at A1 adenosine receptors	3.23	1	0
n,n-dimethylarginine N,N-dimethylarginine: asymmetric dimethylarginine; do not confuse with N,N'-dimethylarginine. N(omega),N(omega)-dimethyl-L-arginine : A L-arginine derivative having two methyl groups both attached to the primary amino moiety of the guanidino group.	3.46	1	1	dimethylarginine; guanidines; L-arginine derivative; non-proteinogenic L-alpha-amino acid	EC 1.14.13.39 (nitric oxide synthase) inhibitor
vadimezan vadimezan : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by a 5,6-dimethyl-9-oxoxanthen-4-yl group.	2.6	1	0	monocarboxylic acid; xanthones	antineoplastic agent
peroxyoxalate [no description available]	2.05	1	0
e 64 E 64: cysteine protease inhibitor of microbial origin, which inhibits cathepsin B (EC 3.4.22.1) and cathepsin L (EC 3.4.22.-)	2.6	1	0	dicarboxylic acid monoamide; epoxy monocarboxylic acid; guanidines; L-leucine derivative; zwitterion	antimalarial; antiparasitic agent; protease inhibitor
methotrexate [no description available]	9.42	6	0	dicarboxylic acid; monocarboxylic acid amide; pteridines	abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent
exp7711 EXP7711: to search, use E#P7711(nm); angiotensin II receptor antagonist; structure given in first source	1.99	1	0
olmesartan medoxomil Olmesartan Medoxomil: An ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to manage HYPERTENSION.	10.51	32	3	biphenyls
umifenovir umifenovir: an antiviral agent	2.6	1	0	indolyl carboxylic acid
sc 51316 SC 51316: structure given in first source; an angiotensin II receptor antagonist	3.15	1	0
safinamide safinamide: short-acting inhibitor of MOA-B; FCE 26743 is (S)-isomer, FCE 28073 is (R)-isomer; structure in first source	2.6	1	0	amino acid amide
3-((2'-carboxybiphenyl-4-yl)methyl)-2-cyclopropyl-7-methyl-3h-imidazo(4,5-b)pyridine 3-((2'-carboxybiphenyl-4-yl)methyl)-2-cyclopropyl-7-methyl-3H-imidazo(4,5-b)pyridine: a non-peptide angiotensin II-receptor antagonist; structure given in first source	3.15	1	0
a 81988 A 81988: angiotensin II antagonist selective for type 1 receptors	3.15	1	0
ilomastat CS 610: matrix metalloproteinase inhibitor; structure in first source. ilomastat : An N-acyl-amino acid obtained by formal condensation of the carboxy group of (2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoic acid with the amino group of N-methyl-L-tryptophanamide. A cell permeable broad-spectrum matrix metalloproteinase (MMP) inhibitor	2.6	1	0	hydroxamic acid; L-tryptophan derivative; N-acyl-amino acid	anti-inflammatory agent; antibacterial agent; antineoplastic agent; EC 3.4.24.24 (gelatinase A) inhibitor; neuroprotective agent
ici d8731 ICI D8731: structure given in first source; an angiotensin II receptor antagonist	3.15	1	0
forasartan forasartan: structure given in first source; an angiotensin AT(1) receptor antagonist; angiotensin II receptor antagonist; used in treatment of congestive heart failure. forasartan : A member of the class of pyridines that is pyridine which is substituted at positions 2 and 5 by o-(tetrazol-5-yl)phenyl and (3,5-dibutyl-1,2,4-triazol-1-yl)methyl groups, respectively. It is a nonpeptide antagonist of angiotensin II, type 1 (AT1) receptors, used for the treatment of hypertension.	3.15	1	0	benzenes; pyridines; tetrazoles; triazoles	angiotensin receptor antagonist; antihypertensive agent
up 269-6 UP 269-6: structure given in first source; angiotensin receptor antagonist	3.15	1	0
omega-n-methylarginine omega-N-Methylarginine: A competitive inhibitor of nitric oxide synthetase.. N(omega)-methyl-L-arginine : A L-arginine derivative with a N(omega)-methyl substituent.	2.08	1	0	amino acid zwitterion; arginine derivative; guanidines; L-arginine derivative; non-proteinogenic L-alpha-amino acid
mk 996 MK 996: an AT1-selective angiotensin II receptor antagonist; structure given in first source	3.15	1	0
escitalopram Escitalopram: S-enantiomer of CITALOPRAM. Belongs to a class of drugs known as SELECTIVE SEROTONIN REUPTAKE INHIBITORS, used to treat depression and generalized anxiety disorder.. escitalopram : A 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile that has S-configuration at the chiral centre. It is the active enantiomer of citalopram.	2.03	1	0	1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile	antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
atazanavir atazanavir : A heavily substituted carbohydrazide that is an antiretroviral drug of the protease inhibitor (PI) class used to treat infection of human immunodeficiency virus (HIV).	2.6	1	0	carbohydrazide	antiviral drug; HIV protease inhibitor
tariquidar [no description available]	3.15	1	0	benzamides
nsc-141549 [no description available]	2.05	1	0
levofloxacin Levofloxacin: The L-isomer of Ofloxacin.. levofloxacin : An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase.	4.25	5	0	9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; fluoroquinolone antibiotic; quinolone antibiotic	antibacterial drug; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; topoisomerase IV inhibitor
cox 189 lumiracoxib: a COX-2 inhibitor. lumiracoxib : An amino acid that is phenylacetic acid which is substituted at position 2 by the nitrogen of 2-chloro-6-fluoroaniline and at position 5 by a methyl group. A highly selective cyclooxygenase 2 inhibitor, it was briefly used for the treatment of osteoarthritis, but was withdrawn due to concersns of hepatotoxicity.	2.05	1	0	amino acid; monocarboxylic acid; organochlorine compound; organofluorine compound; secondary amino compound	cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
n-acetylglucopyranosylamine N-acetylglucopyranosylamine: structure given in first source	2.04	1	0
moxifloxacin Moxifloxacin: A fluoroquinolone that acts as an inhibitor of DNA TOPOISOMERASE II and is used as a broad-spectrum antibacterial agent.. moxifloxacin : A quinolone that consists of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid bearing a cyclopropyl substituent at position 1, a fluoro substitiuent at position 6, a (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl group at position 7 and a methoxy substituent at position 8. A member of the fluoroquinolone class of antibacterial agents.	2.03	1	0	aromatic ether; cyclopropanes; fluoroquinolone antibiotic; pyrrolidinopiperidine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antibacterial drug
vx 497 N-3-(3-(3-methoxy-4-oxazol-5-ylphenyl)ureido)benzylcarbamic acid tetrahydrofuran-3-yl ester: structure in first source	2.6	1	0
bcx 1812 [no description available]	2.6	1	0	3-hydroxy monocarboxylic acid; acetamides; cyclopentanols; guanidines	antiviral drug; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor
hyoscyamine Hyoscyamine: The 3(S)-endo isomer of atropine.. (S)-atropine : An atropine with a 2S-configuration.	2.07	1	0	tropane alkaloid
disopyramide, (s)-isomer [no description available]	2.03	1	0
naproxen Naproxen: An anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout.. naproxen : A methoxynaphthalene that is 2-methoxynaphthalene substituted by a carboxy ethyl group at position 6. Naproxen is a non-steroidal anti-inflammatory drug commonly used for the reduction of pain, fever, inflammation and stiffness caused by conditions such as osteoarthritis, kidney stones, rheumatoid arthritis, psoriatic arthritis, gout, ankylosing spondylitis, menstrual cramps, tendinitis, bursitis, and for the treatment of primary dysmenorrhea. It works by inhibiting both the COX-1 and COX-2 enzymes.	3.02	4	0	methoxynaphthalene; monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; gout suppressant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
isradipine, (s)-isomer [no description available]	2.03	1	0
telbivudine [no description available]	2.6	1	0	pyrimidine 2'-deoxyribonucleoside	antiviral drug; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
celastrol methyl ester celastrol methyl ester: isolated from Tripterygium wilfordii; potent inhibitory activity on both Kir2.1 and ERG1 potassium channels, leading to LONG QT SYNDROME	2.6	1	0	carboxylic ester
resiquimod S 28463: structure given in first source	2.6	1	0	imidazoquinoline
tanshinone ii a tashinone IIA: a cardiovascular agent with antineoplastic activity; isolated from Salvia miltiorrhiza; structure in first source	2.6	1	0	abietane diterpenoid
anacardic acid anacardic acid: isolated from Anacardium occidentale; monophenol monooxygenase inhibitor. anacardic acid : A hydroxybenzoic acid that is salicylic acid substituted by a pentadecyl group at position 6. It is a major component of cashew nut shell liquid and exhibits an extensive range of bioactivities.	2.6	1	0	hydroxy monocarboxylic acid; hydroxybenzoic acid	anti-inflammatory agent; antibacterial agent; anticoronaviral agent; apoptosis inducer; EC 2.3.1.48 (histone acetyltransferase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; neuroprotective agent; plant metabolite
varenicline Varenicline: A benzazepine derivative that functions as an ALPHA4-BETA2 NICOTINIC RECEPTOR partial agonist. It is used for SMOKING CESSATION.. varenicline : An organic heterotetracyclic compound that acts as a partial agonist for nicotinic cholinergic receptors and is used (in the form of its tartate salt) as an aid to giving up smoking.	3.15	1	0
biotin vitamin B7 : Any member of a group of vitamers that belong to the chemical structural class called biotins that exhibit biological activity against vitamin B7 deficiency. Vitamin B7 deficiency is very rare in individuals who take a normal balanced diet. Foods rich in biotin are egg yolk, liver, cereals, vegetables (spinach, mushrooms) and rice. Symptoms associated with vitamin B7 deficiency include thinning hair, scaly skin rashes around eyes, nose and mouth, and brittle nails. The vitamers include biotin and its ionized and salt forms.	2.05	1	0	biotins; vitamin B7	coenzyme; cofactor; Escherichia coli metabolite; fundamental metabolite; human metabolite; mouse metabolite; nutraceutical; prosthetic group; Saccharomyces cerevisiae metabolite
angiotensin ii Giapreza: injectable form of angiotensin II used to increase blood pressure in adult patients with septic or other distributive shock. Ile(5)-angiotensin II : An angiotensin II that acts on the central nervous system (PDB entry: 1N9V).	9.93	69	3	amino acid zwitterion; angiotensin II	human metabolite
migalastat migalastat: a potent inhibitor of glycolipid biosynthesis	2.6	1	0	piperidines
sb 203580 [no description available]	2.11	1	0	imidazoles; monofluorobenzenes; pyridines; sulfoxide	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector; Hsp90 inhibitor; neuroprotective agent
erlotinib [no description available]	2.6	1	0	aromatic ether; quinazolines; secondary amino compound; terminal acetylenic compound	antineoplastic agent; epidermal growth factor receptor antagonist; protein kinase inhibitor
me 3221 ME 3221: an angiotensin II receptor antagonist; structure given in first source	3.15	1	0
limonin [no description available]	2.6	1	0	epoxide; furans; hexacyclic triterpenoid; lactone; limonoid; organic heterohexacyclic compound	inhibitor; metabolite; volatile oil component
ketoprofen [no description available]	2.03	1	0
l 158809 L 158809: RN & structure given in first source; angiotensin receptor antagonist	3.15	1	0
scutellarin scutellarin: see scutellarein for aglycone. scutellarin : The glycosyloxyflavone which is the 7-O-glucuronide of scutellarein.	2.6	1	0	glucosiduronic acid; glycosyloxyflavone; monosaccharide derivative; trihydroxyflavone	antineoplastic agent; proteasome inhibitor
aflatoxin b1 Aflatoxin B1: A potent hepatotoxic and hepatocarcinogenic mycotoxin produced by the Aspergillus flavus group of fungi. It is also mutagenic, teratogenic, and causes immunosuppression in animals. It is found as a contaminant in peanuts, cottonseed meal, corn, and other grains. The mycotoxin requires epoxidation to aflatoxin B1 2,3-oxide for activation. Microsomal monooxygenases biotransform the toxin to the less toxic metabolites aflatoxin M1 and Q1.. aflatoxin B1 : An aflatoxin having a tetrahydrocyclopenta[c]furo[3',2':4,5]furo[2,3-h]chromene skeleton with oxygen functionality at positions 1, 4 and 11.	2.05	1	0	aflatoxin; aromatic ether; aromatic ketone	carcinogenic agent; human metabolite
etravirine [no description available]	2.6	1	0	aminopyrimidine; aromatic ether; dinitrile; organobromine compound	antiviral agent; HIV-1 reverse transcriptase inhibitor
chelidonine chelidonine: benzophenanthridine derived from scoulerine from Chelidonium majus; RN given refers to parent cpd (chelidonine, (5bR-(5balpha,6beta,12alpha))-isomer)	2.6	1	0	alkaloid antibiotic; alkaloid fundamental parent; benzophenanthridine alkaloid
troleandomycin Troleandomycin: A macrolide antibiotic that is similar to ERYTHROMYCIN.. troleandomycin : A semi-synthetic macrolide antibiotic obtained by acetylation of the three free hydroxy groups of oleandomycin. Troleandomycin is only found in individuals that have taken the drug.	2.76	3	0	acetate ester; epoxide; macrolide antibiotic; monosaccharide derivative; polyketide; semisynthetic derivative	EC 1.14.13.97 (taurochenodeoxycholate 6alpha-hydroxylase) inhibitor; xenobiotic
4-n-butylresorcinol 4-n-butylresorcinol: structure in first source	2.6	1	0	resorcinols
lapatinib [no description available]	2.05	1	0	furans; organochlorine compound; organofluorine compound; quinazolines	antineoplastic agent; tyrosine kinase inhibitor
darunavir Darunavir: An HIV PROTEASE INHIBITOR that is used in the treatment of AIDS and HIV INFECTIONS. Due to the emergence of ANTIVIRAL DRUG RESISTANCE when used alone, it is administered in combination with other ANTI-HIV AGENTS.. darunavir : An N,N-disubstituted benzenesulfonamide bearing an unsubstituted amino group at the 4-position, used for the treatment of HIV infection. A second-generation HIV protease inhibitor, darunavir was designed to form robust interactions with the protease enzyme from many strains of HIV, including those from treatment-experienced patients with multiple resistance mutations to other protease inhibitors.	2.6	1	0	carbamate ester; furofuran; sulfonamide	antiviral drug; HIV protease inhibitor
dapivirine Dapivirine: effectively prevented human immunodeficiency virus (HIV) infection in cocultures of monocyte-derived dendritic cells and T cells, representing primary targets in sexual transmission	2.6	1	0
sorafenib [no description available]	7.1	1	0	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; phenylureas; pyridinecarboxamide	angiogenesis inhibitor; anticoronaviral agent; antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; ferroptosis inducer; tyrosine kinase inhibitor
fludrocortisone acetate fludrocortisone acetate : An acetate ester resulting from the formal condensation of the primary hydroxy group of fludrocortisone with acetic acid. A synthetic corticosteroid, it has glucocorticoid actions about 10 times as potent as hydrocortisone, while its mineralocorticoid actions are over 100 times as potent. It is used in partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison's disease and for the treatment of salt-losing adrenal hyperplasia.	2.05	1	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(4) steroid; acetate ester; fluorinated steroid; mineralocorticoid; tertiary alpha-hydroxy ketone
3-nitrotyrosine 3-nitrotyrosine: RN given refers to parent cpd without isomeric designation. 3-nitrotyrosine : A nitrotyrosine comprising tyrosine having a nitro group at the 3-position on the phenyl ring.	2.08	1	0	2-nitrophenols; C-nitro compound; nitrotyrosine; non-proteinogenic alpha-amino acid
vincristine sulfate [no description available]	2.05	1	0	organic sulfate salt	antineoplastic agent; geroprotector
nsc 74859 NSC 74859: inhibits Stat3 binding activity; structure in first source. S3I-201 : An amidobenzoic acid obtained by formal condensation of the carboxy group of [(4-methylbenzene-1-sulfonyl)oxy]acetic acid with the amino group of 4-amino-2-hydroxybenzoic acid.	2.6	1	0	amidobenzoic acid; monohydroxybenzoic acid; tosylate ester	STAT3 inhibitor
berbamine [no description available]	2.6	1	0	bisbenzylisoquinoline alkaloid; isoquinolines
acivicin [no description available]	2.05	1	0	isoxazoles; non-proteinogenic L-alpha-amino acid; organochlorine compound	antileishmanial agent; antimetabolite; antimicrobial agent; antineoplastic agent; EC 2.3.2.2 (gamma-glutamyltransferase) inhibitor; glutamine antagonist; metabolite
u-104 SLC-0111: a carbonic anhydrase inhibitor; structure in first source	2.6	1	0
wortmannin [no description available]	2.03	1	0	acetate ester; cyclic ketone; delta-lactone; organic heteropentacyclic compound	anticoronaviral agent; antineoplastic agent; autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector; Penicillium metabolite; radiosensitizing agent
menthofuran menthofuran: RN given refers to cpd without isomeric designation; derives from cyclization of pulegone. menthofuran : A monoterpenoid that is 4,5,6,7-tetrahydro-1-benzofuran substituted by methyl groups at positions 3 and 6.	2.07	1	0	1-benzofurans; monoterpenoid	nematicide; plant metabolite
7-hydroxy-5-methyl-2-(2-oxopropyl)-8-[3,4,5-trihydroxy-6-(hydroxymethyl)-2-oxanyl]-1-benzopyran-4-one [no description available]	2.6	1	0	glycoside
bortezomib [no description available]	2.6	1	0	amino acid amide; L-phenylalanine derivative; pyrazines	antineoplastic agent; antiprotozoal drug; protease inhibitor; proteasome inhibitor
ritonavir Ritonavir: An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A.. ritonavir : An L-valine derivative that is L-valinamide in which alpha-amino group has been acylated by a [(2-isopropyl-1,3-thiazol-4-yl)methyl]methylcarbamoyl group and in which a hydrogen of the carboxamide amino group has been replaced by a (2R,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl group. A CYP3A inhibitor and antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS, it is often used as a fixed-dose combination with another protease inhibitor, lopinavir. Also used in combination with dasabuvir sodium hydrate, ombitasvir and paritaprevir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.	4.1	4	0	1,3-thiazoles; carbamate ester; carboxamide; L-valine derivative; ureas	antiviral drug; environmental contaminant; HIV protease inhibitor; xenobiotic
tizoxanide tizoxanide: major metabolite of nitazoxanide; structure in first source	2.6	1	0	salicylamides
tryptoquivaline fumitremorgin C : An organic heteropentacyclic compound that is a mycotoxic indole alkaloid produced by several fungi. A potent and specific inhibitor of the breast cancer resistance protein multidrug transporter.	3.15	1	0	aromatic ether; indole alkaloid; organic heteropentacyclic compound	breast cancer resistance protein inhibitor; mycotoxin
dihydropyridines Dihydropyridines: Pyridine moieties which are partially saturated by the addition of two hydrogen atoms in any position.	11.91	53	23
bradykinin [no description available]	2.01	1	0	oligopeptide	human blood serum metabolite; vasodilator agent
glucosamine D-glucosamine : An amino sugar whose structure comprises D-glucose having an amino substituent at position 2.. 2-amino-2-deoxy-D-glucopyranose : A D-glucosamine whose structure comprises D-glucopyranose having an amino substituent at position 2.	2.45	2	0	D-glucosamine	Escherichia coli metabolite; geroprotector; mouse metabolite
elastin [no description available]	2.05	1	0	oligopeptide
ouabain Ouabain: A cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like DIGITALIS. It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-EXCHANGING ATPASE.. cardiac glycoside : Steroid lactones containing sugar residues that act on the contractile force of the cardiac muscles.. ouabain : A steroid hormone that is a multi-hydroxylated alpha-L-rhamnosyl cardenoloide. It binds to and inhibits the plasma membrane Na(+)/K(+)-ATPase (sodium pump). It has been isolated naturally from Strophanthus gratus.	3.15	1	0	11alpha-hydroxy steroid; 14beta-hydroxy steroid; 5beta-hydroxy steroid; alpha-L-rhamnoside; cardenolide glycoside; steroid hormone	anti-arrhythmia drug; cardiotonic drug; EC 2.3.3.1 [citrate (Si)-synthase] inhibitor; EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; ion transport inhibitor; plant metabolite
puromycin [no description available]	2.05	1	0	puromycins	antiinfective agent; antimicrobial agent; antineoplastic agent; EC 3.4.11.14 (cytosol alanyl aminopeptidase) inhibitor; EC 3.4.14.2 (dipeptidyl-peptidase II) inhibitor; nucleoside antibiotic; protein synthesis inhibitor
taurolithocholic acid Taurolithocholic Acid: A bile salt formed in the liver from lithocholic acid conjugation with taurine, usually as the sodium salt. It solubilizes fats for absorption and is itself absorbed. It is a cholagogue and choleretic.. taurolithocholic acid : The bile acid taurine conjugate of lithocholic acid.	2.05	1	0	bile acid taurine conjugate; monocarboxylic acid amide	human metabolite
(+)-limonene (4R)-limonene : An optically active form of limonene having (4R)-configuration.	2.05	1	0	limonene	plant metabolite
arbutin hydroquinone O-beta-D-glucopyranoside : A monosaccharide derivative that is hydroquinone attached to a beta-D-glucopyranosyl residue at position 4 via a glycosidic linkage.	2.6	1	0	beta-D-glucoside; monosaccharide derivative	Escherichia coli metabolite; plant metabolite
quinidine Quinidine: An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.. quinidine : A cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy.	4.27	5	0	cinchona alkaloid	alpha-adrenergic antagonist; anti-arrhythmia drug; antimalarial; drug allergen; EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor; EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; muscarinic antagonist; P450 inhibitor; potassium channel blocker; sodium channel blocker
conessine conessine : A steroid alkaloid that is con-5-enine substituted by a N,N-dimethylamino group at position 3. It has been isolated from the plant species of the family Apocynaceae.	2.6	1	0	steroid alkaloid; tertiary amino compound	antibacterial agent; antimalarial; H3-receptor antagonist; plant metabolite
meropenem Meropenem: A thienamycin derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of bacterial infections, including infections in immunocompromised patients.. meropenem : A carbapenemcarboxylic acid in which the azetidine and pyrroline rings carry 1-hydroxymethyl and in which the azetidine and pyrroline rings carry 1-hydroxymethyl and 5-(dimethylcarbamoyl)pyrrolidin-3-ylthio substituents respectively.	2.07	1	0	alpha,beta-unsaturated monocarboxylic acid; carbapenemcarboxylic acid; organic sulfide; pyrrolidinecarboxamide	antibacterial agent; antibacterial drug; drug allergen
griseofulvin Griseofulvin: An antifungal agent used in the treatment of TINEA infections.. griseofulvin : An oxaspiro compound produced by Penicillium griseofulvum. It is used by mouth as an antifungal drug for infections involving the scalp, hair, nails and skin that do not respond to topical treatment.	2.05	1	0	1-benzofurans; antibiotic antifungal drug; benzofuran antifungal drug; organochlorine compound; oxaspiro compound	antibacterial agent; Penicillium metabolite
cefoxitin Cefoxitin: A semisynthetic cephamycin antibiotic resistant to beta-lactamase.. cefoxitin : A semisynthetic cephamycin antibiotic which, in addition to the methoxy group at the 7alpha position, has 2-thienylacetamido and carbamoyloxymethyl side-groups. It is resistant to beta-lactamase.	2.05	1	0	beta-lactam antibiotic allergen; cephalosporin; cephamycin; semisynthetic derivative	antibacterial drug
digitoxin Digitoxin: A cardiac glycoside sometimes used in place of DIGOXIN. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665). digitoxin : A cardenolide glycoside in which the 3beta-hydroxy group of digitoxigenin carries a 2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl trisaccharide chain.	2.03	1	0	cardenolide glycoside	EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor
moxalactam disodium [no description available]	2.05	1	0
saquinavir Saquinavir: An HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases, and also inhibits CYTOCHROME P-450 CYP3A.. saquinavir : An aspartic acid derivative obtained by formal condensation of the primary amino group of (2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl]-3-hydroxy-1-phenylbutan-2-ylamine with the carboxy group of N(2)(-quinolin-2-ylcarbonyl)-L-asparagine. An inhibitor of HIV-1 protease.	3.88	3	0	L-asparagine derivative; quinolines	antiviral drug; HIV protease inhibitor
abacavir abacavir: a carbocyclic nucleoside with potent selective anti-HIV activity. abacavir : A 2,6-diaminopurine that is (1S)-cyclopent-2-en-1-ylmethanol in which the pro-R hydrogen at the 4-position is substituted by a 2-amino-6-(cyclopropylamino)-9H-purin-9-yl group. A nucleoside analogue reverse transcriptase inhibitor (NRTI) with antiretroviral activity against HIV, it is used (particularly as the sulfate) with other antiretrovirals in combination therapy of HIV infection.	2.78	3	0	2,6-diaminopurines	antiviral drug; drug allergen; HIV-1 reverse transcriptase inhibitor
mometasone furoate Mometasone Furoate: A pregnadienediol derivative ANTI-ALLERGIC AGENT and ANTI-INFLAMMATORY AGENT that is used in the management of ASTHMA and ALLERGIC RHINITIS. It is also used as a topical treatment for skin disorders.	2.05	1	0	11beta-hydroxy steroid; 2-furoate ester; 20-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid; organochlorine compound; steroid ester	anti-allergic agent; anti-inflammatory drug
metyrosine alpha-methyl-L-tyrosine : An L-tyrosine derivative that consists of L-tyrosine bearing an additional methyl substituent at position 2. An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma.	2.07	1	0	L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	antihypertensive agent; EC 1.14.16.2 (tyrosine 3-monooxygenase) inhibitor
nortriptyline hydrochloride [no description available]	2.05	1	0	organic tricyclic compound	geroprotector
erythromycin estolate Erythromycin Estolate: A macrolide antibiotic, produced by Streptomyces erythreus. It is the lauryl sulfate salt of the propionic ester of erythromycin. This erythromycin salt acts primarily as a bacteriostatic agent. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.	2.05	1	0	aminoglycoside sulfate salt; erythromycin derivative	enzyme inhibitor
kanamycin sulfate [no description available]	2.05	1	0	aminoglycoside sulfate salt	antibacterial drug; geroprotector
paromomycin sulfate paromomycin sulfate : An aminoglycoside sulfate salt resulting from the treatment of paromomycin with sulfuric acid. A broad-spectrum antibiotic, it is used for the treatment of acute and chronic intestinal protozoal infections, but is not effective for extraintestinal protozoal infections. It is also used as a therapeutic against visceral leishmaniasis.	2.05	1	0
linezolid [no description available]	2.52	2	0	acetamides; morpholines; organofluorine compound; oxazolidinone	antibacterial drug; protein synthesis inhibitor
cephaelin cephaelin: do not confuse with cephalin of brain; after emetine this is the most important alkaloid of ipecac; protein synthesis inhibitor. cephaeline : A pyridoisoquinoline comprising emetam having a hydroxy group at the 6'-position and methoxy substituents at the 7'-, 10- and 11-positions.	2.6	1	0	pyridoisoquinoline
naringin [no description available]	3.15	1	0	(2S)-flavan-4-one; 4'-hydroxyflavanones; dihydroxyflavanone; disaccharide derivative; neohesperidoside	anti-inflammatory agent; antineoplastic agent; metabolite
ochratoxin a ochratoxin A: structure in first source & in Merck, 9th ed, #6549. ochratoxin A : A phenylalanine derivative resulting from the formal condensation of the amino group of L-phenylalanine with the carboxy group of (3R)-5-chloro-8-hydroxy-3-methyl-1-oxo-3,4-dihydro-1H-2-benzopyran-7-carboxylic acid (ochratoxin alpha). It is among the most widely occurring food-contaminating mycotoxins, produced by Aspergillus ochraceus, Aspergillus carbonarius and Penicillium verrucosum.	2.05	1	0	isochromanes; monocarboxylic acid amide; N-acyl-L-phenylalanine; organochlorine compound; phenylalanine derivative	Aspergillus metabolite; calcium channel blocker; carcinogenic agent; mycotoxin; nephrotoxin; Penicillium metabolite; teratogenic agent
(-)-usnic acid (-)-usnic acid : The (-)-enantiomer of usnic acid.	2.6	1	0	usnic acid	EC 1.13.11.27 (4-hydroxyphenylpyruvate dioxygenase) inhibitor
acetylleucyl-leucyl-norleucinal acetylleucyl-leucyl-norleucinal: a proteasome inhibitor. acetylleucyl-leucyl-norleucinal : A tripeptide composed of N-acetylleucyl, leucyl and norleucinal residues joined in sequence.	2.6	1	0	aldehyde; tripeptide	cysteine protease inhibitor
temocaprilat temocaprilat: the diacid of temocapril; active metabolite of angiotensin converting enzyme inhibitor (CS-622); RN refers to (2S-(2alpha,6beta(R*))) isomer; structure in first source	2.72	3	0	non-proteinogenic alpha-amino acid
chloramphenicol palmitate chloramphenicol palmitate: RN given refers to ((R-(R,R))-isomer)	2.45	2	0	hexadecanoate ester
calcium pantothenate [no description available]	2.05	1	0	polymer
eplerenone Eplerenone: A spironolactone derivative and selective ALDOSTERONE RECEPTOR antagonist that is used in the management of HYPERTENSION and CONGESTIVE HEART FAILURE, post-MYOCARDIAL INFARCTION.	4.09	4	0	3-oxo-Delta(4) steroid; epoxy steroid; gamma-lactone; methyl ester; organic heteropentacyclic compound; oxaspiro compound; steroid acid ester	aldosterone antagonist; antihypertensive agent
temocapril hydrochloride temocapril hydrochloride: structure given in first source	4.67	6	1	dipeptide
doxorubicin hydrochloride [no description available]	2.05	1	0	anthracycline
maleic acid maleic acid: RN given refers to parent cpd(Z)-isomer which is maleic acid; all RR's given refer to (Z)-isomer; (E)-isomer is fumaric acid. maleic acid : A butenedioic acid in which the double bond has cis- (Z)-configuration.	2.05	1	0	butenedioic acid	algal metabolite; mouse metabolite; plant metabolite
trichostatin a trichostatin A: chelates zinc ion in the active site of histone deacetylases, resulting in preventing histone unpacking so DNA is less available for transcription; do not confuse with TRICHOSANTHIN which is a protein; found in STREPTOMYCES	2.1	1	0	antibiotic antifungal agent; hydroxamic acid; trichostatin	bacterial metabolite; EC 3.5.1.98 (histone deacetylase) inhibitor; geroprotector
tretinoin Tretinoin: An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).. retinoic acid : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraenoic acid substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).. all-trans-retinoic acid : A retinoic acid in which all four exocyclic double bonds have E- (trans-) geometry.	2.47	2	0	retinoic acid; vitamin A	anti-inflammatory agent; antineoplastic agent; antioxidant; AP-1 antagonist; human metabolite; keratolytic drug; retinoic acid receptor agonist; retinoid X receptor agonist; signalling molecule
resveratrol trans-resveratrol : A resveratrol in which the double bond has E configuration.	2.6	1	0	resveratrol	antioxidant; phytoalexin; plant metabolite; quorum sensing inhibitor; radical scavenger
cyanoginosin lr cyanoginosin LR: cyclic heptapeptide from cyanobacterium Microcystis aeruginosa. microcystin-LR : A microcystin consisting of D-alanyl, L-leucyl, (3S)-3-methyl-D-beta-aspartyl,L-arginyl, 2S,3S,4E,6E,8S,9S)-3-amino-4,5,6,7-tetradehydro-9-methoxy-2,6,8-trimethyl-10-phenyldecanoyl, D-gamma-glutamyl, and 2,3-didehydro-N-methylalanyl residues joined into a 25-membered macrocycle. Produced by the cyanobacterium Microcystis aeruginosa, it is the most studied of the microcystins.	2.05	1	0	microcystin	bacterial metabolite; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; environmental contaminant; xenobiotic
tacrolimus Tacrolimus: A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.. tacrolimus (anhydrous) : A macrolide lactam containing a 23-membered lactone ring, originally isolated from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis.	3.02	4	0	macrolide lactam	bacterial metabolite; immunosuppressive agent
cerivastatin cerivastatin: cerivastatin is the ((E)-(+))-isomer; structure given in first source. cerivastatin : (3R,5S)-3,5-dihydroxyhept-6-enoic acid in which the (7E)-hydrogen is substituted by a 4-(4-fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)pyridin-3-yl group. Formerly used (as its sodium salt) to lower cholesterol and prevent cardiovascular disease, it was withdrawn from the market worldwide in 2001 following reports of a severe form of muscle toxicity.	2.05	1	0	dihydroxy monocarboxylic acid; pyridines; statin (synthetic)
rosuvastatin rosuvastatin : A dihydroxy monocarboxylic acid that is (6E)-7-{4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-(propan-2-yl)pyrimidin-5-yl} hept-6-enoic acid carrying two hydroxy substituents at positions 3 and 5 (the 3R,5S-diastereomer).	2.07	1	0	dihydroxy monocarboxylic acid; monofluorobenzenes; pyrimidines; statin (synthetic); sulfonamide	anti-inflammatory agent; antilipemic drug; cardioprotective agent; CETP inhibitor; environmental contaminant; xenobiotic
thapsigargin Thapsigargin: A sesquiterpene lactone found in roots of THAPSIA. It inhibits SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES.. thapsigargin : An organic heterotricyclic compound that is a hexa-oxygenated 6,7-guaianolide isolated fron the roots of Thapsia garganica L., Apiaceae. A potent skin irritant, it is used in traditional medicine as a counter-irritant. Thapsigargin inhibits Ca(2+)-transporting ATPase mediated uptake of calcium ions into sarcoplasmic reticulum and is used in experimentation examining the impacts of increasing cytosolic calcium concentrations.	2.02	1	0	butyrate ester; organic heterotricyclic compound; sesquiterpene lactone	calcium channel blocker; EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor
mycophenolic acid Mycophenolic Acid: Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION.. mycophenolate : A monocarboxylic acid anion resulting from the removal of a proton from the carboxy group of mycophenolic acid.. mycophenolic acid : A member of the class of 2-benzofurans that is 2-benzofuran-1(3H)-one which is substituted at positions 4, 5, 6, and 7 by methyl, methoxy, (2E)-5-carboxy-3-methylpent-2-en-1-yl, and hydroxy groups, respectively. It is an antibiotic produced by Penicillium brevi-compactum, P. stoloniferum, P. echinulatum and related species. An immunosuppressant, it is widely used (partiularly as its sodium salt and as the 2-(morpholin-4-yl)ethyl ester prodrug, mycophenolate mofetil) to prevent tissue rejection following organ transplants and for the treatment of certain autoimmune diseases.	4.37	3	0	2-benzofurans; gamma-lactone; monocarboxylic acid; phenols	anticoronaviral agent; antimicrobial agent; antineoplastic agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; environmental contaminant; immunosuppressive agent; mycotoxin; Penicillium metabolite; xenobiotic
lycopene [no description available]	2.76	2	0	acyclic carotene	antioxidant; plant metabolite
zithromax Azithromycin: A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.. azithromycin : A macrolide antibiotic useful for the treatment of bacterial infections.	2.8	3	0	macrolide antibiotic	antibacterial drug; environmental contaminant; xenobiotic
drf 2725 ragaglitazar: a phenoxazine analogue of phenyl propanoic acid; Ragaglitazar is a coligand of PPARalpha and PPARgamma	2.05	1	0
gw 3965 GW 3965: a liver X receptor ligand	2.25	1	0	diarylmethane
t0901317 T0901317: an LXRalpha and LXRbeta agonist	2.25	1	0
diethylstilbestrol Diethylstilbestrol: A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed). diethylstilbestrol : An olefinic compound that is trans-hex-3-ene in which the hydrogens at positions 3 and 4 have been replaced by p-hydroxyphenyl groups.	2.07	1	0	olefinic compound; polyphenol	antifungal agent; antineoplastic agent; autophagy inducer; calcium channel blocker; carcinogenic agent; EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; endocrine disruptor; xenoestrogen
roflumilast [no description available]	2.6	1	0	aromatic ether; benzamides; chloropyridine; cyclopropanes; organofluorine compound	anti-asthmatic drug; phosphodiesterase IV inhibitor
L-cycloserine L-cycloserine : A 4-amino-1,2-oxazolidin-3-one that has S configuration. An antibiotic isolated from Erwinia uredovora.	2.6	1	0	4-amino-1,2-oxazolidin-3-one	anti-HIV agent; anticonvulsant; EC 2.3.1.50 (serine C-palmitoyltransferase) inhibitor
h 89 N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide: structure given in first source. N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide : A member of the class of isoquinolines that is the sulfonamide obtained by formal condensation of the sulfo group of isoquinoline-5-sulfonic acid with the primary amino group of N(1)-[3-(4-bromophenyl)prop-2-en-1-yl]ethane-1,2-diamine. It is a protein kinase A inhibitor.. (E)-N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide : A N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide in which the double bond adopts a trans-configuration.	2.6	1	0	N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide
imidazolidines [no description available]	3.85	2	1	azacycloalkane; imidazolidines; saturated organic heteromonocyclic parent
dactinomycin Dactinomycin: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)	2.47	2	0	actinomycin	mutagen
bevirimat bevirimat: an HIV inhibitor; disrupts late step in processing HIV Major Core Protein p24, preventing the capsid precursor p25 from being converted to mature capsid p24. bevirimat : A pentacyclic triterpenoid obtained by the formal condensation of 2,2-dimethylsuccinic acid with the 3-hydroxy group of betulinic acid. It is isolated from the Chinese herb Syzygium claviflorum. The first in the class of HIV-1 maturation inhibitors to be studied in humans, bevirimat was identified as a potent HIV drug candidate and several clinical trials were conducted, but development into a new drug was plagued by numerous resistance-related problems.	2.6	1	0	dicarboxylic acid monoester; monocarboxylic acid; pentacyclic triterpenoid	HIV-1 maturation inhibitor; metabolite
azaserine Azaserine: Antibiotic substance produced by various Streptomyces species. It is an inhibitor of enzymatic activities that involve glutamine and is used as an antineoplastic and immunosuppressive agent.. azaserine : A carboxylic ester resulting from the formal condensation of the carboxy group of diazoacetic acid with the alcoholic hydroxy group of L-serine. An antibiotic produced by a Streptomyces species.	2.05	1	0	carboxylic ester; diazo compound; L-serine derivative; non-proteinogenic L-alpha-amino acid	antifungal agent; antimetabolite; antimicrobial agent; antineoplastic agent; glutamine antagonist; immunosuppressive agent; metabolite
melphalan Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.. melphalan : A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring.	2.03	1	0	L-phenylalanine derivative; nitrogen mustard; non-proteinogenic L-alpha-amino acid; organochlorine compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent
benzyloxycarbonylleucyl-leucyl-leucine aldehyde benzyloxycarbonylleucyl-leucyl-leucine aldehyde: proteasome inhibitor. N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal : A tripeptide that is L-leucyl-L-leucyl-L-leucine in which the C-terminal carboxy group has been reduced to the corresponding aldehyde and the N-terminal amino group is protected as its benzyloxycarbonyl derivative.	2.6	1	0	amino aldehyde; carbamate ester; tripeptide	proteasome inhibitor
tenofovir tenofovir (anhydrous) : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens is replaced by a [(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(isopropyloxycarbonyloxymethyl) ester (disoproxil ester) prodrug is used as the fumaric acid salt in combination therapy for the treatment of HIV infection.	3.64	2	0	nucleoside analogue; phosphonic acids	antiviral drug; drug metabolite; HIV-1 reverse transcriptase inhibitor
posaconazole [no description available]	2.6	1	0	aromatic ether; conazole antifungal drug; N-arylpiperazine; organofluorine compound; oxolanes; triazole antifungal drug; triazoles	trypanocidal drug
gw 257406x maribavir: has antiviral activity against human cytomegalovirus	2.6	1	0
shikonin shikonin: a naphthazarin; has antineoplastic and angiogenesis inhibiting activities	2.6	1	0	hydroxy-1,4-naphthoquinone
4,4-difluoro-N-[(1S)-3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]-1-cyclohexanecarboxamide [no description available]	2.6	1	0	tropane alkaloid
cmx 001 [no description available]	2.6	1	0
amd 8664 [no description available]	2.6	1	0
bay 41-4109 BAY 41-4109: structure in first source	2.6	1	0
bay 57-1293 pritelivir: herpes simplex virus 1 helicase-primase inhibitor	2.6	1	0
2'-c-methylcytidine 2'-C-methylcytidine: structure in first source	2.6	1	0
isoxanthohumol isoxanthohumol: structure in first source	2.6	1	0	flavanones
arsenic trioxide Tetraarsenic Oxide: A form of As2O3 that exists as As4O6 in the solid state. It dissociates to As2O3 upon heating to the vapor phase above 800 degrees Celsius.	2.05	1	0	arsenic oxide	antineoplastic agent; insecticide
4-(4-chloro-2-methylphenoxy)-n-hydroxybutanamide 4-(4-chloro-2-methylphenoxy)-N-hydroxybutanamide: a c-FLIP inhibitor; structure in first source	2.6	1	0	aromatic ether
mecarbinate [no description available]	2.6	1	0
idarubicin hydrochloride [no description available]	2.05	1	0	anthracycline
carbenoxolone sodium Carbenoxolone: An agent derived from licorice root. It is used for the treatment of digestive tract ulcers, especially in the stomach. Antidiuretic side effects are frequent, but otherwise the drug is low in toxicity.	2.05	1	0	triterpenoid
cefpiramide cefpiramide: antipseudomonal cephalosporin derivative. cefpiramide : A third-generation cephalosporin antibiotic with [(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl and (R)-2-{[(4-hydroxy-6-methylpyridin-3-yl)carbonyl]amino}-2-(4-hydroxyphenyl)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton. It has a broad spectrum of antibacterial activity.	2.07	1	0	carboxylic acid; cephalosporin	antibacterial drug
chloroquine diphosphate [no description available]	2.03	1	0	chloroquine
dextromethadone D-methadone: an NMDA receptor antagonist analgesic that lacks opioid activity. dextromethadone : A 6-(dimethylamino)-4,4-diphenylheptan-3-one that has (S)-configuration. It is the less active enantiomer of methadone and has very little activity on opioid receptors and mainly responsible for the inhibition of hERG K+ channels and thus for cardiac toxicity. The drug is currently under clinical development for the treatment of major depressive disorder.	2.03	1	0	6-(dimethylamino)-4,4-diphenylheptan-3-one	NMDA receptor antagonist; opioid analgesic
acetyl-aspartyl-glutamyl-valyl-aspartal acetyl-aspartyl-glutamyl-valyl-aspartal: a capase inhibitor. Ac-Asp-Glu-Val-Asp-H : A tetrapeptide consisting of two L-aspartic acid residues, an L-glutamyl residue and an L-valine residue with an acetyl group at the N-terminal and with the C-terminal carboxy group reduced to an aldehyde. It is an inhibitor of caspase-3/7.	2.6	1	0	tetrapeptide	protease inhibitor
benidipine benidipine: RN refers to (R,R)-(+-)-isomer	3.44	1	1
leuprolide Leuprolide: A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE that regulates the synthesis and release of pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE.. leuprolide : An oligopeptide comprising pyroglutamyl, histidyl, tryptophyl, seryl, tyrosyl, D-leucyl, leucyl, arginyl, and N-ethylprolinamide residues joined in sequence. It is a synthetic nonapeptide analogue of gonadotropin-releasing hormone, and is used as a subcutaneous hydrogel implant (particularly as the acetate salt) for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty.	2.07	1	0	oligopeptide	anti-estrogen; antineoplastic agent; gonadotropin releasing hormone agonist
octotropine methylbromide octotropine methylbromide: minor descriptor (65-86); on line & INDEX MEDICUS search TROPANES (69-86); RN given refers to endo-isomer. anisotropine methylbromide : A quaternary ammonium salt resulting from the reaction of the amino group of anisotropine with methyl bromide.	2.6	1	0
propylthiouracil Propylthiouracil: A thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534). 6-propyl-2-thiouracil : A pyrimidinethione consisting of uracil in which the 2-oxo group is substituted by a thio group and the hydrogen at position 6 is substituted by a propyl group.	2.46	2	0	pyrimidinethione	antidote to paracetamol poisoning; antimetabolite; antioxidant; antithyroid drug; carcinogenic agent; EC 1.14.13.39 (nitric oxide synthase) inhibitor; hormone antagonist
ipratropium [no description available]	2.07	1	0
n(6)-cyclopentyladenosine [no description available]	3.23	1	0
mercaptopurine Mercaptopurine: An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.. purine-6-thiol : A thiol that is the tautomer of mercaptopurine.. mercaptopurine : A member of the class of purines that is 6,7-dihydro-1H-purine carrying a thione group at position 6. An adenine analogue, it is used in the treatment of acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), Crohn's disease, and ulcerative colitis.	2.8	3	0	aryl thiol; purines; thiocarbonyl compound	anticoronaviral agent; antimetabolite; antineoplastic agent
dexketoprofen dexketoprofen : A monocarboxylic acid that is (S)-hydratropic acid substituted at position 3 on the phenyl ring by a benzoyl group. A cyclooxygenase inhibitor, it is used to relieve short-term pain, such as muscular pain, dental pain and dysmenorrhoea.	2.03	1	0	benzophenones; monocarboxylic acid	cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
jrf 12 N2,N4-dibenzylquinazoline-2,4-diamine: a selective, potent, reversible, and ATP-competitive p97 inhibitor	2.6	1	0
3,4'-dihydroxyflavone 3,4'-dihydroxyflavone: an antioxidant; structure in first source	2.6	1	0
ondansetron, (s)-isomer [no description available]	2.03	1	0
3-(3,4-dimethoxyphenyl)propenoic acid 3-(3,4-dimethoxyphenyl)propenoic acid: structure given in first source; RN given refers to parent cpd. 3,4-dimethoxycinnamic acid : A methoxycinnamic acid that is trans-cinnamic acid substituted by methoxy groups at positions 3' and 4' respectively.	2.6	1	0	methoxycinnamic acid
isoferulic acid isoferulic acid: isomer of ferulic acid; structure. isoferulic acid : A ferulic acid consisting of trans-cinnamic acid bearing methoxy and hydroxy substituents at positions 4 and 3 respectively on the phenyl ring.	2.6	1	0	ferulic acids	antioxidant; biomarker; metabolite
cyclouridine cyclouridine: structure given in third source	2.6	1	0
flunarizine Flunarizine: Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy.	2.08	1	0	diarylmethane
thiothixene [no description available]	2.05	1	0	N-methylpiperazine	anticoronaviral agent
eszopiclone Eszopiclone: A pyridine, pyrazine, and piperazine derivative that is used as a HYPNOTIC AND SEDATIVE in the treatment of INSOMNIA.. eszopiclone : The (5S)- (active) enantiomer of zopiclone. Unlike almost all other hypnotic sedatives, which are approved only for the relief of short-term (6-8 weeks) insomnia, eszopiclone is approved by the U.S. Food and Drug Administration for long-term use.	2.03	1	0	zopiclone	central nervous system depressant; sedative
curcumin Curcumin: A yellow-orange dye obtained from tumeric, the powdered root of CURCUMA longa. It is used in the preparation of curcuma paper and the detection of boron. Curcumin appears to possess a spectrum of pharmacological properties, due primarily to its inhibitory effects on metabolic enzymes.. curcumin : A beta-diketone that is methane in which two of the hydrogens are substituted by feruloyl groups. A natural dyestuff found in the root of Curcuma longa.	2.6	1	0	aromatic ether; beta-diketone; diarylheptanoid; enone; polyphenol	anti-inflammatory agent; antifungal agent; antineoplastic agent; biological pigment; contraceptive drug; dye; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor; EC 1.8.1.9 (thioredoxin reductase) inhibitor; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; flavouring agent; food colouring; geroprotector; hepatoprotective agent; immunomodulator; iron chelator; ligand; lipoxygenase inhibitor; metabolite; neuroprotective agent; nutraceutical; radical scavenger
methimazole Methimazole: A thioureylene antithyroid agent that inhibits the formation of thyroid hormones by interfering with the incorporation of iodine into tyrosyl residues of thyroglobulin. This is done by interfering with the oxidation of iodide ion and iodotyrosyl groups through inhibition of the peroxidase enzyme.. methimazole : A member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen which is attached to a nitrogen.	2.45	2	0	1,3-dihydroimidazole-2-thiones	antithyroid drug
sulindac Sulindac: A sulfinylindene derivative prodrug whose sulfinyl moiety is converted in vivo to an active NSAID analgesic. Specifically, the prodrug is converted by liver enzymes to a sulfide which is excreted in the bile and then reabsorbed from the intestine. This helps to maintain constant blood levels with reduced gastrointestinal side effects.. sulindac : A monocarboxylic acid that is 1-benzylidene-1H-indene which is substituted at positions 2, 3, and 5 by methyl, carboxymethyl, and fluorine respectively, and in which the phenyl group of the benzylidene moiety is substituted at the para position by a methylsulfinyl group. It is a prodrug for the corresponding sulfide, a non-steroidal anti-inflammatory drug, used particularly in the treatment of acute and chronic inflammatory conditions.	2.47	2	0	monocarboxylic acid; organofluorine compound; sulfoxide	analgesic; antineoplastic agent; antipyretic; apoptosis inducer; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug; tocolytic agent
zucapsaicin [no description available]	2.6	1	0	methoxybenzenes; phenols
capsaicin ALGRX-4975: an injectable capsaicin (TRPV1 receptor agonist) formulation for longlasting pain relief. capsaicinoid : A family of aromatic fatty amides produced as secondary metabolites by chilli peppers.	2.46	2	0	capsaicinoid	non-narcotic analgesic; TRPV1 agonist; voltage-gated sodium channel blocker
terbinafine [no description available]	2.06	1	0	acetylenic compound; allylamine antifungal drug; enyne; naphthalenes; tertiary amine	EC 1.14.13.132 (squalene monooxygenase) inhibitor; P450 inhibitor; sterol biosynthesis inhibitor
nbd 556 [no description available]	2.6	1	0
thioguanine anhydrous Thioguanine: An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.. tioguanine : A 2-aminopurine that is the 6-thiono derivative of 2-amino-1,9-dihydro-6H-purine. Incorporates into DNA and inhibits synthesis. Used in the treatment of leukaemia.	2.54	2	0	2-aminopurines	anticoronaviral agent; antimetabolite; antineoplastic agent
(1R,2S)-tranylcypromine hydrochloride (1R,2S)-tranylcypromine hydrochloride : A hydrochloride obtained by combining (1R,2S)-tranylcypromine with one equivalent of hydrochloric acid.	2.05	1	0	hydrochloride
D-fructopyranose [no description available]	2.51	2	0	cyclic hemiketal; D-fructose; fructopyranose	sweetening agent
thioacetamide Thioacetamide: A crystalline compound used as a laboratory reagent in place of HYDROGEN SULFIDE. It is a potent hepatocarcinogen.. thioacetamide : A thiocarboxamide consiting of acetamide having the oxygen replaced by sulfur.	2.05	1	0	thiocarboxamide	hepatotoxic agent
digoxin Digoxin: A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666). digoxin : A cardenolide glycoside that is digitoxin beta-hydroxylated at C-12. A cardiac glycoside extracted from the foxglove plant, Digitalis lanata, it is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation, but the margin between toxic and therapeutic doses is small.	4.53	7	0	cardenolide glycoside; steroid saponin	anti-arrhythmia drug; cardiotonic drug; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; epitope
4,5,6,7-tetrachloroindan-1,3-dione 4,5,6,7-tetrachloroindan-1,3-dione: inhibits ubiquitin C-terminal hydrolase L1	2.6	1	0
streptozocin [no description available]	2.05	1	0
capsazepine capsazepine: modified capsaicin molecule; a capsaicin receptor antagonist. capsazepine : A benzazepine that is 2,3,4,5-tetrahydro-1H-2-benzazepine which is substituted by hydroxy groups at positions 7 and 8 and on the nitrogen atom by a 2-(p-chlorophenyl)ethylaminothiocarbonyl group. A synthetic analogue of capsaicin, it was the first reported capsaicin receptor antagonist.	2.05	1	0	benzazepine; catechols; monochlorobenzenes; thioureas	capsaicin receptor antagonist
tamoxifen [no description available]	2.76	3	0	stilbenoid; tertiary amino compound	angiogenesis inhibitor; antineoplastic agent; bone density conservation agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; estrogen antagonist; estrogen receptor antagonist; estrogen receptor modulator
srpin340 SRPIN340: Serine-Arginine-Rich Protein Kinase Inhibitor	2.6	1	0
pr-619 [no description available]	2.6	1	0
p5091 P5091: inhibits ubiquitin-specific protease 7; structure in first source	2.6	1	0
trovirdine trovirdine: HIV-1 reverse transcriptase inhibitor	2.6	1	0
estrone sulfate estrone sulfate: sulfoconjugated estrone; RN given refers to parent cpd	4.26	5	0	17-oxo steroid; steroid sulfate	human metabolite; mouse metabolite
hmr 3647 [no description available]	2.45	2	0
fti 277 [no description available]	2.6	1	0
u 0126 U 0126: protein kinase kinase inhibitor; structure in first source	2.51	2	0	aryl sulfide; dinitrile; enamine; substituted aniline	antineoplastic agent; antioxidant; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; osteogenesis regulator; vasoconstrictor agent
vicriviroc vicriviroc: structure in first source	2.6	1	0	(trifluoromethyl)benzenes
telaprevir [no description available]	2.6	1	0	cyclopentapyrrole; cyclopropanes; oligopeptide; pyrazines	antiviral drug; hepatitis C protease inhibitor; peptidomimetic
glycylproline Gly-Pro : A dipeptide consisting of L-proline having a glycyl residue attached to its alpha-amino group.	3.15	1	0	dipeptide zwitterion; dipeptide	metabolite
cv 11194 CV 11194: structure given in first source; an angiotensin II receptor antagonist	3.15	1	0
orlistat Orlistat: A lactone derivative of LEUCINE that acts as a pancreatic lipase inhibitor to limit the absorption of dietary fat; it is used in the management of obesity.. orlistat : A carboxylic ester resulting from the formal condensation of the carboxy group of N-formyl-L-leucine with the hydroxy group of (3S,4S)-3-hexyl-4-[(2S)-2-hydroxytridecyl]oxetan-2-one. A pancreatic lipase inhibitor, it is used as an anti-obesity drug.	2.6	1	0	beta-lactone; carboxylic ester; formamides; L-leucine derivative	anti-obesity agent; bacterial metabolite; EC 2.3.1.85 (fatty acid synthase) inhibitor; EC 3.1.1.3 (triacylglycerol lipase) inhibitor
quinine [no description available]	3.56	2	0	cinchona alkaloid	antimalarial; muscle relaxant; non-narcotic analgesic
4-(1h-imidazol-4-ylmethyl)piperidine 4-(1H-imidazol-4-ylmethyl)piperidine: structure in first source	3.23	1	0	piperidines
2-chloro-n(6)-(3-iodobenzyl)adenosine-5'-n-methyluronamide 2-chloro-N(6)-(3-iodobenzyl)adenosine-5'-N-methyluronamide: structure given in first source	3.23	1	0
milfasartan milfasartan: angiotensin I receptor antagonist; structure in first source	3.15	1	0
dasatinib N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1,3-thiazole-5-carboxamide: a dasatinib prodrug; structure in first source. dasatinib (anhydrous) : An aminopyrimidine that is 2-methylpyrimidine which is substituted at position 4 by the primary amino group of 2-amino-1,3-thiazole-5-carboxylic acid and at position 6 by a 4-(2-hydroxyethyl)piperazin-1-yl group, and in which the carboxylic acid group has been formally condensed with 2-chloro-6-methylaniline to afford the corresponding amide. A multi-targeted kinase inhibitor, it is used, particularly as the monohydrate, for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia. Note that the name 'dasatinib' is used to refer to the monohydrate (USAN) as well as to anhydrous dasatinib (INN).	2.6	1	0	1,3-thiazoles; aminopyrimidine; monocarboxylic acid amide; N-(2-hydroxyethyl)piperazine; N-arylpiperazine; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
tocainide, (s)-isomer [no description available]	2.03	1	0
dmp 811 DMP 811: angiotensin II receptor antagonist; structure given in first source	3.52	2	0
yya-021 YYA-021: an HIV entry inhibitor; structure in first source	2.6	1	0
alpha-chymotrypsin Chymotrypsin: A serine endopeptidase secreted by the pancreas as its zymogen, CHYMOTRYPSINOGEN and carried in the pancreatic juice to the duodenum where it is activated by TRYPSIN. It selectively cleaves aromatic amino acids on the carboxyl side.	2	1	0
sb 415286 3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione: a glycogen synthase kinase-3 inhibitor; structure in first source	2.6	1	0	C-nitro compound; maleimides; monochlorobenzenes; phenols; secondary amino compound; substituted aniline	antioxidant; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; neuroprotective agent
sitagliptin sitagliptin : A triazolopyrazine that exhibits hypoglycemic activity.	2.6	1	0	triazolopyrazine; trifluorobenzene	EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; environmental contaminant; hypoglycemic agent; serine proteinase inhibitor; xenobiotic
osteoprotegerin Osteoprotegerin: A secreted member of the TNF receptor superfamily that negatively regulates osteoclastogenesis. It is a soluble decoy receptor of RANK LIGAND that inhibits both CELL DIFFERENTIATION and function of OSTEOCLASTS by inhibiting the interaction between RANK LIGAND and RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B.	8.88	2	1	long-chain fatty acid
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1h-imidazol-2-yl)benzamide 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide: a TGF-beta type I receptor kinase activity inhibitor	2.05	1	0	benzamides; benzodioxoles; imidazoles; pyridines	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
tolcapone Tolcapone: A benzophenone and nitrophenol compound that acts as an inhibitor of CATECHOL O-METHYLTRANSFERASE, an enzyme involved in the metabolism of DOPAMINE and LEVODOPA. It is used in the treatment of PARKINSON DISEASE in patients for whom levodopa is ineffective or contraindicated.. tolcapone : Benzophenone substituted on one of the phenyl rings at C-3 and C-4 by hydroxy groups and at C-5 by a nitro group, and on the other phenyl ring by a methyl group at C-4. It is an inhibitor of catechol O-methyltransferase.	2.05	1	0	2-nitrophenols; benzophenones; catechols	antiparkinson drug; EC 2.1.1.6 (catechol O-methyltransferase) inhibitor
tak-220 TAK-220: structure in first source	2.6	1	0
jtk-303 [no description available]	2.6	1	0	aromatic ether; monochlorobenzenes; organofluorine compound; quinolinemonocarboxylic acid; quinolone	HIV-1 integrase inhibitor
nbd 557 [no description available]	2.6	1	0
bilirubin [no description available]	3.15	1	0	biladienes; dicarboxylic acid	antioxidant; human metabolite; mouse metabolite
dinoprost Dinoprost: A naturally occurring prostaglandin that has oxytocic, luteolytic, and abortifacient activities. Due to its vasocontractile properties, the compound has a variety of other biological actions.. prostaglandin F2alpha : A prostaglandins Falpha that is prosta-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15. It is a naturally occurring prostaglandin used to induce labor.	3.45	1	1	monocarboxylic acid; prostaglandins Falpha	human metabolite; mouse metabolite
calcitriol dihydroxy-vitamin D3: as a major in vitro metabolite of 1alpha,25-dihydroxyvitamin D3, produced in primary cultures of neonatal human keratinocytes	2.44	2	0	D3 vitamins; hydroxycalciol; triol	antineoplastic agent; antipsoriatic; bone density conservation agent; calcium channel agonist; calcium channel modulator; hormone; human metabolite; immunomodulator; metabolite; mouse metabolite; nutraceutical
retinol palmitate retinol palmitate: RN given refers to parent cpd; structure. retinyl palmitate : A palmitate ester of retinol with undefined geometry about the C=C bonds.. all-trans-retinyl palmitate : An all-trans-retinyl ester obtained by formal condensation of the carboxy group of palmitic (hexadecanoic acid) with the hydroxy group of all-trans-retinol. It is used in cosmetic products to treat various skin disorders such as acne, skin aging, wrinkles, dark spots, and also protect against psoriasis.	2.05	1	0	all-trans-retinyl ester; retinyl palmitate	antioxidant; Escherichia coli metabolite; human xenobiotic metabolite
5'-o-caffeoylquinic acid trans-5-O-caffeoyl-D-quinic acid : A cinnamate ester obtained by formal condensation of the carboxy group of trans-caffeic acid with the 5-hydroxy group of quinic acid.	2.6	1	0	cinnamate ester; cyclitol carboxylic acid	plant metabolite
luteolin-7-glucoside luteolin-7-glucoside: has both antiasthmatic and antineoplastic activities; has 3C protease inhibitory activity; isolated from Ligustrum lucidum. luteolin 7-O-beta-D-glucoside : A glycosyloxyflavone that is luteolin substituted by a beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage.	2.6	1	0	beta-D-glucoside; glycosyloxyflavone; monosaccharide derivative; trihydroxyflavone	antioxidant; plant metabolite
alprostadil [no description available]	2.07	1	0	prostaglandins E	anticoagulant; human metabolite; platelet aggregation inhibitor; vasodilator agent
cyclosporine [no description available]	2.6	1	0
vitamin d 2 Ergocalciferols: Derivatives of ERGOSTEROL formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. They differ from CHOLECALCIFEROL in having a double bond between C22 and C23 and a methyl group at C24.. vitamin D2 : A vitamin D supplement and has been isolated from alfalfa.	2.05	1	0	hydroxy seco-steroid; seco-ergostane; vitamin D	bone density conservation agent; nutraceutical; plant metabolite; rodenticide
rutin Hydroxyethylrutoside: Monohydroxyethyl derivative of rutin. Peripheral circulation stimulant used in treatment of venous disorders.	2.58	2	0	disaccharide derivative; quercetin O-glucoside; rutinoside; tetrahydroxyflavone	antioxidant; metabolite
bilirubin diglucuronide [no description available]	3.15	1	0
harmine Harmine: Alkaloid isolated from seeds of PEGANUM HARMALA; ZYGOPHYLLACEAE. It is identical to banisterine, or telepathine, from Banisteria caapi and is one of the active ingredients of hallucinogenic drinks made in the western Amazon region from related plants. It has no therapeutic use, but (as banisterine) was hailed as a cure for postencephalitic PARKINSON DISEASE in the 1920's.. harmine : A harmala alkaloid in which the harman skeleton is methoxy-substituted at C-7.	2.6	1	0	harmala alkaloid	anti-HIV agent; EC 1.4.3.4 (monoamine oxidase) inhibitor; metabolite
amphotericin b Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.	2.47	2	0	antibiotic antifungal drug; macrolide antibiotic; polyene antibiotic	antiamoebic agent; antiprotozoal drug; bacterial metabolite
clavulanic acid Clavulanic Acid: A beta-lactam antibiotic produced by the actinobacterium Streptomyces clavuligerus. It is a suicide inhibitor of bacterial beta-lactamase enzymes. Administered alone, it has only weak antibacterial activity against most organisms, but given in combination with other beta-lactam antibiotics it prevents antibiotic inactivation by microbial lactamase.. clavulanate : The conjugate base of clavulanic acid.. clavulanic acid : Antibiotic isolated from Streptomyces clavuligerus. It acts as a suicide inhibitor of bacterial beta-lactamase enzymes.	2.46	2	0	oxapenam	antibacterial drug; anxiolytic drug; bacterial metabolite; EC 3.5.2.6 (beta-lactamase) inhibitor
pulmicort Budesonide: A glucocorticoid used in the management of ASTHMA, the treatment of various skin disorders, and allergic RHINITIS.. budesonide : A glucocorticoid steroid having a highly oxygenated pregna-1,4-diene structure. It is used mainly in the treatment of asthma and non-infectious rhinitis and for treatment and prevention of nasal polyposis.	2.46	2	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; cyclic acetal; glucocorticoid; primary alpha-hydroxy ketone	anti-inflammatory drug; bronchodilator agent; drug allergen
eprosartan eprosartan: angiotensin II receptor antagonist. eprosartan : A member of the class of imidazoles and thiophenes that is an angiotensin II receptor antagonist used for the treatment of high blood pressure.	4.43	6	0	dicarboxylic acid; imidazoles; thiophenes	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
montelukast montelukast: a leukotriene D4 receptor antagonist	2.74	3	0	aliphatic sulfide; monocarboxylic acid; quinolines	anti-arrhythmia drug; anti-asthmatic drug; leukotriene antagonist
timolol maleate (S)-timolol maleate : The maleic acid salt of the active (S)-enantiomer of timolol, comprising equimolar amounts of (S)-timolol and maleic acid.	2.05	1	0	maleate salt	anti-arrhythmia drug; antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist
brompheniramine maleate brompheniramine maleate : The maleic acid salt of brompheniramine. A histamine H1 receptor antagonist, it is used for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis.	2.05	1	0	maleate salt	anti-allergic agent
chlorpheniramine maleate [no description available]	2.05	1	0	organic molecular entity
clemastine fumarate clemastine fumarate : The fumaric acid salt of clemastine. An antihistamine with antimuscarinic and moderate sedative properties, it is used for the symptomatic relief of allergic conditions such as rhinitis, urticaria, conjunctivitis and in pruritic (severe itching) skin conditions.	2.05	1	0	fumarate salt	anti-allergic agent; antipruritic drug; H1-receptor antagonist; muscarinic antagonist
methylergonovine maleate [no description available]	2.05	1	0	ergoline alkaloid	geroprotector
mycophenolate mofetil mycophenolate mofetil : A carboxylic ester resulting from the formal condensation between the carboxylic acid group of mycophenolic acid and the hydroxy group of 2-(morpholin-4-yl)ethanol. In the liver, it is metabolised to mycophenolic acid, an immunosuppressant for which it is a prodrug. It is widely used to prevent tissue rejection following organ transplants as well as for the treatment of certain autoimmune diseases.	2.6	1	0	carboxylic ester; ether; gamma-lactone; phenols; tertiary amino compound	anticoronaviral agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; immunosuppressive agent; prodrug
entacapone entacapone: structure given in first source. entacapone : A monocarboxylic acid amide that is N,N-diethylprop-2-enamide in which the hydrogen at position 2 is substituted by a cyano group and the hydrogen at the 3E position is substituted by a 3,4-dihydroxy-5-nitrophenyl group.	2.54	2	0	2-nitrophenols; catechols; monocarboxylic acid amide; nitrile	antidyskinesia agent; antiparkinson drug; central nervous system drug; EC 2.1.1.6 (catechol O-methyltransferase) inhibitor
amentoflavone [no description available]	2.6	1	0	biflavonoid; hydroxyflavone; ring assembly	angiogenesis inhibitor; antiviral agent; cathepsin B inhibitor; P450 inhibitor; plant metabolite
baicalein [no description available]	2.6	1	0	trihydroxyflavone	angiogenesis inhibitor; anti-inflammatory agent; antibacterial agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antioxidant; apoptosis inducer; EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; EC 4.1.1.17 (ornithine decarboxylase) inhibitor; ferroptosis inhibitor; geroprotector; hormone antagonist; plant metabolite; prostaglandin antagonist; radical scavenger
genkwanin genkwanin: structure. genkwanin : A monomethoxyflavone that is apigenin in which the hydroxy group at position 7 is methylated.	2.6	1	0	dihydroxyflavone; monomethoxyflavone	metabolite
hyperoside quercetin 3-O-beta-D-galactopyranoside : A quercetin O-glycoside that is quercetin with a beta-D-galactosyl residue attached at position 3. Isolated from Artemisia capillaris, it exhibits hepatoprotective activity.	2.6	1	0	beta-D-galactoside; monosaccharide derivative; quercetin O-glycoside; tetrahydroxyflavone	hepatoprotective agent; plant metabolite
mangostin mangostin: xanthone from rind of Garcinia mangostana Linn. fruit. alpha-mangostin : A member of the class of xanthones that is 9H-xanthene substituted by hydroxy group at positions 1, 3 and 6, a methoxy group at position 7, an oxo group at position 9 and prenyl groups at positions 2 and 8. Isolated from the stems of Cratoxylum cochinchinense, it exhibits antioxidant, antimicrobial and antitumour activities.	2.6	1	0	aromatic ether; phenols; xanthones	antimicrobial agent; antineoplastic agent; antioxidant; plant metabolite
3-methylquercetin isorhamnetin : A monomethoxyflavone that is quercetin in which the hydroxy group at position 3' is replaced by a methoxy group.	2.6	1	0	7-hydroxyflavonol; monomethoxyflavone; tetrahydroxyflavone	anticoagulant; EC 1.14.18.1 (tyrosinase) inhibitor; metabolite
kaempferide kaempferide: structure in first source. kaempferide : A monomethoxyflavone that is the 4'-O-methyl derivative of kaempferol.	2.6	1	0	7-hydroxyflavonol; monomethoxyflavone; trihydroxyflavone	antihypertensive agent; metabolite
orientin orientin: structure given in first source; RN given refers to the (D-glucopyranosyl)-isomer. orientin : A C-glycosyl compound that is luteolin substituted by a beta-D-glucopyranosyl moiety at position 8.	2.6	1	0	3'-hydroxyflavonoid; C-glycosyl compound; tetrahydroxyflavone	antioxidant; metabolite
scutellarein scutellarein: aglycone of scutellarin from Scutellaria baicalensis; carthamidin is 2S isomer of scutellarein; do not confuse with isoscutellarein and/or isocarthamidin which are respective regioisomers, or with the scutelarin protein. scutellarein : Flavone substituted with hydroxy groups at C-4', -5, -6 and -7.	2.6	1	0	tetrahydroxyflavone	metabolite
trans-2,3',4,5'-tetrahydroxystilbene trans-2,3',4,5'-tetrahydroxystilbene: hydroxystilbene oxyresveratrol	2.6	1	0	stilbenoid
polydatin trans-piceid : A stilbenoid that is trans-resveratrol substituted at position 3 by a beta-D-glucosyl residue.	2.6	1	0	beta-D-glucoside; monosaccharide derivative; polyphenol; stilbenoid	anti-arrhythmia drug; antioxidant; geroprotector; hepatoprotective agent; metabolite; nephroprotective agent; potassium channel modulator
chicoric acid chicoric acid: inhibits HIV-1 integrase	2.6	1	0	organooxygen compound	geroprotector; HIV-1 integrase inhibitor
acteoside acteoside: a protein kinase C inhibitor with hepatoprotective, anti-asthmatic, and analgesic activities; a phenylethanoid glycoside related to isoacteoside; from leaves of Lippia multiflora (Verbenaceae). acteoside : A glycoside that is the alpha-L-rhamnosyl-(1->3)-beta-D-glucoside of hydroxytyrosol in which the hydroxy group at position 4 of the glucopyranosyl moiety has undergone esterification by formal condensation with trans-caffeic acid.	2.6	1	0	catechols; cinnamate ester; disaccharide derivative; glycoside; polyphenol	anti-inflammatory agent; antibacterial agent; antileishmanial agent; neuroprotective agent; plant metabolite
flupenthixol cis-flupenthixol : A flupenthixol in which the double bond adopts a cis-configuration.	2.05	1	0	flupenthixol	dopaminergic antagonist
estradiol-17 beta-glucuronide 17beta-estradiol 17-glucosiduronic acid : A steroid glucosiduronic acid that consists of 17beta-estradiol having a beta-glucuronyl residue attached at position 17 via a glycosidic linkage.	3.56	2	0	3-hydroxy steroid; steroid glucosiduronic acid
8-epi-prostaglandin f2alpha 8-epi-prostaglandin F2alpha: a potent preglomerular vasoconstrictor acting principally through thromboxane A2 receptor activation. 8-epi-prostaglandin F2alpha : An isoprostane that is prostaglandin F2alpha having inverted stereochemistry at the 8-position.	3.45	1	1	F2-isoprostane	biomarker; bronchoconstrictor agent; vasoconstrictor agent
isotretinoin Isotretinoin: A topical dermatologic agent that is used in the treatment of ACNE VULGARIS and several other skin diseases. The drug has teratogenic and other adverse effects.. isotretinoin : A retinoic acid that is all-trans-retinoic acid in which the double bond which is alpha,beta- to the carboxy group is isomerised to Z configuration. A synthetic retinoid, it is used for the treatment of severe cases of acne and other skin diseases.	2.05	1	0	retinoic acid	antineoplastic agent; keratolytic drug; teratogenic agent
pitavastatin pitavastatin : A dihydroxy monocarboxylic acid that is (6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]hept-6-enoic acid in which the two hydroxy groups are located at positions 3 and 5 (the 3R,5S-stereoisomer). Used as its calcium salt for treatment of hypercholesterolemia (elevated levels of cholesterol in the blood) on patients unable to sufficiently lower their cholesterol levels by diet and exercise.	2.08	1	0	cyclopropanes; dihydroxy monocarboxylic acid; monofluorobenzenes; quinolines; statin (synthetic)	antioxidant
4-hydroxy-2-nonenal 4-hydroxy-2-nonenal: cytotoxic product from peroxidation of liver microsomal lipids; RN given refers to cpd without isomeric designation. 4-hydroxynon-2-enal : An enal consisting of non-2-ene having an oxo group at the 1-position and a hydroxy group at the 4-position.. 4-hydroxynonenal : A monounsaturated fatty aldehyde that is nonanal that has undergone dehydrogenation to introduce a double bond at any position in the aliphatic chain and in which a hydrogen at position 4 has been replaced by a hydroxy group.	2.97	4	0	4-hydroxynon-2-enal; 4-hydroxynonenal
codeine [no description available]	2.03	1	0	morphinane alkaloid; organic heteropentacyclic compound	antitussive; drug allergen; environmental contaminant; opioid analgesic; opioid receptor agonist; prodrug; xenobiotic
cyclosporine ramihyphin A: one of the metabolites produced by Fusarium sp. S-435; RN given refers to cpd with unknown MF	3.85	3	0	homodetic cyclic peptide	anti-asthmatic drug; anticoronaviral agent; antifungal agent; antirheumatic drug; carcinogenic agent; dermatologic drug; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; geroprotector; immunosuppressive agent; metabolite
phenoxybenzamine hydrochloride [no description available]	2.05	1	0	organic molecular entity
acitretin Acitretin: An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of ETRETINATE with the advantage of a much shorter half-life when compared with etretinate.. acitretin : A retinoid that consists of 3,7-dimethylnona-2,4,6,8-tetraenoic acid having a 4-methoxy-2,3,6-trimethylphenyl group attached at position 9.	2.05	1	0	acitretin; alpha,beta-unsaturated monocarboxylic acid; retinoid	keratolytic drug
cyproterone Cyproterone: An anti-androgen that, in the form of its acetate (CYPROTERONE ACETATE), also has progestational properties. It is used in the treatment of hypersexuality in males, as a palliative in prostatic carcinoma, and, in combination with estrogen, for the therapy of severe acne and hirsutism in females.	2.07	1	0	17alpha-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(4) steroid; chlorinated steroid; tertiary alpha-hydroxy ketone	androgen antagonist
dorzolamide dorzolamide: topically effective ocular hypotensive carbonic anhydrase inhibitor; RN refers to mono-HCl (4S-trans)-isomer. dorzolamide : 5,6-Dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide in which hydrogens at the 4 and 6 positions are substituted by ethylamino and methyl groups, respectively (4S, trans-configuration). A carbonic anhydrase inhibitor, it is used as the hydrochloride in ophthalmic solutions to lower increased intraocular pressure in the treatment of open-angle glaucoma and ocular hypertension.	2.6	1	0	sulfonamide; thiophenes	antiglaucoma drug; antihypertensive agent; EC 4.2.1.1 (carbonic anhydrase) inhibitor
hydrocodone Hydrocodone: Narcotic analgesic related to CODEINE, but more potent and more addicting by weight. It is used also as cough suppressant.. hydrocodone : A morphinane-like compound that is a semi-synthetic opioid synthesized from codeine.	2.07	1	0	morphinane-like compound; organic heteropentacyclic compound	antitussive; mu-opioid receptor agonist; opioid analgesic
hydromorphone Hydromorphone: An opioid analgesic made from MORPHINE and used mainly as an analgesic. It has a shorter duration of action than morphine.. hydromorphone : A morphinane alkaloid that is a hydrogenated ketone derivative of morphine. A semi-synthetic drug, it is a centrally acting pain medication of the opioid class.	2.46	2	0	morphinane alkaloid; organic heteropentacyclic compound	mu-opioid receptor agonist; opioid analgesic
ly 163892 loracarbef: 1-carbacephem antibiotic; has a broad spectrum of antimicrobial activity; structure given in first source; carbacephems differ from cephalosporins in the substitution of a sulfur atom in the dihydrothiazine ring with a methylene group to form a tetrahydropyridine ring. loracarbef : A synthetic "carba" analogue of cefaclor, with carbon replacing sulfur at position 1. Used to treat a wide range of infections caused by both gram-positive and gram-negative bacteria.	2.05	1	0	carbacephem; zwitterion	antibacterial drug; antimicrobial agent
nalmefene nalmefene: RN given refers to 5-alpha isomer	2.05	1	0	morphinane alkaloid
nalorphine Nalorphine: A narcotic antagonist with some agonist properties. It is an antagonist at mu opioid receptors and an agonist at kappa opioid receptors. Given alone it produces a broad spectrum of unpleasant effects and it is considered to be clinically obsolete.	3.23	1	0	morphinane alkaloid
naloxone Naloxone: A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors.. naloxone : A synthetic morphinane alkaloid that is morphinone in which the enone double bond has been reduced to a single bond, the hydrogen at position 14 has been replaced by a hydroxy group, and the methyl group attached to the nitrogen has been replaced by an allyl group. A specific opioid antagonist, it is used (commonly as its hydrochloride salt) to reverse the effects of opioids, both following their use of opioids during surgery and in cases of known or suspected opioid overdose.	2.46	2	0	morphinane alkaloid; organic heteropentacyclic compound; tertiary alcohol	antidote to opioid poisoning; central nervous system depressant; mu-opioid receptor antagonist
oxymorphone Oxymorphone: An opioid analgesic with actions and uses similar to those of MORPHINE, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092)	2.07	1	0	morphinane alkaloid
proscillaridin Proscillaridin: A cardiotonic glycoside isolated from Scilla maritima var. alba (Squill).	2.03	1	0	organic molecular entity
sirolimus Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.. sirolimus : A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.	2.03	1	0	antibiotic antifungal drug; cyclic acetal; cyclic ketone; ether; macrolide lactam; organic heterotricyclic compound; secondary alcohol	antibacterial drug; anticoronaviral agent; antineoplastic agent; bacterial metabolite; geroprotector; immunosuppressive agent; mTOR inhibitor
topiramate Topiramate: A sulfamate-substituted fructose analog that was originally identified as a hypoglycemic agent. It is used for the treatment of EPILEPSY and MIGRAINE DISORDERS, and may also promote weight loss.. topiramate : A hexose derivative that is 2,3:4,5-di-O-isopropylidene-beta-D-fructopyranose in which the hydroxy group has been converted to the corresponding sulfamate ester. It blocks voltage-dependent sodium channels and is used as an antiepileptic and for the prevention of migraine.	2.78	3	0	cyclic ketal; ketohexose derivative; sulfamate ester	anticonvulsant; sodium channel blocker
morphine Meconium: The thick green-to-black mucilaginous material found in the intestines of a full-term fetus. It consists of secretions of the INTESTINAL GLANDS; BILE PIGMENTS; FATTY ACIDS; AMNIOTIC FLUID; and intrauterine debris. It constitutes the first stools passed by a newborn.	3.86	3	0	morphinane alkaloid; organic heteropentacyclic compound; tertiary amino compound	anaesthetic; drug allergen; environmental contaminant; geroprotector; mu-opioid receptor agonist; opioid analgesic; plant metabolite; vasodilator agent; xenobiotic
fluticasone Fluticasone: A STEROID with GLUCOCORTICOID RECEPTOR activity that is used to manage the symptoms of ASTHMA; ALLERGIC RHINITIS, and ATOPIC DERMATITIS.. fluticasone : A trifluorinated corticosteroid used in the form of its propionate ester for treatment of allergic rhinitis.	2.03	1	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 3-oxo-Delta(4) steroid; corticosteroid; fluorinated steroid; thioester	anti-allergic agent; anti-asthmatic drug
fr 190997 FR 190997: structure given in first source	3.23	1	0
benzyloxycarbonyl-phe-ala-fluormethylketone cathepsin B inhibitor : A cysteine protease inhibitor which inhibits cathepsin B (EC 3.4.22.1).	2.6	1	0
n-(n-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester DAPT : A dipeptide consisting of alanylphenylglycine derivatised as a 3,5-difluorophenylacetamide at the amino terminal and a tert-butyl ester at the carboxy terminal. A gamma-secretase inhibitor.	2.58	2	0	carboxylic ester; difluorobenzene; dipeptide; tert-butyl ester	EC 3.4.23.46 (memapsin 2) inhibitor
nalbuphine Nalbuphine: A narcotic used as a pain medication. It appears to be an agonist at KAPPA RECEPTORS and an antagonist or partial agonist at MU RECEPTORS.	2.46	2	0	organic heteropentacyclic compound	mu-opioid receptor antagonist; opioid analgesic
nateglinide Nateglinide: A phenylalanine and cyclohexane derivative that acts as a hypoglycemic agent by stimulating the release of insulin from the pancreas. It is used in the treatment of TYPE 2 DIABETES.. nateglinide : An N-acyl-D-phenylalanine resulting from the formal condensation of the amino group of D-phenylalanine with the carboxy group of trans-4-isopropylcyclohexanecarboxylic acid. An orally-administered, rapidly-absorbed, short-acting insulinotropic agent, it is used for the treatment of type 2 diabetes mellitus.	2.07	1	0	phenylalanine derivative
pd 123319 PD123319 : An imidazopyridine consisting of 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine having 4-(dimethylamino)-3-methylbenzyl, diphenylacetyl and carboxy and groups at positions 1, 5 and 6 respectively	3.65	9	0	imidazopyridine	angiotensin receptor antagonist; endothelin receptor antagonist; vasoconstrictor agent
kn 93 KN 93: reduces dopamine content in PC12h cells. KN-93 : A sulfonamide resulting from the formal condensation of p-methoxybenzenesulfonic acid with the anilino nitrogen of 2-(aminomethyl)-N-(2-hydroxyethyl)aniline in which the hydrogens of the primary amino group have been replaced by methyl and p-chlorocinnamyl groups. KN-93 is a selective inhibitor of Ca(2+)/calmodulin-dependent protein kinase II.	2.1	1	0	monochlorobenzenes; monomethoxybenzene; primary alcohol; sulfonamide; tertiary amino compound	EC 2.7.11.17 (Ca(2+)/calmodulin-dependent protein kinase) inhibitor; geroprotector
casticin casticin: from fruit of Vitex rotundifolia; structure in second source. casticin : A tetramethoxyflavone that consists of quercetagetin in which the hydroxy groups at positions 3, 6, 7 and 4' have been replaced by methoxy groups. It has been isolated from Eremophila mitchellii.	2.6	1	0	dihydroxyflavone; tetramethoxyflavone	apoptosis inducer; plant metabolite
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one: isolated from the Chinese herb Scutellariae radix. oroxylin A : A dihydroxy- and monomethoxy-flavone in which the hydroxy groups are positioned at C-5 and C-7 and the methoxy group is at C-6.	2.6	1	0	dihydroxyflavone; monomethoxyflavone	antineoplastic agent; EC 1.14.13.39 (nitric oxide synthase) inhibitor
(E)-2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucoside 2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside: Tyrosinase inhibitor from Polygonum multiflorum; structure in first source. (E)-2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucoside : A stilbenoid that is trans-stilbene which has been substituted by hydroxy groups at positions 2, 3, 5, and 4', and in which the hydroxy group at positon 2 has then been converted to the corresponding the beta-D-glucoside.	2.6	1	0	beta-D-glucoside; resorcinols; stilbenoid	anti-inflammatory agent; antioxidant; apoptosis inhibitor; cardioprotective agent; cyclooxygenase 2 inhibitor; platelet aggregation inhibitor
furazolidone [no description available]	2.05	1	0
fluvoxamine Fluvoxamine: A selective serotonin reuptake inhibitor that is used in the treatment of DEPRESSION and a variety of ANXIETY DISORDERS.. fluvoxamine : An oxime O-ether that is benzene substituted by a (1E)-N-(2-aminoethoxy)-5-methoxypentanimidoyl group at position 1 and a trifluoromethyl group at position 4. It is a selective serotonin reuptake inhibitor that is used for the treatment of obsessive-compulsive disorder.	2.47	2	0	(trifluoromethyl)benzenes; 5-methoxyvalerophenone O-(2-aminoethyl)oxime	antidepressant; anxiolytic drug; serotonin uptake inhibitor
tyrphostin ag 555 [no description available]	2.6	1	0
bay 11-7082 (E)-3-tosylacrylonitrile : A nitrile that is acrylonitrile in which the hydrogen located beta,trans to the cyano group is replaced by a tosyl group. It is an inhibitor of cytokine-induced IkappaB-alpha phosphorylation in cells.	2.82	3	0	nitrile; sulfone	apoptosis inducer; EC 2.7.11.10 (IkappaB kinase) inhibitor; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor; non-steroidal anti-inflammatory drug; platelet aggregation inhibitor
(6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid : A dihydroxy monocarboxylic acid that is N-isopropylindole which is substituted at position 3 by a p-fluorophenyl group and at position 2 by a 6-carboxy-3,5-dihydroxyhex-1-en-1-yl group. It has four possible diastereoisomers.	2.74	3	0	dihydroxy monocarboxylic acid; indoles; organofluorine compound
pd 151746 [no description available]	2.6	1	0
octylmethoxycinnamate [no description available]	2.05	1	0	cinnamate ester
naltrexone Naltrexone: Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.. naltrexone : An organic heteropentacyclic compound that is naloxone substituted in which the allyl group attached to the nitrogen is replaced by a cyclopropylmethyl group. A mu-opioid receptor antagonist, it is used to treat alcohol dependence.	2.45	2	0	cyclopropanes; morphinane-like compound; organic heteropentacyclic compound	antidote to opioid poisoning; central nervous system depressant; environmental contaminant; mu-opioid receptor antagonist; xenobiotic
dextromethorphan Dextromethorphan: Methyl analog of DEXTRORPHAN that shows high affinity binding to several regions of the brain, including the medullary cough center. This compound is an NMDA receptor antagonist (RECEPTORS, N-METHYL-D-ASPARTATE) and acts as a non-competitive channel blocker. It is one of the widely used ANTITUSSIVES, and is also used to study the involvement of glutamate receptors in neurotoxicity.. dextromethorphan : A 6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene in which the sterocenters at positions 4a, 10 and 10a have S-configuration. It is a prodrug of dextrorphan and used as an antitussive drug for suppressing cough.	2.08	1	0	6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene	antitussive; environmental contaminant; neurotoxin; NMDA receptor antagonist; oneirogen; prodrug; xenobiotic
butorphanol Butorphanol: A synthetic morphinan analgesic with narcotic antagonist action. It is used in the management of severe pain.. butorphanol : Levorphanol in which a hydrogen at position 14 of the morphinan skeleton is substituted by hydroxy and one of the hydrogens of the N-methyl group is substituted by cyclopropyl. A semi-synthetic opioid agonist-antagonist analgesic, it is used as its (S,S)-tartaric acid salt for relief or moderate to severe pain.	2.07	1	0	morphinane alkaloid	antitussive; kappa-opioid receptor agonist; mu-opioid receptor agonist; opioid analgesic
delapril delapril: RN refers to HCl; structure given in first source	4.39	2	2	peptide
lisinopril Lisinopril: One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure.	2.81	3	0	dipeptide	EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
benazepril benazepril: structure given in first source. benazepril : A benzazepine that is benazeprilat in which the carboxy group of the 2-amino-4-phenylbutanoic acid moiety has been converted to the corresponding ethyl ester. It is used (generally as its hydrochloride salt) as a prodrug for the angiotensin-converting enzyme inhibitor benazeprilat in the treatment of hypertension and heart failure.	2.05	1	0	benzazepine; dicarboxylic acid monoester; ethyl ester; lactam	EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
ramipril Ramipril: A long-acting angiotensin-converting enzyme inhibitor. It is a prodrug that is transformed in the liver to its active metabolite ramiprilat.. ramipril : A dipeptide that is the prodrug for ramiprilat, the active metabolite obtained by hydrolysis of the ethyl ester group. An angiotensin-converting enzyme (ACE) inhibitor, used to treat high blood pressure and congestive heart failure.. quark : Quarks comprise one of two classes of the fundamental particles. Quarks possess fractional electric charges and are not observed in free state. The word "quark" first appears in James Joyce's Finnegans Wake and has been chosen by Murray Gell-Mann as a name for fundamental building blocks of particles.	6.61	8	2	azabicycloalkane; cyclopentapyrrole; dicarboxylic acid monoester; dipeptide; ethyl ester	bradykinin receptor B2 agonist; cardioprotective agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; matrix metalloproteinase inhibitor; prodrug
verteporfin (2R,2(1)S)-8-ethenyl-2(1),2(2)-bis(methoxycarbonyl)-17-(3-methoxy-3-oxopropyl)-2,7,12,18-tetramethyl-2,2(1)-dihydrobenzo[b]porphyrin-13-propanoic acid : The 2(1),2(2),17-trimethyl ester of (2R,2(1)S)-2(1),2(2)-dicarboxy-8-ethenyl-2,7,12,18-tetramethyl-2,2(1)-dihydrobenzo[b]porphyrin-13,17-dipropanoic acid.	2.6	1	0
batimastat batimastat: structure given in first source; a synthetic matrix metalloproteinase inhibitor. batimastat : A secondary carboxamide resulting from the formal condensation of the carboxy group of (2S,3R)-5-methyl-3-{[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]carbamoyl}-2-[(thiophen-2-ylsulfanyl)methyl]hexanoic acid with the amino group of hydroxylamine. It a broad-spectrum matrix metalloprotease inhibitor.	2.6	1	0	hydroxamic acid; L-phenylalanine derivative; organic sulfide; secondary carboxamide; thiophenes; triamide	angiogenesis inhibitor; antineoplastic agent; matrix metalloproteinase inhibitor
indinavir sulfate Indinavir: A potent and specific HIV protease inhibitor that appears to have good oral bioavailability.	2.57	2	0	dicarboxylic acid diamide; N-(2-hydroxyethyl)piperazine; piperazinecarboxamide	HIV protease inhibitor
enalapril Enalapril: An angiotensin-converting enzyme inhibitor that is used to treat HYPERTENSION and HEART FAILURE.. enalapril : A dicarboxylic acid monoester that is ethyl 4-phenylbutanoate in which a hydrogen alpha to the carboxy group is substituted by the amino group of L-alanyl-L-proline (S-configuration).	5.97	7	0	dicarboxylic acid monoester; dipeptide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; geroprotector; prodrug
vinblastine sulfate [no description available]	2.05	1	0
trientine hydrochloride [no description available]	2.05	1	0
fumarates Fumarates: Compounds based on fumaric acid.. fumarate(2-) : A C4-dicarboxylate that is the E-isomer of but-2-enedioate(2-)	7.78	11	2	butenedioate; C4-dicarboxylate	human metabolite; metabolite; Saccharomyces cerevisiae metabolite
cysteine Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3.	2.05	1	0	cysteinium	fundamental metabolite
dextromethorphan hydrobromide dextromethorphan hydrobromide : The hydrobromide and monohydrate of the antitussive drug dextromethorphan.	2.05	1	0	hydrate; hydrobromide
indinavir sulfate [no description available]	2.05	1	0	azaheterocycle sulfate salt
imidapril imidapril: structure given in first source. imidapril : A member of the class of imidazolidines that is (4S)-1-methyl-2-oxoimidazolidine-4-carboxylic acid in which the hydrogen of the imidazolidine nitrogen has been substituted by (1S)-1-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}ethyl group. It is the prodrug for imidaprilat, an ACE inhibitor used for the treatment of chronic heart failure.	8.85	2	1	dicarboxylic acid monoester; dipeptide; ethyl ester; imidazolidines; N-acylurea; secondary amino compound	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
cinanserin Cinanserin: A serotonin antagonist with limited antihistaminic, anticholinergic, and immunosuppressive activity.. cinanserin : An aryl sulfide that is (2E)-3-phenyl-N-(2-sulfanylphenyl)prop-2-enamide in which the hydrogen of the thiol group is substituted by a 3-(dimethylamino)propyl group. It is a 5-hydroxytryptamine receptor antagonist and an inhibitor of SARS-CoV replication.	2.25	1	0	aryl sulfide; cinnamamides; secondary carboxamide; tertiary amino compound	anticoronaviral agent; antiviral agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor
solanesol solanesol : A nonaprenol that is hexatriaconta-2,6,10,14,18,22,26,30,34-nonaen-1-ol substituted by 9 methyl groups at positions 3, 7, 11, 15, 19, 23, 27, 31 and 35 (the all-trans0stereoisomer).	2.6	1	0	nonaprenol; primary alcohol	plant metabolite
pepstatin pepstatin: inhibits the aspartic protease endothiapepsin	2.6	1	0	pentapeptide; secondary carboxamide	bacterial metabolite; EC 3.4.23.* (aspartic endopeptidase) inhibitor
ximelagatran ximelagatran: prodrug (via hydroxylation) of melagatran & a direct thrombin inhibitor; liver toxicity concerns so AZD0837 being developed to replace this. ximelagatran : A member of the class of azetidines that is melagatran in which the carboxylic acid group has been converted to the corresponding ethyl ester and in which the amidine group has been converted into the corresponding amidoxime. A prodrug for melagatran, ximelagatran was the first orally available direct thrombin inhibitor to be brought to market as an anticoagulant, but was withdrawn in 2006 following reports of it causing liver damage.	2.05	1	0	amidoxime; azetidines; carboxamide; ethyl ester; hydroxylamines; secondary amino compound; secondary carboxamide; tertiary carboxamide	anticoagulant; EC 3.4.21.5 (thrombin) inhibitor; prodrug; serine protease inhibitor
ceftriaxone [no description available]	2.48	2	0	1,2,4-triazines; 1,3-thiazoles; cephalosporin; oxime O-ether	antibacterial drug; drug allergen; EC 3.5.2.6 (beta-lactamase) inhibitor
l 685458 L 685458: a gamma-secretase inhibitor; structure in first source. L-685,458 : A peptide and carboxamide that is L-leucyl-L-phenylalaninamide, L-Leu-L-Phe-NH2, which has been acylated on the N-terminus by a Phe-Phe hydroxyethylene dipeptide isotere, 2R-benzyl-5S-tert-butoxycarbonylamino-4R-hydroxy-6-phenylhexanoic acid. Compounds based on the structure of L-685,458 are potent inhibitors of gamma-secretase, which mediates the final catalytic step that generates the amyloid beta-peptide (Abeta), which assembles into the neurotoxic aggregates in the brains of sufferers of Alzheimer's disease.	2.6	1	0	carbamate ester; monocarboxylic acid amide; peptide; secondary alcohol	EC 3.4.23.46 (memapsin 2) inhibitor; peptidomimetic
ceftazidime [no description available]	2.47	2	0	cephalosporin; oxime O-ether	antibacterial drug; drug allergen; EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
trandolapril trandolapril : A heterobicylic compound that is (2S,3aR,7aS)-1-[(2S)-2-aminopropanoyl]octahydro-1H-indole-2-carboxylic acid in which the hydrogen of the amino group is substituted by a (2R)-1-ethoxy-1-oxo-4-phenylbutan-2-yl group. It is a angiotensin-converting enzyme inhibitor and a prodrug used for the treatment of hypertension.	2.03	1	0	dicarboxylic acid monoester; dipeptide; ethyl ester; organic heterobicyclic compound; secondary amino compound; tertiary carboxamide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
aliskiren aliskiren: orally active nonpeptidic renin inhibitor. aliskiren : A monomethoxybenzene compound having a 3-methoxypropoxy group at the 2-position and a multi-substituted branched alkyl substituent at the 4-position.	7.78	11	2	monocarboxylic acid amide; monomethoxybenzene	antihypertensive agent
bms 806 BMS 806: prevents entry of HIV into cells by binding HIV envelope protein gp120; no further info available 4/2002	2.6	1	0
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone [no description available]	2.6	1	0
famotidine [no description available]	2.05	1	0	1,3-thiazoles; guanidines; sulfonamide	anti-ulcer drug; H2-receptor antagonist; P450 inhibitor
fenoterol fenoterol hydrobromide : The hydrobromide salt of fenoterol. A beta2-adrenergic agonist, it is used as a bronchodilator in the management of reversible airway obstruction.	2.05	1	0	hydrobromide	beta-adrenergic agonist; bronchodilator agent; sympathomimetic agent
tulobuterol hydrochloride [no description available]	2.6	1	0	organic molecular entity
salubrinal salubrinal: prevents dephosphorylation of eIF2alpha; structure in first source. salubrinal : A member of the class of quinolines that is a mixed aminal resulting from the formal condensation oftrichloroacetaldehyde with the amide nitrogen of trans-cinnamamide and the primary amino group of 1-quinolin-8-ylthiourea. It is a selective inhibitor of cellular complexes that dephosphorylate eukaryotic translation initiation factor 2 subunit alpha (eIF2alpha).	2.6	1	0	aminal; organochlorine compound; quinolines; secondary carboxamide; thioureas
aztreonam [no description available]	2.47	2	0	beta-lactam antibiotic allergen; monobactam	antibacterial drug; drug allergen; EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
(R)-citalopram (R)-citalopram : A 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile that has R-configuration at the chiral centre. It is the inactive enantiomer of citalopram.	2.03	1	0	1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile
oxalates Oxalates: Derivatives of OXALIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that are derived from the ethanedioic acid structure.	2.05	1	0
aluminum hydroxide, magnesium hydroxide, drug combination aluminum hydroxide, magnesium hydroxide, simethicone drug combination: antacid contains aluminum hydroxide, magnesium hydroxide and simethicone; mylanta II contains aluminum/magnesium hydroxide mixture	2	1	0
diphenoxylate hydrochloride diphenoxylate hydrochloride : The hydrochloride salt of diphenoxylate.	2.05	1	0	hydrochloride	antidiarrhoeal drug
germacrone germacrone: isolated from Curcuma wenyujin	2.6	1	0	germacrane sesquiterpenoid; olefinic compound	androgen antagonist; anti-inflammatory agent; antifeedant; antifungal agent; antimicrobial agent; antineoplastic agent; antioxidant; antitussive; antiviral agent; apoptosis inducer; autophagy inducer; hepatoprotective agent; insecticide; neuroprotective agent; plant metabolite; volatile oil component
1-oleoyl-2-acetylglycerol [no description available]	2.13	1	0	1,2-diglyceride
ergonovine maleate ergometrine maleate : A maleate salt resulting form the reaction of equimolar amounts of maleic acid and ergometrine. It is used in the active management of the third stage of labour, and to prevent or treat postpartum of postabortal haemorrhage caused by uterine atony: by maintaining uterine contraction and tone, blood vessels in the uterine wall are compressed and blood flow reduced.	2.05	1	0	maleate salt	diagnostic agent; oxytocic
(2e,4e,6e,10e)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid: an acyclic retinoid that suppresses hepatocellular carcinoma recurrence; structure in first source	2.6	1	0
lithospermic acid [no description available]	2.6	1	0
everolimus [no description available]	3.51	1	1	cyclic acetal; cyclic ketone; ether; macrolide lactam; primary alcohol; secondary alcohol	anticoronaviral agent; antineoplastic agent; geroprotector; immunosuppressive agent; mTOR inhibitor
prostaglandin f-main urinary metabolite prostaglandin F-main urinary metabolite: urinary metabolites of PGF2alpha in rats	3.46	1	1
laq824 LAQ824: Histone deacetylase inhibitor	2.6	1	0
ekb 569 EKB 569: an EGF receptor kinase inhibitor	2.6	1	0	aminoquinoline; monocarboxylic acid amide; monochlorobenzenes; nitrile	protein kinase inhibitor
rilpivirine [no description available]	2.6	1	0	aminopyrimidine; nitrile	EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor; HIV-1 reverse transcriptase inhibitor
(1Ar,7aS,10aS,10bS)-1a,5-dimethyl-8-methylidene-2,3,6,7,7a,8,10a,10b-octahydrooxireno[9,10]cyclodeca[1,2-b]furan-9(1aH)-one [no description available]	2.6	1	0	germacranolide
4,5-di-O-caffeoylquinic acid [no description available]	2.6	1	0	quinic acid
indigo carmine 3,5-di-O-(E)-caffeoylquinic acid: from roots of Lychnophora ericoides; structure in first source. 3,5-di-O-caffeoyl quinic acid : A carboxylic ester that is the diester obtained by the condensation of the hydroxy groups at positions 3 and 5 of (-)-quinic acid with the carboxy group of trans-caffeic acid. Isolated from Brazilian propolis and Suaeda glauca, it exhibits hepatoprotective and cytotoxic activities.	2.6	1	0
verlukast verlukast: LTD4 receptor antagonist	2.05	1	0
ceftizoxime [no description available]	3.15	1	0	cephalosporin	antibacterial drug
1-methyl-d-lysergic acid butanolamide [no description available]	2.03	1	0	ergot alkaloid; monocarboxylic acid amide	serotonergic antagonist; sympatholytic agent; vasoconstrictor agent
dantrolene sodium dantrolene sodium (anhydrous) : The anhydrous sodium salt of dantrolene.	2.05	1	0
nitrofurantoin Nitrofurantoin: A urinary anti-infective agent effective against most gram-positive and gram-negative organisms. Although sulfonamides and antibiotics are usually the agents of choice for urinary tract infections, nitrofurantoin is widely used for prophylaxis and long-term suppression.. nitrofurantoin : An imidazolidine-2,4-dione that is hydantoin substituted at position 1 by a [(5-nitro-2-furyl)methylene]amino group. An antibiotic that damages bacterial DNA.	2.74	3	0	imidazolidine-2,4-dione; nitrofuran antibiotic; organonitrogen heterocyclic antibiotic; organooxygen heterocyclic antibiotic	antibacterial drug; antiinfective agent; hepatotoxic agent
dantrolene [no description available]	2.07	1	0
artesunate artesunic acid: RN given for (3R-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12beta,(2aR*))-isomer; succinic ester of artemether	2.6	1	0	artemisinin derivative; cyclic acetal; dicarboxylic acid monoester; hemisuccinate; semisynthetic derivative; sesquiterpenoid	antimalarial; antineoplastic agent; ferroptosis inducer
dutasteride Dutasteride: A 5-ALPHA-REDUCTASE INHIBITOR that is reported to inhibit both type-1 and type2 isoforms of the enzyme and is used to treat BENIGN PROSTATIC HYPERPLASIA.. dutasteride : An aza-steroid that is inasteride in which the tert-butyl group is replaced by a 2,5-bis(trifluoromethyl)phenyl group. A synthetic 4-azasteroid, dutasteride is a selective inhibitor of both the type 1 and type 2 isoforms of steroid 5alpha-reductase, an intracellular enzyme that converts testosterone to 5alpha-dihydrotestosterone. Dutasteride is used for the treatment of symptomatic benign prostatic hyperplasia in men with an enlarged prostate gland.	2.03	1	0	(trifluoromethyl)benzenes; aza-steroid; delta-lactam	antihyperplasia drug; EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor
(3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone [no description available]	2.6	1	0	oligopeptide
vildagliptin [no description available]	2.6	1	0	amino acid amide
belinostat [no description available]	2.6	1	0	hydroxamic acid; olefinic compound; sulfonamide	antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor
hdac-42 HDAC-42: structure in first source	2.6	1	0	amidobenzoic acid
chlorhexidine Chlorhexidine: A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.. chlorhexidine : A bisbiguanide compound with a structure consisting of two (p-chlorophenyl)guanide units linked by a hexamethylene bridge.	2.6	1	0	biguanides; monochlorobenzenes	antibacterial agent; antiinfective agent
gemifloxacin Gemifloxacin: A naphthyridine and fluoroquinolone derivative antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used for the treatment of community-acquired pneumonia and acute bacterial infections associated with chronic bronchitis.. gemifloxacin : A 1,4-dihydro-1,8-naphthyridine with a carboxy group at the 3-position, an oxo sustituent at the 4-position, a fluoro substituent at the 5-position and a substituted pyrrolin-1-yl group at the 7-position.	2.03	1	0	1,8-naphthyridine derivative; fluoroquinolone antibiotic; monocarboxylic acid; quinolone antibiotic	antibacterial drug; antimicrobial agent; topoisomerase IV inhibitor
gs-7340 tenofovir alafenamide: component of Biktarvy. tenofovir alafenamide : An L-alanine derivative that is isopropyl L-alaninate in which one of the amino hydrogens is replaced by an (S)-({[(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy}methyl)(phenoxy)phosphoryl group. A prodrug for tenofovir, it is used (as the fumarate salt) in combination therapy for the treatment of HIV-1 infection.	2.6	1	0	6-aminopurines; ether; isopropyl ester; L-alanine derivative; phosphoramidate ester	antiviral drug; HIV-1 reverse transcriptase inhibitor; prodrug
fosinopril [no description available]	3.15	1	0
iniparib [no description available]	2.6	1	0	carbonyl compound; organohalogen compound
n-(2-amino-5-fluorobenzyl)-4-(n-(pyridine-3-acrylyl)aminomethyl)benzamide [no description available]	2.6	1	0
pri-2205 [no description available]	2.6	1	0
exp-3179 [no description available]	2.52	2	0
pratosartan pratosartan: angiotensin II type 1 receptor blocker	3.15	1	0	biphenylyltetrazole	antihypertensive agent
mk 0752 [no description available]	2.6	1	0
givinostat [no description available]	2.6	1	0	carbamate ester
sacubitril [no description available]	6.26	3	2	biphenyls
norfenfluramine Dexnorfenfluramine: D-isomer of Norfenfluramine	2.03	1	0	amphetamines
pd 144418 [no description available]	2.6	1	0
bicyclol bicyclol: an antihepatitis drug, on the metabolism and hepatotoxicity of aflatoxin B1 (AFB1) in rats.	2.6	1	0
zd 7155 [no description available]	2.17	1	0
midostaurin midostaurin : An organic heterooctacyclic compound that is the N-benzoyl derivative of staurosporine.	2.6	1	0	benzamides; gamma-lactam; indolocarbazole; organic heterooctacyclic compound	antineoplastic agent; EC 2.7.11.13 (protein kinase C) inhibitor
sincalide Sincalide: An octapeptide hormone present in the intestine and brain. When secreted from the gastric mucosa, it stimulates the release of bile from the gallbladder and digestive enzymes from the pancreas.	3.55	2	0	oligopeptide
ly 450139 [no description available]	2.6	1	0	peptide
muromonab-cd3 xestospongin C: was indexed to xestospongin A; from Xestospongia sponge; empties the ER calcium store but does not inhibit InsP3-induced Ca2+ release. xestospongin C : An organic heteropentacyclic compound that is isolated from the marine sponge Xestospongia exigua.	2.04	1	0	alkaloid; macrocycle; organic heteropentacyclic compound; organonitrogen heterocyclic compound; oxacycle; tertiary amino compound	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; IP3 receptor antagonist; marine metabolite
mocetinostat mocetinostat: undergoing phase II clinical trials for treatment of cancer. mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11).	4.62	5	1	aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline	antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent
fimasartan fimasartan: an angiotensin II receptor antagonist	9.55	1	1	biphenyls
rivaroxaban Rivaroxaban: A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.. rivaroxaban : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-chlorothiophene-2-carboxylic acid with the amino group of 4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholin-3-one. An anticoagulant used for prophylaxis of venous thromboembolism in patients with knee or hip replacement surgery.	2.6	1	0	aromatic amide; lactam; monocarboxylic acid amide; morpholines; organochlorine compound; oxazolidinone; thiophenes	anticoagulant; EC 3.4.21.6 (coagulation factor Xa) inhibitor
sb 3ct compound SB 3CT compound: a matrix metalloproteinase-2 inhibitor; structure in first source	2.6	1	0	aromatic ether
molindone hydrochloride [no description available]	2.05	1	0	indoles
ginsenoside rb1 [no description available]	2.6	1	0	ginsenoside; glycoside; tetracyclic triterpenoid	anti-inflammatory drug; anti-obesity agent; apoptosis inhibitor; neuroprotective agent; plant metabolite; radical scavenger
gentamicin sulfate [no description available]	2.07	1	0
sr 14150 SR 14150: mixed NOP and mu-opioid receptor ligand and antinociceptive; structure in first source	3.23	1	0
rucaparib AG14447: Poly(ADP-ribose) polymerase inhibitor; structure in first source	2.6	1	0	azepinoindole; caprolactams; organofluorine compound; secondary amino compound	antineoplastic agent; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, 4-(4-chlorophenyl)-n-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6s)- [no description available]	2.6	1	0	organonitrogen heterocyclic compound; organosulfur heterocyclic compound
cetilistat cetilistat: lipase inhibitor in randomized, placebo-controlled study of weight reduction in obese patients (3/2007)	2.6	1	0	benzoxazine
ym 201636 6-amino-N-(3-(4-(4-morpholinyl)pyrido(3',2'-4,5)furo(3,2-d)pyrimidin-2-yl)phenyl)-3-pyridinecarboxamide: an antiviral agent; structure in first source	2.6	1	0	aromatic amide
linagliptin Linagliptin: A purine and quinazoline derivative that functions as an INCRETIN and DIPEPTIDYL-PEPTIDASE IV INHIBTOR. It is used as a HYPOGLYCEMIC AGENT in the treatment of TYPE II DIABETES MELLITUS.. linagliptin : A xanthine that is 7H-xanthine bearing (4-methylquinazolin-2-yl)methyl, methyl, but-2-yn-1-yl and 3-aminopiperidin-1-yl substituents at positions 1, 3, 7 and 8 respectively (the R-enantiomer). Used for treatment of type II diabetes.	2.6	1	0	aminopiperidine; quinazolines	EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; hypoglycemic agent
azd 6244 AZD 6244: a MEK inhibitor	2.6	1	0	benzimidazoles; bromobenzenes; hydroxamic acid ester; monochlorobenzenes; organofluorine compound; secondary amino compound	anticoronaviral agent; antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
odanacatib odanacatib: a selective inhibitor of cathepsin K for the treatment of post-menopausal osteoporosis; structure in first source	2.6	1	0
apilimod [no description available]	2.6	1	0
apixaban [no description available]	2.6	1	0	aromatic ether; lactam; piperidones; pyrazolopyridine	anticoagulant; EC 3.4.21.6 (coagulation factor Xa) inhibitor
betrixaban betrixaban: a highly potent, selective, and orally efficacious factor Xa inhibitor; structure in first source. betrixaban : A secondary carboxamide obtained by formal condensation of the carboxy group of 4-(N,N-dimethylcarbamimidoyl)benzoic acid with the amino group of 2-amino-N-(5-chloropyridin-2-yl)-5-methoxybenzamide. A synthetic anticoagulant compound that targets activated factor Xa in the coagulation cascade.	2.6	1	0	benzamides; guanidines; monochloropyridine; monomethoxybenzene; secondary carboxamide	anticoagulant; EC 3.4.21.6 (coagulation factor Xa) inhibitor
edoxaban edoxaban : A monocarboxylic acid amide that is used (as its tosylate monohydrate) for the treatment of deep vein thrombosis and pulmonary embolism.	2.6	1	0	chloropyridine; monocarboxylic acid amide; tertiary amino compound; thiazolopyridine	anticoagulant; EC 3.4.21.6 (coagulation factor Xa) inhibitor; platelet aggregation inhibitor
saracatinib [no description available]	2.6	1	0	aromatic ether; benzodioxoles; diether; N-methylpiperazine; organochlorine compound; oxanes; quinazolines; secondary amino compound	anticoronaviral agent; antineoplastic agent; apoptosis inducer; autophagy inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; radiosensitizing agent
n-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide boceprevir : A synthetic tripeptide consisting of N-(tert-butylcarbamoyl)-3-methyl-L-valyl, a cyclopropyl-fused prolyl and 3-amino-4-cyclobutyl-2-oxobutanamide residues joined in sequence. Used for treatment of chronic hepatitis C virus genotype 1 infection.	2.6	1	0	tripeptide; ureas	antiviral drug; hepatitis C protease inhibitor; peptidomimetic
4-[3-(1H-imidazol-5-yl)propyl]piperidine [no description available]	3.23	1	0	aralkylamine
homatropine methylbromide homatropine methylbromide: RN given refers to bromide (endo-(+-))-isomer	2.07	1	0
ly 411575 [no description available]	2.6	1	0	dibenzoazepine; difluorobenzene; lactam; secondary alcohol	EC 3.4.23.46 (memapsin 2) inhibitor
galidesivir [no description available]	2.6	1	0
glaucocalyxin a glaucocalyxin A: chemical constituent of Rabdosia japonica var. glaucocalyx	2.25	1	0
PB28 PB28 : A member of the class of tetralins that is tetralin that is substituted by 3-(4-cyclohexylpiperazin-1-yl)propyl and methoxy groups at positions 1 and 5, respectively. It is a sigma 2 (sigma2) receptor agonist (Ki = 0.68 nM) and exhibits antineoplastic and anti SARS-CoV-2 activities.	2.6	1	0	aromatic ether; piperazines; tetralins	anticoronaviral agent; antineoplastic agent; apoptosis inducer; sigma-2 receptor agonist
oxadiazoles Oxadiazoles: Compounds containing five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom which exist in various regioisomeric forms.	11.98	18	11
baci-im [no description available]	2.05	1	0	homodetic cyclic peptide; polypeptide; zwitterion	antibacterial agent; antimicrobial agent
degrasyn degrasyn: a JAK2 kinase inhibitor that induces rapid degradation of c-Myc protein in MM-1 multiple myeloma and other tumor cell lines; structure in first source	2.6	1	0
epoxomicin [no description available]	2.6	1	0	morpholines; tripeptide	proteasome inhibitor
bms 477118 [no description available]	2.6	1	0	adamantanes; azabicycloalkane; monocarboxylic acid amide; nitrile; tertiary alcohol	EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; hypoglycemic agent
pha 680632 PHA 680632: Aurora kinase inhibitor with potent antitumoral activity; structure in first source	2.6	1	0
tmc 353121 [no description available]	2.6	1	0
amd 070 mavorixafor: a derivative of AMD3100; a CXCR4 blocker	2.6	1	0	aminoquinoline
danoprevir [no description available]	2.6	1	0
bms-626529 [no description available]	2.6	1	0
bms-663068 fostemsavir: an HIV-1 attachment inhibitor; structure in first source	2.6	1	0
amenamevir ASP2151: a herpesvirus helicase-primase inhibitor, in a guinea pig model of genital herpes; structure in first source	2.6	1	0
vx 765 belnacasan: a NSAID	2.6	1	0	dipeptide
Dihydrotanshinone I dihydrotanshinone I: extracted from Radix Salviae	2.6	1	0	abietane diterpenoid	anticoronaviral agent
alogliptin alogliptin: structure in first source. alogliptin : A piperidine that is 3-methyl-2,4-dioxo-3,4-dihydropyrimidine carrying additional 2-cyanobenzyl and 3-aminopiperidin-1-yl groups at positions 1 and 2 respectively (the R-enantiomer). Used in the form of its benzoate salt for treatment of type 2 diabetes.	2.6	1	0	nitrile; piperidines; primary amino compound; pyrimidines	EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; hypoglycemic agent
fr 180204 FR 180204: structure in first source	2.6	1	0	pyrazoles; ring assembly
quisinostat [no description available]	2.6	1	0	indoles
carfilzomib [no description available]	2.72	2	0	epoxide; morpholines; tetrapeptide	antineoplastic agent; proteasome inhibitor
hcv 796 HCV 796: inhibits HCV RdRp; structure in first source	2.6	1	0
cytidine diphosphate choline [no description available]	2.05	1	0	nucleotide-(amino alcohol)s; phosphocholines	human metabolite; mouse metabolite; neuroprotective agent; psychotropic drug; Saccharomyces cerevisiae metabolite
resminostat resminostat: a histone deacetylase inhibitor; structure in first source	2.6	1	0
milnacipran [no description available]	2.03	1	0	acetamides
zk 756326 2-(2-(4-(3-phenoxybenzyl)piperazin-1-yl)ethoxy)ethanol: a CC chemokine receptor CCR8 agonist; structure in first source	2.6	1	0	aromatic ether
balapiravir balapiravir: a prodrug of R1479; structure in first source	2.6	1	0
trametinib [no description available]	2.6	1	0	acetamides; aromatic amine; cyclopropanes; organofluorine compound; organoiodine compound; pyridopyrimidine; ring assembly	anticoronaviral agent; antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector
deoxyarbutin 4-((tetrahydro-2H-pyran-2-yl)oxy)phenol: has antineoplastic activity; structure in first source	2.6	1	0
abexinostat abexinostat: structure in first source	2.6	1	0	benzofurans
losartan potassium Erythropoietin: Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.	2.03	1	0
silvestrol silvestrol: isolated from the fruit and twig of Aglaia silvestris. silvestrol : An organic heterotricyclic compound that consists of a 2,3,3a,8b-tetrahydro-H-benzo[b]cyclopenta[d]furan framework substituted by hydroxy groups at positions C-1 and C-8b, a methoxycarbonyl group at C-2, a phenyl group at C-3, a 4-methoxyphenyl group at C-3a, a methoxy group at C-8 and a 1,4-dioxan-2-yloxy group at position C-6 which in turn is substituted by a methoxy group at position 3 and a 1,2-dihydroxyethyl group at position 6. Isolated from Aglaia silvestris, it exhibits antineoplastic activity.	2.6	1	0	dioxanes; ether; methyl ester; organic heterotricyclic compound	antineoplastic agent; metabolite
narlaprevir narlaprevir: an antiviral agent that inhibits hepatitis C virus NS3 protease. narlaprevir : An azabicyclohexane that is (1R,5S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane substituted by [(3S)-1-(cyclopropylamino)-1,2-dioxoheptan-3-yl]aminoacyl and N-({1-[(tert-butylsulfonyl)methyl]cyclohexyl}carbamoyl)-3-methyl-L-valyl groups at positions 2S and 3, respectively. It is a hepatitis C virus (HCV) NS3/4A serine protease inhibitor (Ki = 6 nM) that is used for the treatment of chronic hepatitis C.	2.6	1	0	azabicyclohexane; cyclopropanes; pyrrolidinecarboxamide; secondary carboxamide; sulfone; tertiary carboxamide; ureas	anticoronaviral agent; antiviral drug; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; hepatitis C protease inhibitor
teneligliptin [no description available]	2.6	1	0	amino acid amide
dextrothyroxine [no description available]	2.6	1	0
veliparib [no description available]	2.6	1	0	benzimidazoles	EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
pf 03491390 [no description available]	2.6	1	0
alloin [no description available]	2.6	1	0	anthracenes; C-glycosyl compound; cyclic ketone; phenols	laxative; metabolite
icatibant icatibant: a potent bradykinin (B2) receptor antagonist; WIN 65365 is an L-Tic(7) stereoisomer. icatibant : A ten-membered synthetic oligopeptide consisting of D-Arg, Arg, Pro, Hyp, Gly, Thi, Ser, D-Tic, Oic, and Arg residues joined in sequrence. A bradykinin receptor antagonist used as its acetate salt for the treatment of acute attacks of hereditary angioedema in adult patients.	2.01	1	0
mdv 3100 [no description available]	2.6	1	0	(trifluoromethyl)benzenes; benzamides; imidazolidinone; monofluorobenzenes; nitrile; thiocarbonyl compound	androgen antagonist; antineoplastic agent
amodiaquine hydrochloride [no description available]	2.07	1	0
clindamycin hydrochloride [no description available]	2.05	1	0	S-glycosyl compound
bms-650032 asunaprevir: an NS3 protease inhibitor against hepatitis C virus	2.6	1	0	oligopeptide
rg 7128 2'-fluoro-2'-methyl-3',5'-diisobutyryldeoxycytidine: inhibits HCV polymerase; structure in first source	2.6	1	0
atrial natriuretic factor Atrial Natriuretic Factor: A potent natriuretic and vasodilatory peptide or mixture of different-sized low molecular weight PEPTIDES derived from a common precursor and secreted mainly by the HEART ATRIUM. All these peptides share a sequence of about 20 AMINO ACIDS.	3.17	5	0	polypeptide
angiotensinogen Angiotensinogen: An alpha-globulin of about 453 amino acids, depending on the species. It is produced by the liver in response to lowered blood pressure and secreted into blood circulation. Angiotensinogen is the inactive precursor of the ANGIOTENSINS produced in the body by successive enzyme cleavages. Cleavage of angiotensinogen by RENIN yields the decapeptide ANGIOTENSIN I. Further cleavage of angiotensin I (by ANGIOTENSIN CONVERTING ENZYME) yields the potent vasoconstrictor octapeptide ANGIOTENSIN II; and then, via other enzymes, other angiotensins also involved in the hemodynamic-regulating RENIN-ANGIOTENSIN SYSTEM.	3.31	6	0
oritavancin oritavancin : A semisynthetic glycopeptide used (as its bisphosphate salt) for the treatment of acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms including MRSA.	2.6	1	0	disaccharide derivative; glycopeptide; semisynthetic derivative	antibacterial drug; antimicrobial agent
c-peptide C-Peptide: The middle segment of proinsulin that is between the N-terminal B-chain and the C-terminal A-chain. It is a pancreatic peptide of about 31 residues, depending on the species. Upon proteolytic cleavage of proinsulin, equimolar INSULIN and C-peptide are released. C-peptide immunoassay has been used to assess pancreatic beta cell function in diabetic patients with circulating insulin antibodies or exogenous insulin. Half-life of C-peptide is 30 min, almost 8 times that of insulin.	2.05	1	0
natriuretic peptide, c-type Natriuretic Peptide, C-Type: A PEPTIDE of 22 amino acids, derived mainly from cells of VASCULAR ENDOTHELIUM. It is also found in the BRAIN, major endocrine glands, and other tissues. It shares structural homology with ATRIAL NATRIURETIC FACTOR. It has vasorelaxant activity thus is important in the regulation of vascular tone and blood flow. Several high molecular weight forms containing the 22 amino acids have been identified.	2.1	1	0
quinine sulfate [no description available]	2.05	1	0	hydrate
endothelin-1 Endothelin-1: A 21-amino acid peptide produced in a variety of tissues including endothelial and vascular smooth-muscle cells, neurons and astrocytes in the central nervous system, and endometrial cells. It acts as a modulator of vasomotor tone, cell proliferation, and hormone production. (N Eng J Med 1995;333(6):356-63)	3.84	2	1
pevonedistat pevonedistat: a potent and selective inhibitor of NAE (NEDD8-activating enzyme). pevonedistat : A pyrrolopyrimidine that is 7H-pyrrolo[2,3-d]pyrimidine which is substituted by a (1S)-2,3-dihydro-1H-inden-1-ylnitrilo group at position 4 and by a (1S,3S,4S)-3-hydroxy-4-[(sulfamoyloxy)methyl]cyclopentyl group at position 7. It is a potent and selective NEDD8-activating enzyme inhibitor with an IC50 of 4.7 nM, and currently under clinical investigation for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes.	2.6	1	0	cyclopentanols; indanes; pyrrolopyrimidine; secondary amino compound; sulfamidate	antineoplastic agent; apoptosis inducer
uk 453,061 UK 453,061: a reverse transcriptase inhibitor/anti-HIV agent; structure in first source	2.6	1	0	aromatic ether
N-(2-aminophenyl)-2-pyrazinecarboxamide [no description available]	2.6	1	0	aromatic amide
calpain Calpain: Cysteine proteinase found in many tissues. Hydrolyzes a variety of endogenous proteins including NEUROPEPTIDES; CYTOSKELETAL PROTEINS; proteins from SMOOTH MUSCLE; CARDIAC MUSCLE; liver; platelets; and erythrocytes. Two subclasses having high and low calcium sensitivity are known. Removes Z-discs and M-lines from myofibrils. Activates phosphorylase kinase and cyclic nucleotide-independent protein kinase. This enzyme was formerly listed as EC 3.4.22.4.	2.1	1	0
cefotiam hydrochloride [no description available]	2.05	1	0
tegobuvir tegobuvir: a non-structural protein 5B polymerase inhibitor	2.6	1	0
pf-429242 PF-429242: a subtilisin kexin isozyme-1/site-1 protease inhibitor	2.6	1	0
potassium aminobenzoate [no description available]	2.05	1	0
ampicillin sodium [no description available]	2.05	1	0	organic sodium salt
taurocholic acid, monosodium salt [no description available]	3.15	1	0	bile salt
methicillin sodium [no description available]	2.05	1	0	organic sodium salt
nafcillin sodium [no description available]	2.05	1	0	organic sodium salt
penicillin g sodium [no description available]	2.05	1	0	organic sodium salt
cefamandole nafate cefamandole sodium : An organic sodium salt that is the sodium salt of cefamandole.	2.05	1	0	organic sodium salt	antibacterial drug
cephapirin sodium cephapirin sodium : The sodium salt of cephapirin. A first-generation cephalosporin antibiotic, it is effective against gram-negative and gram-positive organisms. Being more resistant to beta-lactamases than penicillins, it is effective agains most staphylococci, though not methicillin-resistant staphylococci.	2.05	1	0	cephalosporin; organic sodium salt	antibacterial drug
sodium cephalothin [no description available]	2.05	1	0	organic sodium salt
dicloxacillin sodium [no description available]	2.05	1	0	hydrate
azlocillin sodium [no description available]	2.05	1	0	organic sodium salt
olaparib [no description available]	2.6	1	0	cyclopropanes; monofluorobenzenes; N-acylpiperazine; phthalazines	antineoplastic agent; apoptosis inducer; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
cx 4945 [no description available]	2.6	1	0
pci 34051 PCI 34051: an HDAC8 inhibitor	2.6	1	0	indolecarboxamide
lomibuvir lomibuvir: an antiviral agent with polymerase NS5 inhibitory activity	2.6	1	0	thiophenecarboxylic acid
delanzomib [no description available]	2.6	1	0	C-terminal boronic acid peptide; phenylpyridine; secondary alcohol; threonine derivative	antineoplastic agent; apoptosis inducer; proteasome inhibitor
pci 32765 ibrutinib: a Btk protein inhibitor. ibrutinib : A member of the class of acrylamides that is (3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine in which the piperidine nitrogen is replaced by an acryloyl group. A selective and covalent inhibitor of the enzyme Bruton's tyrosine kinase, it is used for treatment of B-cell malignancies.	2.25	1	0	acrylamides; aromatic amine; aromatic ether; N-acylpiperidine; pyrazolopyrimidine; tertiary carboxamide	antineoplastic agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
pitavastatin(1-) pitavastatin(1-) : A hydroxy monocarboxylic acid anion that is the conjugate base of pitavastatin, obtained by deprotonation of the carboxy group.	2.6	1	0	hydroxy monocarboxylic acid anion
GRL-0617 GRL-0617 : A benzamide resulting from the formal condensation of the carboxy group of 5-amino-2-methylbenzoic acid with the amino group of (1R)-1-(naphthalen-1-yl)ethan-1-amine. It is a potent noncovalent inhibitor (IC50 = 600 nM) of severe acute respiratory syndrome-coronavirus papain-like protease (SARS-CoV PLpro).	2.6	1	0	benzamides; naphthalenes; secondary carboxamide; substituted aniline	anticoronaviral agent; protease inhibitor
N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester CAY10603: a HDAC6 inhibitor	2.6	1	0	carbamate ester
niraparib niraparib: structure in first source. niraparib : A 2-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamide that has S-configuration. It is a potent inhibitor of PARP1 and PARP2 (IC50 of 3.8 and 2.1 nM, respectively) and approved as a first-line maintenance treatment for women with advanced ovarian cancer after responding to platinum-based chemotherapy.	2.6	1	0	2-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamide	antineoplastic agent; apoptosis inducer; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; radiosensitizing agent
jzl 184 JZL 184: inhibits monoacylglycerol lipase; structure in first source	2.6	1	0	benzodioxoles
gsk 650394 [no description available]	2.6	1	0	phenylpyridine
oprozomib ONX 0912: antineoplastic; an orally active proteasome inhibitor; structure in first source	2.6	1	0
az 960 [no description available]	2.6	1	0
golgicide a golgicide A: inhibits the cis-golgi ArfGEF GBF1; structure in first source. golgicide A : A diastereoisomeric mixture comprising racemic cis- and racemic trans-goglioside A in a 10:1 ratio. It is a potent and rapidly reversible GBF1 (Golgi-specific brefeldin A-resistance guanine nucleotide exchange factor 1) inhibitor. The (3aS,4R,9bR) isomer is the most active (see Bioorg. Med. Chem. Lett., 2012, 22, 5177-5181).	2.6	1	0	diastereoisomeric mixture	cis-Golgi ArfGEF GBF inhibitor
cobicistat [no description available]	2.6	1	0	1,3-thiazoles; carbamate ester; monocarboxylic acid amide; morpholines; ureas	P450 inhibitor
bms-790052 daclatasvir: an HCV NS5A inhibitor. daclatasvir : A member of the class of biphenyls that is a potent inhibitor of nonstructural protein 5A and is used (as its hydrochloride salt) for treatment of hepatitis C.	2.6	1	0	biphenyls; carbamate ester; carboxamide; imidazoles; valine derivative	antiviral drug; nonstructural protein 5A inhibitor
ixazomib ixazomib: a proteasome inhibitor with antineoplastic activity; MLN2238 is the biologically active form of MLN9708; structure in first source. ixazomib : A glycine derivative that is the amide obtained by formal condensation of the carboxy group of N-(2,5-dichlorobenzoyl)glycine with the amino group of [(1R)-1-amino-3-methylbutyl]boronic acid. The active metabolite of ixazomib citrate, it is used in combination therapy for treatment of multiple myeloma.	2.6	1	0	benzamides; boronic acids; dichlorobenzene; glycine derivative	antineoplastic agent; apoptosis inducer; drug metabolite; orphan drug; proteasome inhibitor
ucph 101 2-amino-4-(4-methoxyphenyl)-7-(naphthalen-1-yl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile: structure in first source	2.6	1	0
5-(3-methylsulfonylphenyl)-4-[(1-methyl-5-tetrazolyl)thio]thieno[2,3-d]pyrimidine [no description available]	2.6	1	0	aryl sulfide; thienopyrimidine
baricitinib [no description available]	2.6	1	0	azetidines; nitrile; pyrazoles; pyrrolopyrimidine; sulfonamide	anti-inflammatory agent; antirheumatic drug; antiviral agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; immunosuppressive agent
KOM70144 KOM70144 : A benzamide that is GRL-0617 in which one of the hydrogen's of the primary amino group is replaced by an acetyl group. It an inhibitor of SARS-CoV and SARS-CoV-2 papain-like protease (PLpro) with an IC50 of 2.6 muM and 5.0 muM, respectively. It also inhibits SARS-CoV and SARS-CoV-2 infection of Vero E6 cells in vitro (EC50 values are 13.1 and 21 muM, respectively).	2.6	1	0	acetamides; benzamides; naphthalenes; secondary carboxamide	anticoronaviral agent; protease inhibitor
piperidines Piperidines: A family of hexahydropyridines.	2.17	1	0
e-52862 [no description available]	2.6	1	0
ly2811376 [no description available]	2.6	1	0
interleukin-8 Interleukin-8: A member of the CXC chemokine family that plays a role in the regulation of the acute inflammatory response. It is secreted by variety of cell types and induces CHEMOTAXIS of NEUTROPHILS and other inflammatory cells.	3.47	1	1
anagliptin anagliptin: anagliptin hydrochloride salt is the active compound	2.6	1	0	amino acid amide
gardiquimod [no description available]	2.6	1	0
grazoprevir grazoprevir: has antiviral activity; component of Zepatier. grazoprevir : An azamacrocyclic compound that is a hepatitis C protease inhibitor used in combination with elbasvir (under the brand name Zepatier) for treatment of chronic HCV genotypes 1 or 4 infection in adults.	2.6	1	0	aromatic ether; azamacrocycle; carbamate ester; cyclopropanes; lactam; N-sulfonylcarboxamide; quinoxaline derivative	antiviral drug; hepatitis C protease inhibitor; hepatoprotective agent
abt-450 paritaprevir: inhibits HCV NS3 protease. paritaprevir : An azamacrocycle which is used which is in combination with dasabuvir sodium hydrate, ombitasvir and ritonavir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.	2.6	1	0
letermovir letermovir: has antiviral activity; structure in first source	2.6	1	0
sofosbuvir Sofosbuvir: A uridine monophosphate analog inhibitor of HEPATITIS C VIRUS (HCV) polymerase NS5B that is used as an ANTIVIRAL AGENT in the treatment of CHRONIC HEPATITIS C.. sofosbuvir : A nucleotide conjugate that is used in combination with ledipasvir (under the trade name Harvoni) for the treatment of chronic hepatitis C genotype 1 infection.	2.6	1	0	isopropyl ester; L-alanyl ester; nucleotide conjugate; organofluorine compound; phosphoramidate ester	antiviral drug; hepatitis C protease inhibitor; prodrug
5-(4-amino-1-propan-2-yl-3-pyrazolo[3,4-d]pyrimidinyl)-1,3-benzoxazol-2-amine sapanisertib: an mTOR inhibitor	2.6	1	0	benzoxazole
blz 945 [no description available]	2.6	1	0
azd3839 AZD3839: a BACE1 inhibitor; structure in first source	2.6	1	0
pf 3084014 nirogacestat: an antineoplastic agent. nirogacestat : A member of the class of imidazoles that is 1H-imidazole substituted by a 1-[(2,2-dimethylpropyl)amino]-2-methylpropan-2-yl group at position 1 and a {N-[(2S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]-L-norvalyl}amino group at position 4. It is a gamma-secretase inhibitor whose hydrobromide salt is indicated for adult patients with progressing desmoid tumours who require systemic treatment.	2.6	1	0
unc 0638 UNC 0638: inhibits lysine methyltransferases G9a and GLP; structure in first source	2.6	1	0	quinazolines
gs-9620 [no description available]	2.6	1	0
n-((5-(methanesulfonyl)pyridin-2-yl)methyl)-6-methyl-5-(1-methyl-1h-pyrazol-5-yl)-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxamide N-((5-(methanesulfonyl)pyridin-2-yl)methyl)-6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxamide: structure in first source	2.6	1	0
bms 708163 BMS 708163: structure in first source	2.6	1	0	oxadiazole; ring assembly
jq1 compound [no description available]	2.6	1	0	carboxylic ester; organochlorine compound; tert-butyl ester; thienotriazolodiazepine	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; bromodomain-containing protein 4 inhibitor; cardioprotective agent; ferroptosis inducer
1-(5-((2,4-difluorophenyl)thio)-4-nitrothiophen-2-yl)ethanone 1-(5-((2,4-difluorophenyl)thio)-4-nitrothiophen-2-yl)ethanone: a USP7 inhibitor; structure in first source	2.6	1	0
gsk525762a molibresib: mimicks acetylated histones; structure in first source	2.6	1	0	benzodiazepine
ML240 ML240 : A member of the class of quinazolines that is quinazoline which is substituted at positions 2, 5 and 8 by 2-amino-1H-benzimidazol-1-yl, benzylnitrilo and methoxy groups, respectively. It is a ATP-competetive inhibitor of AAA ATPase p97, also known as valosin-containing protein (VCP).	2.6	1	0	aromatic amine; aromatic ether; benzimidazoles; primary amino compound; quinazolines; secondary amino compound	antineoplastic agent
birinapant birinapant: a Smac mimetic with antineoplastic activity	2.6	1	0	dipeptide
ly2886721 [no description available]	2.6	1	0
nms-p118 NMS-P118: a PARP-1 inhibitor; structure in first source	2.6	1	0
tubastatin a [no description available]	2.6	1	0	hydroxamic acid; pyridoindole; tertiary amino compound	EC 3.5.1.98 (histone deacetylase) inhibitor
pracinostat pracinostat : A hydroxamic acid that is N-hydroxyacrylamide which is substituted at position 3 by a 2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl group (the E isomer). An orally available pan-histone deacetylase inhibitor with demonstrated activity in the treatment of advanced solid tumours.	2.6	1	0	benzimidazole; hydroxamic acid; olefinic compound; tertiary amino compound	antimalarial; antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
spautin-1 [no description available]	2.6	1	0
ldn 57444 LDN 57444: inhibitor of ubiquitin C-terminal hydrolase-L1; structure in first source	2.6	1	0
gsk1210151a GSK1210151A: inhibitor of the BET family of proteins; structure in first source	2.6	1	0	imidazoquinoline
i-bet726 [no description available]	2.6	1	0
natriuretic peptide, brain Natriuretic Peptide, Brain: A PEPTIDE that is secreted by the BRAIN and the HEART ATRIA, stored mainly in cardiac ventricular MYOCARDIUM. It can cause NATRIURESIS; DIURESIS; VASODILATION; and inhibits secretion of RENIN and ALDOSTERONE. It improves heart function. It contains 32 AMINO ACIDS.	4.9	4	2	polypeptide
acy-1215 ricolinostat: an HDAC6 inhibitor; structure in first source	2.6	1	0	pyrimidinecarboxylic acid
cudc-907 [no description available]	2.6	1	0
ascorbic acid Ascorbic Acid: A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant.. L-ascorbic acid : The L-enantiomer of ascorbic acid and conjugate acid of L-ascorbate.. L-ascorbate : The L-enantiomer of ascorbate and conjugate base of L-ascorbic acid, arising from selective deprotonation of the 3-hydroxy group. Required for a range of essential metabolic reactions in all animals and plants.. vitamin C : Any member of a group of vitamers that belong to the chemical structural class called butenolides that exhibit biological activity against vitamin C deficiency in animals. The vitamers include L-ascorbic acid and its salt, ionized and oxidized forms.	2.44	2	0	ascorbic acid; vitamin C	coenzyme; cofactor; flour treatment agent; food antioxidant; food colour retention agent; geroprotector; plant metabolite; skin lightening agent
novobiocin Novobiocin: An antibiotic compound derived from Streptomyces niveus. It has a chemical structure similar to coumarin. Novobiocin binds to DNA gyrase, and blocks adenosine triphosphatase (ATPase) activity. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p189). novobiocin : A coumarin-derived antibiotic obtained from Streptomyces niveus.	3.56	2	0	carbamate ester; ether; hexoside; hydroxycoumarin; monocarboxylic acid amide; monosaccharide derivative; phenols	antibacterial agent; antimicrobial agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; Escherichia coli metabolite; hepatoprotective agent
tetracycline Tetracycline: A naphthacene antibiotic that inhibits AMINO ACYL TRNA binding during protein synthesis.. tetracycline : A broad-spectrum polyketide antibiotic produced by the Streptomyces genus of actinobacteria.	4.08	4	0
chlortetracycline Chlortetracycline: A TETRACYCLINE with a 7-chloro substitution.. chlortetracycline : A member of the class of tetracyclines with formula C22H23ClN2O8 isolated from Streptomyces aureofaciens.	2.03	1	0
oxytetracycline, anhydrous Oxytetracycline: A TETRACYCLINE analog isolated from the actinomycete STREPTOMYCES RIMOSUS and used in a wide variety of clinical conditions.. oxytetracycline : A tetracycline used for treatment of infections caused by a variety of Gram positive and Gram negative microorganisms including Mycoplasma pneumoniae, Pasteurella pestis, Escherichia coli, Haemophilus influenzae (respiratory infections), and Diplococcus pneumoniae.	2.03	1	0
minocycline Minocycline: A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections.. minocycline : A tetracycline analogue having a dimethylamino group at position 7 and lacking the methyl and hydroxy groups at position 5.	2.97	4	0
methacycline Methacycline: A broad-spectrum semisynthetic antibiotic related to TETRACYCLINE but excreted more slowly and maintaining effective blood levels for a more extended period.. methacycline : A tetracycline that is the 6-methylene analogue of oxytetracycline, obtained by formal dehydration at position 6.	2.03	1	0
piroxicam [no description available]	2.97	4	0	benzothiazine; monocarboxylic acid amide; pyridines	analgesic; antirheumatic drug; cyclooxygenase 1 inhibitor; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug
acenocoumarol Acenocoumarol: A coumarin that is used as an anticoagulant. Its actions and uses are similar to those of WARFARIN. (From Martindale, The Extra Pharmacopoeia, 30th ed, p233). acenocoumarol : A hydroxycoumarin that is warfarin in which the hydrogen at position 4 of the phenyl substituent is replaced by a nitro group.	2.05	1	0	C-nitro compound; hydroxycoumarin; methyl ketone	anticoagulant; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor
lfm a13 LFM-A13 : An enamide obtained by formal condensation of the carboxy group of (2Z)-2-cyano-3-hydroxybut-2-enoic acid with the amino group of 2,5-dibromoaniline. It is a dual-function inhibitor of Bruton's tyrosine kinase (BTK) and Polo-like kinases (PLK) that exhibits anticancer properties.	2.25	1	0	aromatic amide; dibromobenzene; enamide; enol; nitrile; secondary carboxamide	antineoplastic agent; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 2.7.11.21 (polo kinase) inhibitor; geroprotector; platelet aggregation inhibitor
mobic Meloxicam: A benzothiazine and thiazole derivative that acts as a NSAID and cyclooxygenase-2 (COX-2) inhibitor. It is used in the treatment of RHEUMATOID ARTHRITIS; OSTEOARTHRITIS; and ANKYLOSING SPONDYLITIS.. meloxicam : A benzothiazine that is piroxicam in which the pyridin-2-yl group is replaced by a 5-methyl-1,3-thiazol-2-yl group. A non-steroidal anti-inflammatory drug and selective inhibitor of COX-2, it is used particularly for the management of rheumatoid arthritis.	2.54	2	0	1,3-thiazoles; benzothiazine; monocarboxylic acid amide	analgesic; antirheumatic drug; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
mobiflex tenoxicam : A thienothiazine-derived monocarboxylic acid amide obtained by formal condensation of the carboxy group of 4-hydroxy-2-methylthieno[2,3-e][1,2]thiazine-3-carboxylic acid 1,1-dioxide with the amino group of 2-aminopyridine. Used for the treatment of pain and inflammation in osteoarthritis and rheumatoid arthritis. It is also indicated for short term treatment of acute musculoskeletal disorders including strains, sprains and other soft-tissue injuries.	2.08	1	0	heteroaryl hydroxy compound; monocarboxylic acid amide; pyridines; thienothiazine	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
isoxicam isoxicam : A monocarboxylic acid amide that is piroxicam in which the pyrid-2-yl group is replaced by a 5-methyl-1,2-oxazol-3-yl group. A non-steroidal anti-inflammatory drug, it was withdrawn from the market in the 1980s following its association with cases of Stevens-Johnson syndrome.	2.05	1	0	benzothiazine; isoxazoles; monocarboxylic acid amide	antirheumatic drug; non-steroidal anti-inflammatory drug
warfarin Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.	3.14	5	0	benzenes; hydroxycoumarin; methyl ketone
tipranavir tipranavir: inhibits HIV-1 protease. tipranavir : A pyridine-2-sulfonamide substituted at C-5 by a trifluoromethyl group and at the sulfonamide nitrogen by a dihydropyrone-containing m-tolyl substituent. It is an HIV-1 protease inhibitor.	2.6	1	0	sulfonamide	antiviral drug; HIV protease inhibitor
chlortetracycline hydrochloride Alexomycin: a thiopeptide; a cyclic peptide antibiotic produced by Streptomyces arginensis isolated from the soil	2.05	1	0
tasquinimod tasquinimod: a lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer; structure in first source	2.6	1	0
sudoxicam sudoxicam: proposed ant-inflammatory agent; minor descriptor (75-86); on-line & INDEX MEDICUS search THIAZINES (75-86)	2.05	1	0
methacycline monohydrochloride [no description available]	2.05	1	0
minocycline hydrochloride [no description available]	2.05	1	0
demeclocycline hydrochloride demeclocycline hydrochloride : The hydrochloride salt of demeclocycline. A tetracycline antibiotic, it is used (mainly as the hydrochloride) for the treatment of Lyme disease, acne and bronchitis, as well as for hyponatraemia (low blood sodium concentration) due to the syndrome of inappropriate antidiuretic hormone (SIADH) where fluid restriction alone has been ineffective.	2.05	1	0
(S)-warfarin (S)-warfarin : A 4-hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one that has (S)-configuration (the racemate is warfarin, an anticoagulant drug and rodenticide).	2.03	1	0	4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one
gsk1265744 [no description available]	2.6	1	0	difluorobenzene; monocarboxylic acid amide; organic heterotricyclic compound; secondary carboxamide	HIV-1 integrase inhibitor
abt-267 ombitasvir: inhibits HCV NS5A protein, component of Viekirax. ombitasvir : A dipeptide derivative which is used which is in combination with dasabuvir sodium hydrate, paritaprevir and ritonavir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.	2.6	1	0	aromatic amide; carbamate ester; dipeptide; pyrrolidines	antiviral drug; hepatitis C virus nonstructural protein 5A inhibitor
abt-333 dasabuvir: an antiviral agent. dasabuvir : A member of the class of pyrimidone, which is (as the monohydrate of its sodium salt) in combination with ombitasvir, paritaprevir and ritonavir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.	2.6	1	0	aromatic ether; naphthalenes; pyrimidone; sulfonamide	antiviral drug; nonnucleoside hepatitis C virus polymerase inhibitor
rgfp966 [no description available]	2.6	1	0
rg2833 RG2833: a histone deacetylase inhibitor; structure in first source	2.6	1	0
transforming growth factor beta Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.	3.32	6	0
pi-1840 PI-1840: has both antineoplastic and proteasome inhibitory activities; structure in first source	2.6	1	0
acy-738 [no description available]	2.6	1	0
pelabresib CPI-0610: a bromodomain and extra-terminal protein inhibitor with antineoplastic activity; structure in first source	2.6	1	0	monochlorobenzenes; organic heterotricyclic compound; primary carboxamide	antineoplastic agent; bromodomain-containing protein 4 inhibitor
gs-5806 presatovir: a respiratory syncytial virus entry inhibitor	2.6	1	0
doravirine [no description available]	2.6	1	0
gn6958 GN6958: inhibits SUMO-sentrin specific protease 1 (SENP1); structure in first source	2.6	1	0
vx-787 pimodivir: non‐nucleotide inhibitor of the polymerase basic protein 2 (PB2) subunit of the influenza A that is active against H1N1, H7N9 and H5N1, as well as influenza A strains with reduced susceptibility to NAIs	2.6	1	0
ledipasvir ledipasvir : A benzimidazole derivative that is used in combination with sofosbuvir (under the trade name Harvoni) for the treatment of chronic hepatitis C genotype 1 infection.	2.6	1	0	azaspiro compound; benzimidazole; bridged compound; carbamate ester; carboxamide; fluorenes; imidazoles; L-valine derivative; N-acylpyrrolidine; organofluorine compound	antiviral drug; hepatitis C protease inhibitor
gs-5816 velpatasvir: an NS5A inhibitor used for treating hepatitis C infections. velpatasvir : A complex organic heteropentacyclic compound that is a hepatitis C virus nonstructural protein 5A inhibitor used in combination with sofosbuvir (under the brand name Epclusa) for treatment of patients with chronic hepatitis C of all six major genotypes.	2.6	1	0	carbamate ester; ether; imidazoles; L-valine derivative; N-acylpyrrolidine; organic heteropentacyclic compound; ring assembly	antiviral drug; hepatitis C virus nonstructural protein 5A inhibitor
g007-lk G007-LK: potent and specific small-molecule tankyrase inhibitor; structure in first source	2.6	1	0
acp-196 acalabrutinib: inhibits Bruton’s tyrosine kinase; has antineoplastic activity. acalabrutinib : A member of the class of imidazopyrazines that is imidazo[1,5-a]pyrazine substituted by 4-(pyridin-2-ylcarbamoyl)phenyl, (2S)-1-(but-2-ynoyl)pyrrolidin-2-yl, and amino groups at positions 1, 3 and 8, respectively. It is an irreversible second-generation Bruton's tyrosine kinase (BTK) inhibitor that is approved by the FDA for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.	2.25	1	0	aromatic amine; benzamides; imidazopyrazine; pyridines; pyrrolidinecarboxamide; secondary carboxamide; tertiary carboxamide; ynone	antineoplastic agent; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
4-((1-butyl-3-phenylureido)methyl)-n-hydroxybenzamide 4-((1-butyl-3-phenylureido)methyl)-N-hydroxybenzamide: inhibits HDAC6; structure in first source	2.6	1	0
selinexor selinexor: inhibits karyopherin XPO1	2.6	1	0
verdinexor verdinexor: a selective inhibitor of nuclear export	2.6	1	0
cb-839 [no description available]	2.6	1	0
mk-8742 elbasvir: inhibits NS5A protein of hepatitis C virus. elbasvir : A complex organic heterotetracyclic compound that is a hepatitis C virus nonstructural protein 5A inhibitor used in combination with grazoprevir (under the brand name Zepatier) for treatment of chronic HCV genotypes 1 or 4 infection in adults.	2.6	1	0	carbamate ester; imidazoles; L-valine derivative; N-acylpyrrolidine; organic heterotetracyclic compound; ring assembly	antiviral drug; hepatitis C virus nonstructural protein 5A inhibitor; hepatoprotective agent
atglistatin atglistatin: inhibits adipose triglyceride lipase; structure in first source. atglistatin : A biphenyl that is 1,1'-biphenyl substituted by (dimethylcarbamoyl)amino and dimethylamino groups at positions 3 and 4', respectively. It is a potent inhibitor of adipose triglyceride lipase activity (IC50 = 700nM).	2.6	1	0
xen445 [no description available]	2.6	1	0
santacruzamate a santacruzamate A: HDAC2 inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp.; structure in first source	2.6	1	0	organonitrogen compound; organooxygen compound
ldc4297 LDC4297: a CDK7 inhibitor with antineoplastic activity; structure in first source. LDC4297 : A pyrazolotriazine that is pyrazolo[1,5-a][1,3,5]triazine substituted by a piperidin-3-yloxy group, [2-(1H-pyrazol-1-yl)benzyl]nitrilo group and an isopropyl group at positions 2, 4 and 8 respectively. It is a potent and selective CDK7 inhibitor and exhibits antiviral activity.	2.6	1	0	aromatic ether; piperidines; pyrazoles; pyrazolotriazine; secondary amino compound	antineoplastic agent; antiviral agent; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
enasidenib [no description available]	2.6	1	0	1,3,5-triazines; aminopyridine; aromatic amine; organofluorine compound; secondary amino compound; tertiary alcohol	antineoplastic agent; EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor
angiotensin i Angiotensin I: A decapeptide that is cleaved from precursor angiotensinogen by RENIN. Angiotensin I has limited biological activity. It is converted to angiotensin II, a potent vasoconstrictor, after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME.. angiotensin I : A ten amino acid peptide formed by renin cleavage of angiotensinogen. Angiotensin I has no direct biological function except that high levels can stimulate catecholamine production. It is metabolized to its biologically active byproduct angiotensin II, a potent vasoconstrictor, by angiotensin converting enzyme (ACE) through cleavage of the two terminal amino acids.. angiotensin I dizwitterion : A peptide zwitterion that is the dizwitterionic form of angiotensin I having both carboxy groups deprotonated and the aspartyl amino group and arginine side-chain protonated. It is the major species at pH 7.3.	9.77	11	0	angiotensin; peptide zwitterion	human metabolite; neurotransmitter agent
nephrin nephrin: gene nephrin is mutated in congenital nephrotic syndrome; amino acid sequence in first source; GenBank F19541; RefSeq NM_019459 (mouse), NM_004646 (human), NM_022628 (rat)	2.48	2	0
s 8932 [no description available]	2.6	1	0	aromatic amine; C-nucleoside; carboxylic ester; nitrile; phosphoramidate ester; pyrrolotriazine	anticoronaviral agent; antiviral drug; prodrug
cyclosporine Cyclosporine: A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).	2.1	1	0
flavin mononucleotide Flavin Mononucleotide: A coenzyme for a number of oxidative enzymes including NADH DEHYDROGENASE. It is the principal form in which RIBOFLAVIN is found in cells and tissues.	3.5	1	1
cytochalasin d Cytochalasin D: A fungal metabolite that blocks cytoplasmic cleavage by blocking formation of contractile microfilament structures resulting in multinucleated cell formation, reversible inhibition of cell movement, and the induction of cellular extrusion. Additional reported effects include the inhibition of actin polymerization, DNA synthesis, sperm motility, glucose transport, thyroid secretion, and growth hormone release.. cytochalasin D : An organic heterotricyclic compound that is a mycotoxin produced by Helminthosporium and other moulds which is cell permeable and a potent inhibitor of actin polymerisation and DNA synthesis.	2.05	1	0
orabase Orabase: used in therapy of oral mucosal ulcers	2.41	1	0
thromboplastin Thromboplastin: Constituent composed of protein and phospholipid that is widely distributed in many tissues. It serves as a cofactor with factor VIIa to activate factor X in the extrinsic pathway of blood coagulation.	2.05	1	0
amyloid beta-peptides amyloid beta-protein (1-40): although acutely neurotoxic in both rat & monkey cerebral cortex, neuronal degeneration in primates resembles more closely to that found in Alzheimer's disease; amino acid sequence has been determined	2.47	2	0
entecavir entecavir (anhydrous) : Guanine substituted at the 9 position by a 4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl group. A synthetic analogue of 2'-deoxyguanosine, it is a nucleoside reverse transcriptase inhibitor with selective antiviral activity against hepatitis B virus. Entecavir is phosphorylated intracellularly to the active triphosphate form, which competes with deoxyguanosine triphosphate, the natural substrate of hepatitis B virus reverse transcriptase, inhibiting every stage of the enzyme's activity, although it has no activity against HIV. It is used for the treatment of chronic hepatitis B.	2.6	1	0	2-aminopurines; oxopurine; primary alcohol; secondary alcohol	antiviral drug; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
acyclovir Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections.	3.91	3	0	2-aminopurines; oxopurine	antimetabolite; antiviral drug
nu 1025 NU 1064: structure in first source	2.6	1	0	phenols; quinazolines	EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
cyclic gmp Cyclic GMP: Guanosine cyclic 3',5'-(hydrogen phosphate). A guanine nucleotide containing one phosphate group which is esterified to the sugar moiety in both the 3'- and 5'-positions. It is a cellular regulatory agent and has been described as a second messenger. Its levels increase in response to a variety of hormones, including acetylcholine, insulin, and oxytocin and it has been found to activate specific protein kinases. (From Merck Index, 11th ed). 3',5'-cyclic GMP : A 3',5'-cyclic purine nucleotide in which the purine nucleobase is specified as guanidine.	3.15	1	0	3',5'-cyclic purine nucleotide; guanyl ribonucleotide	Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
deoxyguanosine [no description available]	5.09	5	2	purine 2'-deoxyribonucleoside; purines 2'-deoxy-D-ribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
inosine diphosphate Inosine Diphosphate: An inosine nucleotide containing a pyrophosphate group esterified to C5 of the sugar moiety.	3.5	1	1	inosine phosphate; purine ribonucleoside 5'-diphosphate	fundamental metabolite
folic acid folcysteine: used to promote fertility in chickens. vitamin B9 : Any B-vitamin that exhibits biological activity against vitamin B9 deficiency. Vitamin B9 refers to the many forms of folic acid and its derivatives, including tetrahydrofolic acid (the active form), methyltetrahydrofolate (the primary form found in blood), methenyltetrahydrofolate, folinic acid amongst others. They are present in abundance in green leafy vegetables, citrus fruits, and animal products. Lack of vitamin B9 leads to anemia, a condition in which the body cannot produce sufficient number of red blood cells. Symptoms of vitamin B9 deficiency include fatigue, muscle weakness, and pale skin.	2.05	1	0	folic acids; N-acyl-amino acid	human metabolite; mouse metabolite; nutrient
rifampin Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)	4.25	5	0	cyclic ketal; hydrazone; N-iminopiperazine; N-methylpiperazine; rifamycins; semisynthetic derivative; zwitterion	angiogenesis inhibitor; antiamoebic agent; antineoplastic agent; antitubercular agent; DNA synthesis inhibitor; EC 2.7.7.6 (RNA polymerase) inhibitor; Escherichia coli metabolite; geroprotector; leprostatic drug; neuroprotective agent; pregnane X receptor agonist; protein synthesis inhibitor
clozapine Clozapine: A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.. clozapine : A benzodiazepine that is 5H-dibenzo[b,e][1,4]diazepine substituted by a chloro group at position 8 and a 4-methylpiperazin-1-yl group at position 11. It is a second generation antipsychotic used in the treatment of psychiatric disorders like schizophrenia.	3.16	5	0	benzodiazepine; N-arylpiperazine; N-methylpiperazine; organochlorine compound	adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; GABA antagonist; histamine antagonist; muscarinic antagonist; second generation antipsychotic; serotonergic antagonist; xenobiotic
dacarbazine (E)-dacarbazine : A dacarbazine in which the N=N double bond adopts a trans-configuration.	2.47	2	0	dacarbazine
didanosine Didanosine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite.. didanosine : A purine 2',3'-dideoxyribonucleoside that is inosine in which the hydroxy groups at both the 2' and the 3' positions on the sugar moiety have been replaced by hydrogen. An antiviral drug, it is used as a medication to treat HIV/AIDS.	2.8	3	0	purine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor; geroprotector; HIV-1 reverse transcriptase inhibitor
ganciclovir [no description available]	2.6	1	0	2-aminopurines; oxopurine	antiinfective agent; antiviral drug
valacyclovir Valacyclovir: A prodrug of acyclovir that is used in the treatment of HERPES ZOSTER and HERPES SIMPLEX VIRUS INFECTION of the skin and mucous membranes, including GENITAL HERPES.	3.64	2	0	L-valyl ester	antiviral drug
sildenafil sildenafil : A pyrazolo[4,3-d]pyrimidin-7-one having a methyl substituent at the 1-position, a propyl substituent at the 3-position and a 2-ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl group at the 5-position.	2.03	1	0	piperazines; pyrazolopyrimidine; sulfonamide	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
olanzapine Olanzapine: A benzodiazepine derivative that binds SEROTONIN RECEPTORS; MUSCARINIC RECEPTORS; HISTAMINE H1 RECEPTORS; ADRENERGIC ALPHA-1 RECEPTORS; and DOPAMINE RECEPTORS. It is an antipsychotic agent used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER; and MAJOR DEPRESSIVE DISORDER; it may also reduce nausea and vomiting in patients undergoing chemotherapy.. olanzapine : A benzodiazepine that is 10H-thieno[2,3-b][1,5]benzodiazepine substituted by a methyl group at position 2 and a 4-methylpiperazin-1-yl group at position 4.	2.47	2	0	benzodiazepine; N-arylpiperazine; N-methylpiperazine	antiemetic; dopaminergic antagonist; histamine antagonist; muscarinic antagonist; second generation antipsychotic; serotonergic antagonist; serotonin uptake inhibitor
penciclovir penciclovir : A member of the class of 2-aminopurines that is guanine in which the hydrogen at position 9 is substituted by a 4-hydroxy-3-(hydroxymethyl)but-1-yl group. An antiviral drug, it is administered topically for treatment of herpes labialis. A prodrug, famciclovir, is used for oral administration.	2.6	1	0	2-aminopurines; propane-1,3-diols	antiviral drug
vardenafil vardenafil : The sulfonamide resulting from formal condensation of the sulfo group of 4-ethoxy-3-(5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4(1H)-one-2-yl)benzenesulfonic acid and the secondary amino group of 4-ethylpiperazine.	2.03	1	0	imidazotriazine; N-alkylpiperazine; N-sulfonylpiperazine	EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; vasodilator agent
allopurinol Allopurinol: A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.. allopurinol : A bicyclic structure comprising a pyrazole ring fused to a hydroxy-substituted pyrimidine ring.	2.47	2	0	nucleobase analogue; organic heterobicyclic compound	antimetabolite; EC 1.17.3.2 (xanthine oxidase) inhibitor; gout suppressant; radical scavenger
citrovorum factor [no description available]	2.05	1	0	tetrahydrofolic acid
4-hydroxyquinazoline 4-oxo-3,4-dihydroquinazoline: structure in first source	2.6	1	0	quinazolines
tegaserod tegaserod: a nonbenzamide 5-hydroxytryptamine(4) agonist; used in treatment of irritable bowel syndrome; marketing suspended 2007 in US due to higher incidence of MI, stroke, and unstable angina; structure given in first source	2.6	1	0	carboxamidine; guanidines; hydrazines; indoles	gastrointestinal drug; serotonergic agonist
norclozapine norclozapine: structure given in first source. N-desmethylclozapine : A dibenzodoazepine substituted with chloro and piperazino groups which is a major metabolite of clozapine; a potent and selective 5-HT2C serotonin receptor antagonist.	2.6	1	0	dibenzodiazepine; organochlorine compound; piperazines	delta-opioid receptor agonist; metabolite; serotonergic antagonist
tak 491 azilsartan medoxomil: an azilsartan prodrug and angiotensin II type 1 receptor blocker. azilsartan medoxomil : A carboxylic ester obtained by formal condensation of the carboxy group of azilsartan with the hydroxy group of 4-(hydroxymethyl)-5-methyl-1,3-dioxol-2-one. A prodrug for azilsartan, it is used for treatment of hypertension.	9.07	9	8	1,2,4-oxadiazole; aromatic ether; benzimidazoles; carboxylic ester; cyclic carbonate ester; dioxolane	angiotensin receptor antagonist; antihypertensive agent; prodrug
pemetrexed pemetrexed disodium : An organic sodium salt that is the disodium salt of N-{4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid. Inhibits thymidylate synthase (TS), 421 dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT).	2.6	1	0	N-acyl-L-glutamic acid; pyrrolopyrimidine	antimetabolite; antineoplastic agent; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; EC 2.1.1.45 (thymidylate synthase) inhibitor; EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor
aprepitant Aprepitant: A morpholine neurokinin-1 (NK1) receptor antagonist that is used in the management of nausea and vomiting caused by DRUG THERAPY, and for the prevention of POSTOPERATIVE NAUSEA AND VOMITING.. aprepitant : A morpholine-based antiemetic, which is or the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors.	2.52	2	0	(trifluoromethyl)benzenes; cyclic acetal; morpholines; triazoles	antidepressant; antiemetic; neurokinin-1 receptor antagonist; peripheral nervous system drug; substance P receptor antagonist
rifabutin [no description available]	2.05	1	0
azilsartan azilsartan: an angiotensin type 1 receptor blocker; receptor blocker. azilsartan : A benzimidazolecarboxylic acid that is benzimidazole-7-carboxylic acid substituted at position 2 by a methoxy group and at position 1 by a 2'-[(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl group. Used (as the prodrug, azilsartan medoxomil) for treatment of hypertension.	8.5	12	3	1,2,4-oxadiazole; aromatic ether; benzimidazolecarboxylic acid	angiotensin receptor antagonist; antihypertensive agent
hesperadin [no description available]	2.6	1	0
8-hydroxy-2'-deoxyguanosine 8-Hydroxy-2'-Deoxyguanosine: Common oxidized form of deoxyguanosine in which C-8 position of guanine base has a carbonyl group.. 8-hydroxy-2'-deoxyguanosine : Guanosine substituted at the purine 8-position by a hydroxy group. It is used as a biomarker of oxidative DNA damage.	5.09	5	2	guanosines	biomarker
6-bromoindirubin-3'-acetoxime 6-bromoindirubin-3'-acetoxime: a synthetic derivative of a compound from the Mediterranean mollusk Hexaplex trunculus, protects cells from varicella infection	2.6	1	0
n'-(3,4-dihydroxybenzylidene)-3-hydroxy-2-naphthahydrazide [no description available]	2.6	1	0	catechols; hydrazide; hydrazone; naphthols	EC 3.6.5.5 (dynamin GTPase) inhibitor
XL413 XL413 : A benzofuropyrimidine that is 3,4-dihydro[1]benzofuro[3,2-d]pyrimidine substituted by (2S)-pyrrolidin-2-yl, oxo and chloro groups at positions 2, 4, and 8, respectively. It is a potent ATP competitive inhibitor of Cdc7 kinase (IC50 = 3.4 nM) and exhibits anticancer properties.	2.6	1	0	benzofuropyrimidine; organochlorine compound; pyrrolidines	antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
me0328 ME0328: inhibits ARTD3; structure in first source	2.6	1	0
nvp-tnks656 [no description available]	2.6	1	0
technetium tc 99m bicisate [no description available]	2.05	1	0
leptin Leptin: A 16-kDa peptide hormone secreted from WHITE ADIPOCYTES. Leptin serves as a feedback signal from fat cells to the CENTRAL NERVOUS SYSTEM in regulation of food intake, energy balance, and fat storage.	2.03	1	0

olmesartan

Description

Cross-References

Synonyms (106)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (2)

Drug Classes (1)

Pathways (4)

Protein Targets (8)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (34)

Molecular Functions (30)

Ceullar Components (12)

Bioassays (93)

Research

Studies (803)

Market Indicators

Research Demand Index: 123.15

Study Types

Clinical Trials (133)

Trial Overview

Trial Outcomes

AIM 1: Change in hsCRP (High Sensitivity C-reactive Peptide) Level

AIM 1: Change in Flow Mediated Dilation (FMD) (%)

Number of Participants Experiencing Cardiovascular Composite Outcomes

The Change in Proteinuria

Renal Composite Outcomes

Reciprocal (1/Serum Creatinine) of Serum Creatinine

Mean Change From Period 3 Baseline in Seated Systolic and Diastolic Blood Pressure Measurements to the End of Period 3

Mean Change From Baseline in Seated Systolic and Diastolic Blood Pressure Measurements to the End of Period 4 (End of Study)

Mean Change From Period 3 Baseline in Seated Systolic and Diastolic Blood Pressure Measurements to the End of Period 3

Mean Change From Baseline in Seated Systolic and Diastolic Blood Pressure Measurements to the End of Period 4 (End of Study)

Mean Change From Baseline in Seated Systolic and Diastolic Blood Pressure Measurements to the End of Period 2 (3 Weeks)

Least Squares Mean Change From Baseline in Seated Systolic Blood Pressure to the End of Period 2 (3 Weeks)

For Olmesartan, the Apparent Oral Clearance

For Olmesartan, the Maximum Plasma Concentration Over the Entire Sampling Phase

For Olmesartan, Area Under the Concentration-time Curve From the Time of the Dose to Infinity

For Olmesartan, the Elimination Half-life of the Drug in Plasma

For Olmesartan, the Elimination Constant Rate

For Olmesartan, the Area Under the Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC 0-t)

For Olmesartan, the Apparent Oral Volume of Distribution

Foe Olmesartan, the Time of Maximum Plasma Concentration

The Percentage of Participants Treated to Target Blood Pressure Goals Overall and for Each Treatment Step From Baseline to Completion of Treatment During Which the Goal Was Achieved.

Percentage of Participants Who Were Systolic Responders Overall and for Each Treatment From Baseline to the Completion of the Treatment During Which Blood Pressure Goals Were Achieved

Percentage of Participants Who Were Diastolic Responders Overall and for Each Treatment From Baseline to the Completion of Treatment During Which Blood Pressure Goals Were Achieved.

Percentage of Participants Who Achieved Normalized Blood Pressure Overall and for Each Treatment From Baseline to Completion of the Treatment During Which Blood Pressure Goals Were Achieved

Mean Change in Systolic Blood Pressure Overall and for Each Treatment From Baseline to the Completion of the Treatment

Mean Change in Diastolic Blood Pressure Overall and for Each Treatment From Baseline to the Completion of the Treatment

Change From Baseline in the 24-36-Hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

Change From Baseline in the 24-36-Hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

Change From Baseline in the 10-12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

Change From Baseline in Standing Clinic Systolic Blood Pressure.

Change From Baseline in Standing Clinic Diastolic Blood Pressure.

Change From Baseline in Sitting Clinic Systolic Blood Pressure.

Change From Baseline in Sitting Clinic Diastolic Blood Pressure.

Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

Change From Baseline in 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

Change From Baseline in 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

Change From Baseline in the 10-12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

Change From Baseline in the 34-36-Hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

Change From Baseline in the 34-36-Hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.